text string | url string | crawl_date timestamp[ms] | label int64 | id string |
|---|---|---|---|---|
10 thoughts on Jonathan Taylor's contract standoff with the Colts, where it goes from here
Ten thoughts on the Jonathan Taylor vs. the Colts soap opera that has become the dominant storyline of training camp:
1. This first week has been quite a year on the Colts beat. We'll get to those leaks and tweets from Sunday night in a moment, but I want to start with Saturday’s first night practice, where two 11-on-11 groups were running drills on the field and I spent it tracking a luxury bus parked outside the fences.
Fans have strong reasons to be excited about this Colts team, with Shane Steichen building a fascinating offensive system around a historic but unproven quarterback like Anthony Richardson.
But rolling back so much of last year's team meant inheriting at least some of its scars. And that's how this Jonathan Taylor contract situation is starting to feel.
2. Taylor met with owner Jim Irsay on a bus for close to an hour for something that wasn’t a contract negotiation and wasn’t really a trade talk but more of a clearing-the-air session. The two emerged, and as Irsay was holding his ground with us in the media, Taylor’s trade request was leaked to NFL Network.
That explained the frosty vibe we’d seen all week from the normally wide-smiling Taylor, with his hood up, arms crossed, face blank, engaging with few teammates. The contract he wanted wasn’t here, but the clock to start practicing and risking injury was.
RELATED:Jim Irsay holds hour-long bus chat with Jonathan Taylor amid contract and trade requests
3. That mood was never about that ankle surgery in January.
ESPN’s Stephen Holder and Fox59’s Mike Chappell both reported Sunday night that Taylor arrived to camp on Tuesday complaining about a back injury he suffered while training away from the facility, in addition to the repaired ankle.
Taylor is refuting those reports, saying on Twitter he never reported an injury or pain in his back.
MORE: Jonathan Taylor refutes reports that he suffered back injury away from Colts
When it comes to PUP, the recovering ankle qualifies but realistically only for so long. The procedure he had done is called arthroscopic debridement, NFL Network reported. A source with knowledge of these types of procedures told me that it carries a 2-4-week recovery for football players. Even the toughest ankle injuries often take around three months to heal.
It’s been six months.
4. Back injuries are trickier to map out, of course, and we don't even know if this one happened.
If it did, and if it occurred away from the facility, then it could qualify him for the Non-Football Injury List.
That list does not entitle a player to his salary while he’s on it, though those payments don’t come until Week 1. If it were to extend into the regular season, the player must miss four games, which means nearly a quarter of his base salary. If it were to extend to six games, a player in a contract year like Taylor would then have that contract year moved to the next season.
Why was the possibility leaked instead of just making a move?
That’s what we call a threat.
And Taylor's denial only muddies these dirty waters.
5. It’s not a coincidence that these prickly measures come after that hour-long conversation on the bus. Words aren’t working anymore. They haven’t all offseason, as Taylor hasn’t received a single contract offer. And they certainly haven’t this week, as Irsay and Taylor’s agent, Malki Kawa, have exchanged Twitter shots about the state of the position and Taylor’s lack of an offer.
6. This play also comes one day after Irsay told IndyStar and other outlets, “We will not trade Jonathan Taylor. That is a certainty. Not now, or not in October.”
Taylor went the trade route because it’s one of his final cards to play in a brutal landscape for running backs, even ones as talented as he is. It's not a strong one, because a team trading for him will have to give up enough draft compensation to convince the Colts to diminish their backfield support for Richardson while likely agreeing to the type of extension Taylor wants. With Dalvin Cook and Zeke Elliott available to sign for no draft picks and a lot less money, that’s not an enticing market.
It becomes even less enticing if the player in question isn’t practicing due to an injury situation. Especially a running back. Especially in 2023.
7. There’s so much noise right now, but this much we know: Taylor and the Colts could not be further apart in their desires and expectations.
Taylor wants a multi-year deal, with security for possible injuries like the high-ankle sprain that caused him to miss six games last year, plus a pay rate that hits market value for his All-Pro and rushing title abilities, which based on current deals would be at least in the $12 million-16 million annual range.
The Colts want him to play this year out to see how he rebounds from the ankle before deciding on anything. They know they have the franchise tag in their hand as free agency approaches. That’s why they hold the aces here, and Taylor is left playing a 10.
8. It’s interesting that the Colts haven’t used that leverage in the form of a lower-ball offer. It would give Taylor a panic move to make if he runs out of cards and grows uncomfortable with the negative spotlight every day at camp. That’s what the Giants used with Saquon Barkley, and he eventually came around to a one-year, $11 million deal that was only slightly above the franchise tag number due to incentives.
The Colts have said they are just letting all contracts play out with a new coaching staff right now, and that appears true, but the inaction invites Taylor to take the volatile route, which is what changing agents in late May and going to Twitter is. Asking Taylor to practice and play 17 more games of a brutal position behind the same starting five offensive linemen he got bottled up and hurt behind last year is obviously going to upset him, especially after he watched Quenton Nelson, Shaquille Leonard, Ryan Kelly, Braden Smith, Kenny Moore II and Nyheim Hines all receive a life raft from the same owner and general manager at this stage in their rookie contracts.
Those emotions are running white-hot now.
9. I had thought a possible compromise could be to schedule a contract meeting in, say, late September, once Taylor has healed up and shown his fit in Steichen’s RPO-heavy backfield with Richardson. If the two can meld their explosive upside into a dual threat to be feared, the Colts should be encouraged to lock that up since all that ultimately matters is raising Richardson’s floor and tapping his upside anyway.
The franchise tag is why they don’t have to, but the animosity has risen so high, you wonder whether promises can work again.
They tried the bus meeting once already. I'm not sure if it has any gas left.
10. It’s safe to say two sides could have handled this so much better. The sub-tweeting, the pouting, the threats and the demands can weigh heavy on any team that is kicking off a new season, but especially one with a rookie head coach and rookie quarterback. I don’t sense we’re close to a resolution, and for as long as that is true, the work of Steichen and Richardson and the energy they create is not going to light the momentum this franchise so desperately needed after last year's went up in flames.
Irsay and Taylor are two good men who have done tremendous acts in and away from the game of football. They’re also intense competitors in a win-now league and billion-dollar industry, staring each other down in the most bizarre time in history for a running back standoff.
Buckle in. We have turbulence now.
Contact Colts insider Nate Atkins at natkins@indystar.com. Follow him on Twitter @NateAtkins_. | https://www.indystar.com/story/sports/nfl/colts/2023/07/31/colts-10-thoughts-on-jonathan-taylors-contract-standoff/70489689007/ | 2023-07-31T11:16:15 | 1 | https://www.indystar.com/story/sports/nfl/colts/2023/07/31/colts-10-thoughts-on-jonathan-taylors-contract-standoff/70489689007/ |
The nights before games were always the toughest times for Darrelle Revis.
One of the NFL’s most dominant cornerbacks would lie in bed thinking about what he needed to accomplish the next day on the field. Revis would go over the game plan, the notes from his film studies, the receivers’ routes and their tendencies.
Over and over until he’d fall asleep.
He’d wake up mentally prepared — and that brief anxiety would be replaced by supreme confidence.
“Restless nights, I’d say to start with,” Revis said. “Covering some of the greatest wide receivers in the game and future Hall of Famers at that time, I was probably the most nervous out of anybody on the field if I had that assignment.
“For me, it’s kind of looking at yourself in the mirror and saying to yourself, ‘It’s either me or him. I just have to stand up to the challenge.’ For me, I just took on the responsibility to take that assignment and try to shut him down.”
Revis did exactly that for most of his brilliant 11-year NFL career, including eight seasons over two stints with the New York Jets.
So much so, he earned the popular “Revis Island” nickname, a fitting tribute to how he’d single-handedly make many receivers disappear — lost on an island — from opponents’ game plans.
“This is a once-in-a-lifetime type corner,” former Jets coach Rex Ryan once said. “And that’s a fact.”
Tough to argue, and voters for the Pro Football Hall of Fame made Revis a first-ballot inductee following a career during which he routinely locked down one side of the field with his air-tight coverage.
He also gave plenty of opposing offensive coordinators plenty of restless nights of their own.
“I just felt I had the ability and skill set and the coaching staff who believed in me that I had the ability to shut them down,” Revis said.
That was perhaps most evident during the 2009 season, when Revis had arguably the greatest year at his position.
Ever.
Randy Moss, Chad Johnson, Andre Johnson, Steve Smith, Terrell Owens, Reggie Wayne and Roddy White were all non-factors against the Jets that season — because they couldn’t shake Revis.
“I shouldn’t have even suited up,” Wayne said after having just a 1-yard catch in Indianapolis’ playoff loss to New York that season.
Green Bay cornerback Charles Woodson won the AP Defensive Player of the Year award that year, but Ryan insisted Revis should’ve been the choice after having “the best year a corner has ever had.”
Revis had six interceptions and set an NFL record that still stands with 31 passes defensed that season. He never really came close to matching those marks in any season the rest of his career — because teams simply stopped throwing his way.
That was the ultimate sign of respect.
“It was a very comforting thing as a player that we’d have a guy that can take away the greatest weapon of the other team’s offensive players,” former Jets center and long-time teammate Nick Mangold said. “So it was very much like a security blanket, like, we’ve got him, so we’re good.”
Revis was drafted by the Jets out of the University of Pittsburgh with the 14th overall pick in 2007 when they traded up 11 spots to add a player they believed could change their defense. And he certainly delivered, making an instant impact under coach Eric Mangini before thriving as the heart of Ryan’s defense.
“One of the highlights for me is just being drafted,” Revis said. “Just fulfilling that dream. Just the hills I had to run at an incline, the abs, the pushups, the overtime, just put into everything to try to even dare myself to be one of the best or one of the greatest or amount to be somewhat of the next Deion Sanders, in a way.”
The comparisons quickly became a regular thing for Revis, whose abilities were often measured up against the likes of Sanders, Woodson, Rod Woodson, Ty Law, Champ Bailey and Mel Blount.
Until the debates began about whether Revis was actually the best cornerback ever.
That’s subjective, of course, with some pointing out Revis’ relatively short period of greatness. A knee injury wiped out his 2012 season and a contract dispute — he had a few of those, helping set the market for cornerbacks — ended with him being traded to Tampa Bay the following offseason.
Revis won a Super Bowl the next year with New England, irking Jets fans, but he returned to New York in 2015 and played two more seasons for his original team. After a short stint with Kansas City in 2017, Revis retired. He was inducted into the Jets’ ring of honor last year.
His playing legacy came with his performance in games, but he built a reputation for striving to be great with his intense approach during practice. Revis would get on teammates who weren’t giving their all, and his goal was to not give up a catch to anyone.
And if he did, Revis would be ticked off. About catches that didn’t even count — to everyone other than Revis.
“Every practice, to him, was a game,” Mangold said. “So he was going out there and no one was going to catch a ball on him. It was the result of his competitive nature. He was always working to win.”
Download the FREE WPXI News app for breaking news alerts.
Follow Channel 11 News on Facebook and Twitter. | Watch WPXI NOW
TRENDING NOW:
©2023 Cox Media Group | https://www.wpxi.com/news/local/revis-shut-down-his-nerves-then-nfls-best-wide-receivers-his-way-hall-fame/FC5IA5UZPFARFKGCO6RYICEGMI/ | 2023-07-31T11:16:21 | 1 | https://www.wpxi.com/news/local/revis-shut-down-his-nerves-then-nfls-best-wide-receivers-his-way-hall-fame/FC5IA5UZPFARFKGCO6RYICEGMI/ |
Insider: Can Colts coach Shane Steichen design an explosive offense without Jonathan Taylor?
WESTFIELD — Colts owner Jim Irsay still wants to see the dream pairing.
Jonathan Taylor and Anthony Richardson, lined up in the same backfield, forcing defenses to make an impossible choice, leaving themselves open to the pure power and blinding speed of two supreme athletes.
Irsay loves the idea, repeatedly saying Saturday night that he hopes they will be in the backfield together this fall, leading the Colts to a good season.
But there is a chance it never happens.
Taylor has requested a trade, and although Irsay responded by saying the Colts will not trade their star running back, the relationship is fractured and appears to be rapidly deteriorating.
Doyel:Taylor joins Luck, Oladipo as star athletes receiving bad advice
If Taylor does not play for Indianapolis this season, the Colts coaching staff loses its best offensive weapon, the one skill player who’s proven he can carry the offense.
A player Shane Steichen’s staff has been excited about unleashing. For example, take Indianapolis offensive coordinator Jim Bob Cooter, who responded to a question in March asking if he preferred the bell cow or committee approach by pointing at the player with a unanimous first team All-Pro nod in his past.
“When you have somebody like Jonathan Taylor, you probably ought to play him a little bit more, right?” Cooter said.
The reason is simple.
In an era where NFL teams increasingly view running backs as replaceable, a healthy Taylor is special because he can turn just about any carry into a touchdown, to create the explosive plays that are supposed to be a hallmark of Steichen’s offense.
“There are guys that can get three or four yards a pop, but when you’ve got a guy that can really hit it and create those explosives in the run game; I think that definitely helps your offense,” Steichen said in June.
When he was fully healthy in 2021, Taylor had an eye-popping 50 runs of 10 yards or more, the NFL’s definition of an explosive run. In three seasons in the NFL, he already has nine plays of 40 yards or more, the kind of plays that make life easy on an offense by ending a drive with one swing.
Playing through a high ankle sprain and behind a struggling offensive line for most of his 2022 season — the Colts offensive line didn’t start improving in the running game until Taylor had already been hurt — the explosiveness went away.
But Irsay said Saturday night that the arthroscopic debridement Taylor went through to clean up debris in his ankle shouldn’t have significant long-term implications, adding that linebacker E.J. Speed has been through the procedure in the past couple of seasons.
If that’s true, Taylor’s the same player who ran the 40-yard dash in 4.38 seconds at the NFL scouting combine, who ran away from the entire Patriots defense to salt away a huge win in 2021.
The other backs on the Colts roster can't do that.
Taylor’s immediate backup, Zack Moss, is coming off an impressive trial period after coming to Indianapolis in a trade from Buffalo last season. Moss rushed for 365 yards in a Colts uniform, including a 114-yard performance in the season finale against Houston.
But Moss doesn’t have Taylor’s elite burst. Moss, a former third-round pick, ran the 40-yard dash in 4.65 seconds at the NFL scouting combine, had just one run longer than 20 yards in a Colts uniform last season (34) and has a long of 43 yards in more than four NFL seasons.
The only back on the roster who has Taylor's kind of speed, Deon Jackson, hasn’t had a play cover more than 27 yards in two seasons in Indianapolis. Fifth-round pick Evan Hull ran the 40 in 4.47 seconds.
The Colts coaching staff can likely put together a solid running game without Taylor.
Richardson’s incredible physical gifts make the rookie Indianapolis quarterback a threat to make a big play every time he tucks and gets into the open.
Getting explosive plays out of the running back position will be much more difficult, and Steichen will likely have to manufacture those plays. When Taylor was out of action down the stretch last season, the Colts put up solid numbers against a schedule that featured several of the NFL’s worst rushing defenses.
Big plays were still hard to come by.
“I mean, you definitely feel it,” Colts center Ryan Kelly said. “(Taylor's) obviously our guy. … They always say it’s a plug-and-play business, but when you’re missing a star player like that, it is tough.”
If Indianapolis has Richardson and Taylor in the same backfield, the Colts coaching staff would be limited only by their imaginations. Taylor and Richardson are capable of handling just about any kind of carry, from pounding up the middle to turning the corner on the outside.
Take Taylor away, and those options dwindle, forcing Steichen, Cooter and the Indianapolis staff to tailor each play to what the running back does best, allowing the defense to eliminate possibilities based on skill set.
Indianapolis could still be successful by doing that. Under Steichen and focused on Jalen Hurts, Philadelphia had one of the league’s best rushing attacks in 2022, getting 1,269 yards from Miles Sanders, who’s now in Carolina.
But Hurts is in his third year in the NFL, and he's flanked by receivers A.J. Brown and Devonta Smith on the outside, and they are capable of producing explosive plays. That might be difficult for an unproven passer in Richardson and a group of wide receivers that hasn’t proven they can be consistent big-play threats.
If Taylor’s healthy and ready to go, he’d likely make up for some of those explosive plays, and the hesitation of defenses unsure how to attack creates more chances for big plays. If he’s not on the field, a team can sell out on Richardson, forcing the running backs to beat them.
If Taylor’s not on the field, Steichen’s job will be a whole lot harder. | https://www.indystar.com/story/sports/nfl/colts/2023/07/31/losing-jonathan-taylor-would-likely-make-shane-steichens-job-harder/70495324007/ | 2023-07-31T11:16:21 | 1 | https://www.indystar.com/story/sports/nfl/colts/2023/07/31/losing-jonathan-taylor-would-likely-make-shane-steichens-job-harder/70495324007/ |
HONG KONG — (AP) — A French man is believed to have fallen to his death from a high-rise residential building in Hong Kong last week, police said on Monday, with local media outlets identifying him as daredevil Remi Lucidi.
Police said a 30-year-old man's body was found on a patio in the city's upscale Mid-Levels area. He was believed to have engaged in extreme sports, police said, without identifying him.
Officers conducted an initial investigation and said he apparently fell from a rooftop. No suicide note was found at the scene, they said. The cause of his death would have to be verified by an autopsy, they added.
Local media, including the South China Morning Post, said the man was Lucidi, 30. The Post cited an unnamed source saying he was last seen alive knocking on a penthouse window on the 68th floor of a residential tower on Thursday evening. The Associated Press has not been able to verify his identity.
Lucidi, who used the name “Remi Enigma” on social media, last posted a photo of Hong Kong's night view a week ago on Instagram and tagged the location as Times Square in shopping district Causeway Bay. The photo appeared to be taken from above.
Supporters mourned him on social media.
Lucidi posted to Instagram as he climbed various tall structures around the world and took selfies, including one he captioned, “Above the Sky, 425m” and tagged Dubai as the location.
Copyright 2023 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission. | https://www.wpxi.com/news/world/french-daredevil-who/BOCSWEPJTUXJ76KWYQUFU7VAUU/ | 2023-07-31T11:16:27 | 0 | https://www.wpxi.com/news/world/french-daredevil-who/BOCSWEPJTUXJ76KWYQUFU7VAUU/ |
KYIV, Ukraine — (AP) — Russian missiles slammed into an apartment complex and a university building in the central Ukrainian city of Kryvyi Rih, killing four people and wounding dozens of others Monday as the blasts trapped residents beneath rubble, Ukraine's interior minister said.
One of the two missiles destroyed a section of the apartment building between the fourth and ninth floors, Interior Minister Ihor Klymenko said. Video showed black smoke billowing from corner units and burned out or damaged cars on a tree-lined street.
A 10-year-old child was among those killed, Klymenko said. Serhii Kruk, head of Ukraine’s State Emergency Service, said 44 people were wounded in the morning attack, which also destroyed part of the four-story university building.
Meanwhile, a Ukrainian artillery strike on partially occupied Donetsk province killed two people and wounded six in the regional capital, according to Denis Pushilin, the Moscow-installed leader of the illegally annexed province.
A bus was also hit as Ukrainian forces shelled the city of Donetsk multiple times Monday, Pushilin said.
Neither side's claims could be independently verified.
A Ukrainian counteroffensive aimed at driving Russian forces out of occupied areas intensified last week. At the same time, Ukraine has sought to take the war deep into Russia, reportedly using drones to hit targets as far away as Moscow.
Ukrainian drone attacks on Russia and Moscow-annexed territory, especially Crimea, have become more frequent. The latest strike, on Sunday, damaged two office buildings a few miles (kilometers) from the Kremlin.
In Kryvyi Rih, which is the hometown of Ukrainian President Volodymyr Zelenskyy, rescue crews searched Monday for people who were trapped in the wreckage of the two hit buildings. The Kremlin's forces have occasionally targeted the city since they invaded Ukraine in February 2022.
Bombarding populated areas with missiles, artillery and drones has been a hallmark of Moscow’s military strategy during the war, an approach that has continued during the Ukrainian counteroffensive that started in June.
Russian officials insist they only take aim at legitimate military targets, but Ukraine and its supporters say mass civilian deaths during previous attacks provide evidence of war crimes.
“In recent days, the enemy has been stubbornly attacking cities, city centers, shelling civilian objects and housing,” Zelenskyy said in a statement on social media. “But this terror will not frighten us or break us.”
Russian shelling Monday also killed a 70-year-old woman in her home in a Kharkiv province village near Izyum, as well as a civilian in the southern Ukrainian city of Kherson, local authorities said.
In eastern Ukraine’s Donetsk province, one person was reported killed and seven people were injured after Russia shelled 12 cities and villages, according to Gov. Pavlo Kirilenko.
Ukrainian officials didn’t acknowledge Sunday's drone attacks in the Moscow region. In his nightly video address, Zelenskyy said: “Gradually, the war is returning to the territory of Russia — to its symbolic centers and military bases, and this is an inevitable, natural and absolutely fair process.”
Meanwhile, Russian mercenary leader Yevgeny Prigozhin said Monday his Wagner Group is not currently recruiting fighters.
In an audio message published on a Telegram channel associated with the Wagner chief, Prigozhin said the company had suspended recruitment as there is currently “no shortage of personnel.”
Prigozhin previously agreed with Western estimates that he lost more than 20,000 men in the long battle for the Ukrainian city Bakhmut.
Prigozhin last month led a short-lived mutiny against Moscow, demanding a leadership change in the Russian military. In an attempt to control him, Russian authorities insisted that Wagner fighters can only return to Ukraine if they join Russia's regular army.
___
Follow AP's coverage of the war in Ukraine at https://apnews.com/hub/russia-ukraine
Copyright 2023 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission. | https://www.wpxi.com/news/world/russian-missiles/UAN3SRIW33CWD42EBFI6PYAGUU/ | 2023-07-31T11:16:33 | 0 | https://www.wpxi.com/news/world/russian-missiles/UAN3SRIW33CWD42EBFI6PYAGUU/ |
Trump could be indicted soon in Georgia. Here’s a look at that investigation
ATLANTA (AP) — A Georgia prosecutor is expected to seek a grand jury indictment in the coming weeks in her investigation into efforts by Donald Trump and his Republican allies to overturn the former president’s 2020 election loss.
Fulton County District Attorney Fani Willis began investigating more than two years ago, shortly after a recording was released of a January 2021 phone call Trump made to Georgia’s secretary of state.
Willis has strongly hinted that any indictment would come between July 31 and August 18. One of two grand juries seated July 11 is expected to hear the case.
If Trump is indicted by a Georgia grand jury, it would add to a growing list of legal troubles as he campaigns for president. Trump is set to go to trial in New York in March to face state charges related to hush-money payments made during the 2016 presidential campaign. And he has another trial scheduled for May on federal charges related to his handling of classified documents. He has pleaded not guilty in those cases.
The Justice Department is also investigating Trump’s role in trying to halt the certification of 2020 election results in the run-up to the Jan. 6, 2021, assault on the U.S. Capitol. Trump said he’s been told he’s a target of that investigation, which likely has some overlap with the one in Georgia.
Details of the Georgia investigation that have become public have fed speculation that Willis, a Democrat, is building a case under the Georgia Racketeer Influenced and Corrupt Organizations Act, which would allow her to charge numerous people in a potentially wide-ranging scheme.
Here are six investigative threads Willis and her team have explored:
THE PHONE CALLS
The Georgia investigation was prompted by the Jan. 2, 2021 phone call Trump made to Georgia Secretary of State Brad Raffensperger. Trump suggested the state’s top elections official could help “find” the votes needed to put him ahead of Democrat Joe Biden in the state.
“All I want to do is this: I just want to find 11,780 votes, which is one more than we have,” Trump is heard saying on a recording of the call, which was leaked to news outlets. “Because we won the state.”
Trump has insisted he did nothing wrong and has repeatedly said the call was “perfect.”
Trump also called other top state officials in his quest to overturn his 2020 election loss, including Gov. Brian Kemp, then-House Speaker David Ralston, Attorney General Chris Carr and the top investigator in the secretary of state’s office.
U.S. Sen. Lindsey Graham, a South Carolina Republican, also called Raffensperger shortly after the November election. Raffensperger said at the time that Graham asked whether he had the power to reject certain absentee ballots, which Raffensperger has said he interpreted as a suggestion to toss out legally cast votes.
Graham has denied wrongdoing, saying he just wanted to learn about the signature verification process.
FAKE ELECTORS
Biden won Georgia by a margin of fewer than 12,000 votes. Just over a month after the election, on Dec. 14, 2020, a group 16 Georgia Democratic electors met in the Senate chamber at the state Capitol to cast the state’s Electoral College votes for him. They each marked paper ballots that were counted and confirmed by a voice roll call.
That same day, in a committee meeting room at the Capitol, 16 prominent Georgia Republicans — a lawmaker, activists and party officials — met to sign a certificate falsely stating that Trump had won and declaring themselves the state’s “duly elected and qualified” electors. They sent that certificate to the National Archives and the U.S. Senate.
Georgia was one of seven battleground states that Trump lost where Republican fake electors signed and submitted similar certificates. Trump allies in the U.S. House and Senate used those certificates to argue for delaying or blocking the certification of the election during a joint session of Congress.
Prosecutors in Fulton County have said in court filings that they believe Trump associates worked with state Republicans to coordinate and execute the plan.
The multi-state effort was ultimately unsuccessful. Despite public pressure from Trump and his supporters, then-Vice President Mike Pence refused on Jan. 6, 2021, to introduce the unofficial pro-Trump electors. After the attack on the U.S. Capitol put a violent halt to the certification process, lawmakers certified Biden’s win in the early hours of Jan. 7, 2021.
At least eight of the fake electors have since reached immunity deals with Willis’ team. And a judge last summer barred Willis from prosecuting another one, Lt. Gov. Burt Jones, because of a conflict of interest.
FALSE CLAIMS OF ELECTION FRAUD
Republican state lawmakers held several hearings at the Georgia Capitol in December 2020 to examine alleged problems with the November election. During those meetings, former New York mayor Rudy Giuliani and other Trump allies made unproven claims of widespread election fraud.
They alleged that election workers tallying absentee ballots at State Farm Arena in Atlanta had told outside observers to leave and then pulled out “suitcases” of unlawful ballots and began scanning them. The Trump allies played clips of surveillance video from the arena to support their allegations. State and federal officials investigated and said there was no evidence of election fraud at the site.
Some Trump allies also said thousands of people who were ineligible — including people convicted of felonies, people younger than the age of 18, people who had voted in another state — had cast votes in Georgia. The secretary of state’s office has debunked those claims.
ALLEGED ATTEMPTS TO PRESSURE ELECTION WORKER
Two of the election workers seen in the State Farm Arena surveillance video, Ruby Freeman and her daughter Wandrea “Shaye” Moss, said they faced relentless harassment online and in person as a result of the allegations made by Trump and his allies.
Giuliani last week conceded that statements he made about the two election workers were false.
In a bizarre episode detailed by prosecutors in court filings, a woman traveled from Chicago to Georgia and met with Freeman on Jan. 4, 2021. The woman initially said she wanted to help Freeman but then warned that Freeman could go to prison and tried to pressure her into falsely confessing to committing election fraud, prosecutors wrote in court filings last year.
ELECTION EQUIPMENT ACCESSED
Trump-allied lawyer Sidney Powell and others hired a computer forensics team to copy data and software on election equipment in Coffee County, some 200 miles southeast of Atlanta, according to invoices, emails, security video and deposition testimony produced in response to subpoenas in a long-running lawsuit.
The county Republican Party chair at the time — who also served as a fake elector — greeted them when they arrived at the local elections office on Jan. 7, 2021, and some county elections officials were also on hand during the daylong visit. The secretary of state’s office has said this amounted to “alleged unauthorized access” of election equipment, and the Georgia Bureau of Investigation is looking into it at the secretary of state’s request.
Two other men who have been active in efforts to question the 2020 election results also visited Coffee County later that month and spent hours inside.
U.S. ATTORNEY RESIGNATION
U.S. Attorney BJay Pak, the top federal prosecutor in Atlanta, abruptly resigned two days after Trump called Raffensperger and a day after a recording of that call was made public. During that conversation, Trump called Pak a “never-Trumper,” implying that he didn’t support the president.
In December 2020, then-U.S. Attorney General William Barr asked Pak to investigate allegations by Giuliani and other Trump allies of widespread election fraud. Pak, who had been appointed by Trump in 2017, reported back that he had found no evidence of such fraud.
In August 2021, Pak told the U.S. Senate Judiciary Committee, which was investigating Trump’s post-election actions, that he resigned on Jan. 4, 2021, after learning from Department of Justice officials that Trump did not believe enough was being done to investigate allegations of election fraud and wanted him gone as U.S. attorney.
Copyright 2023 The Associated Press. All rights reserved. | https://www.kbtx.com/2023/07/31/trump-could-be-indicted-soon-georgia-heres-look-that-investigation/ | 2023-07-31T11:18:23 | 1 | https://www.kbtx.com/2023/07/31/trump-could-be-indicted-soon-georgia-heres-look-that-investigation/ |
WATCH: Concertgoer throws drink at Cardi B; she hurls microphone at them
Published: Jul. 31, 2023 at 5:58 AM CDT|Updated: 19 minutes ago
LAS VEGAS (CNN) - Cardi B hurled her microphone at a fan during a concert in Las Vegas on Saturday.
The rapper was performing her song “Bodak Yellow” when a concertgoer threw a drink at her.
In seconds, Cardi B threw her microphone into the crowd as the song continued to play.
Security guards rushed to the stage.
More security guards are then seen flocking to the person in the crowd as she watched from the stage before continuing with her set.
There’s no word on what happened to the fan or if any charges will be filed.
Copyright 2023 CNN Newsource. All rights reserved. | https://www.kbtx.com/2023/07/31/watch-concertgoer-throws-drink-cardi-b-she-hurls-microphone-them/ | 2023-07-31T11:18:29 | 1 | https://www.kbtx.com/2023/07/31/watch-concertgoer-throws-drink-cardi-b-she-hurls-microphone-them/ |
WATCH: Concertgoer throws drink at Cardi B; she hurls microphone at them
Published: Jul. 31, 2023 at 5:58 AM CDT|Updated: 20 minutes ago
LAS VEGAS (CNN) - Cardi B hurled her microphone at a fan during a concert in Las Vegas on Saturday.
The rapper was performing her song “Bodak Yellow” when a concertgoer threw a drink at her.
In seconds, Cardi B threw her microphone into the crowd as the song continued to play.
Security guards rushed to the stage.
More security guards are then seen flocking to the person in the crowd as she watched from the stage before continuing with her set.
There’s no word on what happened to the fan or if any charges will be filed.
Copyright 2023 CNN Newsource. All rights reserved. | https://www.kfyrtv.com/2023/07/31/watch-concertgoer-throws-drink-cardi-b-she-hurls-microphone-them/ | 2023-07-31T11:18:48 | 1 | https://www.kfyrtv.com/2023/07/31/watch-concertgoer-throws-drink-cardi-b-she-hurls-microphone-them/ |
SHANGHAI, July 31, 2023 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced that it will report its unaudited financial results for the second quarter ended June 30, 2023, before the U.S. market opens on Thursday, August 24, 2023.
111's management team will host an earnings conference call at 7:30 AM U.S. Eastern Time on Thursday, August 24, 2023 (7:30 PM Beijing Time on the same day).
Details for the conference call are as follows:
Conference Topic: 111, Inc. Second Quarter 2023 Earnings Conference Call
Registration Link: https://s1.c-conf.com/diamondpass/10032701-ygfhis.html
All participants must use the link provided above to complete the online registration process in advance of the conference call. Upon registering, each participant will receive a set of participant dial-in numbers, the Direct Event passcode, and a unique Registration ID, which can be used to join the conference call.
Please dial in 15 minutes before the call is scheduled to begin and provide the Direct Event passcode and unique Registration ID you have received upon registering to join the call.
A telephone replay of the call will be available after the conclusion of the conference call until August 31, 2023
United States: +1 855 883 1031
Mainland China: 4001 209 216
Hong Kong: 800 930 639
International: +61 7 3107 6325
Conference ID: 10032701
A live and archived webcast of the conference call will be available on the website at https://edge.media-server.com/mmc/p/iw7ck9oc
About 111, Inc.
111, Inc. (NASDAQ: YI) ("111" or the "Company") is a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China. The Company provides consumers with better access to pharmaceutical products and healthcare services directly through its online retail pharmacy, 1 Pharmacy, and indirectly through its offline virtual pharmacy network. The Company also offers online healthcare services through its internet hospital, 1 Clinic, which provides consumers with cost-effective and convenient online consultation, electronic prescription service, and patient management service. In addition, the Company's online platform, 1 Medicine Marketplace, serves as a one-stop shop for pharmacies to source a vast selection of pharmaceutical products. With the largest virtual pharmacy network in China, 111 enables offline pharmacies to better serve their customers with cloud-based services. 111 also provides an omni-channel drug commercialization platform to its strategic partners, which includes services such as digital marketing, patient education, data analytics, and pricing monitoring.
For more information on 111, please visit: http://ir.111.com.cn/.
View original content:
SOURCE 111, Inc. | https://www.kfyrtv.com/prnewswire/2023/07/31/111-announce-second-quarter-2023-unaudited-financial-results-august-24-2023-conference-call-follow/ | 2023-07-31T11:18:50 | 0 | https://www.kfyrtv.com/prnewswire/2023/07/31/111-announce-second-quarter-2023-unaudited-financial-results-august-24-2023-conference-call-follow/ |
- Cash, cash equivalents, and marketable securities totaled $349.0 million as of June 30, 2023
- Announced positive interim data from BHV-7000 EEG biomarker study demonstrating evidence of central nervous system (CNS) target engagement, confirming previously reported preclinical and clinical data, and highlighting the paradigm-changing potential of BHV-7000 in the treatment of epilepsy and mood disorders
- Brain penetrant TYK2/JAK1 inhibitor, BHV-8000, advanced into Phase 1 with projected therapeutic concentrations achieved and well-tolerated profile observed to date
- Advanced targeted extracellular protein degradation platform with potential to support numerous clinical candidates across a broad range of high unmet need indications
- Orphan drug designation (ODD) granted by the European Commission for taldefgrobep alfa a novel anti-myostatin adnectin, for the treatment of spinal muscular atrophy (SMA)
- Type A meeting planned with FDA regarding troriluzole program in Spinocerebellar Ataxia Type 3 (SCA3) and enrollment in Phase 3 obsessive compulsive disorder (OCD) trial expected to complete at end of 2023
NEW HAVEN, Conn., July 31, 2023 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today reported financial results for the second quarter ended June 30, 2023, and provided a review of recent accomplishments and anticipated upcoming milestones.
Vlad Coric, M.D., Chairman and Chief Executive Officer of Biohaven, commented, "In less than a year since our spin-off, the Biohaven team has driven strong and consistent progress across multiple drug development platforms. We were excited to recently report positive interim data from the ongoing EEG biomarker study of our lead Kv7 activator, BHV-7000. As expected, BHV-7000 demonstrated CNS activity consistent with what has been reported in EEG studies with other Kv7 channel activators in development that are clinically effective in treating epilepsy and with other approved anti-seizure medications. Importantly, BHV-7000 demonstrates CNS target engagement but is not associated with the typical CNS adverse events associated with other ASMs, like somnolence and fatigue. We look forward to completing the higher dose groups in this EEG study and initiating Phase 2/3 studies with our once daily, extended-release oral formulation later this year."
Dr. Coric continued, "We also shared a number of equally exciting announcements across our broader pipeline this quarter. We successfully administered the first three doses in the SAD portion of our ongoing SAD/MAD study evaluating BHV-8000, an oral, brain-penetrant, dual TYK2/JAK1 inhibitor. Potential therapeutic concentrations of BHV-8000 were achieved and BHV-8000 was well tolerated with only mild adverse events reported, reinforcing our plans to start a Phase 2 clinical trial with BHV-8000 in Parkinson's disease and potentially other neuroinflammatory diseases in 2024. In addition, we have advanced IND enabling preclinical studies and remain on track to submit an IND with our IgG degrader, BHV-1300, later this year. We also anticipate submitting an IND with our IgA degrader in 2024 as we continue to advance multiple clinical degrader candidates across a wide range of indications. We also shared key updates for our taldefgrobep alfa program (an anti-myostatin) with enrollment completion in our pivotal study in SMA and a planned Phase 2 trial initiation in obesity."
"Finally, I want to reaffirm Biohaven's commitment to the SCA3 patient community in spite of the recent disappointing regulatory decision by the FDA not to review our submitted NDA. Given the seriousness of SCA3 and consistent treatment benefits observed across multiple prespecified outcome measures, including an 80% delay in disease progression over the one-year study period with substantial risk reduction in falls, we believe that full consideration of all available data is warranted for this ultra-rare disease. Biohaven has built its foundation around our patient mission and we plan to continue to work with regulatory agencies to try to advance troriluzole for individuals suffering from SCA3."
Second Quarter 2023 and Recent Business Highlights
- Announced positive interim data from EEG biomarker study with BHV-7000 - In July 2023, the Company provided a preliminary data update from the ongoing electroencephalogram (EEG) biomarker study for the Kv7 Channel Activator platform. Preliminary Phase 1 data confirmed evidence of target engagement in the central nervous system for subjects with projected therapeutic concentrations of BHV-7000 (based on the EC50 from preclinical models), measured by changes from baseline in EEG spectral power that occurred after dosing. These pharmacodynamic (PD) effects were similar to those reported in the literature for anti-seizure medicines (ASMs), including Kv7 activators in development that are clinically effective in treating epilepsy. BHV-7000's PD effects were also differentiated from those reported for other Kv7 activators including, specifically, the absence of increases in EEG spectral power in frequency bands associated with drowsiness and somnolence. Results from the low-dose group validate the preclinical hypothesis, confirm the Phase 1 SAD/MAD clinical data, and provide strong support for Biohaven's plans to initiate pivotal studies with BHV-7000 in focal epilepsy and bipolar disorder in the second half of 2023. The preliminary data highlight BHV-7000's differentiation and potentially favorable clinical profile compared to other ASMs, and the Company expects to present the complete EEG results by the end of the year. Additionally, new pharmacokinetic data from multiple clinical formulations being studied has now confirmed a once daily extended-release oral formulation that will be used in the Phase 2/3 clinical programs.
- Successfully dosed three cohorts with single ascending doses of oral, brain penetrant, dual TYK2/JAK1 agent, BHV-8000 - In July 2023, the Company announced that it successfully dosed three cohorts in the SAD portion of an ongoing SAD/MAD Phase 1 study evaluating brain penetrant TYK2/JAK1 agent, BHV-8000 in healthy volunteers. The ongoing Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics (PK) and PD of single and multiple ascending doses of BHV-8000 in healthy volunteers. Based on the preliminary data available, projected therapeutic concentrations of BHV-8000 were achieved, and BHV-8000 was well tolerated with only mild adverse events reported. These data provide support for further development of BHV-8000, and the Company anticipates beginning a Phase 2 clinical trial with BHV-8000 in Parkinson's disease and potentially other neuroinflammatory diseases in 2024. The Company had previously reported initiation of dosing with BHV-8000 in the Phase 1 study at Biohaven's R&D Day in May 2023.
- Reported on continued progress observed with Biohaven's first-in-class bispecific IgG degrader, BHV-1300, as compound advances to IND filing in 2H2023 - In July 2023, the Company shared an update on BHV-1300's highly competitive safety, manufacturable and PD profile. The Company is assembling a pipeline of partially de-risked, follow-on IgG degraders as well as antigen-specific degraders providing both optionality and a sustainable output of drug candidates for several years. An IND application for BHV-1300 is on track for submission in 2023 and an IND application for Biohaven's IgA degrader on track for submission in 2024
- Type A meeting planned to comprehensively address FDA's concerns in connection with Troriluzole program in SCA3 - In July 2023, the Company announced that the FDA informed Biohaven it would not review the recently submitted New Drug Application (NDA) for troriluzole for the treatment of spinocerebellar ataxia type 3 (SCA3), an ultra-rare, genetically-defined, neurodegenerative disease associated with progressive disability, frequent falls, loss of ambulation, speech and swallowing impairment, and premature death that is the most common SCA genotype worldwide. The FDA informed Biohaven it would not review the application given that the study's primary endpoint was not met and thus, would not permit a substantive review. Biohaven is committed to working closely with the FDA to bring troriluzole to people with SCA3 as quickly as possible given no therapy is currently approved for this ultra-rare genetic disorder. Biohaven plans to request a Type A meeting to comprehensively address FDA's concerns cited in the refusal to file letter.
- EMA orphan drug designation granted for taldefgrobep alfa for the treatment of SMA: - In July 2023, the Company announced that taldefgrobep alfa received orphan drug designation (ODD) from the European Commission for taldefgrobep for the treatment of SMA. Taldefgrobep previously received Fast-Track and ODD from the FDA. At Biohaven's R&D Day, the Company announced plans to complete randomization of approximately 180 patients in global SMA trial.
Upcoming Milestones:
Biohaven is progressing its product candidates through clinical programs in a number of common and rare disorders. The Company plans to reach significant pipeline milestones in the coming periods. Biohaven expects to:
- Announce Phase 1 EEG study results by year-end 2023: The Company expects to present complete results from its ongoing EEG study with BHV-7000 in healthy volunteers by the end of the year.
- Initiate Phase 2/3 studies with BHV-7000 in the second half of 2023: Biohaven expects to initiate pivotal trials in patients with focal epilepsy and bipolar disorder in the second half of 2023.
- Submit IND with BHV-1300, the Company's lead extracellular degrader: The Company expects to submit an IND with pan-IgG degrader BHV-1300 in the second half of 2023 and expects to initiate Phase 2 studies in 2024.
- Submit IND with selective Gd-IgA1 degrader: The Company expects to submit an IND with a Gd-IgA1 degrader indicated for IgA nephropathy in the first half of 2024.
- Initiate Phase 2 study with BHV-8000: The Company commenced Phase 1 studies with BHV-8000, an oral, brain-penetrant, dual TYK2/JAK1 inhibitor for neuroinflammatory disorders, in the first half of 2023 and expects to initiate a Phase 2 study in Parkinson's disease in 2024.
- Submit IND with BHV-2100 in chronic pain: The Company expects to submit an IND with BHV-2100, a selective TRPM3 antagonist in the Company's ion channel platform, in the second half of 2023.
- Complete enrollment in Phase 3 study of troriluzole in OCD in 2023: Two Phase 3 randomized, double-blind, placebo-controlled studies of troriluzole in OCD are expected to enroll up to 700 patients (in each trial) across nearly 200 global study sites. The Company anticipates completing enrollment in at least one Phase 3 trial by year-end 2023.
- Complete enrollment in Phase 3 clinical study of taldefgrobep alfa in SMA: The Company expects to complete enrollment in the study of taldefgrobep in SMA in the second half of 2023.
- Continue advancements across multiple neuroscience and immunoscience indications: The Company's preclinical pipeline includes a platform of bispecific degraders of extracellular proteins directed against IgG, IgA and other targets, TRPM3 and Kv7 family of ion channels, and other undisclosed targets, including those with disease-modifying potential.
Capital Position:
Cash, cash equivalents and marketable securities as of June 30, 2023 was $349.0 million, including $13.9 million of restricted cash, and excluding $40.4 million of cash payable to Biohaven Pharmaceutical Holding Company Ltd. (the Former Parent), compared to $467.9 million, including $2.5 million of restricted cash, and excluding $35.2 million of cash payable to the Former Parent, as of December 31, 20221.
Second Quarter 2023 Financial Highlights:
Research and Development (R&D) Expenses: R&D expenses, including non-cash share-based compensation costs, were $79.5 million for the three months ended June 30, 2023, compared to $177.1 million for the three months ended June 30, 2022. Non-cash share-based compensation expense was $2.5 million for the three months ended June 30, 2023, a decrease of $10.3 million as compared to the same period in 2022. Non-cash share-based compensation expense was higher in the second quarter of 2022 primarily because expense allocated from the Former Parent equity plan, prior to the spin-off, was based on equity awards with higher grant date fair values.
General and Administrative (G&A) Expenses: General and administrative expenses were $14.5 million for the three months ended June 30, 2023, compared to $20.0 million for the three months ended June 30, 2022. The decrease of $5.5 million was primarily due to decreased non-cash share-based compensation costs. Non-cash share-based compensation expense was $2.2 million for the three months ended June 30, 2023, a decrease of $5.8 million as compared to the same period in 2022. Non-cash share-based compensation expense was higher in the second quarter of 2022 primarily because expense allocated from the Former Parent equity plan, prior to the spin-off, was based on equity awards with higher grant date fair values.
Other Income (Expense), Net: Other income (expense), net was a net income of $5.8 million for the three months ended June 30, 2023, compared to net expense of $0.1 million for the three months ended June 30, 2022. The increase of $5.9 million was primarily due to an increase in net investment income and an increase of $1.7 million in other income related to our transition services provided to the Former Parent, which is largely non-recurring.
Net Loss: Biohaven reported a net loss for the three months ended June 30, 2023, of $90.3 million, or $1.32 per share, compared to $203.3 million, or $5.16 per share, for the same period in 2022. Non-GAAP adjusted net loss for the three months ended June 30, 2023 was $85.7 million, or $1.25 per share, compared to $182.5 million, or $4.63 per share for the same period in 2022. These non-GAAP adjusted net loss and non-GAAP adjusted net loss per share measures, more fully described below under "Non-GAAP Financial Measures," exclude non-cash share-based compensation charges. A reconciliation of the GAAP financial results to non-GAAP financial results is included in the tables below. For periods prior to Biohaven's spin-off from the Former Parent on October 3, 2022 (the "Spin-Off"), net loss per share and non-GAAP adjusted net loss per share were calculated based on the 39,375,944 common shares of Biohaven distributed to the Former Parent shareholders at the time of the distribution, including common shares issued in connection with the Former Parent share options that were settled on October 3, 2022 and common shares issued in connection with the Former Parent restricted share units that vested on October 3, 2022. The same number of shares is being utilized for the calculation of basic and diluted earnings per share for all periods presented prior to the Spin-Off.
Non-GAAP Financial Measures
This press release includes financial results prepared in accordance with accounting principles generally accepted in the United States (GAAP), and also certain non-GAAP financial measures. In particular, Biohaven has provided non-GAAP adjusted net loss and adjusted net loss per share, which are adjusted to exclude non-cash share-based compensation, which is substantially dependent on changes in the market price of common shares. Non-GAAP financial measures are not an alternative for financial measures prepared in accordance with GAAP. However, Biohaven believes the presentation of non-GAAP adjusted net loss and adjusted net loss per share, when viewed in conjunction with GAAP results, provides investors with a more meaningful understanding of ongoing operating performance and can assist investors in comparing Biohaven's performance between periods.
In addition, these non-GAAP financial measures are among those indicators Biohaven uses as a basis for evaluating performance, and planning and forecasting future periods. These non-GAAP financial measures are not intended to be considered in isolation or as a substitute for GAAP financial measures. A reconciliation between these non-GAAP measures and the most directly comparable GAAP measures is provided later in this news release.
About Biohaven
Biohaven is a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases. Biohaven's experienced management team brings with it a track record of delivering new drug approvals for products for diseases such as migraine, depression, bipolar and schizophrenia. The company is advancing a pipeline of therapies for diseases, many of which have limited or no treatment options, leveraging its proven drug development capabilities and proprietary platforms, including Kv7 ion channel modulation for epilepsy and neuronal hyperexcitability, glutamate modulation for obsessive-compulsive disorder and spinocerebellar ataxia, myostatin inhibition for neuromuscular diseases and metabolic disorders, and brain-penetrant TYK2/JAK1 inhibition for neuroinflammatory disorders. Biohaven's portfolio of early- and late-stage product candidates also includes discovery research programs focused on TRPM3 channel activation for neuropathic pain, CD-38 antibody recruiting, bispecific molecules for multiple myeloma, antibody drug conjugates (ADCs), and targeted extracellular protein degradation platform technology (MoDE™) with potential application in neurological disorders, cancer, and autoimmune diseases.
Forward-looking Statements
This news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including "continue", "plan", "will", "believe", "may", "expect", "anticipate" and similar expressions, is intended to identify forward-looking statements. Investors are cautioned that any forward-looking statements, including statements regarding the future development, timing and potential marketing approval and commercialization of development candidates, are not guarantees of future performance or results and involve substantial risks and uncertainties. Actual results, developments and events may differ materially from those in the forward-looking statements as a result of various factors including: the expected timing, commencement and outcomes of Biohaven's planned and ongoing clinical trials; the timing of planned interactions and filings with the FDA; the timing and outcome of expected regulatory filings; complying with applicable U.S. regulatory requirements; the potential commercialization of Biohaven's product candidates; the potential for Biohaven's product candidates to be first in class therapies; and the effectiveness and safety of Biohaven's product candidates. Additional important factors to be considered in connection with forward-looking statements are described in Biohaven's filings with the Securities and Exchange Commission, including within the sections titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations". The forward-looking statements are made as of the date of this new release, and Biohaven does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
MoDEs is a trademark of Biohaven Therapeutics Ltd.
Investor Contact:
Jennifer Porcelli
Vice President, Investor Relations
jennifer.porcelli@biohavenpharma.com
+1 (201) 248-0741
Media Contact:
Mike Beyer
Sam Brown Inc.
mikebeyer@sambrown.com
+1 (312) 961-2502
View original content to download multimedia:
SOURCE Biohaven Ltd. | https://www.kfyrtv.com/prnewswire/2023/07/31/biohaven-reports-second-quarter-2023-financial-results-recent-business-developments/ | 2023-07-31T11:18:53 | 1 | https://www.kfyrtv.com/prnewswire/2023/07/31/biohaven-reports-second-quarter-2023-financial-results-recent-business-developments/ |
SAN FRANCISCO, July 31, 2023 /PRNewswire/ -- Today, Blitz Insurance, a specialty insurance carrier, partners with Ascend to modernize payment experiences for insurance brokers selling in specialty markets. With this partnership, Blitz Insurance will open new customer segments by offering both direct bill and premium financing into their payments workflow.
"When we looked into the market for a solution, Ascend was the right choice. Ascend meets our needs for a better payments experience for our partners while reducing everyone's operational expenses," said Brandon Murphy, Chief Distribution Officer of Blitz Insurance. "We will now have the ability to not only expand to direct bill and a premium finance option but also simplify the movement of money between us and our partners."
With Ascend, Blitz Insurance is now able to provide a direct bill in addition to their existing agency bill workflow - allowing brokers to decide what billing method works best for them. By utilizing Ascend, Blitz Insurance not only grows their footprint of appointed brokers but also gains administrative efficiency by automating what would otherwise have been a large operational undertaking.
Ascend automatically attributes incoming payments to policies in real time, speeding up the reconciliation process. By modernizing the payments experience and speeding up the reconciliation of incoming premiums, Blitz Insurance can offer a best-in-class experience to its brokers and agents.
"We find that across the insurance ecosystem - companies want to provide a seamless payment workflow for their customers and their teams," said Andrew Wynn, co-CEO of Ascend. "Ascend is built so brokers and carriers can offer this experience without shouldering the administrative resources and costs needed to support these operations."
About Ascend
Ascend is the first insurance payments platform that automates financial operations from collections and financing to carrier and commission payables. Founded by two-time insurtech entrepreneurs Andrew Wynn and Praveen Chekuri, Ascend helps insurance brokers, MGAs, and carriers improve their bottom lines by eliminating expensive and labor-intensive payment workflows. To learn more, please visit LinkedIn, Twitter or check out https://www.useascend.com/.
About Blitz Insurance
Blitz is a tech-driven insurer revolutionizing the $60B specialty market catering to SME segment. By leveraging industry knowledge and cutting-edge technology, we deliver a simpler, smarter, and faster coverage experience.
The company is led by a veteran team of insurance and technology experts and has been funded with $25M from its founder & CEO, a Forbes-listed serial entrepreneur in the real estate and insurance industries.
Contact:
Mike Nguyen
press@useascend.com
View original content to download multimedia:
SOURCE Ascend | https://www.kfyrtv.com/prnewswire/2023/07/31/blitz-insurance-partners-with-ascend-expand-payment-financing-offerings/ | 2023-07-31T11:18:53 | 0 | https://www.kfyrtv.com/prnewswire/2023/07/31/blitz-insurance-partners-with-ascend-expand-payment-financing-offerings/ |
STAMFORD, Conn., July 31, 2023 /PRNewswire/ -- Emeren Group Ltd ("Emeren" or the "Company") (www.emeren.com) (NYSE: SOL), a leading global solar project developer, owner, and operator, recently announced the successful sale of an 11.5 MWp PV project to the Swiss-based energy company MET Group. The project was sold at the Ready-to-Build ("RTB") stage and MET Group will complete the construction and operate the power plant. This is the first project developed to RTB stage by Emeren Germany GmbH, the Berlin-based subsidiary of Emeren Group, since its entry into the market in early 2021. Capcora, a German consulting company, acted as the exclusive sell-side M&A advisor to Emeren.
The new PV power plant will be located in Kentzlin nestled in the state of Mecklenburg-Western Pomerania and the commercial operations are expected to start in the second half of 2024.
Yumin Liu, CEO of Emeren Group, commented, "This project is an important milestone for our business in Germany and represents our commitment to developing renewable energy infrastructure in the region. We look forward to continuing to work with our local partners to build a more sustainable future."
Bernd Wollwerth-Carl, Director of Emeren Germany GmbH, added, "We are delighted to have sold our first RTB project in Germany. Starting from scratch in 2021, we managed to grow quickly in a competitive German PV market, establishing partnerships and building a pipeline of medium and large-scale ground mounted PV plants. With MET, we found a reliable and competent partner and we look forward to further expanding our cooperation."
Christian Hürlimann, Renewables CEO of MET Group, commented, "The Kentzlin project fits well into MET's strategic vision to enter the highly competitive German renewables market, as well as to further expand its renewables portfolio across Europe and particularly in Western Europe. Emeren Group's expertise in renewable energy was instrumental in achieving this milestone, and we anticipate future collaboration on additional projects."
Henning Prigge, Director at Capcora, adds: "We are delighted to have played a pivotal role in Emeren's successful project sale to MET Group, a prominent integrated European energy company. Our long-standing partnership with Emeren has allowed us to witness their growth and success, and we couldn't be happier to have been a part of this milestone. This collaboration reinforces our commitment to providing top-notch support and solutions to our valued clients."
About Emeren Group Ltd
Emeren Group Ltd (NYSE: SOL) is a leading global solar project developer, owner, and operator with a pipeline of projects and IPP assets totaling over 3 GW, as well as a storage pipeline of over 6 GWh across Europe, North America, and Asia. The Company focuses on solar power project development, construction management and project financing services with local professional teams across multiple countries. For more information, go to www.emeren.com.
About MET Group
MET Group is an integrated European energy company, headquartered in Switzerland, with activities and assets in natural gas and power markets. MET is present in 14 countries through subsidiaries, 30 national gas markets, and 22 international trading hubs. MET has extensive experience in operating green (renewable) and flexible (conventional) energy assets, thus providing the widest possible support to energy transition. In 2022, MET Group's consolidated sales revenue amounted to EUR 41.5 billion, the total traded volume of natural gas was 109 BCM including futures, total traded electricity 67 TWh including futures.
About Capcora
Capcora is an independent financial advisory boutique specializing in M&A and project finance services to accelerate the energy transition in Europe. Founded in 2015, the Frankfurt-based company helps its clients succeed in the renewable energy and infrastructure sectors by advising them on sell-side and buy-side transactions, and by raising mezzanine, unitranche or senior debt.
View original content to download multimedia:
SOURCE Emeren Group Ltd | https://www.kfyrtv.com/prnewswire/2023/07/31/emeren-group-announces-sale-first-rtb-solar-power-project-germany/ | 2023-07-31T11:18:54 | 1 | https://www.kfyrtv.com/prnewswire/2023/07/31/emeren-group-announces-sale-first-rtb-solar-power-project-germany/ |
BEIJING, July 31, 2023 /PRNewswire/ -- Gravitas Education Holdings, Inc. ("GEHI" or the "Company") (NYSE: GEHI), a leading early childhood education service provider in China, today announced that it will hold an extraordinary general meeting of shareholders (the "EGM") at 3/F, No. 28 Building, Fangguyuan Section 1, Fangzhuang Fengtai District, Beijing 100078, People's Republic of China, at 10:00 a.m. (Beijing time) on September 11, 2023, for the purposes of considering and, if thought fit, approving the transactions contemplated in the Agreement and Plan of Merger (the "Merger Agreement"), dated April 18, 2023, by and among the Company, Bright Sunlight Limited, a Cayman Islands exempted company and a direct, wholly owned subsidiary of the Company ("Merger Sub"), Best Assistant Education Online Limited, a Cayman Islands exempted company ("Best Assistant") and a controlled subsidiary of NetDragon Websoft Holdings Limited (HKEX: 0777, "NetDragon"), a Cayman Islands exempted company, and solely for purposes of certain named sections thereof, NetDragon. It is contemplated that Best Assistant will transfer the education business of NetDragon outside of the PRC to Elmtree Inc., a Cayman Islands exempted company limited by shares ("eLMTree") and currently a wholly owned subsidiary of Best Assistant. Pursuant to the Merger Agreement, Merger Sub will merge with and into eLMTree with eLMTree continuing as the surviving company and becoming a wholly owned subsidiary of the Company (the "Merger").
Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each ordinary share of eLMTree issued and outstanding immediately prior to the Effective Time (excluding the Dissenting Shares and the Excluded Shares, each as defined in the Merger Agreement) will be cancelled in exchange for the right to receive a number of validly issued, fully paid and non-assessable ordinary shares of the Company in a transaction exempt from the registration requirements under the Securities Act of 1933.
Shareholders of the Company will also be asked to consider and vote on certain additional Merger-related proposals at the EGM, including, among others:
- that, subject to and conditional upon the Merger becoming effective, the fifth amended and restated memorandum and article of association of the Company be amended and restated by their deletion in their entirety and the substitution of in their place of the sixth amended and restated memorandum and articles of association of the Company (the "A&R MAA") effective immediately prior to the Effective Time of the Merger;
- that, subject to and conditional upon the Merger becoming effective, the name of the Company be changed from "Gravitas Education Holdings, Inc." to "Mynd.ai, Inc." effective immediately prior to the Effective Time;
- that, subject to and conditional upon the Merger becoming effective, immediately prior to the Effective Time, the authorized share capital of the Company be varied as follows: (a) the authorized share capital of the Company shall be varied to US$1,000,000 divided into 1,000,000,000 shares comprising of (i) 990,000,000 ordinary shares of a par value of US$0.001 each (each a "ListCo Ordinary Share") and (ii) 10,000,000 shares of a par value of US$0.001 each of such class or classes (however designated) as the board of directors may determine in accordance with the A&R MAA, and (b) all Class A ordinary shares of the Company prior to the adoption of the A&R MAA, par value US$0.001 per share ("ListCo Class A Ordinary Shares") and all Class B ordinary shares of the Company prior to the adoption of the A&R MAA, par value US$0.001 per share ("ListCo Class B Ordinary Shares") in the authorized share capital of the Company (including all issued and outstanding ListCo Class A Ordinary Shares and ListCo Class B Ordinary Shares, and all authorized but unissued ListCo Class A Ordinary Shares and ListCo Class B Ordinary Shares) shall be re-designated as ListCo Ordinary Shares.
Holders of the Company's ordinary shares whose names are on the register of members of the Company at the close of business in the Cayman Islands on August 7, 2023, are entitled to notice of, and to vote at, the EGM or any adjournment or postponement thereof in person. Holders of the Company's American depositary shares ("ADSs") at the close of business in New York City on August 7, 2023, are entitled to exercise their voting rights for the underlying ordinary shares and must act through Citibank, N.A., the depositary of the Company's ADS program.
The notice of the EGM, which contains the detailed proposals to be presented at the EGM, and the proxy statement related to the EGM, are being filed today with the U.S. Securities and Exchange Commission ("SEC") and can be obtained without charge from the SEC's website (http://www.sec.gov). These documents are also available in the "Financial Information" section of the Company's investor relations website at https://ir.geh.com.cn/. In addition, the proxy materials (including the proxy statement) will be mailed to the Company's shareholders and holders of ADSs.
SHAREHOLDERS AND ADS HOLDERS ARE URGED TO READ CAREFULLY AND IN THEIR ENTIRETY THE PROXY MATERIALS AND OTHER MATERIALS FILED WITH OR FURNISHED TO THE SEC WHEN THEY BECOME AVAILABLE, AS THEY CONTAIN VOTING INSTRUCTIONS AND IMPORTANT INFORMATION ABOUT THE COMPANY, ELMTREE, THE MERGER AND RELATED MATTERS.
This press release is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the transactions described above and shall not constitute an offer to sell or a solicitation of an offer to buy the securities of eLMTree or the Company, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or an exemption therefrom.
Forward-Looking Statements
This press release contains certain "forward-looking statements." These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the pending transactions described herein, and the parties' perspectives and expectations, are forward-looking statements. Such statements include, but are not limited to, statements regarding the Merger, including the equity values, the benefits of the Merger, expected revenue opportunities, anticipated future financial and operating performance and results, including estimates for growth, the expected management and governance of the combined company, and the expected timing of the transactions. The words "will," "expect," "believe," "estimate," "intend," "plan" and similar expressions indicate forward-looking statements.
Such forward-looking statements are inherently uncertain, and shareholders and other potential investors must recognize that actual results may differ materially from the expectations as a result of a variety of factors. Such forward-looking statements are based upon management's current expectations and include known and unknown risks, uncertainties and other factors, many of which are hard to predict or control, that may cause the actual results, performance, or plans to differ materially from any future results, performance or plans expressed or implied by such forward-looking statements. Such risks and uncertainties include, but are not limited to: (i) risks related to the expected timing and likelihood of completion of the Merger, including the risk that the transaction may not close due to one or more closing conditions to the transaction not being satisfied or waived, such as regulatory approvals not being obtained, on a timely basis or otherwise, or that a governmental entity prohibited, delayed or refused to grant approval for the consummation of the transaction or required certain conditions, limitations or restrictions in connection with such approvals; (ii) the occurrence of any event, change or other circumstances that could give rise to the termination of the applicable transaction agreements; (iii) the risk that there may be a material adverse change with respect to the financial position, performance, operations or prospects of the Company or eLMTree; (iv) risks related to disruption of management time from ongoing business operations due to the Merger; (v) the risk that any announcements relating to the Merger could have adverse effects on the market price of the Company's securities; (vi) the risk that the Merger and its announcement could have an adverse effect on the ability of eLMTree to retain customers and retain and hire key personnel and maintain relationships with their suppliers and customers and on their operating results and businesses generally; (vii) any changes in the business or operating prospects of eLMTree or its businesses; (viii) changes in applicable laws and regulations; and (ix) risks relating to the combined company's ability to enhance its services and products, execute its business strategy, expand its customer base and maintain stable relationship with its business partners.
A further list and description of risks and uncertainties can be found in the proxy statement that will be filed with the SEC by the Company in connection with the Merger, and other documents that the parties may file with or furnish to the SEC, which you are encouraged to read. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. Accordingly, you are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements relate only to the date they were made, and eLMTree, the Company and their subsidiaries and affiliates undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made except as required by law or applicable regulation.
Additional Information and Where to Find It
The Company will file with the SEC and mail to its shareholders and ADS holders a proxy statement in connection with the Merger. Investors and security holders are urged to read the proxy statement when it becomes available because it will contain voting instructions and important information regarding the proposed arrangement. You may access the proxy statement (when available) and other related documents filed by the Company with the SEC at the SEC's website at www.sec.gov. You also may obtain the proxy statement and other documents filed by the Company with the SEC relating to the proposed arrangement for free by accessing the Company's website at https://ir.geh.com.cn/ by clicking on the link for "Financial Information," and then clicking on the link for "SEC Filings."
CONTACT: Gravitas Education Holdings, Inc., Investor Relations, E-mail: ir@geh.com.cn
View original content:
SOURCE Gravitas Education Holdings Inc. | https://www.kfyrtv.com/prnewswire/2023/07/31/gehi-hold-extraordinary-general-meeting-shareholders-september-11-2023/ | 2023-07-31T11:19:08 | 0 | https://www.kfyrtv.com/prnewswire/2023/07/31/gehi-hold-extraordinary-general-meeting-shareholders-september-11-2023/ |
LA ROMANA, Dominican Republic, July 31, 2023 /PRNewswire/ -- The international known company Hilton Hotels & Resorts opens its doors to its Hilton Garden Inn La Romana hotel project in the Dominican Republic, in collaboration with a group of important investors under the company Riverhome Capital S.A.S., whose main shareholder is the prominent Dominican former major league player, Edwin Encarnación; together with the vision of the lawyer Guillermo Estrella Ramia and the Minister of Tourism, David Collado.
The inauguration was led by Luis Abinader Corona, president of the Dominican Republic and who expressed that "This hotel has something very special, opening up the beach and the sector of La Caleta of La Romana, which for a long time was closed to the province and its visitors. Since private investment must always be accompanied by public infrastructure, we are working on creating them, so we are all part of this development of La Romana."
With an investment of 25 million united states dollars and the creation of more than 300 direct jobs, it is considered as a hotel option for the growing flows of tourists that the area is currently receiving. Located a short distance from other points of relevance, such as La Romana Airport 18 minutes away, Casa de Campo 12 minutes away and Central Romana just a few blocks away.
The new hotel facility has a privileged location on a 5,000 square meters property, located on the coast of the municipal district of La Caleta, La Romana province. With a capacity of 130 rooms, distributed in five of the seven floors of the building, it also counts with swimming pools, two bars, a restaurant, gym, event, meeting and multipurpose rooms, and outdoor areas, ideal for social and corporate celebrations.
The hotel responds to the interest of Edwin Encarnación to invest in the development of his province of origin, who expressed that "from the moment this project was presented to me, I knew that I had to be part and be the one to assume this. I joined the development of this hotel, with the only requirement that most of the workers came from here, from my town La Romana, and we achieved this."
View original content to download multimedia:
SOURCE Grupo De Valle | https://www.kfyrtv.com/prnewswire/2023/07/31/hilton-garden-inn-la-romana-dominican-republic-celebrates-its-opening/ | 2023-07-31T11:19:15 | 1 | https://www.kfyrtv.com/prnewswire/2023/07/31/hilton-garden-inn-la-romana-dominican-republic-celebrates-its-opening/ |
Juggernaut and Mr. Highman will continue as substantial shareholders of Bobbie. The acquisition positions the combined company as the third largest fully integrated infant and toddler brand in the U.S., creating a more resilient industry for American families
WASHINGTON, July 31, 2023 /PRNewswire/ -- Juggernaut Capital Partners, a leading middle market private equity investor primarily in the consumer and healthcare sectors, is pleased to announce the sale of Nature's One, the pediatric nutrition company founded by Jay Highman which set the bar for quality and innovation in formula over decades. Joining forces with Bobbie Baby, Inc., the nation's fastest growing infant formula company, the combined business will be the first of its kind in pediatric nutrition.
"Nature's One is a true pioneer in the pediatric nutrition space. Juggernaut partnered with founder, Jay Highman, to accelerate product development and vertical integration initiatives. Over the past five years, the company completed the first FDA-approved clinical feeding study of an organic infant formula and designed and constructed the first newly built infant formula facility in the U.S. in 35 years," said John Shulman, Founder and Managing Partner at Juggernaut. "It has been a pleasure to partner with Jay and his team. We believe the combination with Bobbie cements the organization as a continued disruptor and a next-generation industry leader. We are proud to continue as a meaningful shareholder in the go-forward company."
Founded in 1997, Nature's One introduced the first organic baby formula to the U.S. market. Recognized for its dedication to purity and quality, all of the company's formulas have received the Clean Label Project's Purity Award and have tested best in class for purity and nutrition when compared to popular baby formulas sold in the U.S. Nature's One operates the only independent, FDA audited organic infant nutrition facility in the U.S.
Nature's One was advised by CG / Sawaya Partners (operating under Canaccord Genuity) and Morgan Lewis & Bockius LLP. Bobbie was advised by Perella Weinberg Partners LP and Goodwin Procter LLP.
About Juggernaut Capital Partners:
Juggernaut Capital Partners is a leading private equity firm focusing on lower middle market companies, primarily in the consumer and healthcare sectors. Juggernaut is currently investing out of Juggernaut Capital Partners V, L.P. For more information on Juggernaut Capital Partners, please visit www.juggernautcap.com.
About Nature's One:
Founded in 1997, Nature's One introduced the first organic formula, Baby's Only® Organic in the United States. Nature's One has dedicated 25 years to the research, development, and sourcing of pure ingredients. Recognized as the first and highest-ranked formulas for purity and nutritional superiority by the Clean Label Project, Baby's Only Formulas are preferred by parents who want to offer their child a "Better Start…for Life™." Baby's Only Formulas are sold nationally at Whole Foods, Target, Walmart, Sam's Club, and many fine natural food retailers, as well online at www.naturesone.com.
About Bobbie:
Bobbie is the mission-driven organic pediatric nutrition company that exists to build a parenting culture of confidence, not comparison. Founded in 2018, Bobbie hit the market with its flagship European-inspired formula in 2021 as the first direct-to-consumer, subscription-based infant formula in the U.S. Today, it's proud to be the only mom-founded and led infant formula brand in the world, and the fastest-growing in the U.S. since the 1980's. Bobbie is focused on providing purposefully sourced, USDA Organic products made with simple ingredients – crafted right here in America, for American families. For more information, visit www.hibobbie.com.
View original content:
SOURCE Juggernaut Capital Partners | https://www.kfyrtv.com/prnewswire/2023/07/31/juggernaut-capital-partners-natures-one-founder-jay-highman-have-sold-natures-one-bobbie-baby-inc/ | 2023-07-31T11:19:21 | 0 | https://www.kfyrtv.com/prnewswire/2023/07/31/juggernaut-capital-partners-natures-one-founder-jay-highman-have-sold-natures-one-bobbie-baby-inc/ |
BURLINGTON, N.C., July 31, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced it will host an Investor Day on Thursday, September 14, 2023, in New York City, beginning at 1:00 p.m. ET and is expected to conclude by approximately 4:00 p.m. ET.
This event will highlight Labcorp's go-forward strategy from Labcorp Chairman & CEO Adam Schechter, followed by business overviews and a longer-term financial outlook. Presentations will be followed by a Q&A session.
A live webcast of the event will be available through the Labcorp Investor Relations website beginning at 1:00 p.m. ET. A replay of the webcast and supporting materials will be available after the conclusion of the event.
About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's more than 60,000 employees serve clients in over 100 countries, worked on over 80% of the new drugs approved by the FDA in 2022 and performed more than 600 million tests for patients around the world. Learn more about us at www.Labcorp.com or follow us on LinkedIn and Twitter @Labcorp.
View original content to download multimedia:
SOURCE Labcorp | https://www.kfyrtv.com/prnewswire/2023/07/31/labcorp-host-investor-day-september-14-2023/ | 2023-07-31T11:19:28 | 0 | https://www.kfyrtv.com/prnewswire/2023/07/31/labcorp-host-investor-day-september-14-2023/ |
BELMONT, the Bronx (WABC) -- Firefighters were tackling flames out of a building in the Bronx Monday morning.
NewsCopter 7 was live over East 187th Street between Southern Boulevard and Prospect Avenue.
The flames broke out at around 6:30 a.m. Firefighters extinguished the fire in a few minutes.
Officials say the fire started in the basement of the four-story apartment building. Clouds of smoke flooded on to the street from the lowest floor of the building.
Part of the building was evacuated during the fire.
There is no word on any injuries in the fire. It appears an e-bike may have been the cause of this fire.
This is a developing story. Check back for details. | https://abc7ny.com/belmont-bronx-apartment-fire-fdny/13576700/ | 2023-07-31T11:19:30 | 1 | https://abc7ny.com/belmont-bronx-apartment-fire-fdny/13576700/ |
DEAR AMY: My partner of four years has a group of college friends.
With every reunion, I have done my best to be kind, to participate, to be funny and inquire about their lives.
It’s hard for me to engage with many of the members of his friend group.
They don’t understand my humor, I am rarely asked questions about how I am doing or what I am up to, and I find that the majority of their conversations are satirical put-downs of other people from college.
I’m a realistic person; I don’t need to be liked by everyone, simply because I, myself, do not like everyone.
That being said, I love my partner.
He makes a notable effort with my numerous friends and family, winning approvals and gaining acceptance with each encounter.
I don’t understand why I haven’t had the same experience with his friends and family members.
The people in his life don’t seem to reflect the man that I know, and it is upsetting to me that I may never fit into some parts of his life as well as he fits into mine.
I’ve talked to him about this many times. He seems to want to be supportive, but completely lacks the ability to understand how I feel.
I feel lonely and worthless in my efforts to make things better.
The more effort I put into trying to make these people like me, the more it feels like I’m not myself.
I’m using so much energy to gain the acceptance of people I would never choose to be around. It’s exhausting and has ignited deep-seated insecurities.
Of course, I have considered just not going to any of his gatherings, but I want to support my partner just as he supports me.
I feel I am losing no matter what decision I make, and I am asking for some guidance on how to handle this.
– Unsure
DEAR UNSURE: There is one sure way not to “lose” in this dynamic, and that is not to care quite so much and not to try so very hard to befriend people who are not your primary connections, and who might also be jerks.
If you don’t enjoy these friend reunions, then you could either skip them altogether, or show up to say hello and make your exit when you’re ready to leave.
Your boyfriend can’t necessarily change the way you feel.
Changing how you feel is within your power, and this power is accessed by changing your behavior.
Ease up. Liberate yourself from the need to impress, amuse, or befriend these people. Conserve your energy. You may see that if you spend less energy, others will spend more.
There are ways your boyfriend could be more generous toward you by drawing you in, but when he is with his obnoxious friends, some of their attitudes may rub off on him.
***
DEAR AMY: “Devastated” was trying to cope with his wife’s drunken rages.
I was surprised and disappointed that you didn’t recommend Al-anon for him! Attending Al-anon meetings absolutely saved my sanity in a similar situation.
– Upset
DEAR UPSET: In my response, I did recommend Al-anon.
Readers have notified me that some newspapers edited out that line, and I’m upset, too.
***
MORE FROM ASK AMY:
Ask Amy: Father/daughter trip leaves mother feeling left out
Ask Amy: Neighbor opens misdirected mail ... not once, but twice
Ask Amy: My son’s wife made it clear he was too close to his mother and that it must stop
Ask Amy: Vietnam vet hopes to reconcile with his sister and her husband, who dodged the draft
Ask Amy: Life with a low-level pot dealer
***
(You can email Amy Dickinson at askamy@amydickinson.com or send a letter to Ask Amy, P.O. Box 194, Freeville, NY 13068. You can also follow her on Twitter @askingamy or Facebook.)
©2023 Amy Dickinson. Distributed by Tribune Content Agency, LLC. | https://www.nj.com/advice/2023/07/ask-amy-the-more-i-try-to-make-these-people-like-me-the-more-it-feels-like-im-not-myself.html | 2023-07-31T11:19:30 | 0 | https://www.nj.com/advice/2023/07/ask-amy-the-more-i-try-to-make-these-people-like-me-the-more-it-feels-like-im-not-myself.html |
Adult Males are Slightly More Likely to Live with Parents Than Their Female Counterparts
58% of Gen Z Consumers Live with Family Members
SAN FRANCISCO, July 31, 2023 /PRNewswire/ -- LendingClub Corporation (NYSE: LC), the parent company of LendingClub Bank, America's leading digital marketplace bank, today released findings from the 24th edition of the Reality Check: Paycheck-To-Paycheck research series, conducted in partnership with PYMNTS. The Household Finances Deep Dive Edition examines the impact of household composition on consumers' ability to manage expenses and put aside savings. The series draws on insights from a survey of 4,602 U.S. consumers conducted from June 5 to June 16, as well as analysis of other economic data.
The Paycheck-to-Paycheck Landscape
In June 2023, 61% of U.S. consumers lived paycheck to paycheck, unchanged from June 2022 — as is the share of those struggling to pay bills (at 21%) — even though more middle-income consumers cited living paycheck to paycheck in June 2023 than last year. Among consumers earning $50,000 to $100,000, 65% lived paycheck to paycheck as of June 2023, compared to 60% in June 2022. Meanwhile, the shares of high-income consumers — those earning more than $100,000 annually — and low-income consumers — those earning less than $50,000 annually — living paycheck to paycheck in June 2023 sit at 45% and 77%, respectively, relatively unchanged from June 2022.
This stability in the financial situation of U.S. households indicates that consumers continue to adapt to inflationary pressures, finding ways to manage their spending and live within their means.
Household Composition Determines Financial Lifestyle
Consumers living with only a partner or spouse are likely to face less financial hardship, while those with dependents and those living with friends or housemates are more likely to live paycheck to paycheck.
The research finds that 86% of consumers live with one or more people, and one-third of paycheck-to-paycheck consumers live in households of four or more people. Consumers not living paycheck to paycheck are most likely to reside in two-person households, at 41%. Meanwhile, 49% of millennials and 55% of bridge millennials live in households of four or more people, making them the age groups most likely to reside in the largest households.
There is also a direct correlation among household size, stage of life and financial lifestyle. As household size increases, the ratio of income earners to non-earners typically falls, attributable to households with dependent children. When looking at the share of paycheck-to-paycheck consumers who live in a two-member household, the data finds that 54% do so — 7 percentage points below the sample average. Meanwhile, at 66%, consumers with children under the age of 18 are 12% more likely to live paycheck to paycheck than those without children, at 59%. Among consumers living with friends or housemates, 77% live paycheck to paycheck — the most likely to do so. This suggests that those sharing expenses with a partner or spouse fare better, that is until they have children or even parents to support.
"As household size increases, the ratio of income earners to household members typically falls, creating a higher likelihood of financial distress," said Alia Dudum, LendingClub's Money Expert. "The relationship between household income and household composition explains why many families tend to struggle financially and why millennials and bridge millennials, many of whom are in their peak child-rearing years, tend to remain financially vulnerable."
Economic Considerations Top Reason to Stay in the Family Household
Economics are the main driver for consumers to live with family longer, with 43% wanting to save money and 30% unable to afford housing independently. Besides economic reasons, consumers remain at home to maintain family ties (24%), for transitional reasons (23%), and to provide care (22%).
At one-fifth (20%), adult males are slightly more likely to live with parents than their female counterparts (18%), a phenomenon that grows significantly among those financially struggling (26% of males compared to 18% of females). At 58%, Gen Z is the generation most likely to stay with family members, with 50% citing economic reasons. Members of Gen Z living with three or more people — often familial settings — spent 22% of their income on housing, compared to 30% of those living alone or with a partner.
That said, consumers living with family members to offset expenses are not planning extended stays. For example, one-third of those consumers expect to move out in the coming year, particularly millennials and bridge millennials.
Financial Transparency Determined by Relationship Status
Financial transparency within shared households is paramount to ensure bills are paid and expenses are covered, but the transparency level depends on who consumers live with. Couples living together share financial information 87% of the time and have a joint bank account 76% of the time. Parents are also likely to discuss finances with the children residing in their household, with 45% of parents sharing financial information with their children and 34% granting them access to a shared account. Bill splitting is the most common financial interaction for consumers living with friends or housemates, at 74%. Additionally, borrowing money from other household members is a financial option many use to make ends meet, with consumers mostly engaging in this practice with parents or siblings, at 47%, and friends and housemates, at 44%.
Families and couples maintain outstanding credit card balances that are significantly higher, on average, than those of consumers who live alone. Consumers with children under the age of 18 average 50% more credit card debt than those who live alone. Families represent the lion's share of credit card spending, holding average balances of $6,300 for consumers living with a partner and $7,200 for those living with children under 18. Living with a partner or children also significantly increases a consumer's likelihood of having an auto loan or mortgage.
"With today's inflationary pressures, sharing household finances has become not only common but crucial," continued Dudum. "The increasing complexity of modern lifestyles and the rising cost of living have necessitated a shift in the way consumers approach household finances. One person solely bearing the burden of managing all financial matters has become a minority practice. Instead, couples, families, and even roommates increasingly jointly navigate their economic realities, and it's a trend that is here to stay."
To view the full report, visit: https://www.pymnts.com/study/reality-check-paycheck-to-paycheck-inflation-household-spending-shared-expenses/
Methodology
New Reality Check: The Paycheck-to-Paycheck Report — The Household Finances Deep Dive Edition is based on a census-balanced survey of 4,602 U.S. consumers conducted from June 5 to June 16, as well as analysis of other economic data. The data in this report is not intended to be a representation of LendingClub's core member base. The Paycheck-to-Paycheck series expands on existing data published by government agencies, such as the Federal Reserve System and the Bureau of Labor Statistics, to provide a deep look into the core elements of American consumers' financial wellness: income, savings, debt and spending choices. Our sample was balanced to match the U.S. adult population in a set of key demographic variables: 51% of respondents identified as female, 33% were college-educated and 38% declared incomes of more than $100,000 per year.
About LendingClub
LendingClub Corporation (NYSE: LC) is the parent company of LendingClub Bank, National Association, Member FDIC. LendingClub Bank is the leading digital marketplace bank in the U.S., where members can access a broad range of financial products and services designed to help them pay less when borrowing and earn more when saving. Based on more than 150 billion cells of data and over $85 billion in loans, our advanced credit decisioning and machine-learning models are used across the customer lifecycle to expand seamless access to credit for our members while generating compelling risk-adjusted returns for our loan investors. Since 2007, more than 4.7 million members have joined the Club to help reach their financial goals. For more information about LendingClub, visit https://www.lendingclub.com.
Contact:
For Investors: IR@lendingclub.com
Media Contact: Press@lendingclub.com
PYMNTS Contact: information@PYMNTS.com
View original content to download multimedia:
SOURCE LendingClub Corporation | https://www.kfyrtv.com/prnewswire/2023/07/31/lendingclub-pymnts-research-shows-86-consumers-live-with-one-or-more-people-yet-those-living-with-only-partners-or-spouses-reap-financial-benefits/ | 2023-07-31T11:19:35 | 0 | https://www.kfyrtv.com/prnewswire/2023/07/31/lendingclub-pymnts-research-shows-86-consumers-live-with-one-or-more-people-yet-those-living-with-only-partners-or-spouses-reap-financial-benefits/ |
Trump could be indicted soon in Georgia. Here’s a look at that investigation
ATLANTA (AP) — A Georgia prosecutor is expected to seek a grand jury indictment in the coming weeks in her investigation into efforts by Donald Trump and his Republican allies to overturn the former president’s 2020 election loss.
Fulton County District Attorney Fani Willis began investigating more than two years ago, shortly after a recording was released of a January 2021 phone call Trump made to Georgia’s secretary of state.
Willis has strongly hinted that any indictment would come between July 31 and August 18. One of two grand juries seated July 11 is expected to hear the case.
If Trump is indicted by a Georgia grand jury, it would add to a growing list of legal troubles as he campaigns for president. Trump is set to go to trial in New York in March to face state charges related to hush-money payments made during the 2016 presidential campaign. And he has another trial scheduled for May on federal charges related to his handling of classified documents. He has pleaded not guilty in those cases.
The Justice Department is also investigating Trump’s role in trying to halt the certification of 2020 election results in the run-up to the Jan. 6, 2021, assault on the U.S. Capitol. Trump said he’s been told he’s a target of that investigation, which likely has some overlap with the one in Georgia.
Details of the Georgia investigation that have become public have fed speculation that Willis, a Democrat, is building a case under the Georgia Racketeer Influenced and Corrupt Organizations Act, which would allow her to charge numerous people in a potentially wide-ranging scheme.
Here are six investigative threads Willis and her team have explored:
THE PHONE CALLS
The Georgia investigation was prompted by the Jan. 2, 2021 phone call Trump made to Georgia Secretary of State Brad Raffensperger. Trump suggested the state’s top elections official could help “find” the votes needed to put him ahead of Democrat Joe Biden in the state.
“All I want to do is this: I just want to find 11,780 votes, which is one more than we have,” Trump is heard saying on a recording of the call, which was leaked to news outlets. “Because we won the state.”
Trump has insisted he did nothing wrong and has repeatedly said the call was “perfect.”
Trump also called other top state officials in his quest to overturn his 2020 election loss, including Gov. Brian Kemp, then-House Speaker David Ralston, Attorney General Chris Carr and the top investigator in the secretary of state’s office.
U.S. Sen. Lindsey Graham, a South Carolina Republican, also called Raffensperger shortly after the November election. Raffensperger said at the time that Graham asked whether he had the power to reject certain absentee ballots, which Raffensperger has said he interpreted as a suggestion to toss out legally cast votes.
Graham has denied wrongdoing, saying he just wanted to learn about the signature verification process.
FAKE ELECTORS
Biden won Georgia by a margin of fewer than 12,000 votes. Just over a month after the election, on Dec. 14, 2020, a group 16 Georgia Democratic electors met in the Senate chamber at the state Capitol to cast the state’s Electoral College votes for him. They each marked paper ballots that were counted and confirmed by a voice roll call.
That same day, in a committee meeting room at the Capitol, 16 prominent Georgia Republicans — a lawmaker, activists and party officials — met to sign a certificate falsely stating that Trump had won and declaring themselves the state’s “duly elected and qualified” electors. They sent that certificate to the National Archives and the U.S. Senate.
Georgia was one of seven battleground states that Trump lost where Republican fake electors signed and submitted similar certificates. Trump allies in the U.S. House and Senate used those certificates to argue for delaying or blocking the certification of the election during a joint session of Congress.
Prosecutors in Fulton County have said in court filings that they believe Trump associates worked with state Republicans to coordinate and execute the plan.
The multi-state effort was ultimately unsuccessful. Despite public pressure from Trump and his supporters, then-Vice President Mike Pence refused on Jan. 6, 2021, to introduce the unofficial pro-Trump electors. After the attack on the U.S. Capitol put a violent halt to the certification process, lawmakers certified Biden’s win in the early hours of Jan. 7, 2021.
At least eight of the fake electors have since reached immunity deals with Willis’ team. And a judge last summer barred Willis from prosecuting another one, Lt. Gov. Burt Jones, because of a conflict of interest.
FALSE CLAIMS OF ELECTION FRAUD
Republican state lawmakers held several hearings at the Georgia Capitol in December 2020 to examine alleged problems with the November election. During those meetings, former New York mayor Rudy Giuliani and other Trump allies made unproven claims of widespread election fraud.
They alleged that election workers tallying absentee ballots at State Farm Arena in Atlanta had told outside observers to leave and then pulled out “suitcases” of unlawful ballots and began scanning them. The Trump allies played clips of surveillance video from the arena to support their allegations. State and federal officials investigated and said there was no evidence of election fraud at the site.
Some Trump allies also said thousands of people who were ineligible — including people convicted of felonies, people younger than the age of 18, people who had voted in another state — had cast votes in Georgia. The secretary of state’s office has debunked those claims.
ALLEGED ATTEMPTS TO PRESSURE ELECTION WORKER
Two of the election workers seen in the State Farm Arena surveillance video, Ruby Freeman and her daughter Wandrea “Shaye” Moss, said they faced relentless harassment online and in person as a result of the allegations made by Trump and his allies.
Giuliani last week conceded that statements he made about the two election workers were false.
In a bizarre episode detailed by prosecutors in court filings, a woman traveled from Chicago to Georgia and met with Freeman on Jan. 4, 2021. The woman initially said she wanted to help Freeman but then warned that Freeman could go to prison and tried to pressure her into falsely confessing to committing election fraud, prosecutors wrote in court filings last year.
ELECTION EQUIPMENT ACCESSED
Trump-allied lawyer Sidney Powell and others hired a computer forensics team to copy data and software on election equipment in Coffee County, some 200 miles southeast of Atlanta, according to invoices, emails, security video and deposition testimony produced in response to subpoenas in a long-running lawsuit.
The county Republican Party chair at the time — who also served as a fake elector — greeted them when they arrived at the local elections office on Jan. 7, 2021, and some county elections officials were also on hand during the daylong visit. The secretary of state’s office has said this amounted to “alleged unauthorized access” of election equipment, and the Georgia Bureau of Investigation is looking into it at the secretary of state’s request.
Two other men who have been active in efforts to question the 2020 election results also visited Coffee County later that month and spent hours inside.
U.S. ATTORNEY RESIGNATION
U.S. Attorney BJay Pak, the top federal prosecutor in Atlanta, abruptly resigned two days after Trump called Raffensperger and a day after a recording of that call was made public. During that conversation, Trump called Pak a “never-Trumper,” implying that he didn’t support the president.
In December 2020, then-U.S. Attorney General William Barr asked Pak to investigate allegations by Giuliani and other Trump allies of widespread election fraud. Pak, who had been appointed by Trump in 2017, reported back that he had found no evidence of such fraud.
In August 2021, Pak told the U.S. Senate Judiciary Committee, which was investigating Trump’s post-election actions, that he resigned on Jan. 4, 2021, after learning from Department of Justice officials that Trump did not believe enough was being done to investigate allegations of election fraud and wanted him gone as U.S. attorney.
Copyright 2023 The Associated Press. All rights reserved. | https://www.kalb.com/2023/07/31/trump-could-be-indicted-soon-georgia-heres-look-that-investigation/ | 2023-07-31T11:19:36 | 0 | https://www.kalb.com/2023/07/31/trump-could-be-indicted-soon-georgia-heres-look-that-investigation/ |
NEW YORK CITY (WABC) -- Starting Monday, restaurants and other food service establishments in New York City will only provide plastic utensils for takeout orders if you specifically ask for them.
The law also affects condiment packets like ketchup.
City leaders hope the new rule will cut down on waste.
Restaurants won't get in trouble for violating the legislation for one year.
However, starting next July, they could be fined anywhere from $50 for a first violation up to $250 for anything past the second.
A similar bill is also being considered in the state of New Jersey.
ALSO READ | Grieving mom seeks answers from school board after 6-year-old daughter dies on school bus
----------
* Get Eyewitness News Delivered
* Download the abc7NY app for breaking news alerts
Submit a tip or story idea to Eyewitness News
Have a breaking news tip or an idea for a story we should cover? Send it to Eyewitness News using the form below. If attaching a video or photo, terms of use apply. | https://abc7ny.com/plastic-utensils-condiment-packets-new-york-city-food-service/13576723/ | 2023-07-31T11:19:36 | 1 | https://abc7ny.com/plastic-utensils-condiment-packets-new-york-city-food-service/13576723/ |
PHILADELPHIA – Eagles running back Rashaad Penny has had several mentors, from Norwalk High School in California through his time at San Diego State, continuing after he was selected 27th overall by the Seattle Seahawks in 2018.
He has been a only call or text away from advice from former Eagles running back Donnel Pumphrey, Seahawks running back Chris Carson and former Arizona Cardinals running back David Johnson — guys who have succeeded in the NFL.
Want to bet on the NFL?
See the best NJ Sports Betting sites
“You have to always be prepared, be on top of your stuff, and be responsible,” Penny told NJ Advance Media after practice. “I think that’s the biggest thing from the transition from college to NFL, because you’re a kid, now becoming a grown man. You have to always be responsible, but don’t make excuses. That’s always been my thing since growing up. I had many guys in my corner who always wanted to see me succeed and always told me the right thing, so giving them the right honor and respect goes a long way for me.”
Penny, a five-year veteran, signed a one-year, $1.35 million contract in March and has looked sharp early in camp, catching the ball out of the backfield and looking decisive in the running game.
Penny is trying to establish a role in a rotation that includes D’Andre Swift, Kenneth Gainwell, Boston Scott, Trey Sermon and Kennedy Brooks. The talent always has been there for Penny, who averages 5.7 yards per carry on 337 career attempts. However, injuries have sidelined him, and over the last three season, he played in only 18 games, starting 11 of them. During those times, advice from those mentors and the support of his family, including his brother and former Giants running back Elijhaa Penny, got him through it, he said.
Penny, who was signed immediately after the Eagles allowed Mile Sanders to walk, has a chance to start over with a unit that finished third overall in total offense last season (389.1 yards per game) and has many of the same players returning.
“This is a fresh start for me,” Penny said. “Playing with an offense like this, I get to unleash something that a lot of people probably have never seen me do. I have the chance for more big plays and more catches, being a part of this offense and taking pride in what they do here.”
BUY EAGLES TICKETS: STUBHUB, VIVID SEATS, TICKETMASTER
Penny said that, at 231, he is seven pounds lighter than his playing weight in Seatte. He said he wants to get as close to his college playing weight (220) as possible, hoping it will help him play an entire season.
Just as others have done for him, Penny is trying to mentor others and show the importance of having someone available to ask for guidance. In the Two Cents Family Foundation that Penny, Elijhaa, and his family started, mentoring is an important feature.
“During my childhood, where we lived in Norwalk, we never really had a Pop Warner team,” Penny said. “It was always in and out. I hate to say it like this, but as a big name in Norwalk, a small city in California, we just wanted to give back to a lot of people who didn’t have the opportunity to play football, be around sports, or be around people who made it out the same city.
“For us, being there has kind of made a difference. We have a new Pop Warner team that’s going on our second year, and my brother is the head coach at John Glenn High School in Norwalk, so it all has come to fruition, and it’s actually really cool.”
Thank you for relying on us to provide the journalism you can trust. Please consider supporting us with a subscription.
Chris Franklin may be reached at cfranklin@njadvancemedia.com. | https://www.nj.com/eagles/2023/07/how-eagles-rashaad-penny-plans-to-use-advice-from-mentors-to-unleash-his-talent-this-season.html | 2023-07-31T11:19:37 | 1 | https://www.nj.com/eagles/2023/07/how-eagles-rashaad-penny-plans-to-use-advice-from-mentors-to-unleash-his-talent-this-season.html |
WATCH: Concertgoer throws drink at Cardi B; she hurls microphone at them
Published: Jul. 31, 2023 at 5:58 AM CDT|Updated: 19 minutes ago
LAS VEGAS (CNN) - Cardi B hurled her microphone at a fan during a concert in Las Vegas on Saturday.
The rapper was performing her song “Bodak Yellow” when a concertgoer threw a drink at her.
In seconds, Cardi B threw her microphone into the crowd as the song continued to play.
Security guards rushed to the stage.
More security guards are then seen flocking to the person in the crowd as she watched from the stage before continuing with her set.
There’s no word on what happened to the fan or if any charges will be filed.
Copyright 2023 CNN Newsource. All rights reserved. | https://www.kalb.com/2023/07/31/watch-concertgoer-throws-drink-cardi-b-she-hurls-microphone-them/ | 2023-07-31T11:19:39 | 1 | https://www.kalb.com/2023/07/31/watch-concertgoer-throws-drink-cardi-b-she-hurls-microphone-them/ |
Welcome to the NJ.com food and culture team’s local dining guide series! For the next several months, our writers will publish a weekly guide to eating in a different foodie hub, tapping North, Central and South Jersey and everything in between. These lists are curated to give diners a mix of cuisines and the best restaurant experiences to indulge this summer and beyond. Let’s dig in!
For two centuries, New Jersey’s largest city has boasted some of the finest and most diverse gathering of eateries in the entire state. With more than 100 cultures and ethnicities represented, Newark remains a mecca of sorts for eclectic and adventurous foodies. | https://www.nj.com/food/2023/07/newarks-11-greatest-restaurants-ranked-for-2023.html | 2023-07-31T11:19:39 | 1 | https://www.nj.com/food/2023/07/newarks-11-greatest-restaurants-ranked-for-2023.html |
The Giants are now through four training camp practices, after Sunday’s session, which followed Saturday’s first off day of camp.
This week, the Giants practice Monday, Tuesday (when the pads go on), Thursday, Friday, and Saturday. Busy week.
The Giants are now through four training camp practices, after Sunday’s session, which followed Saturday’s first off day of camp.
This week, the Giants practice Monday, Tuesday (when the pads go on), Thursday, Friday, and Saturday. Busy week.
If you purchase a product or register for an account through one of the links on our site, we may receive compensation. By browsing this site, we may share your information with our social media partners in accordance with our Privacy Policy. | https://www.nj.com/giants/2023/07/giants-training-camp-takeaways-from-first-4-practices-including-deonte-banks-struggles.html | 2023-07-31T11:19:40 | 0 | https://www.nj.com/giants/2023/07/giants-training-camp-takeaways-from-first-4-practices-including-deonte-banks-struggles.html |
HOUSTON, July 31, 2023 /PRNewswire/ -- McDermott has been awarded a project management consultancy (PMC) and engineering, procurement, and construction management (EPCM) contract for the Naphtha Cracker Expansion (Phase II) polypropylene expansion and new ethylene derivative unit project from Indian Oil Corporation Limited (IOCL). The project is located at the Panipat Refinery and Petrochemical Complex, located 62 miles (100 kilometers) from New Delhi, India.
The project will increase the ethylene production capacity of the naphtha cracker unit (NCU) by approximately 20 percent. The additional ethylene and propylene production will act as feed for downstream polymer units. The polymer products will be used for the manufacture of household and industrial items, including containers, automobile parts, furniture, and heavy-duty films.
"McDermott is currently executing four other projects for IOCL, including the maleic anhydride (MAH) unit at the same site, allowing us to leverage our local resources and expertise while realizing synergies," said Vaseem Khan, Senior Vice President, Global Operations. "Furthermore, the project supports the growing demand for ethylene and propylene which will reduce imports and accelerate economic development in the area."
McDermott will provide comprehensive EPCM services and overall project management for the duration of the project, which will be executed from its Center of Excellence in Gurugram, India.
About McDermott
McDermott is a premier, fully-integrated provider of engineering and construction solutions to the energy industry. Our customers trust our technology-driven approach engineered to responsibly harness and transform global energy resources into the products the world needs. From concept to commissioning, McDermott's innovative expertise and capabilities advance the next generation of global energy infrastructure—empowering a brighter, more sustainable future for us all. Operating in over 54 countries, McDermott's locally-focused and globally-integrated resources include more than 30,000 employees, a diversified fleet of specialty marine construction vessels and fabrication facilities around the world. To learn more, visit www.mcdermott.com.
Forward-Looking Statements
McDermott cautions that statements in this press release which are forward-looking, and provide other than historical information, involve risks, contingencies and uncertainties. These forward-looking statements include, among other things, statements about the expected scope and execution of the project discussed in this press release. Although we believe that the expectations reflected in those forward-looking statements are reasonable, we can give no assurance that those expectations will prove to have been correct. Those statements are made by using various underlying assumptions and are subject to numerous risks, contingencies and uncertainties, including, among others: adverse changes in the markets in which we operate or credit or capital markets; our inability to successfully execute on contracts in backlog; changes in project design or schedules; the availability of qualified personnel; changes in the terms, scope or timing of contracts, contract cancellations, change orders and other modifications and actions by our customers and other business counterparties; changes in industry norms; actions by lenders, other creditors, customers and other business counterparties of McDermott; and adverse outcomes in legal or other dispute resolution proceedings. If one or more of these risks materialize, or if underlying assumptions prove incorrect, actual results may vary materially from those expected. You should not place undue reliance on forward-looking statements. This communication reflects the views of McDermott's management as of the date hereof. Except to the extent required by applicable law, McDermott undertakes no obligation to update or revise any forward-looking statement.
Contacts:
Global Media Relations
Reba Reid
Senior Director, Global Communications and Marketing
+1 281 588 5636
RReid@McDermott.com
Business Line Media Relations
Barbara Knight
Senior Director, Business Line Communications and Marketing
+971 56 403 2903
BBKnight@McDermott.com
View original content to download multimedia:
SOURCE McDermott International, Ltd | https://www.kfyrtv.com/prnewswire/2023/07/31/mcdermott-selected-petrochemical-expansion-project-by-iocl/ | 2023-07-31T11:19:41 | 0 | https://www.kfyrtv.com/prnewswire/2023/07/31/mcdermott-selected-petrochemical-expansion-project-by-iocl/ |
The retired cop had come to North Carolina to say goodbye.
Charles Upshaw’s brother was dying. And the same cruel condition was slowly killing him too.
Charles’ diseased heart was failing, winding down in September 2022 like a tired clock straining to keep ticking.
A walk across the room would soon send him gasping for air. Just speaking would leave him panting and exhausted. And dizzy spells were growing more frequent, sometimes resulting in fainting.
Charles, 67, needed a new heart. But the West Orange man had already spent three years waiting on the transplant list. Three years in which he watched his older brother Mark painfully deteriorate.
Death didn’t scare him, Charles told his wife, Lisa. He just didn’t want to suffer like Mark.
“He was my hero,” the former Newark police officer told NJ Advance Media. “I did a lot of crying.”
Mark Brewer died without a second chance at life. Would Charles?
Seventeen Americans die each day waiting for an organ transplant, according to the Health Resources and Services Administration, an agency of the U.S. Department of Health and Human Services.
Charles wondered if he would be one of them.
The first heart transplant was conducted in 1967. Despite advances in technology and leaps in knowledge over the decades, 3,378 Americans and 109 New Jersey residents are currently on the waiting list for a donor, according to the Organ Procurement and Transplantation Network.
All the innovation and progress cannot make up for a priceless and scarce resource: the human heart. Many patients will wait more than six months for a transplant — if they get one at all.
“Why is it difficult? It’s difficult because less than 1% of people who pass away can actually be organ donors,” said Carolyn M. Welsh, president and CEO of NJ Sharing Network, a nonprofit organ and tissue donation organization based in New Providence.
A record 3,817 heart transplants were performed across the country in 2021, according to the United Network for Organ Sharing. More than 31,000 lifesaving heart transplants were performed from 2012-2021 at U.S. hospitals.
Why weren’t there more when the waiting list extends into the thousands? There simply weren’t enough hearts to meet demand.
So people like Charles wait and wait. And loved ones like Lisa and their son Chase, 28, watch them slowly decline, powerless to stop it.
By late last fall, Charles’ worst fears were coming to pass. His heart was functioning at just 12% when he returned from North Carolina and that final visit with Mark. It couldn’t pump enough blood to keep his body functioning due to decompensated heart failure.
He was slowly fading as the most basic actions depleted him of breath and energy.
“You have to fight,” Lisa told him one day with tears welling in her eyes, “because you can’t leave me here.”
♥♥♥
‘You can’t leave me’
Three years.
Charles Upshaw Jr. had been waiting three long years.
A heart transplant is considered a treatment of last resort. But his doctors were in agreement: Time was running out.
Charles was in what doctors called “end-stage decompensated heart failure” and growing progressively weaker.
He knew it might come to this.
Heart issues ran deep in his family. His mother and father both suffered from heart-related ailments. Then Mark died in March of heart failure and diabetes.
The 76-year-old Army veteran was fading when Charles visited him. Charles was horrified, barely recognizing the once strong man he idolized.
Mark was frail and could barely speak or walk. He was blind in one eye and on dialysis.
Charles feared he was staring at his own future.
“That’s what he saw his brother doing — suffering,” said Lisa, 54.
By December 2022, Charles — a tall, bald man with a gentle smile and a soothing, baritone voice — was rapidly declining himself. One day, he panted on his living room sofa in the white split-level home he has lived in for 15 years, startled and scared.
He and Lisa had planned to go to the grocery store. But his body wouldn’t allow it.
“I just can’t believe I’m this fatigued,” he told her. “I just can’t believe this.”
She saw the look on his face.
“It was almost as if tears were in his eyes,” recalled Lisa, his wife of 28 years and an administrator for the Essex County Division of Family Assistance and Benefits.
A battery of heart procedures — aortic valve replacement, inserting an intra-aortic balloon pump, inserting a pacemaker and inserting a defibrillator — had only delayed the inevitable for Charles.
Mark had been too sick and too old to be considered for a heart transplant. But Charles met the rigorous health standards after undergoing a battery of blood and imaging tests.
“We look at them from head to toe — every organ,” said Dr. Margarita Camacho, surgical director of cardiac transplantation at Newark Beth Israel Medical Center.
Dr. Matthew Montgomery, Charles’ cardiologist, had wanted to admit him to the hospital in early fall and begin the supervised wait for a donor. But Charles delayed it as long as he could.
This wasn’t just about him, he knew. It was about Lisa. And it was about Chase, who was planning a March wedding.
Charles could be in the hospital for months before a donor was found. He wanted to spend as much quality time with Lisa as he could.
“I requested some time to get some things in order with my family,” said Charles, who also has two children from his first marriage.
By mid-January, he couldn’t put it off any longer. He was admitted to Newark Beth Israel Medical Center, fighting for his life.
“My symptoms got worse,” Charles said. “Getting lightheaded, dizzy, short of breath. I couldn’t even talk on the phone for more than a minute before I became short of breath.”
Lisa tried to conceal her fear, wanting to be strong for him. She waited and she prayed, gripping her hands tightly, begging God to see Charles through.
“I’ve never been alone without him since we’ve been married,” she said.
♥♥♥
Hard lessons
Charles Upshaw was used to blocking out dark thoughts.
He had been a Newark cop from the early 1980s through the ‘90s, a time when Brick City ranked among the most dangerous communities in the nation and was dubbed the stolen car capital of the U.S.
The Newark native served on the city’s tactical force, a specialized unit tasked with resolving high-risk street crime. Its work included drug arrests and the pursuit of some of the city’s most menacing figures.
But Charles found nearly as much drama within the corridors of City Hall as he did on the streets before retiring in 1999.
While talking about his time as a police officer, he mentioned something in passing, something that had clearly stayed with him. In 1986, he was chosen to work on then-Mayor Sharpe James’ security detail and was eventually appointed to the city’s Alcoholic Beverage Control board.
James ended up at the center of a corruption probe involving cash withdrawals from a charity made by members of that security detail, according to reports. Charles says he was asked to cash some checks for the mayor. He didn’t know what they were for, he said, but was just doing what his boss asked.
“(The mayor) would write out a check to cash, and we would take it across the street to the bank, cash it, come back and give him the money,” Charles explained.
Those checks eventually came under scrutiny in the mid-’90s, and Charles suddenly found himself written about in The New York Times as the investigation progressed.
During the probe, few would talk to investigators. But Charles saw it as a test of his integrity.
One day, a member of James’ staff called, asking how Charles would respond if an investigator questioned him about the money, he said.
“That was the beginning of the — how can I put it? — the demise of that relationship,” he said.
Charles did cooperate with investigators when they called. Soon after, he was reassigned to an undesirable post with the city’s prison detention bureau working the midnight shift, he says.
He filed a federal lawsuit against James, Assemblyman Jackie R. Mattison — the mayor’s chief of staff — and other administration figures accusing them of retaliation. They settled out of court.
“In the world of politics, when you wind up on the wrong side of the powers that be, they look for ways to try to punish,” Charles said.
In 2008, James — by then out of office — was convicted of multiple counts of fraud. Mattison was convicted in 1997 of accepting bribes and was sentenced to 41 months in prison.
The entire affair was a life lesson for Charles, one that came in handy as he grew weaker and weaker.
“I used to always tell my son: ‘It’s not what happens to you that matters. It’s how you manage what happens to you that matters,’” he said.
♥♥♥
A ticking clock
Charles Upshaw’s life was defined by a ticking clock.
Eight years living with a failing heart. Three years waiting on the transplant list.
Now, his life could be measured in months — the months he had left.
Everything seemed to be working against him. He was deteriorating. He was tall — nearly 6-foot-2 — meaning he would need a donor heart that could support his size. And his blood type was O-positive.
Type O heart patients wait more than three times as long as those with A or B blood and exponentially longer than those with type AB, according to statistics from the United Network for Organ Sharing, which runs the nation’s transplant system. Type O organs can be transplanted into patients of all blood types, experts say, often extending the wait for O patients, who can only receive O organs.
“I think most people think that everyone can be an organ donor when they pass away. And that’s not the case,” said Welsh, the NJ Sharing Network CEO.
But Charles wasn’t overcome by fear or depression. Friends and family visited him at Beth Israel and kept his spirits up, he says. They prayed together. Charles had a sense that everything would work out.
“I felt encouraged,” he said.
And he still believed he would make Chase’s wedding in March.
But doctors prepared him for what could be a very long wait. And they upgraded his donor status: His condition had deteriorated even further.
For each transplant patient, a team of doctors — cardiologists, surgeons, cardiac anesthesiologists, infectious disease specialists, metabolic specialists and nurses — gather weekly to discuss the case and everything that could arise.
They started meeting about Charles before he was even admitted to the hospital.
“A lot of people are there … and each presentation takes a while because we go through that entire head-to-toe workup,” Camacho said.
Then on the evening of Feb. 8, a nurse burst into Charles’ hospital room clutching a cordless phone. Tears streamed down her face as she handed it to him.
They had found a donor heart.
“It fits your profile exactly,” Dr. Saurabh Kapoor told him. “‘And it’s a young heart.”
Charles had been in the hospital just three weeks.
The blessing wasn’t lost on him. Someone died to give him this precious gift.
The donor remains anonymous, but Charles did write a letter to their family expressing his appreciation, his gratitude and his condolences.
“I’m overwhelmed with emotion knowing that you suffered the loss of a beloved family member in this organ exchange, so I pray for God to provide comfort, care, and peace for your family,” he wrote in a note the organ network gave to the donor’s family.
“I pray for the family of the donor all the time,” Charles said.
Now after all the waiting, things moved rapidly. Hearts last only a few hours once they’re removed from a donor. Surgeons had to move fast.
The heart arrived in a medical cooler on ice. Charles had the surgery the next morning.
Despite all the rigorous procedures and tests and meetings leading up to the delicate surgery, the transplant itself was fairly routine, said Camacho, who performed it.
The surgeon held the fragile organ in her hands. She implanted the heart. Valves were connected. Clamps were removed. Blood began to flow.
The donor’s heart was beating in Charles’ chest.
One life had saved another.
It took less than an hour to implant the heart, and about three and a half hours to complete the surgery.
The enormity of it wasn’t lost on Camacho, who has performed nearly 700 transplants.
“You took this gift, and you put it in someone who truly was going to die soon,” she said.
After surgeries, she’ll sometimes reflect on the profoundness of it.
“When I’m in surgery, I’m extremely focused … but then afterwards, it can become a little overwhelming to realize that you took this beautiful heart from a donor,” she said.
Charles woke up to the smiling faces of his wife and son.
♥♥♥
A unpayable debt
The anxiety set in after the transplant.
Charles was given a priceless gift. Now he had to take care of it.
Maintaining a donor heart is quite demanding. There are a host of medications. A litany of follow-up appointments. A battery of tests.
Patients must take immunosuppressant medication the rest of their lives to prevent organ rejection. The regimen can be rigorous.
Every single day, Charles takes 17 pills in the morning and 10 at night.
“If they don’t take it every day, they’re going to die,” Camacho said.
But the medication presents its own risks.
Besides the increased risk of infection, immunosuppressants also increase the risk of cancer. Charles will have to be closely monitored the rest of his life.
And of course, there was Chase’s wedding, which the proud dad was adamant he would make.
“I did have some angst about whether or not I was going to make it to my son’s wedding because that was very important,” Charles said.
He was released from the hospital 10 days after the transplant. He had less than two weeks to make his goal: attend the nuptials.
“I’m coming to the wedding,” he told Chase about a week after the surgery. “I got to figure out a tuxedo thing.”
Twenty-three days after the transplant, Charles was there in Spring Lake Heights. And yes, he was wearing a tux.
He felt weak after a bout with anemia. He had to wear a mask and could not hug or kiss anyone. But he beamed with pride as tears streamed down his face during the ceremony.
“I felt so emotional,” Charles said.
He’s getting stronger every day. There’s a 70% chance Charles will live at least another decade, Camacho said.
He undergoes weekly blood tests. He sees his cardiac team monthly. And a nurse practitioner regularly monitors him.
“I feel great,” he said.
For many, the euphoria of being saved is followed by a unique brand of remorse.
“Guilt sets in a lot for people who are waiting and people who receive organs because they feel someone died for them to live,” Welsh said.
Charles understands, feeling the full weight of the gift he has been given. He has reached out to the NJ Sharing Network hoping to advocate for organ donations.
He’s been given a second shot at life, something Mark didn’t have.
“I can do anything now,” Charles said.
You can register as an organ donor. Visit https://www.njsharingnetwork.org or https://www.registerme.org.
Our journalism needs your support. Please subscribe today to NJ.com.
Spencer Kent may be reached at skent@njadvancemedia.com. | https://www.nj.com/healthfit/2023/07/a-betraying-heart.html | 2023-07-31T11:19:46 | 0 | https://www.nj.com/healthfit/2023/07/a-betraying-heart.html |
Recruiting Season Is in Full Swing for Professional Football Players to Join Virtual Fan Engagement Channel
NAPLES, Fla., July 31, 2023 /PRNewswire/ -- Notable Live is announcing that it has added three more Pro Football Hall of Fame players to the Notable Live line-up for the upcoming season. In addition to existing players Emmitt Smith and Ray Lewis, Notable Live is excited to add Cris Carter, Champ Bailey and Ed Reed to the Notable Live team. This comes as a fast follow to Notable Live's recent multi-year commercial agreement with eBay and its Series A financing round led by eBay Ventures.
Notable Live is a tech-enabled virtual engagement platform that connects fans to teams, leagues and players in a way they have always dreamed about through an immersive experience. Notable Live, co-founded in 2018 by Pro Football Hall of Famer Emmitt Smith and entrepreneurial veteran Mike Antonucci, helps players monetize their image and personal brands not just on game day, but every day.
Through one set of login credentials, the Notable Live platform unlocks an expansive catalog of one-to-many engagement experiences, including live events and on-demand content. On the platform's commerce-enabled exchange, players, teams and leagues can activate live auction or marketplace functions to sell physical memorabilia, digital content, in-person experiences or other unique offerings. All items offered on the Notable Live platform and its associated channels can be authentically bought and sold across the growing and loyal community of Notable Live fans.
"The multi-billion annual sports memorabilia market is rapidly evolving to include new digital experiences, and Notable Live continues to grow its comprehensive platform for both the college and professional sports markets. We are pleased to announce the continued expansion of our roster of NFL athletes on our platform," said Mike Antonucci, co-founder and CEO of Notable Live.
"The fans bring their passion for the game and for their favorite players, ensuring the memorabilia space remains more about the fans than about the athletes," added Emmitt Smith, co-founder of Notable Live. "We are excited to continue expanding our platform with fellow Hall of Famers and other athletes."
About Notable Live
Notable Live was co-founded in 2018 by avid sports fan Mike Antonucci and Pro Football Hall of Famer Emmitt Smith to create a unique platform providing sports fans with unparalleled access to their favorite notables via virtual interactive events. Notable Live, a mobile app available on the App Store and Google Play, grants fans real access to notables by putting them "in the room" together for memorable virtual experiences. Connect with Notable Live at www.notable.live or on Instagram, Facebook, Twitter, YouTube, Threads for iOS and Threads for Google Play.
View original content to download multimedia:
SOURCE Notable Live | https://www.kfyrtv.com/prnewswire/2023/07/31/notable-live-adds-three-gold-jackets/ | 2023-07-31T11:19:48 | 1 | https://www.kfyrtv.com/prnewswire/2023/07/31/notable-live-adds-three-gold-jackets/ |
Jets fans filled the stands and lined the fence during Sunday’s open training camp practice in Florham Park, feeling truly optimistic for the first time in more than a decade.
The excitement surrounding future-hall-of-fame quarterback Aaron Rodgers was palpable. Fans sporting No. 8 jerseys and t-shirts were everywhere. “Rodgers” chants rang out from the beginning to end of practice. | https://www.nj.com/jets/2023/07/jets-fans-share-2023-season-predictions-on-aaron-rodgers-sauce-gardner-and-more.html | 2023-07-31T11:19:50 | 1 | https://www.nj.com/jets/2023/07/jets-fans-share-2023-season-predictions-on-aaron-rodgers-sauce-gardner-and-more.html |
BALTIMORE, July 31, 2023 /PRNewswire/ -- Opteev Technologies, Inc., a pioneering technology company at the forefront of diagnostics, has filed a patent (Patent Application #63/513,007) for a revolutionary multiplex biochip for respiratory infection diagnostics. The groundbreaking polymer-based biochip offers the potential to test multiple pathogens responsible for respiratory infections, including SARS-CoV-2, RSV, and Influenza, and precisely identify the specific virus or bacteria in under 1 minute. This game-changing technology paves the way for an ultra-rapid, portable, and accurate syndromic diagnostic device to empower healthcare providers with immediate results at their fingertips.
The tiny biochip can directly detect whole viruses in real-time in both processed and unprocessed samples such as saliva or nasal swab and has demonstrated an unprecedented accuracy rate of 99.49% with an impressive limit of detection in its analytical performance evaluation. Furthermore, the biosensor achieves fine-tuned specificity by carefully selecting specific virus-binding peptides, enabling accurate identification of target viruses in complex samples. To ensure precise and reliable virus detection, the biochip utilizes artificial intelligence to optimize the frequency range effectively mitigating the impact of interfering noise signals.
Unlike conventional respiratory panels that cost tens of thousands of dollars and take days to provide results, Opteev's multiplex biochip will offer healthcare providers affordable syndromic testing with the ability to process samples at the point of care, allowing for the simultaneous detection and specific identification of multiple pathogens instantaneously. This breakthrough technology will eliminate the need for speculation by providing healthcare providers with the critical information needed to deliver the most effective treatment options at the point of care.
"With the development of our multiplex biochip, we are revolutionizing point-of-care diagnostics," said Dr. Mesfin Meshesha, Vice President of Virology & Diagnostics at Opteev Technologies. "The potential of this technology to transform patient care, streamline operations, and reduce costs is truly remarkable."
As Opteev Technologies continues to push the boundaries of point-of-care diagnostics, the company welcomes potential collaborations and partnerships to further develop and commercialize its multiplex biochip. "Together, we can shape the future of diagnostics and unlock the massive potential of our game-changing multiplex biochip," said Conrad Bessemer, Opteev's Chairman and Co-founder.
For more information about Opteev Technologies and its groundbreaking multiplex biochip, please visit www.opteev.com.
Opteev Technologies, Inc., headquartered in Baltimore, MD, is a pioneering technology company at the forefront of diagnostics. With a strong focus on respiratory pathogen detection, Opteev is committed to developing innovative solutions that revolutionize the field of point-of-care diagnostics. As a subsidiary of Novatec, Inc., a trusted manufacturer and supplier of machinery and sensor technology, Opteev leverages decades of experience to drive advancements in healthcare.
Media Contact:
Dana Gardner
Vice President
dgardner@opteev.com
Phone: 443-457-5214
View original content to download multimedia:
SOURCE Opteev Technologies, Inc | https://www.kfyrtv.com/prnewswire/2023/07/31/opteev-develops-worlds-first-multiplex-biochip-that-precisely-identifies-covid-flu-rsv-respiratory-pathogens-under-1-minute/ | 2023-07-31T11:19:55 | 0 | https://www.kfyrtv.com/prnewswire/2023/07/31/opteev-develops-worlds-first-multiplex-biochip-that-precisely-identifies-covid-flu-rsv-respiratory-pathogens-under-1-minute/ |
Two second-prize, $1 million lottery tickets were purchased in New Jersey for Saturday’s Powerball drawing.
New Jersey Lottery officials will disclose where the lucky tickets were sold later Monday. Each ticket matched five numbers but not the Powerball.
No one across the county hit the $68.5 million jackpot, pushing the top prize for Monday’s drawing to $74 million with a cash option of $37.5 million.
Saturday’s winning numbers were: 10, 25, 27, 34 and 38. The Powerball was 2, with a Power Play of 3X.
There was also a $1 million ticket sold in Kentucky.
In addition, no one won Saturday’s secondary $10 million Double Play drawing. The winning numbers were: 10, 23, 27, 62 and 65. The Double Play number was 15.
The jackpot is slowly climbing 12 days after someone who bought a ticket in Los Angeles won a massive $1.08 billion prize.
The odds of hitting the Powerball jackpot are 292,201,388 to 1. A player who buys a $2 ticket has about a 1 in 11,688,053 chance to match five numbers and win at least $1 million, while the odds are 913,129 to 1 to win a third prize of at least $50,000.
Powerball drawings are held each Monday, Wednesday and Saturday in 45 states, the District of Columbia, Puerto Rico and the U.S. Virgin Islands.
Meanwhile, Tuesday’s Mega Millions jackpot is worth an estimated $1.05 billion with a cash option of $527.9 million. As of Monday morning, it’s tied for the fourth largest Mega prize and the seventh largest U.S. lottery jackpot.
Our journalism needs your support. Please subscribe today to NJ.com.
Jeff Goldman may be reached at jeff_goldman@njadvancemedia.com. | https://www.nj.com/lottery/2023/07/powerball-tickets-worth-1m-sold-at-2-nj-locations-for-weekend-drawing.html | 2023-07-31T11:19:57 | 1 | https://www.nj.com/lottery/2023/07/powerball-tickets-worth-1m-sold-at-2-nj-locations-for-weekend-drawing.html |
Mobile Visual Processing Solutions Coupled with Dedicated Game Tuning Services Take Mobile Gaming Experience to a Brand-New Level
SHANGHAI, July 31, 2023 /PRNewswire/ -- Pixelworks, Inc. (NASDAQ: PXLW), a leading provider of innovative visual processing solutions, today announced the official launch of its new IRX gaming experience brand. As a brand targeted at smartphone users, IRX is grounded on Pixelworks' mobile visual processing solutions and coupled with in-depth game tuning services. This combination leverages Pixelworks' expertise to achieve ultra-smooth gaming experience and the highest picture quality for different types of games on mobile devices. In addition, it exercises effective control of power consumption, latency and other performance variables to ensure stable and long-lasting gaming with optimal visual performance, providing end users with unparalleled mobile gaming experiences.
The IRX gaming experience is enabled by a portfolio of technology advantages and product application experiences based on the Company's innovative distributed rendering architecture. More specifically, Pixelworks' ultra-low latency MotionEngine® technology, low power super-resolution technology, AI Always-on HDR and other technologies bring optimized rendering capabilities to smartphones that exceed what can be achieved by a traditional chipset. Together with Pixelworks' profound tuning experience for different games on various mobile devices the result is a meaningfully enriched visual experience for smartphone users, which is the core foundation for the IRX gaming experience.
The IRX gaming experience brand will be supported by a certification program for mobile devices that incorporates Pixelworks visual processors. The certification program will be backed by a suite of visual quality evaluation systems agreed upon with smartphone manufacturers to ensure that Pixelworks powered smartphones provide the most outstanding gaming performance and utmost visual quality for consumers.
The IRX branded certification program is comprised of both device certification and game tuning services. Pixelworks will optimize the rendering capabilities and display quality of top games on mobile devices based on its visual processors' capabilities as well as the devices' performance characteristics. Smartphones that meet the technical requirements as well as Pixelworks' visual processing standards will be granted the IRX branded certification, and games that meet Pixelworks' visual quality requirements will be included in the IRX-supported game list. To date, there are 20 top games being enlisted on the IRX-supported game list, which can be found on Pixelworks' official IRX gaming experience website. Furthermore, Pixelworks plans to establish expanded communication channels with consumers to help further educate end users on the benefits of the IRX gaming experience.
"IRX is a gaming experience brand from Pixelworks targeted directly towards mobile device users." said Ting Xiong, President of Pixelworks China. "Pixelworks would like to empower smartphone manufacturers to break the ceiling of mobile gaming experience from content optimization to performance enhancement with its innovative rendering technologies and years of game tuning and optimization experience. Additionally, we are also aiming to develop and promote consumer awareness around how to better evaluate visual display quality and the mobile gaming experience, enabling them to make smarter choices when purchasing a smartphone. By utilizing professional technologies and services to build more links across both products and users, we hope to drive mutual growth through in-depth interactions while bringing display performance and the mobile gaming experience to a brand-new level."
About Pixelworks
Pixelworks provides industry-leading content creation, video delivery and display processing solutions and technology that enable highly authentic viewing experiences with superior visual quality, across all screens – from cinema to smartphone and beyond. The Company has more than 20 years of history delivering image processing innovation to leading providers of consumer electronics, professional displays and video streaming services.
For more information, please visit the company's web site at www.pixelworks.com.
Note: Pixelworks, MotionEngine and the Pixelworks logo are trademarks of Pixelworks, Inc. All other trademarks are the property of their respective owners.
View original content to download multimedia:
SOURCE Pixelworks, Inc. | https://www.kfyrtv.com/prnewswire/2023/07/31/pixelworks-announces-launch-irx-gaming-experience-brand/ | 2023-07-31T11:20:01 | 0 | https://www.kfyrtv.com/prnewswire/2023/07/31/pixelworks-announces-launch-irx-gaming-experience-brand/ |
With four privately run bus routes in Jersey City reaching the end of the line in three months, it is imperative that NJ Transit step in and replace – preferably even enhance -- the service.
Everyone seemed to be taken by surprise last week when it was learned that the nearly century-old A&C Bus Corp. would be shutting down the Nos. 30, 31, 32 and 33 lines at the end of October. | https://www.nj.com/opinion/2023/07/nj-transit-cant-let-ac-bus-routes-die-jersey-journal-editorial.html | 2023-07-31T11:20:03 | 1 | https://www.nj.com/opinion/2023/07/nj-transit-cant-let-ac-bus-routes-die-jersey-journal-editorial.html |
Introducing the industry's first-ever utility side-by-side with a 1500cc 3-cylinder engine for more power to make tough jobs easier and the industry's only STEELDRIVE transmission for greater durability
MINNEAPOLIS, July 31, 2023 /PRNewswire/ -- Polaris Off Road, the global leader in powersports and off-road innovation, is once again breaking new ground with the industry's first extreme duty utility side-by-side: the all-new RANGER XD 1500. With its unprecedented capability, brute strength and unmatched comfort, the new extreme duty class of RANGER side-by-sides are engineered with the first-ever ProStar 1500cc 3-cylinder engine that offers an industry-leading 110 horsepower, the industry-exclusive STEELDRIVE automatic transmission for greater durability and precise control, and over 70 new accessories for enhanced customization, highlighted by Polaris' exclusive Lock & Ride MAX system. The RANGER XD 1500 establishes a new benchmark for utility side-by-sides.
"We spent over five years meeting with farmers, ranchers, large acreage property owners and big game hunters to develop an extreme duty vehicle that was missing from the market. From its ProStar 1500cc engine to the industry's only STEELDRIVE transmission, RANGER XD 1500 is unlike anything else offered today and is yet another example of our relentless commitment to advancing the industry with fresh thinking and innovative solutions that meet the real-world needs of our utility customers," said Steve Menneto, President of Polaris Off Road.
"Polaris RANGER has been the No. 1 selling utility side-by-side brand for more than 15 years and with the introduction of RANGER Extreme Duty, we've taken the industry's hardest-working lineup and expanded it," said Chris Judson, Vice President of Off Road Utility. "A segment of our utility customers said they are facing exceptionally large tasks and they simply need a machine with more power, more torque, more hauling and towing capacity, and more durability. And our team set out to deliver just that, incorporating dozens of new features and the latest engineering to make the RANGER XD 1500 more capable, stronger, and more comfortable than any other utility side-by-side out there."
Unprecedented Capability
Farmers, ranchers, and large landowners routinely haul and tow heavy loads around the property, and they've been asking for a solution when it comes to their heaviest tasks. The RANGER XD 1500 delivers unprecedented capability for hard-working customers to haul more, tow more, and get more done in less time. With the industry's only 1500cc utility engine, the RANGER XD 1500 provides over 30% more power and over 50% more torque than the next closest competitor.
- ProStar 1500cc 3-Cylinder Engine – Effortless towing, hauling, and confidence in tough terrain with an industry-leading 110HP and 105 lb-ft torque.
- 1,500 lb Cargo Box Capacity – Three-quarter ton box capacity providing nearly 50% more box volume than existing models for maximum productivity with fewer trips and bigger loads.
- 3,500 lb Towing Capacity – For those routinely towing heavy loads on the property, drive better productivity with nearly 40% more towing than existing models.
- Industry-leading Ground Clearance – All RANGER XD 1500 models get 15" of ground clearance with high-clearance arched A-arms to overcome large obstacles.
Brute Strength
Utility customers asked for a more durable, longer lasting offering to maximize their uptime and drive efficiency. Designed to last longer than any model before it, RANGER XD 1500 is the industry's most durable utility side-by-side and has been engineered from the ground up to be stronger and stand up to the demands of the longest days.
- Industry-exclusive STEELDRIVE transmission – Offers a 100 percent steel constructed belt that delivers smooth, precise operation and a fully sealed, liquid-cooled design for unmatched durability.
- High-Strength Steel Heavy Duty Frame – RANGER XD 1500 has a high-strength steel one-piece chassis featuring 160 percent more torsional stiffness for a smoother ride and better cab sealing.
- Industry-leading Service Intervals – RANGER XD 1500 offers the industry's longest service intervals so customers can maximize their uptime.
Unmatched Comfort
- From the farm to remote backcountry, utility customers work from before the sun rises to after it sets, and need something that delivers all-day comfort. Beyond industry-leading capability and durability, the RANGER XD 1500 prioritizes comfort across the entire lineup to keep customers going strong on the longest days.
- Most Spacious Interior – Equipped with the most spacious and premium cab available in utility side-by-sides, the XD 1500 offers increased leg and shoulder room, making it easy to enter and exit the vehicle. Adjustable seating and a telescopic steering wheel lets drivers find the perfect fit for height and riding preferences.
- Premium Seating – Contoured seating with added bolstering provides more rider comfort along with a center seat that flips down into an armrest with additional cup holders.
- Available Heated Seats – For comfort on the coldest days, RANGER XD 1500 NorthStar Ultimate is the first utility side-by-side that comes from the factory with heated seats.
- Drive Modes – RANGER XD 1500 comes with an intuitive and easy-to-use rotary drive mode selector that lets customers choose from four different drive modes, including:
- Heating and Air Conditioning (HVAC) – Riders can stay comfortable in harsh weather conditions in the RANGER XD 1500 NorthStar Edition, featuring an all-new HVAC system and a fully-enclosed, next generation ProShield cab that's been redesigned with improved sealing to prevent dust and water intrusion, while locking in the temperature from the climate-controlled cab.
- Sun Visors – All-new integrated sun visors provide improved visibility throughout the day for added confidence while driving.
- RIDE COMMAND – Available 7" waterproof touchscreen display powered by RIDE COMMAND technology featuring a back-up camera, GPS navigation regardless of cell service, and AM/FM radio with Bluetooth® streaming capability.
- RIDE COMMAND+ – Customers can keep tabs on their vehicle directly from the Polaris App and access critical vehicle information like vehicle location, maintenance reminders, and issue diagnostics right from the palm of their hand with the industry's only connected-vehicle technology. Available from the factory on NorthStar Ultimate.
Customization
Customers have been asking for increased versatility, durability, and ease of use for the different work applications they face throughout the day. With over 70 new Polaris Engineered Accessory options designed specifically for the RANGER XD 1500, plus options from partners brands including JBL®, Rhino Rack®, Pro Armor, Kolpin, and HD Parts, customers have more opportunity than ever before to make their vehicle fit their specific needs.
- Lock & Ride MAX – Polaris' easiest to use, most versatile, and confident accessory attachment platform ever. With customizable configurations and the ability to reconfigure on the fly with no tools required, this new accessory platform allows users to prepare for their day, their way. Customers can simply choose and place their accessory, lock it in place, and ride confidently knowing their gear is secure.
- New JBL® Audio – Polaris partnered with JBL® to create the highest performing audio system ever included in a RANGER from the factory. For customers wanting to turn it up a notch, the JBL® Trail Pro 4200 audio upgrade adds rear speakers and two subwoofers for an immersive audio experience.
- Glacier Pro HD Plow – New 84" plow designed for faster, more efficient plowing during the winter months. A hydraulic plow lift and angle kit can be paired with an all-new plow controller to manage the largest plow Polaris has ever offered, all without ever leaving the comfort of the cab.
2024 RANGER XD 1500 Premium: Starting at US $29,999 / CAN $36,199
The RANGER XD 1500 Premium commands a large presence thanks to heavy-duty components and the industry's largest bumper, providing complete front-end protection. The vehicle comes equipped with one of the most comprehensive standard packages in a side-by-side to date including 29" tires, tilt steering and seat slider for customizable comfort, four drive modes, high output LED headlights for enhanced visibility, and USB ports with multiple charging capabilities. The vehicle also comes equipped with boosted brakes and heavy-duty suspension to ensure performance across a variety of off-road environments.
2024 RANGER XD 1500 NorthStar Premium: Starting at US $39,999 / CAN $48,799
The next step up is the RANGER XD 1500 NorthStar Premium. This machine features a fully enclosed cab with HVAC temperature and five different mode controls, lockable full doors with power windows and a fixed front glass windshield. Additional features include an electronically controlled power tilt bed to dump heavy loads with ease, an overhead switch panel for easy accessorization, and an overhead rear work light to illuminate the cargo box in low-light conditions. NorthStar Premium comes stock with 30" Kenda® CrossTrail tires and available 32" tires to overcome large obstacles and tough terrain.
2024 RANGER XD 1500 NorthStar Ultimate: Starting at US $44,999 / CAN $54,499
Rounding out the lineup is the RANGER XD 1500 NorthStar Ultimate, which features everything from the NorthStar Premium trim, plus the 7" infotainment display powered by RIDE COMMAND and heated seats. The NorthStar Ultimate trim also delivers an immersive sound experience, featuring full AM/FM radio with Bluetooth® streaming capability and industry-exclusive JBL® speakers for precise audio and premium sound. Finally, the vehicle comes standard with RIDE COMMAND+, allowing for vehicle health monitoring and more.
The 2024 RANGER XD 1500 lineup is expected to begin shipping to dealers in late summer. To learn more about the 2024 RANGER family, please visit https://ranger.polaris.com/en-us/ or join the conversation and follow on Facebooksm, Instagramsm, YouTubesm and Twittersm.
About Polaris
As the global leader in powersports, Polaris Inc. (NYSE: PII) pioneers product breakthroughs and enriching experiences and services that have invited people to discover the joy of being outdoors since our founding in 1954. Polaris' high-quality product line-up includes the Polaris RANGER®, RZR® and Polaris GENERAL™ side-by-side off-road vehicles; Sportsman® all-terrain off-road vehicles; military and commercial off-road vehicles; snowmobiles; Indian Motorcycle® mid-size and heavyweight motorcycles; Slingshot® moto-roadsters; Aixam quadricycles; Goupil electric vehicles; and pontoon and deck boats, including industry-leading Bennington pontoons. Polaris enhances the riding experience with a robust portfolio of parts, garments, and accessories. Proudly headquartered in Minnesota, Polaris serves more than 100 countries across the globe. www.polaris.com
Warning: vehicle rollaway can cause serious injury or death. This vehicle can roll whenever the gear selector is not in the park position. Always shift to park when stopping the engine or leaving the vehicle. When leaving the vehicle on an incline is unavoidable, use extra care. If leaving the vehicle unattended, block the rear wheels on the downhill side and keep children, pets, and others away form the gear selector. Notice: Vehicle payload and trailer weight will affect the angle of hill on which the vehicle will hold.
Kenda® is a registered trademark of Kenda Rubber Industrial Co, Ltd.
Bluetooth® is a registered trademark of Bluetooth Sig, Inc.
JBL® is a registered trademark of Harman International Industries, Incorporated
Rhino-Rack® is a registered trademark of Rhino Rack Australia Pty Limited
Unless noted, trademarks are the property of Polaris Industries Inc.
View original content to download multimedia:
SOURCE Polaris Inc. | https://www.kfyrtv.com/prnewswire/2023/07/31/polaris-expands-its-ranger-lineup-with-all-new-ranger-xd-1500-an-entirely-new-class-extreme-duty-utility-side-by-sides/ | 2023-07-31T11:20:08 | 0 | https://www.kfyrtv.com/prnewswire/2023/07/31/polaris-expands-its-ranger-lineup-with-all-new-ranger-xd-1500-an-entirely-new-class-extreme-duty-utility-side-by-sides/ |
Phillies star Bryce Harper often talks about how he knows president Dave Dombrowski will make the moves necessary to help the team.
Whether that’s re-signing catcher J.T. Realmuto or bringing in the likes of Kyle Schwarber, Nick Castellanos and Trea Turner in the offseason or acquiring a Brandon Marsh at the trade deadline, Harper has often approved of Dombrowski’s acquisitions, earning jokes he has an added role of assistant GM.
The trade deadline is 6 p.m. on Tuesday, and the Phillies are expected to be buyers. Their place in the standings – a half-game out in a crowded wild card field – and the history of the man making the decisions says as much.
Dombrowski has never been shy about making deals both with the Phillies and his previous stops in Boston, Detroit, Miami and Montreal – all but the Expos going to the World Series under his leadership.
This will be his third trade deadline as the guy calling the shots in Philadelphia. Two years ago, he sent top pitching prospect Spencer Howard to Texas as part of a package for starting pitcher Kyle Gibson and closer Ian Kennedy.
Last year, he shuffled the deck picking up four players – infielder Edmundo Sosa, starting pitcher Noah Syndergaard, center fielder Brandon Marsh and Robertson. All four played a role in the Phillies reaching the World Series for the first time in 14 years.
When speaking with the Philadelphia media on the recent homestand, Dombrowski indicated a right-handed hitter and starting pitching depth would be on his wish list. Cristopher Sanchez continues to shine as the Phillies’ fifth starter though if an injury occurred, there is some concern about what is in the minor league system.
“You always looking to get better any way you possibly can,” said Dombrowski. “I think really what we’re looking for is someone who can swing the bat from the right-hand side is the best way to put it, but not just anyone. Like every organization in baseball we’re looking for starting pitching depth.
“I don’t think I’ll say any more on the trading stuff. I think I’ve tipped my hand enough. You’re never looking to trade your top prospects, I also can’t say when somebody drops something in your lap you can’t say no. … I’ve probably said enough.”
The Phillies could use some tweaks more than the heavy lifting that occurred at last year’s deadline – with the moves helping propel them into the World Series.
The Mets moved ace Max Scherzer and closer David Robertson in the last few days.
Perhaps a player like right-handed hitting Mark Canha – a right-handed-hitting outfielder who could fill a Phillies needs – might be the next headed out of New York, with his destination down the road to Philadelphia.
The Phillies missed a chance to take control in the playoff race when they gave away two games to the Pittsburgh Pirates over the weekend with poor fielding, questionable decisions and bad defense. More than a new player, the Phillies could use struggling players like Turner and Castellanos to start hitting the way they are capable.
Still a trade deadline addition often sends a message to the clubhouse the front office is fully invested in contending. Other contenders have started adding pieces.
Phillies manager Rob Thomson declined to say what position group or skill set he would like to see Dombrowski pursue – former manager Charlie Manuel wasn’t so shy, lobbying for more offense, particularly a home run hitter, during his tenure.
But asked if given Dombrowski’s history he expected his team to look differently by the time the Phillies return home on Aug. 4, Thomson said he wasn’t sure.
“I don’t know, we might be,” said Thomson. “We might not be. The trade deadline is tough sometimes because you have to give up something to get something. It all depends on what people are asking for.”
Thomson added he would be fine if the Phillies stayed pat, noting he liked the current construction of the team.
But it would be surprising if Dombrowski didn’t at least make a subtle move or two.
Thank you for relying on us to provide the journalism you can trust. Please consider supporting NJ.com with a subscription.
Bill Evans can be reached at bevans@njadvancemedia.com. | https://www.nj.com/phillies/2023/07/as-trade-deadline-nears-does-phillies-dave-dombrowski-have-move-up-his-sleeve.html | 2023-07-31T11:20:09 | 0 | https://www.nj.com/phillies/2023/07/as-trade-deadline-nears-does-phillies-dave-dombrowski-have-move-up-his-sleeve.html |
The following is a listing of all home transfers in Morris County reported from July 24 to July 30. There were 73 transactions posted during this time. During this period, the median sale for the area was a 1,505-square-foot home on Coachlight Drive in Chatham that sold for $565,000.
Budd Lake
17 Old Budd Lake Road, Budd Lake, $375,000, 1,432 square feet, $262 per square-foot. | https://www.nj.com/realestate-news/2023/07/see-all-homes-sold-in-morris-county-july-24-to-july-30.html | 2023-07-31T11:20:11 | 1 | https://www.nj.com/realestate-news/2023/07/see-all-homes-sold-in-morris-county-july-24-to-july-30.html |
The Avocados From Mexico® Chocolate Dulce De Leche Cupcake will be available at Sprinkles bakeries nationwide for one week beginning July 31
DALLAS, July 31, 2023 /PRNewswire/ -- Talk about a perfect pairing! Avocados From Mexico®, the number one selling avocado brand in the U.S., is making National Avocado Day even better by partnering with renowned dessert bakery chain Sprinkles for a delicious collaboration – a limited-edition cupcake featuring fresh Mexican avocados.
The Avocados From Mexico® Chocolate Dulce De Leche Sprinkles cupcake is a delectable banana cupcake that's studded with pecans and generously filled with a soft dulce de leche core. And to top it all off? A zesty frosting that blends rich cream cheese and chocolate made with fresh Mexican avocados for a delightful, creamy finish.
"The new Avocados From Mexico Chocolate Dulce De Leche cupcake features the highest quality and best-tasting ingredients," said Sprinkles Vice President, Culinary, Charles Craig. "By blending fresh avocado and smooth cream cheese alongside the banana and dulce de leche cupcake, we were able to elevate all the ingredients resulting in a cupcake that is out-of-this world. We can't wait for fans to try it!"
Beginning on July 31, National Avocado Day, consumers can make their week better by enjoying Avocados From Mexico in cupcake form — available at Sprinkles nationwide through August 6.
"Avocados From Mexico make everything better, and we're so proud that our avocados will get to shine in a unique way on National Avocado Day," said Kelly Burke, Director of Brand Marketing at Avocados From Mexico. "Our brand is known for bringing the good times with great tasting avocados. We are excited to partner with a beloved brand like Sprinkles to spark good times in a new way with everyone's favorite sweet treat."
"Sprinkles Cupcakes has always taken an innovative approach to classic desserts, and this new collaboration with Avocados From Mexico is no exception," said Sprinkles CMO, Michelle Wong. "Avocados From Mexico was an obvious choice for their quality and taste, and we can't wait for our guests to discover our latest cupcake, starring this beloved fruit."
To learn more about Avocados From Mexico, visit https://avocadosfrommexico.com, Facebook (facebook.com/avocadosfrommexico), Instagram (@avocadosfrommexico) or Twitter (@AvosFromMexico). #MakeItBetter #AFMxSprinkles
About Avocados From Mexico
Avocados From Mexico is a wholly-owned subsidiary of the Mexican Hass Avocado Importers Association (MHAIA), formed for the purpose of advertising, promotion, public relations and research for all stakeholders of Avocados From Mexico. Under agreements, MHAIA and the Association of Avocado Exporting Producers & Packers of Mexico (APEAM) have combined resources to fund and manage Avocados From Mexico, with the intent to provide a focused, highly- effective and efficient marketing program in the United States. Avocados From Mexico is headquartered in Irving, Texas.
About Sprinkles
Sprinkles offers premium cupcakes, cakes and cookies that are baked fresh in small batches throughout the day and handcrafted with only the finest ingredients. Sprinkles opened its first bakery in Beverly Hills in 2005, drawing long lines of loyal cupcake fans and celebrity endorsements. Sprinkles prides themselves in being passionate innovators and since debuting the world's first Cupcake ATM, the brand has introduced layer cakes, cookies and brownies, launched a national shipping platform and has grown to over 70 bakeries and ATMs coast-to-coast. Sprinkles launched domestic and international franchising in 2022. For additional information on Sprinkles, follow @sprinklescupcakes on social and visit www.sprinkles.com.
CONTACT: Ana Ambrosi, aambrosi@avocadosfrommexico.com
View original content to download multimedia:
SOURCE Avocados From Mexico | https://www.kfyrtv.com/prnewswire/2023/07/31/sweet-news-avocados-mexico-sprinkles-launch-limited-edition-cupcake-national-avocado-day/ | 2023-07-31T11:20:14 | 0 | https://www.kfyrtv.com/prnewswire/2023/07/31/sweet-news-avocados-mexico-sprinkles-launch-limited-edition-cupcake-national-avocado-day/ |
The House and Senate left Washington for the month of August with a lengthy, time-sensitive to-do list waiting when they return, including multiple key health care priorities.
There will only be three weeks before the end of the fiscal year to get everything done, and just 11 legislative days when both chambers will be in session at the same time.
Congress faces a Sept. 30 deadline to reauthorize a sweeping pandemic preparedness bill, fund community health centers and renew opioid addiction services.
But the largest looming deadline is the appropriations bills to fund the Food and Drug Administration (FDA) and the Department of Health and Human Services (HHS), which are tied up in the House amid disagreements over abortion and spending levels.
GOP leaders scuttled a vote planned for Friday on legislation funding the FDA and the Department of Agriculture after moderate Republicans objected to a provision that would reverse the FDA’s decision to allow the abortion pill mifepristone drug to be dispensed through the mail and in retail pharmacies.
House Freedom Caucus members have also been demanding even deeper spending cuts than agreed to in the bipartistan debt ceiling deal.
The Labor-HHS bill advanced through a House Appropriations subcommittee earlier this month, but hadn’t even made it to the full committee before recess. The Republican-led House bill would slash or eliminate funding from a range of programs that deal with everything from family planning to teen pregnancy and even HIV.
Both FDA and HHS funding bills face a major fight in the Democratic-controlled Senate, where the Appropriations Committee has already passed its own version by near unanimous margins, owing to an agreement by Democratic and Republican leaders not to insert “poison pill” amendments.
House Democratic Whip Katherine Clark (Mass.) argued in a floor speech that lawmakers should stay in Washington to strip out the “toxic, divisive, bigoted riders” in the bills, and ripped Republicans for delaying votes until September.
Pandemic preparedness
The House and Senate are taking different tracks in the reauthorization of the pandemic preparedness bill, complicating its path forward.
The Senate advanced a bipartisan version of the Pandemic All-Hazards Preparedness Act out of committee, but the House is divided. House Energy and Commerce Committee Republicans advanced a bill on party lines after Democrats introduced their own version.
The primary disagreement is over drug shortages. Democrats are clamoring to give FDA more oversight authority to address the shortages, but Republicans are insisting on keeping the issues separate.
The Senate version contains some provisions addressing drug shortages, but only one involves beefing up FDA authority.
Congress is under pressure to stem drug shortages amid reports of doctors rationing cancer drugs and other medicine. Republicans on the Energy and Commerce Committee have said they are committed to dealing with the problems, but that it shouldn’t be part of the preparedness bill.
Energy and Commerce Committee GOP leaders released a discussion draft on Friday of drug shortage legislation focusing on the economic reasons for shortages, including giving some generic drug manufacturers the ability to raise the cost of their drugs if hospitals keep prices “artificially low” to the point where there’s no economic incentive.
Health centers
Legislation to reauthorize funding for community health centers also faces partisan challenges. But in this case, the House cleared its bill on a bipartisan basis, while the Senate is still working through disagreements, highlighting the work to be done.
Sen. Bernie Sanders (I-Vt.), chair of the Senate Health, Education, Labor and Pensions (HELP) Committee, originally wanted tens of billions of dollars more for the centers. He was asking for $130 billion to fund the centers over the next five years as well as $60 billion to help grow the health care workforce.
But Sanders ended up canceling a planned markup during the last week of July. Raising some eyebrows, Sanders said he is working with Sen. Roger Marshall (R-Kan.) to craft a bipartisan bill that will be “ready by the first week of September.”
Separately, Sanders and Senate Finance Committee Chairman Ron Wyden (D-Ore.) issued a joint statement pledging to partner and work towards legislation in the fall aimed at addressing primary care and other health care workforce shortages.
Opioids
At issue are several provisions of sweeping legislation signed into law in 2018 called the Support Act, which aimed to tackle the country’s drug overdose epidemic.
The House Energy and Commerce Committee advanced a bipartisan reauthorization and expansion bill, but advocates are concerned the Senate is behind.
HELP Committee ranking member Bill Cassidy (R-La.) introduced his own version of the bill on July 20, but hearings won’t be scheduled until September. Cassidy has warned that the committee is wasting time on partisan bills instead of easy bipartisan wins, such as the Support Act.
Insulin/PBM reform
Senate Majority Leader Chuck Schumer (D-N.Y.) has said for months that he wants to move legislation that would cap the cost of insulin at $35 per month for people with private insurance.
There’s hope to combine it with legislation reforming the pharmacy benefit manager (PBM) industry into a package that could get bipartisan support.
But there’s no looming deadline and no guarantee it will get taken up in September.
Sen. Jeanne Shaheen (D-N.H.), who is a co-sponsor of one of the insulin bills with Sen. Susan Collins (R-Maine), said she still has Schumer’s support heading into the fall, but has not heard anything about timing.
Multiple committees have advanced PBM reform bills in both the House and Senate, so they will all need to be combined into one floor-friendly package. | https://www.yourbasin.com/hill-politics/lawmakers-set-to-face-ticking-clock-on-health-care-priorities/ | 2023-07-31T11:20:16 | 1 | https://www.yourbasin.com/hill-politics/lawmakers-set-to-face-ticking-clock-on-health-care-priorities/ |
Lexington police investigate following death at mobile home park
LEXINGTON, S.C. (WIS) - The Lexington Police Department has started an investigation after a death at a mobile home park (MHP).
Officers said the death happened in the early hours of Monday, July 17, at the Victorian Lakes MHP in Phase I.
LPD is investigating a death that happened early this morning at the Victorian Lakes MHP in Phase I.
— Lexington Police(SC) (@LexingtonPD) July 31, 2023
SLED Crime Scene and Lexington County Coroner’s Office are assisting our investigators in this investigation and the roadway near the scene will be closed for several hours. pic.twitter.com/R6ukPP66zC
SLED Crime Scene and the Lexington County Coroner’s Office have assisted Lexington detectives in this investigation according to officials, the roadway near the scene will be closed for several hours officers added.
Notice a spelling or grammar error in this article? Click or tap here to report it. Please include the article's headline.
Stay up to date with WIS News 10. Get the app from the Apple App Store or Google Play Store and Stream us on Roku, YouTube, Amazon Fire, or Apple TV.
Copyright 2023 WIS. All rights reserved. | https://www.wistv.com/2023/07/31/lexington-police-investigate-following-death-mobile-home-park/ | 2023-07-31T11:20:16 | 0 | https://www.wistv.com/2023/07/31/lexington-police-investigate-following-death-mobile-home-park/ |
The following is a listing of all home transfers in Salem County reported from July 24 to July 30. There were 29 transactions posted during this time. During this period, the median sale for the area was a 1,735-square-foot home on Third Street in Elmer that sold for $210,000.
Deepwater
58 Van Buren Street, Deepwater, $157,500, 891 square feet, $177 per square-foot. | https://www.nj.com/realestate-news/2023/07/see-all-homes-sold-in-salem-county-july-24-to-july-30.html | 2023-07-31T11:20:17 | 1 | https://www.nj.com/realestate-news/2023/07/see-all-homes-sold-in-salem-county-july-24-to-july-30.html |
SHENZHEN, China, July 31, 2023 /PRNewswire/ -- Taoping Inc. (Nasdaq: TAOP, the "Company" or "Taoping"), today announced that the board of directors of the Company approved a one-for-ten reverse stock split of the Company's issued and outstanding ordinary shares, no par value (the "Ordinary Shares"). Beginning August 1, 2023, the Company's Ordinary Shares will be trading on a split-adjusted basis under the same symbol "TAOP" but with new CUSIP number, G8675V 127.
As a result of the share consolidation, each ten Ordinary Shares outstanding will automatically combine and convert to one issued and outstanding Ordinary Share without any action on the part of shareholders who hold their shares in brokerage accounts or "street name". Shareholders holding certificates of Ordinary Shares are expected to receive instructions from the Company's transfer agent, Transhare Corporation, regarding procedures for exchanging share certificates. All outstanding options, warrants and other rights to purchase the Company's Ordinary Shares will be adjusted proportionately as a result of the reverse stock split. No fractional shares will be issued as a result of the reverse stock split, and instead, all such fractional shares resulting from the reverse stock split will be rounded up to the nearest whole share.
The reverse stock split is intended to increase the per share trading price of the Ordinary Shares to satisfy the $1.00 minimum bid price requirement for continued listing on the NASDAQ Stock Market. Following the reverse stock split the Company will have approximately 1.86 million Ordinary Shares issued and outstanding, exclusive of shares issuable under outstanding options and warrants. The reverse stock split will not affect the number of total authorized Ordinary Shares of the Company.
About Taoping Inc.
Taoping Inc. (Nasdaq: TAOP) has a long history of successfully leveraging technology in the development of innovative solutions to help customers in both the private and public sectors to more effectively communicate and market to their desired targets. The Company has built a far-reaching city partner ecosystem and comprehensive portfolio of high-value, high-traffic areas for its products, which are aligned together with Taoping's smart cloud platform, cloud services and solutions, new media and artificial intelligence. For more information about Taoping, please visit www.taop.com. You can also follow us via LinkedIn, Twitter or YouTube.
Safe Harbor Statement
This press release contains "forward-looking statements" that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, such as statements regarding our estimated future results of operations and financial position, our strategy and plans, and our objectives or goals, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. We have attempted to identify forward-looking statements by terminology including "anticipates," "believes," "can," "continue," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "should," or "will" or the negative of these terms or other comparable terminology. Our actual results may differ materially or perhaps significantly from those discussed herein, or implied by, these forward-looking statements. There are a significant number of factors that could cause actual results to differ materially from statements made in this press release, including: our potential inability to achieve or sustain profitability or reasonably predict our future results due to our limited operating history of providing smart cloud services, the effects of the global Covid-19 pandemic, the emergence of additional competing technologies, changes in domestic and foreign laws, regulations and taxes, uncertainties related to China's legal system and economic, political and social events in China, the volatility of the securities markets; and other risks including, but not limited to, those that we discussed or referred to in the Company's disclosure documents filed with the U.S. Securities and Exchange Commission (the "SEC") available on the SEC's website at www.sec.gov, including the Company's most recent Annual Report on Form 20-F as well as in our other reports filed or furnished from time to time with the SEC. The forward-looking statements included in this press release are made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking statements, other than as required by applicable law.
View original content to download multimedia:
SOURCE Taoping Inc. | https://www.kfyrtv.com/prnewswire/2023/07/31/taoping-announces-1-for-10-reverse-stock-split/ | 2023-07-31T11:20:20 | 1 | https://www.kfyrtv.com/prnewswire/2023/07/31/taoping-announces-1-for-10-reverse-stock-split/ |
NEW YORK (AP) — Six straight days of 12-hour driving. Single digit paychecks. The complaints come from workers in vastly different industries: UPS delivery drivers and Hollywood actors and writers.
But they point to an underlying factor driving a surge of labor unrest: The cost to workers whose jobs have changed drastically as companies scramble to meet customer expectations for speed and convenience in industries transformed by technology.
The COVID-19 pandemic accelerated those changes, pushing retailers to shift online and intensifying the streaming competition among entertainment companies. Now, from the picket lines, workers are trying to give consumers a behind-the-scenes look at what it takes to produce a show that can be binged any time or get dog food delivered to their doorstep with a phone swipe.
Overworked and underpaid employees is an enduring complaint across industries — from delivery drivers to Starbucks baristas and airline pilots — where surges in consumer demand have collided with persistent labor shortages. Workers are pushing back against forced overtime, punishing schedules or company reliance on lower-paid, part-time or contract forces.
At issue for Hollywood screenwriters and actors staging their first simultaneous strikes in 40 years is the way streaming has upended entertainment economics, slashing pay and forcing showrunners to produce content faster with smaller teams.
“This seems to happen to many places when the tech companies come in. Who are we crushing? It doesn’t matter,” said Danielle Sanchez-Witzel, a screenwriter and showrunner on the negotiating team for the Writers Guild of America, whose members have been on strike since May. Earlier this month, the Screen Actors Guild–American Federation of Television and Radio Artists joined the writers’ union on the picket line.
Actors and writers have long relied on residuals, or long-term payments, for reruns and other airings of films and televisions shows. But reruns aren’t a thing on streaming services, where series and films simply land and stay with no easy way, such as box office returns or ratings, to determine their popularity.
Consequently, whatever residuals streaming companies do pay often amount to a pittance, and screenwriters have been sharing tales of receiving single digit checks.
Adam Shapiro, an actor known for the Netflix hit “Never Have I Ever,” said many actors were initially content to accept lower pay for the plethora of roles that streaming suddenly offered. But the need for a more sustainable compensation model gained urgency when it became clear streaming is not a sideshow, but rather the future of the business, he said.
“Over the past 10 years, we realized: ‘Oh, that’s now how Hollywood works. Everything is streaming,’” Shapiro said during a recent union event.
Shapiro, who has been acting for 25 years, said he agreed to a contract offering 20% of his normal rate for “Never Have I Ever” because it seemed like “a great opportunity, and it’s going to be all over the world. And it was. It really was. Unfortunately, we’re all starting to realize that if we keep doing this we’re not going to be able to pay our bills.”
Then there’s the rising use of “mini rooms,” in which a handful of writers are hired to work only during pre-production, sometimes for a series that may take a year to be greenlit, or never get picked up at all.
Sanchez-Witzel, co-creator of the recently released Netflix series “Survival of the Thickest,” said television shows traditionally hire robust writing teams for the duration of production. But Netflix refused to allow her to keep her team of five writers past pre-production, forcing round-the-clock work on rewrites with just one other writer.
“It’s not sustainable and I’ll never do that again,” she said.
Sanchez-Witzel said she was struck by the similarities between her experience and those of UPS drivers, some of whom joined the WGA for protests as they threatened their own potentially crippling strike. UPS and the Teamsters last week reached a tentative contract staving off the strike.
Jeffrey Palmerino, a full-time UPS driver near Albany, New York, said forced overtime emerged as a top issue during the pandemic as drivers coped with a crush of orders on par with the holiday season. Drivers never knew what time they would get home or if they could count on two days off each week, while 14-hour days in trucks without air conditioning became the norm.
“It was basically like Christmas on steroids for two straight years. A lot of us were forced to work six days a week, and that is not any way to live your life,” said Palmerino, a Teamsters shop steward.
Along with pay raises and air conditioning, the Teamsters won concessions that Palmerino hopes will ease overwork. UPS agreed to end forced overtime on days off and eliminate a lower-paid category of drivers who work shifts that include weekends, converting them to full-time drivers. Union members have yet to ratify the deal.
The Teamsters and labor activists hailed the tentative deal as a game-changer that would pressure other companies facing labor unrest to raise their standards. But similar outcomes are far from certain in industries lacking the sheer economic indispensability of UPS or the clout of its 340,000-member union.
Efforts to organize at Starbucks and Amazon stalled as both companies aggressively fought against unionization.
Still, labor protests will likely gain momentum following the UPS contract, said Patricia Campos-Medina, executive director of the Worker Institute at the School of Industrial and Labor Relations at Cornell University, which released a report this year that found the number of labor strikes rose 52% in 2022.
“The whole idea that consumer convenience is above everything broke down during the pandemic. We started to think, ‘I’m at home ordering, but there is actually a worker who has to go the grocery store, who has to cook this for me so that I can be comfortable,’” Campos-Medina said. | https://www.yourbasin.com/news/national-news/customers-want-instant-gratification-workers-say-theyre-on-the-brink/ | 2023-07-31T11:20:22 | 0 | https://www.yourbasin.com/news/national-news/customers-want-instant-gratification-workers-say-theyre-on-the-brink/ |
Trump could be indicted soon in Georgia. Here’s a look at that investigation
ATLANTA (AP) — A Georgia prosecutor is expected to seek a grand jury indictment in the coming weeks in her investigation into efforts by Donald Trump and his Republican allies to overturn the former president’s 2020 election loss.
Fulton County District Attorney Fani Willis began investigating more than two years ago, shortly after a recording was released of a January 2021 phone call Trump made to Georgia’s secretary of state.
Willis has strongly hinted that any indictment would come between July 31 and August 18. One of two grand juries seated July 11 is expected to hear the case.
If Trump is indicted by a Georgia grand jury, it would add to a growing list of legal troubles as he campaigns for president. Trump is set to go to trial in New York in March to face state charges related to hush-money payments made during the 2016 presidential campaign. And he has another trial scheduled for May on federal charges related to his handling of classified documents. He has pleaded not guilty in those cases.
The Justice Department is also investigating Trump’s role in trying to halt the certification of 2020 election results in the run-up to the Jan. 6, 2021, assault on the U.S. Capitol. Trump said he’s been told he’s a target of that investigation, which likely has some overlap with the one in Georgia.
Details of the Georgia investigation that have become public have fed speculation that Willis, a Democrat, is building a case under the Georgia Racketeer Influenced and Corrupt Organizations Act, which would allow her to charge numerous people in a potentially wide-ranging scheme.
Here are six investigative threads Willis and her team have explored:
THE PHONE CALLS
The Georgia investigation was prompted by the Jan. 2, 2021 phone call Trump made to Georgia Secretary of State Brad Raffensperger. Trump suggested the state’s top elections official could help “find” the votes needed to put him ahead of Democrat Joe Biden in the state.
“All I want to do is this: I just want to find 11,780 votes, which is one more than we have,” Trump is heard saying on a recording of the call, which was leaked to news outlets. “Because we won the state.”
Trump has insisted he did nothing wrong and has repeatedly said the call was “perfect.”
Trump also called other top state officials in his quest to overturn his 2020 election loss, including Gov. Brian Kemp, then-House Speaker David Ralston, Attorney General Chris Carr and the top investigator in the secretary of state’s office.
U.S. Sen. Lindsey Graham, a South Carolina Republican, also called Raffensperger shortly after the November election. Raffensperger said at the time that Graham asked whether he had the power to reject certain absentee ballots, which Raffensperger has said he interpreted as a suggestion to toss out legally cast votes.
Graham has denied wrongdoing, saying he just wanted to learn about the signature verification process.
FAKE ELECTORS
Biden won Georgia by a margin of fewer than 12,000 votes. Just over a month after the election, on Dec. 14, 2020, a group 16 Georgia Democratic electors met in the Senate chamber at the state Capitol to cast the state’s Electoral College votes for him. They each marked paper ballots that were counted and confirmed by a voice roll call.
That same day, in a committee meeting room at the Capitol, 16 prominent Georgia Republicans — a lawmaker, activists and party officials — met to sign a certificate falsely stating that Trump had won and declaring themselves the state’s “duly elected and qualified” electors. They sent that certificate to the National Archives and the U.S. Senate.
Georgia was one of seven battleground states that Trump lost where Republican fake electors signed and submitted similar certificates. Trump allies in the U.S. House and Senate used those certificates to argue for delaying or blocking the certification of the election during a joint session of Congress.
Prosecutors in Fulton County have said in court filings that they believe Trump associates worked with state Republicans to coordinate and execute the plan.
The multi-state effort was ultimately unsuccessful. Despite public pressure from Trump and his supporters, then-Vice President Mike Pence refused on Jan. 6, 2021, to introduce the unofficial pro-Trump electors. After the attack on the U.S. Capitol put a violent halt to the certification process, lawmakers certified Biden’s win in the early hours of Jan. 7, 2021.
At least eight of the fake electors have since reached immunity deals with Willis’ team. And a judge last summer barred Willis from prosecuting another one, Lt. Gov. Burt Jones, because of a conflict of interest.
FALSE CLAIMS OF ELECTION FRAUD
Republican state lawmakers held several hearings at the Georgia Capitol in December 2020 to examine alleged problems with the November election. During those meetings, former New York mayor Rudy Giuliani and other Trump allies made unproven claims of widespread election fraud.
They alleged that election workers tallying absentee ballots at State Farm Arena in Atlanta had told outside observers to leave and then pulled out “suitcases” of unlawful ballots and began scanning them. The Trump allies played clips of surveillance video from the arena to support their allegations. State and federal officials investigated and said there was no evidence of election fraud at the site.
Some Trump allies also said thousands of people who were ineligible — including people convicted of felonies, people younger than the age of 18, people who had voted in another state — had cast votes in Georgia. The secretary of state’s office has debunked those claims.
ALLEGED ATTEMPTS TO PRESSURE ELECTION WORKER
Two of the election workers seen in the State Farm Arena surveillance video, Ruby Freeman and her daughter Wandrea “Shaye” Moss, said they faced relentless harassment online and in person as a result of the allegations made by Trump and his allies.
Giuliani last week conceded that statements he made about the two election workers were false.
In a bizarre episode detailed by prosecutors in court filings, a woman traveled from Chicago to Georgia and met with Freeman on Jan. 4, 2021. The woman initially said she wanted to help Freeman but then warned that Freeman could go to prison and tried to pressure her into falsely confessing to committing election fraud, prosecutors wrote in court filings last year.
ELECTION EQUIPMENT ACCESSED
Trump-allied lawyer Sidney Powell and others hired a computer forensics team to copy data and software on election equipment in Coffee County, some 200 miles southeast of Atlanta, according to invoices, emails, security video and deposition testimony produced in response to subpoenas in a long-running lawsuit.
The county Republican Party chair at the time — who also served as a fake elector — greeted them when they arrived at the local elections office on Jan. 7, 2021, and some county elections officials were also on hand during the daylong visit. The secretary of state’s office has said this amounted to “alleged unauthorized access” of election equipment, and the Georgia Bureau of Investigation is looking into it at the secretary of state’s request.
Two other men who have been active in efforts to question the 2020 election results also visited Coffee County later that month and spent hours inside.
U.S. ATTORNEY RESIGNATION
U.S. Attorney BJay Pak, the top federal prosecutor in Atlanta, abruptly resigned two days after Trump called Raffensperger and a day after a recording of that call was made public. During that conversation, Trump called Pak a “never-Trumper,” implying that he didn’t support the president.
In December 2020, then-U.S. Attorney General William Barr asked Pak to investigate allegations by Giuliani and other Trump allies of widespread election fraud. Pak, who had been appointed by Trump in 2017, reported back that he had found no evidence of such fraud.
In August 2021, Pak told the U.S. Senate Judiciary Committee, which was investigating Trump’s post-election actions, that he resigned on Jan. 4, 2021, after learning from Department of Justice officials that Trump did not believe enough was being done to investigate allegations of election fraud and wanted him gone as U.S. attorney.
Copyright 2023 The Associated Press. All rights reserved. | https://www.wistv.com/2023/07/31/trump-could-be-indicted-soon-georgia-heres-look-that-investigation/ | 2023-07-31T11:20:22 | 1 | https://www.wistv.com/2023/07/31/trump-could-be-indicted-soon-georgia-heres-look-that-investigation/ |
The New York Jets face the Cleveland Browns in the NFL Hall of Fame preseason game on Thursday, August 3, 2023 (8/3/23) at Tom Benson Stadium in Canton, Ohio.
TICKETS: Fans who want to attend the game can buy tickets at StubHub, TicketSmarter and Vivid Seats. Book your flights at Expedia, CheapTickets or Priceline, and find a hotel with Hotels.com or Choice Hotels.
According to Vivid Seats, ticket prices to this game range from $166 to $325.
Here’s what you need to know:
What: NFL Hall of Fame game
Who: New York Jets vs. Cleveland Browns
When: Thursday, August 3, 2023
Time: 8 p.m.
Where: Tom Benson Stadium
TV: NBC
Channel finder: Verizon Fios, Comcast Xfinity,Spectrum/Charter,Optimum/Altice,Cox,DIRECTV,Dish,Hulu, fuboTV, Sling.
Live stream: Fubotv (free trial), Peacock ($5.99 a month)
***
Here’s a recent AP story on Dalvin Cook:
FLORHAM PARK, N.J. (AP) — Dalvin Cook got an up-close view of Aaron Rodgers and the New York Jets while watching practice from the sideline Sunday.
The free agent running back has to see if he’ll spend the rest of training camp in their backfield — or elsewhere.
Cook spent Sunday meeting with the Jets as he ponders the next stop of his playing career. The four-time Pro Bowl selection was released by the Vikings on June 8 for salary cap savings, according to a person familiar with Minnesota’s decision.
The Jets are the first team Cook has officially visited as a free agent, with his hometown Miami Dolphins also among possible suitors. New York also must consider whether to make him an offer before he leaves the team’s practice facility.
Cook, who turns 28 on Aug. 10, was greeted by chants of “Dal-vin Cooook! Sign that contract!” from fans in the stands as he walked onto the field. He later responded to the post on X, formerly known as Twitter, with a green heart emoji.
Several Jets players, including Rodgers, greeted Cook and he spent a few moments chatting with owner Woody Johnson.
“He’s a good young man, a very good young man,” Jets coach Robert Saleh said. “We didn’t interact too much. There’s a lot of stuff going on, especially when it’s open to the public. But it was good to say hello.”
Cook has talked up the Jets in TV interviews in recent days, telling NFL Network’s “Good Morning Football” on Friday they “are right at the top of the list” and the odds of him signing with them were “pretty high.”
“It’s a unique situation because I think they’re building something special over there,” Cook told “Good Morning Football” during the interview. “When you look at it, you always want to be around a great QB, you always want to be around somebody you can pick his brain and just learn from. A-Rod is a four-time MVP. So, just being around a guy like that you can learn a lot more and just develop as a player.
“That’s what I’m looking to do.”
He reiterated those comments Saturday during an interview with ESPN, saying he thinks “the coaching staff, I think everything about what they got going on, just says winning.”
But Cook, a former Florida State star, also said in the interview he was interested in the Dolphins and it would be “a Cinderella story” to play for his hometown team.
He was the guest of the Jets on Sunday, though. And now they have to wait to see if they offer Cook a deal and he accepts — or explores his options.
Both sides have expressed interest, and the Jets wanted Cook to take a physical to be sure his surgically repaired shoulder is healthy.
“That’s pretty much it,” Saleh said. “Call it a meet and greet.”
Cook, who has run for at least 1,000 yards in each of the past four seasons, was scheduled to count more than $14.1 million against the Vikings’ salary cap before he was released. He’s third on Minnesota’s career rushing list with 5,993 yards in six seasons.
With the Jets, Cook could give New York some insurance in the backfield with Breece Hall working his way back from a knee injury that cut short a promising rookie season. New York also has Michael Carter, Zonovan Knight, Damarea Crockett, fifth-round draft pick Israel Abanikanda and undrafted free agent Travis Dye at the position.
NOTES: Saleh said WR Garrett Wilson has a lower right ankle injury and the Jets are being cautious by holding him out of practice. Wilson appeared to have a slight limp and his right ankle was wrapped. ... WR Corey Davis remains out with an illness, but Saleh said he could return to practice Monday. ... WR Randall Cobb was activated from the physically unable to perform list and participated in practice. ... Saleh said the starters aren’t expected to play Thursday night in the Hall of Fame game against Cleveland in Canton, Ohio. Among those players who will play include QB Zach Wilson and OT Mekhi Becton.
(The Associated Press contributed to this report.)
Thank you for relying on us to provide the journalism you can trust. Please consider supporting us with a subscription.
Cayden Steele may be reached at CSteele@njadvancemedia.com | https://www.nj.com/sports/2023/07/new-york-jets-vs-cleveland-browns-tickets-at-tom-benson-stadium-where-to-buy-cheapest-last-minute-tickets-for-nfl-hall-of-fame-game.html | 2023-07-31T11:20:23 | 1 | https://www.nj.com/sports/2023/07/new-york-jets-vs-cleveland-browns-tickets-at-tom-benson-stadium-where-to-buy-cheapest-last-minute-tickets-for-nfl-hall-of-fame-game.html |
16TH annual event features turtles named after characters in Disney's frighteningly fun adventure movie, "Haunted Mansion," now playing in theaters.
VERO BEACH, Fla., July 31, 2023 /PRNewswire/ -- Over the weekend at Disney's Vero Beach Resort, researchers from the Sea Turtle Conservancy (STC) and Disney Conservation released two sea turtles as part of the 16th annual Tour de Turtles "migration marathon." Tour de Turtles is a fun, educational event that follows the migration of sea turtles from their nesting beaches to their feeding grounds and, ultimately, provides scientific data on how best to protect their species.
The Disney Conservation Fund (DCF) and Disney Cruise Line are each sponsoring a turtle this year, whose names, Madame Leota and Harriet, are the names of characters in Disney's frighteningly fun adventure movie "Haunted Mansion," now playing in theaters. Not unlike Gabbie, another character in the film who enlists a motley crew of so-called spiritual experts to help rid their home of supernatural squatters – Tour de Turtles brings together a team of researchers from the STC and Disney Conservation annually to undertake a daunting mission - using satellite telemetry to track two female turtles to determine where and how far they swim during the migration season.
Each turtle swims to raise awareness about various threats to sea turtle survival. The turtle to swim the furthest distance will win the Tour de Turtles race.
"Disney's commitment to sea turtle conservation in Vero Beach spans 20 years, and we are very proud to have recently watched our 1.5 millionth sea turtle hatchling leave the nest and shuffle its way to the ocean," said Mark Penning, Vice President of Disney's Animals, Science and Environment. "Southeast Florida hosts one of the largest nesting aggregations of loggerhead sea turtles, making up to 40 percent of the global loggerhead population. The team has recorded more than 20,000 sea turtle nests on our survey route since the program began."
The data collected during Tour de Turtles helps researchers, conservationists and governing agencies make more informed decisions about sea turtle conservation and management. Since the launch of the event in 2008, STC and Disney have collaborated to study 29 sea turtles outfitted with satellite transmitters and released from Disney's Vero Beach Resort. Continuing its commitment to strengthen youth education programs in port communities around the world, Disney Cruise Line proudly supported local students from Club Esteem from Melbourne, Florida, to participate in this year's event. DCF also has directed more than $5.1 million to support global sea turtle conservation efforts.
"Disney is a fantastic collaborator," said David Godfrey, STC Executive Director. "Disney's commitment to conservation, passion for environmental education, and effectiveness at communicating with audiences have made the Tour de Turtles a fun and successful program since it was launched over a decade ago."
In addition to Tour de Turtles, the Disney Conservation team has dedicated nearly 19,000 hours to studying and monitoring sea turtle nests during the summer nesting season along the five-mile coastline at Disney's Vero Beach Resort. From approximately May to October, Disney Vacation Club members and resort guests also have the opportunity to assist the team by joining outings to observe real-time sea turtle research while learning how they can take action to protect sea turtles. So far this year, the Disney Conservation team has a record-breaking number of nests along their survey route – nearly 2,000 by August, well above the average 1,500 normally counted in an entire season.
Tour de Turtles is a research and education program of the Sea Turtle Conservancy and Disney's support is just one example of bringing Disney Planet Possible to life by taking action to make a happier, healthier planet possible for all. To learn more and follow the turtles' migration, visit the Tour de Turtles website at www.tourdeturtles.org
ABOUT DISNEY'S VERO BEACH RESORT
Disney's Vero Beach Resort, a Disney Vacation Club Resort, offers spacious vacation villas along the pristine Atlantic coastline. The resort is located less than a two-hour drive from the Walt Disney World Resort, and its design reflects the Treasure Coast region where it is situated. Disney Vacation Club, a leader in vacation ownership, debuted in 1991 with a flexible, vacation points-based system rather than the traditional fixed-week timeshare model. Disney Vacation Club Members are able to choose from among a variety of exciting vacation destinations, including a stay at any Disney Vacation Club Resort or one of thousands of other vacation options in destinations around the world.
ABOUT DISNEY'S "HAUNTED MANSION"
Inspired by the classic theme park attraction, Disney's "Haunted Mansion" is about a woman and her son who enlist a motley crew of so-called spiritual experts to help rid their home of supernatural squatters.
Directed by Justin Simien, the film features an all-star cast ensemble including LaKeith Stanfield, Tiffany Haddish, Owen Wilson, Danny DeVito, Rosario Dawson, Chase W. Dillon and Daniel Levy, with Jamie Lee Curtis and Jared Leto as The Hatbox Ghost. The film's producers are Dan Lin and Jonathan Eirich, with Nick Reynolds and Tom Peitzman serving as executive producers.
View original content to download multimedia:
SOURCE Walt Disney World | https://www.kfyrtv.com/prnewswire/2023/07/31/tour-de-turtles-celebrates-sea-turtles-supernatural-science-disneys-vero-beach-resort/ | 2023-07-31T11:20:26 | 0 | https://www.kfyrtv.com/prnewswire/2023/07/31/tour-de-turtles-celebrates-sea-turtles-supernatural-science-disneys-vero-beach-resort/ |
(The Hill) – Dozens of former Cabinet officials under former President Trump’s administration declined to publicly support the former president’s third bid for the White House, NBC News reported.
NBC News reached out to 44 people who previously served in Trump’s Cabinet during his four years in office to gauge whether they would support the former president during the 2024 presidential election. The outlet reported that most of the people declined to comment or ignored the requests and that only four said publicly they would support Trump for the presidency.
Trump’s Cabinet saw a higher rate of turnover compared with many of his predecessors, with many new officials rotating in and out of his administration over the four years. The only four former Cabinet members who NBC News reached out to who said they would support Trump are former acting Attorney General Matthew Whitaker, former chief of staff Mark Meadows, former Office of Management and Budget (OMB) director Russell Vought and former acting director of national intelligence Richard Grenell.
A spokesperson for Meadows told NBC News that he “fully” supports Trump. In May, Vought posted on X, the site formerly known as Twitter, that the former president is “the only person I trust to take a wrecking ball to the Deep State.”
Other former administration officials were reluctant to support Trump or have publicly said they will not support him. Former Attorney General Bill Barr told NBC News that he opposes Trump getting the 2024 GOP nomination but declined whether to say he would support him in the general election if pitted against President Biden.
Top Stories from The Hill
- White House takes the gloves off ahead of 2024
- Trump attorney calls him ‘the most ethical American I know’ in wake of superseding indictment
- Murphy says Alito’s Supreme Court seat ‘exists only because of an act passed by Congress’
- Trump attorney calls him ‘the most ethical American I know’ in wake of superseding indictment
Former chief of staff Mick Mulvaney also said that he does not want Trump to get the Republican nomination for president.
“I am working hard to make sure that someone else is the nominee,” Mulvaney told NBC News. “I think he’s the Republican who is most likely to lose in a general election, of all our leading candidates. If anyone can lose to Joe Biden, it would be him.”
Other former officials who have not endorsed Trump yet include former Secretary of State Mike Pompeo, former Defense Secretary Patrick Shanahan, former chief of staff John Kelly and Joseph Maguire and Dan Coats, who each once served as director of national intelligence. Coats told NBC News that he would be supporting former Vice President Mike Pence for the GOP primary.
The Hill has reached out to Trump’s campaign for comment. | https://www.yourbasin.com/news/national-news/dozens-of-former-trump-cabinet-officials-wont-publicly-support-his-2024-bid/ | 2023-07-31T11:20:28 | 0 | https://www.yourbasin.com/news/national-news/dozens-of-former-trump-cabinet-officials-wont-publicly-support-his-2024-bid/ |
WATCH: Concertgoer throws drink at Cardi B; she hurls microphone at them
Published: Jul. 31, 2023 at 6:58 AM EDT|Updated: 22 minutes ago
LAS VEGAS (CNN) - Cardi B hurled her microphone at a fan during a concert in Las Vegas on Saturday.
The rapper was performing her song “Bodak Yellow” when a concertgoer threw a drink at her.
In seconds, Cardi B threw her microphone into the crowd as the song continued to play.
Security guards rushed to the stage.
More security guards are then seen flocking to the person in the crowd as she watched from the stage before continuing with her set.
There’s no word on what happened to the fan or if any charges will be filed.
Copyright 2023 CNN Newsource. All rights reserved. | https://www.wistv.com/2023/07/31/watch-concertgoer-throws-drink-cardi-b-she-hurls-microphone-them/ | 2023-07-31T11:20:28 | 1 | https://www.wistv.com/2023/07/31/watch-concertgoer-throws-drink-cardi-b-she-hurls-microphone-them/ |
The New York Yankees, led by Aaron Judge, face the Tampa Bay Rays in an MLB regular season game on Monday, July 31, 2023 (7/31/23) at Yankee Stadium in Bronx, New York.
HOW TO WATCH (LOCAL): Local fans can watch the game for free via a trial of DirecTV Stream, which carries YES Network (New York) and Bally Sports Sun (Florida).
BUY YANKEES TICKETS: STUBHUB, VIVID SEATS, TICKETSMARTER
Here’s what you need to know:
What: MLB regular season
Who: Yankees vs. Rays
When: Monday, July 31, 2023
Where: Yankee Stadium
Time: 7 p.m. ET
TV: YES Network (New York) and Bally Sports Sun (Florida)
Channel finder: Verizon Fios, Comcast Xfinity, Spectrum/Charter, Optimum/Altice, Cox, DIRECTV, Dish, Hulu, fuboTV, Sling.
Live stream: DirecTV Stream (free trial)
Here’s a recent AP Story on the New York Yankees:
BALTIMORE (AP) — Aaron Judge is giving the New York Yankees an immediate boost — at a time when their front office has some tough decisions to make.
Judge homered and singled twice in his second game back from the injured list and the Yankees beat the Baltimore Orioles 8-3 on Saturday night. Giancarlo Stanton and Kyle Higashioka went deep as well for New York, which is still 3 1/2 games behind Toronto and Houston for the last two wild cards in the American League.
That’s a tricky spot with Tuesday’s trade deadline approaching.
“We’ve had years where we stick with who we got. We’ve had years where we get some bullpen arms, starters, a big bat,” Judge said. “It comes down to us doing our job on the field and then letting them take care of the rest. We’ll see what happens.”
The Yankees knocked out struggling Orioles starter Tyler Wells (7-6) in the third inning. In the sixth, Isiah Kiner-Falefa capped a 10-pitch at-bat with a three-run double to make it 8-3.
Judge has three walks and three hits in nine plate appearances since returning Friday from the toe injury that kept him out since early June.
Ryan Mountcastle homered for the Orioles, but Clarke Schmidt (7-6) made it through five tough innings and the New York bullpen took it from there.
The Orioles remained 1 1/2 games ahead of Tampa Bay atop the AL East.
Judge walked three times Friday night, but the Yankees lost that game 1-0 on a ninth-inning homer by Baltimore’s Anthony Santander. New York’s offense was relentless a night later.
Stanton’s first-inning drive easily cleared the big wall in left field at Camden Yards. Mountcastle tied it in the second, and Baltimore went ahead 2-1 on an RBI infield single by Ramón Urías. That lead was short-lived.
Judge hit a two-run shot — 442 feet to center field — in the third. Then Gleyber Torres added a sacrifice fly an inning later.
Santander made it 4-3 with an RBI groundout in the fifth, but New York broke the game open in the sixth. Cole Irvin allowed a leadoff homer by Higashioka — his third hit of the night — and then one-out singles to Judge, Stanton and Anthony Rizzo.
Bryan Baker came in and struck out DJ LeMahieu, but after fouling off five pitches, Kiner-Falefa cleared the bases with a line drive to left.
“One of the best at-bats of the season right there,” Yankees manager Aaron Boone said.
Wells entered the game with a major league-leading WHIP of 0.99, but he allowed three runs, three hits and three walks in 2 2/3 innings. In three starts since the All-Star break, he’s lasted just nine innings total.
“I think we’re going to be talking about a lot of things here coming up,” Orioles manager Brandon Hyde said. “Obviously, we’re in a weird week. He’s had tough times his last few starts. I think there are going to be discussions going on.”
Boone said he’s leaning toward giving Judge a day off in the series finale Sunday night. The Yankees are in a stretch of 13 games in 13 days.
“I kind of look at it as, hopefully he’s in a position to start nine or 10 of them,” Boone said. “Forget the toe. He hasn’t come close to playing games for almost two months. As much as I want him in there, we’ve got to be smart here a little bit, especially in this run.”
DIFFERENT ORDER
The Orioles used catcher Adley Rutschman in the leadoff spot because of his ability to get on base. He was hit by a pitch, walked and scored a run.
UP NEXT
New York’s Luis Severino (2-4) starts Sunday night against Baltimore’s Dean Kremer (10-4). It’s the final game of the season series, which is tied 6-all.
(The Associated Press contributed to this report.)
Thank you for relying on us to provide the journalism you can trust. Please consider supporting us with a subscription.
Cayden Steele may be reached at CSteele@njadvancemedia.com | https://www.nj.com/sports/2023/07/what-channel-is-the-yankees-game-on-tonight-free-live-stream-time-tv-channel-for-new-york-yankees-vs-tampa-bay-rays.html | 2023-07-31T11:20:29 | 1 | https://www.nj.com/sports/2023/07/what-channel-is-the-yankees-game-on-tonight-free-live-stream-time-tv-channel-for-new-york-yankees-vs-tampa-bay-rays.html |
BALTIMORE — Yankees utilityman Isiah Kiner-Falefa isn’t like many ballplayers this time of the year. His name hasn’t been in any trade rumors, but he’s been thinking about Tuesday’s deadline.
IKF admitted being worried that he could be moved before the Yankees’ game at Oriole Park on Sunday night, a 9-3 loss to the Orioles.
And how about this for a different take:
“At the end of the day, if I get traded and it helps these guys get a ring, I get a ring.”
BUY YANKEES TICKETS: STUBHUB, VIVID SEATS, TICKETSMARTER, TICKETMASTER
Kiner-Falefa wants to stay with the Yankees. After starting at shortstop last year, he’s enjoying his new role, a lot of outfield and some infield.
IKF probably is a longshot to be traded, but he knows that he could lose playing time if GM Brian Cashman addresses his club’s biggest need:
Left field.
There aren’t many good options.
The Yankees were linked to Cody Bellinger, who would be a great fit, but the Cubs took the former MVP off the market over the weekend because they got really hot to play their way into a playoff race.
That probably left Randal Grichuk as the next best option for the Yankees.
Until Sunday night.
While the Yankees were being blown out at Oriole Park, the Rockies traded Grichuk and first baseman C.J. Cron to the Angels.
Grichuk isn’t Bellinger at the plate or in the field, but he has good right-handed power and is batting a career-best .308. He would have been an upgrade for the Yankees in left over what the Yankees have been starting in left — IKF, Billy McKinney, Jake Bauers and Greg Allen.
Now what?
The Yankees could address left field by dealing with the Mets for Tommy Pham or trade with the Cardinals for Dylan Carlson.
The one home run that Cashman could hit is giving up a big chunk of the farm system to pry Juan Soto from the Padres.
That’s a pipedream though. Soto probably won’t be moved and the Yankees probably wouldn’t meet San Diego’s very steep price if it wanted to move him. Also, Hal Steinbrenner might not OK adding Soto’s contract (prorated $23M this season) without subtracting elsewhere with the Yankees up against the highest luxury-tax threshold.
Meanwhile, the Yankees’ current left fielders are waiting to see what Cashman does. They know a regular could be dealt their way and shake up their world.
“I watch MLB Network enough to see what’s going on,” Bauers said. “You see what’s being talked about. But I’m all for making the team better. If that means bringing someone in, then that’s bringing someone in.
“Really all I want to do is win baseball games. If that means coming off the bench, if that means playing left field, it is what it is. I’m ready for whatever role they have for me.”
The thing is, if the Yankees trade for an outfielder, someone is losing their roster spot.
“I know it’s easy to say you don’t think about it, but you wake up and you see the date and you know,” McKinney said.
McKinney can’t help but pay attention because he’s been moved three times in trade-deadline deals.
IKF was traded twice in two days early into 2022 spring training, but never during a season. With the Yankees out of a playoff spot with two months to go, he’s concerned he could be moved if Cashman opts to dump salary because he’ll be a free agent after the 2023 season.
“It could be me,” Kiner-Falefa said. “I really want to be here, but it is what it is. It’s a business. Everybody understands that.”
Thank you for relying on us to provide the journalism you can trust. Please consider supporting us with a subscription.
Randy Miller may be reached at rmiller@njadvancemedia.com. | https://www.nj.com/yankees/2023/07/its-slim-pickings-for-yankees-who-watch-a-big-bat-go-elsewhere-with-trade-deadline-looming.html | 2023-07-31T11:20:31 | 1 | https://www.nj.com/yankees/2023/07/its-slim-pickings-for-yankees-who-watch-a-big-bat-go-elsewhere-with-trade-deadline-looming.html |
This Launch Marks the Latest Expansion of the Brand's Complexion Offerings as it Doubles Down on The Skincare-Meets-Makeup Hybrid Category
NEW YORK, July 31, 2023 /PRNewswire/ -- TULA Skincare, the leading clinically proven probiotic extract powered skincare brand has announced the expansion of its complexion offerings to include concealer.
After learning that TULA's customers were looking for a skin brightening eye treatment along with a concealer, the brand created a state-of-the-art clean skincare-makeup hybrid that delivers skin-boosting benefits with high-performance medium-to-full coverage.
Available in a 20-shade range, the dermatologist-tested, Radiant Skin Brightening Serum Concealer is infused with TULA's unique Rainbow Seabright™ Elixir. This clinically-proven serum-like formula instantly conceals dark circles and discoloration for longwearing, crease-proof results, while brightening the appearance of skin over time. Additional ingredients include TULA's S6Pro Complex® - a US patent pending super six blend of prebiotics and probiotic extracts to help soothe skin, improve skin smoothness and maintain skin balance, along with eye peptides and tea leaf caffeine to help improve the look of dark circles, skin texture, and eye bags. The Radiant Skin Brightening Serum Concealer can be paired with the brand's Radiant Skin Brightening Serum Skin Tint or Filter Primer Blurring & Moisturizing Primer to help build one's complexion wardrobe, or spot conceal for a no-makeup, makeup look.
"Expanding our complexion category to include a concealer was a natural next step for us, especially knowing the strong desire our customers have had for an eye treatment with brightening benefits." said TULA Skincare CEO, Savannah Sachs. " We are excited to have another offering for our glow getters that will surely be a staple in their skincare and beauty routines."
To mark the launch, TULA will be executing a multi-channel launch campaign across its digital platform, and organic social, paid media, and influencer channels. Efforts will include launching a custom "shade finder" on tula.com to help customers find their perfect match concealer shade, highlighting content speaking to the "no-makeup, makeup" and makeup-skincare hybrid trends across TikTok and Instagram, and partnering with a curated set of influencers and providing them with an early access link exclusively for their followers to purchase the concealer prior to launch. In addition to tula.com, the concealer will launch in Ulta Beauty stores nationwide and online and will be featured in an upcoming issue of the Ulta Beauty Magazine, with in-store complexion events planned in the coming months in multiple doors.
TULA's Radiant Skin Brightening Serum Concealer will be available for purchase on July 31 on tula.com, and will retail for $32.
About TULA Skincare
TULA is a doctor-founded skincare brand built on clinically proven formulas powered by probiotic extracts. We believe that the same types of ingredients which are good for your body are also great for your skin. We focus on being healthy, not perfect and on empowering everyone to feel confident in their skin.
Media Contact: Zoe Jeans at Bux + Bewl Communications: zoe@buxandbewl.com
View original content to download multimedia:
SOURCE TULA Skincare | https://www.kfyrtv.com/prnewswire/2023/07/31/tula-skincare-launches-new-radiant-skin-brightening-serum-concealer/ | 2023-07-31T11:20:33 | 0 | https://www.kfyrtv.com/prnewswire/2023/07/31/tula-skincare-launches-new-radiant-skin-brightening-serum-concealer/ |
DENVER (AP) — As Denver neared triple-digit temperatures, Ben Gallegos sat shirtless on his porch swatting flies off his legs and spritzing himself with a misting fan to try to get through the heat. Gallegos, like many in the nation’s poorest neighborhoods, doesn’t have air conditioning.
The 68-year-old covers his windows with mattress foam to insulate against the heat and sleeps in the concrete basement. He knows high temperatures can cause heat stroke and death, and his lung condition makes him more susceptible. But the retired brick layer, who survives on about $1,000 a month largely from Social Security, says air conditioning is out of reach.
“Take me about 12 years to save up for something like that,” he said. “If it’s hard to breathe, I’ll get down to emergency.”
As climate change fans hotter and longer heat waves, breaking record temperatures across the U.S. and leaving dozens dead, the poorest Americans suffer the hottest days with the fewest defenses. Air conditioning, once a luxury, is now a matter of survival.
As Phoenix weathered its 27th consecutive day above 110 degrees (43 Celsius) Wednesday, the nine who died indoors didn’t have functioning air conditioning, or it was turned off. Last year, all 86 heat-related deaths indoors were in uncooled environments.
“To explain it fairly simply: Heat kills,” said Kristie Ebi, a University of Washington professor who researches heat and health. “Once the heat wave starts, mortality starts in about 24 hours.”
It’s the poorest and people of color, from Kansas City to Detroit to New York City and beyond, who are far more likely to face grueling heat without air conditioning, according to a Boston University analysis of 115 U.S. metros.
“The temperature differences … between lower-income neighborhoods, neighborhoods of color and their wealthier, whiter counterparts have pretty severe consequences,” said Cate Mingoya-LaFortune of Groundwork USA, an environmental justice organization. “There are these really big consequences like death. … But there’s also ambient misery.”
Some have window units that can offer respite, but “in the dead of heat, it don’t do nothing,” said Melody Clark, who stopped Friday to get food at a nonprofit in Kansas City, Kansas, as temperatures soared to 101, and high humidity made it feel like 109. When the central air conditioning at her rental house went on the fritz, her landlord installed a window unit. But it doesn’t do much during the day.
So the 45-year-old wets her hair, cooks outside on a propane grill and keeps the lights off indoors. She’s taken the bus to the library to cool off. At night she flips the box unit on, hauling her bed into the room where it’s located to sleep.
As far as her two teenagers, she said: “They aren’t little bitty. We aren’t dying in the heat. … They don’t complain.”
While billions in federal funding have been allocated to subsidize utility costs and the installation of cooling systems, experts say they often only support a fraction of the most vulnerable families and some still require prohibitive upfront costs. Installing a centralized heat pump system for heating and cooling can easily reach $25,000.
President Joe Biden announced steps on Thursday to defend against extreme heat, highlighting the expansion of the Low Income Home Energy Assistance Program, which funnels money through states to help poorer households pay utility bills.
While the program is critical, said Michelle Graff, who studies the subsidy at Cleveland State University, only about 16% of the nation’s eligible population is actually reached. Nearly half of states don’t offer the federal dollars for summer cooling.
“So people are engaging in coping mechanisms, like they’re turning on their air conditioners later and leaving their homes hotter,” Graff said.
While frigid temperatures and high heating bills birthed the term “heat or eat,” she said, “we can now transition to AC or eat, where people are going to have to make difficult decisions.”
As temperatures rise, so does the cost of cooling. And temperatures are already hotter in America’s low-income neighborhoods like Gallegos’ Denver suburb of Globeville, where people live along stretches of asphalt and concrete that hold heat like a cast-iron skillet. Surface temperatures there can be roughly 8 degrees hotter than in Denver’s wealthier neighborhoods, where a sea of vegetation cools the area, according to the environmental advocacy group American Forests.
This disparity plays out nationwide. Researchers at the University of San Diego analyzed 1,056 counties and in over 70%, the poorest areas and those with higher Black, Hispanic and Asian populations were significantly hotter.
About one in 10 U.S. households have no air conditioning, a disparity compounded for marginalized groups, according to a study by the Brookings Institution. Less than 4% of Detroit’s white households don’t have air conditioning; it’s 15% for Black households.
At noon on Friday, Katrice Sullivan sat on the porch of her rented house on Detroit’s westside. It was hot and muggy, but even steamier inside the house. Even if she had air conditioning, Sullivan said she’d choose her moments to run it to keep her electricity bill down.
The 37-year-old factory worker pours water on her head, freezes towels to put around her neck, and sits in her car with the air conditioner on. “Some people here spend every dollar for food, so air conditioning is something they can’t afford,” she said.
Shannon Lewis, 38, lived in her Detroit home for nearly 20 years without air conditioning. Lewis’s bedroom was the only place with a window unit, so she’d squeeze her teenager, 8-year-old and 3-year-old-twins into her queen-size bed to sleep, eat meals and watch television.
“So it was like cool in one room and a heat stroke in another,” Lewis said. For the first time, Lewis now has air conditioning through a local non-profit, she said. “We don’t have to sleep or eat in the same room, we are able to come out, sit at the dining room table, eat like a family.”
After at least 54 died during a 2021 heat wave, mostly elderly people without air conditioning, in the Portland area, Oregon passed a law prohibiting landlords from placing blanket bans on air conditioning units. By and large, however, states don’t have laws requiring landlords to provide cooling.
In the federal Inflation Reduction Act, billions were set aside for tax credits and rebates to help families install energy-efficient cooling systems, but some of those are yet to be available. For people like Gallegos, who doesn’t pay taxes, the available credits are worthless.
The law also offers rebates, the kind of state and federal point-of-sale discounts that Amanda Morian has looked into for her 640-square-foot home.
Morian, who has a 13-week-old baby susceptible to hot weather, is desperate to keep her house in Denver’s Globeville suburb cool. She bought thermal curtains, ceiling fans and runs a window unit. At night she tries to do skin-to-skin touch to regulate the baby’s body temperature. When the back door opens in the afternoon, she said, the indoor temperature jumps a degree.
“All of those are just to take the edge off, it’s not enough to actually make it cool. It’s enough to keep us from dying,” she said.
She got estimates from four different companies for installing a cooling system, but every project was between $20,000 and $25,000, she said. Even with subsidies she can’t afford it.
“I’m finding that you have to afford the project in the first place and then it’s like having a bonus coupon to take $5,000 off of the sticker price,” she said.
Lucy Molina, a single mom in Commerce City, one of Denver’s poorest areas, said her home has reached 107 degrees without air conditioning. Nearby, Molina’s two teenage children slurped popsicles to cool off, lingering in front of the open freezer.
For Molina, who bustled around her kitchen on a recent day when temperatures reached 99 degrees outdoors, it’s hard to see any path to a cooling respite.
“We’re just too poor,” she said. | https://www.yourbasin.com/news/national-news/were-just-too-poor-record-heat-waves-reveal-plight-of-americans-without-air-conditioning/ | 2023-07-31T11:20:34 | 1 | https://www.yourbasin.com/news/national-news/were-just-too-poor-record-heat-waves-reveal-plight-of-americans-without-air-conditioning/ |
BALTIMORE — There never is music in the Yankees clubhouse after losses. Too bad. Don’t Stop Believin’ would have a perfect backdrop to Anthony Rizzo standing there at his Oriole Park locker late Sunday night telling reporters with a straight face the Yankees had plenty of time to let their fabulous roster save the season.
You know what that Journey classic is best known for, right? If only someone had turned out the lights while Rizzo was talking and the clubhouse had become pitch black like the last scene in The Sopranos’ finale. | https://www.nj.com/yankees/2023/07/like-sopranos-finale-anthony-rizzo-and-yankees-look-headed-for-a-blackout-analysis.html | 2023-07-31T11:20:37 | 1 | https://www.nj.com/yankees/2023/07/like-sopranos-finale-anthony-rizzo-and-yankees-look-headed-for-a-blackout-analysis.html |
Launch demonstrates companies' commitment to bringing complex generic medicines to the market to help increase patient access
PITTSBURGH and WOODBURY, Minn., July 31, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, and Kindeva Drug Delivery L.P. today announced the launch of Breyna™ (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, the first generic version of AstraZeneca's Symbicort® with an Abbreviated New Drug Application (ANDA) approved by the U.S. Food and Drug Administration (FDA). Breyna, a drug-device combination product, is indicated for certain patients with asthma or chronic obstructive pulmonary disease (COPD) and will be immediately available in both 80 mcg/4.5 mcg and 160 mcg/4.5 mcg dosage strengths.
Viatris Head of North America Jose Cotarelo said: "We are excited to bring Breyna to the U.S. market for the many Americans living with asthma and COPD. This launch represents years of hard work breaking down barriers to access and builds upon our past successes of bringing other complex products to market as we continue to move up the value chain. Being the first to bring an FDA-approved generic version of Symbicort to patients is a true example of how access is the cornerstone of our mission to empower people worldwide to live healthier at every stage of life."
The indications for Breyna include asthma in patients six years of age and older, and the maintenance treatment of airflow obstruction and reducing exacerbations in patients with COPD, including chronic bronchitis and/or emphysema. Breyna is not indicated for the relief of acute bronchospasm. The 160 mcg/4.5 mcg is the only strength indicated for the treatment of COPD. COPD is a term used to describe a certain kind of chronic lung disease and is characterized by breathlessness; it affects more than 16 million Americans. Asthma causes swelling of the airways resulting in difficulty breathing, and approximately 25 million Americans have the chronic condition.
Milton Boyer, CEO of Kindeva Drug Delivery, added: "The launch of Breyna represents a significant milestone as it is the first FDA-approved generic version of Symbicort in the U.S., one of the most prescribed complex drug-device combination products to treat asthma and COPD. We are pleased for Viatris as well as the many Kindeva colleagues who have worked tirelessly to leverage our complex drug-delivery expertise for this important respiratory product — supporting a persistent need to continue bringing more quality medicines for asthma and COPD to patients."
To further expand access to Breyna, Viatris has established a copay program offered for eligible commercially-insured patients, which may help reduce out-of-pocket expenses on prescriptions to as little as $20 per 30-day supply. The program offers $30/month or up to $360 per year with 12 refills annually. The program will be available in August.
About Breyna
Breyna is indicated for the treatment of asthma in patients 6 years and older not adequately controlled on a long-term asthma-control medication such as an inhaled corticosteroid (ICS) or whose disease warrants initiation of treatment with both an ICS and long-acting beta2-adrenergic agonists (LABA). Breyna 160 mcg/4.5 mcg dosage is indicated for the maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema, and Breyna 160 mcg/4.5 mcg is also indicated to reduce exacerbations of COPD. Breyna is NOT indicated for the relief of acute bronchospasm.
Important Safety Information
Breyna is contraindicated in the primary treatment of status asthmaticus or other acute episode of asthma or COPD where intensive measures are required, and in hypersensitivity to any of the ingredients in Breyna. Use of long-acting beta2-adrenergic agonists (LABA) as monotherapy (without inhaled corticosteroids [ICS]) for asthma is associated with an increased risk of asthma-related death. Available data from controlled clinial trials also suggest that use of LABA as monotherapy increases the risk of asthma-related hospitalization in pediatric and adolescent patients. These findings are considered a class effect of LABA. When LABA are used in fixed dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared to ICS alone. Breyna is NOT a rescue medication and does NOT replace fast-acting inhalers to treat acute symptoms. Breyna should not be initiated in patients during rapidly deteriorating episodes of asthma or COPD. Patients who are receiving Breyna should not use additional formoterol or other LABA for any reason. Localized infections of the mouth and pharynx with Candida albicans has occurred in patients treated with Breyna. Patients should rinse the mouth after inhalation of Breyna. Lower respiratory tract infections, including pneumonia, have been reported following the administration of ICS. Due to possible immunosuppression, potential worsening of infections could occur. A more serious or even fatal course of chickenpox or measles can occur in susceptible patients. It is possible that systemic corticosteroid effects such as hypercorticism and adrenal suppression may occur, particularly at higher doses. Particular care is needed for patients who are transferred from systemically active corticosteroids to ICS. Deaths due to adrenal insufficiency have occurred in asthmatic patients during and after transfer from systemic corticosteroids to less systemically available ICS. Caution should be exercised when considering administration of Breyna in patients on long-term ketoconazole and other known potent CYP3A4 inhibitors. As with other inhaled medications, paradoxical bronchospasm may occur with Breyna. Immediate hypersensitivity reactions may occur, as demonstrated by cases of urticaria, angioedema, rash, and bronchospasm. Excessive beta-adrenergic stimulation has been associated with central nervous system and cardiovascular effects. Breyna should be used with caution in patients with cardiovascular disorders especially coronary insufficiency, cardiac arrhythmias, and hypertension. Long-term use of ICS may result in a decrease in bone mineral density (BMD Assessment of BMD is recommended prior to initiating Breyna and periodically thereafter. ICS may result in a reduction in growth velocity when administered to pediatric patients. Glaucoma, increased intracolular pressure, and cataracts have been reported following the administration of ICS, including budesonide, a component of Breyna. Close monitoring for glaucoma and cataracts is warranted in patients with a change in vision or history of increased intraocular pressure. In rare cases, patients on ICS may present with systemic eosinophilic conditions. Breyna should be used with caution in patients with convulsive disorders, thyrotoxicosis, diabetes mellitus, ketoacidosis, and in patients who are unusually responsive to sympathomimetic amines. The most common adverse reactions ≥3% reported in asthma clinical trials included nasopharyngitis, headache, upper respiratory tract infection, pharyngolaryngeal pain, sinusitis, influenza, back pain, nasal congestion, stomach discomfort, vomiting, and oral candidiasis. The most common adverse reactions ≥3% reported in COPD clinical trials included nasopharyngitis, oral candidiasis, bronchitis, sinusitis, and upper respiratory tract infection. Breyna should be administered with caution to patients being treated with MAO inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents. Beta-blockers may not only block the pulmonary effect of beta-agonists, such as formoterol, but may produce severe bronchospasm in patients with asthma. ECG changes and/or hypokalemia associated with nonpotassium-sparing diuretics may worsen with concomitant beta-agonists. Use caution with the coadministration of Breyna.
About Viatris
Viatris Inc. (NASDAQ: VTRS) is a global healthcare company empowering people worldwide to live healthier at every stage of life. We provide access to medicines, advance sustainable operations, develop innovative solutions and leverage our collective expertise to connect more people to more products and services through our one-of-a-kind Global Healthcare Gateway®. Formed in November 2020, Viatris brings together scientific, manufacturing and distribution expertise with proven regulatory, medical and commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories. Viatris' portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally recognized brands, complex generic and branded medicines, and a variety of over-the-counter consumer products. With more than 38,000 colleagues globally, Viatris is headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at viatris.com and investor.viatris.com, and connect with us on Twitter at @ViatrisInc, LinkedIn and YouTube.
About Kindeva Drug Delivery
Kindeva Drug Delivery is a global contract development manufacturing organization focused on drug-device combination products. Kindeva Drug Delivery develops and manufactures products across a broad range of complex drug-delivery formats, including injectables (autoinjector, intradermal, microneedle), pulmonary & nasal, and transdermal patches. Its service offering spans early-stage feasibility through commercial scale drug product fill-finish, container closure system manufacturing, and drug-device product assembly. Kindeva Drug Delivery serves a global client base from its nine manufacturing and research and development facilities located in the U.S. and U.K. For more information, please visit www.kindevadd.com.
Forward-Looking Statements
This press release includes statements that constitute "forward-looking statements." These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward looking statements may include statements that the launch of Breyna demonstrates the companies' commitment to bringing complex generic medicines to the market to help increase patient access; Breyna will be immediately available in both 80 mcg/4.5 mcg and 160 mcg/4.5 mcg dosage strengths; this launch represents years of hard work breaking down barriers to access and builds upon our past successes of bringing other complex products to market as we continue to move up the value chain; to further expand access to Breyna, Viatris has established a copay program offered for eligible commercially-insured patients, which may help reduce out-of-pocket expenses on prescriptions to as little as $20 per 30-day supply; and, the program will be available in August. Factors that could cause or contribute to such differences include, but are not limited to: the possibility that the Company may be unable to realize the intended benefits of, or achieve the intended goals or outlooks with respect to, its strategic initiatives; the possibility that the Company may be unable to achieve expected benefits, synergies and operating efficiencies in connection with acquisitions, divestitures, or its global restructuring program, within the expected timeframe or at all; impairment charges or other losses related to the divestiture or sale of businesses or assets; the Company's failure to achieve expected or targeted future financial and operating performance and results; the potential impact of public health outbreaks, epidemics and pandemics, including the ongoing challenges and uncertainties posed by COVID-19; actions and decisions of healthcare and pharmaceutical regulators; changes in healthcare and pharmaceutical laws and regulations in the U.S. and abroad; any regulatory, legal or other impediments to Viatris' ability to bring new products to market, including but not limited to "at-risk" launches; Viatris' or its partners' ability to develop, manufacture, and commercialize products; the scope, timing and outcome of any ongoing legal proceedings, and the impact of any such proceedings; any significant breach of data security or data privacy or disruptions to our information technology systems; risks associated with international operations; the ability to protect intellectual property and preserve intellectual property rights; changes in third-party relationships; the effect of any changes in Viatris' or its partners' customer and supplier relationships and customer purchasing patterns; the impacts of competition; changes in the economic and financial conditions of Viatris or its partners; uncertainties and matters beyond the control of management, including general economic conditions, inflation and exchange rates; failure to execute stock repurchases consistent with current expectations; stock price volatility; and the other risks described in Viatris' filings with the Securities and Exchange Commission (SEC). Viatris routinely uses its website as a means of disclosing material information to the public in a broad, non-exclusionary manner for purposes of the SEC's Regulation Fair Disclosure (Reg FD). Viatris undertakes no obligation to update these statements for revisions or changes after the date of this release other than as required by law.
View original content to download multimedia:
SOURCE Viatris Inc. | https://www.kfyrtv.com/prnewswire/2023/07/31/viatris-announces-launch-breyna-budesonide-formoterol-fumarate-dihydrate-inhalation-aerosol-first-fda-approved-generic-version-symbicort-people-with-asthma-chronic-obstructive-pulmonary-disease-partnership-with-kindeva/ | 2023-07-31T11:20:39 | 0 | https://www.kfyrtv.com/prnewswire/2023/07/31/viatris-announces-launch-breyna-budesonide-formoterol-fumarate-dihydrate-inhalation-aerosol-first-fda-approved-generic-version-symbicort-people-with-asthma-chronic-obstructive-pulmonary-disease-partnership-with-kindeva/ |
For more Permian Basin weather…check here on https://www.yourbasin.com/weather/forecast/. Meteorologist Ryan DePhillips once again expects more sunshine than the few clouds on this Monday with more triple-digit temperatures returning across West Texas because of southerly winds returning. As temperatures skyrocket into the upper 90’s and triple digits for many, the humid start will transition into drier air this afternoon. Very isolated rain activity will be confined to southwestern areas today as this trend will continue to be prevalent for tomorrow as stable air will continue to mostly dampen the Monsoonal flow of moisture in producing more-widespread rainfall. Despite even hotter air inbound tomorrow for some, low-level moisture will sneak on in a bit.
Close
Thanks for signing up!
Watch for us in your inbox.
Subscribe Now | https://www.yourbasin.com/weather/forecast/hotter-on-this-monday-7-31-2023/ | 2023-07-31T11:20:40 | 0 | https://www.yourbasin.com/weather/forecast/hotter-on-this-monday-7-31-2023/ |
BALTIMORE - There comes a point in a every baseball season when a struggling team is forced to admit it’s hit rock bottom. That’s when the delusions give way to reality and the excuses no longer camouflage what’s obvious to everyone else.
We’re talking about the Yankees, who’ve been hit over the head enough times to realize nothing is getting better.
A humiliating 9-3 loss to the Orioles was a nationally televised embarrassment, not to mention an indictment of a pitcher who couldn’t anyone out (Luis Severino), a superstar who wasn’t allowed to rescue a pathetic lineup (Aaron Judge) and a manager (Aaron Boone) who continues to harp on imaginary silver linings.
Meanwhile, the pool of available talent on the trade market keeps dwindling. GM Brian Cashman is feverishly working the phones, but while the Yankees lost two of three to the O’s this weekend, the Cubs decided to hang on to the industry’s No. 1 prize, Cody Bellinger.
The news only got worse late Sunday night when the Rockies sent Randal Grichuk to the Angels. Both he and Bellinger were targeted by the Yankees as emergency reinforcements.
Now they’re gone, as are former-Bomber Jordan Montgomery and Max Scherzer (both pitchers to the Rangers), reliever Jordan Hicks (to the Blue Jays), and starter Lucas Giolito and reliever Reynaldo Lopez (both to the Angels).
That means two of the Yankees’ primary wild-card rivals (the Blue Jays and Angels) are stronger today than 48 hours ago. And the Rangers, who were already credible World Series contenders, have become an outright powerhouse.
Where does that leave the Yankees? Cashman may have no choice but abandon his search for an 11th-hour savior. The Marlins are interested in Gleyber Torres, according to NJ Advance Media’s Randy Miller, with a possible return of two young starters, Edward Cabrera and Braxton Garrett, plus two prospects.
One industry, uninvolved with the Yankees’ trade talks, said, “this is probably a good time for (Cashman) to start thinking about selling.”
BUY YANKEES TICKETS: STUBHUB, VIVID SEATS, TICKETMASTER
If the shrinking field of targets wasn’t enough to sway Cashman, then Sunday night’s fiasco in Baltimore should’ve pushed him over the brink. At this point, selling wouldn’t be considered a surrender by the Yankees, but an acceptance of reality, similar to the Mets’ unloading of Scherzer and David Robertson in the last few days. Justin Verlander could be next.
Thing is, the Yankees arrived in Baltimore full of optimism. Judge was back in time for Friday night’s series opener, Gerrit Cole was on the mound and Boone’s crew was riding a mini-hot streak, having won four of five.
But except for Saturday night’s 8-3 victory, which Judge single-handedly engineered, nothing went according to plan.
Cole was brilliant but was matched by rookie Grayson Rodriguez in Friday night’s 1-0 walk-off loss. The defeat was especially jarring to the franchise’s self-confidence. If Cole couldn’t beat the first-place O’s, then who could?
Judge answered the question 24 hours later, but that set the stage for the Yankees’ stunning decision to sit the slugger in Sunday’s series finale.
Why? How could they? Judge waited nearly two months for the chance to take pressure off Anthony Rizzo and Giancarlo Stanton and DJ LeMahieu. The idea was to wake the Yankees up from a summer-long trance. Finally, a scorched-earth march through the division, from last place to first, would begin in earnest.
But no, absolutely not, said Boone, who insisted on resting Judge. The manager explained to reporters before batting practice – and again to ESPN during the game – that Judge simply isn’t ready to play every day.
The Yankees were treating his return as the equivalent of a rehab stint, except the games normally played at the minor league level were shifted to the pennant race.
“We’re in the middle of 13 games in a row,” Boone said, suggesting Judge would be susceptible to injury without a breather. The Yankees’ fear? If Judge’s toe is subjected to constant wear and tear this soon, a slight change in his gait could damage his knees or hamstrings.
Judge was at a loss to understand the logic, especially since he was allowed to take batting practice. So why not serve as the DH? If rest was mandatory, at least wait a day until the start of the Rays series at the Stadium.
Want to bet on sports?
See the best Sports Betting apps
The Yankees, after all, had a chance to take a critical three-game set from the first-place O’s. That would’ve been a sign of progress. In last place with barely 50 games to go, the Bombers are desperate for momentum, and not just from sweeping easy marks like the Royals.
No one in the clubhouse had to state the obvious: without Judge, the Yankees were de-fanged and promptly stomped. Orioles pitchers registered a whopping 18 strikeouts, including five punch outs of Rizzo alone.
And coincidence or not, Severino blew up whatever chance the Yankees had of surprising the Orioles, allowing seven runs in the first inning. The rest of the night was a pick-up game. He later crowned himself, “the worst pitcher in the game.”
No argument there. With a 7.49 ERA, Severino is now the rotation’s greatest liability, certain to be banished to the bullpen when Nestor Cortes comes off the injured list.
But that’s at least a week away. That might be too late, no matter what the Yankees say about continuing to grind.
“Gotta keep showing up,” said Jake Bauers, unaware he was using coded language for slogging along as the East’s worst team.
Better to say it bluntly: Welcome to rock bottom.
Thank you for relying on us to provide the journalism you can trust. Please consider supporting us with a subscription.
Bob Klapisch may be reached at bklapisch@njadvancemedia.com. | https://www.nj.com/yankees/2023/07/yankees-last-place-going-nowhere-tell-the-world-were-terrible-klapisch.html | 2023-07-31T11:20:43 | 0 | https://www.nj.com/yankees/2023/07/yankees-last-place-going-nowhere-tell-the-world-were-terrible-klapisch.html |
WATCH: Concertgoer throws drink at Cardi B; she hurls microphone at them
Published: Jul. 31, 2023 at 5:58 AM CDT|Updated: 22 minutes ago
LAS VEGAS (CNN) - Cardi B hurled her microphone at a fan during a concert in Las Vegas on Saturday.
The rapper was performing her song “Bodak Yellow” when a concertgoer threw a drink at her.
In seconds, Cardi B threw her microphone into the crowd as the song continued to play.
Security guards rushed to the stage.
More security guards are then seen flocking to the person in the crowd as she watched from the stage before continuing with her set.
There’s no word on what happened to the fan or if any charges will be filed.
Copyright 2023 CNN Newsource. All rights reserved. | https://www.wlbt.com/2023/07/31/watch-concertgoer-throws-drink-cardi-b-she-hurls-microphone-them/ | 2023-07-31T11:20:43 | 1 | https://www.wlbt.com/2023/07/31/watch-concertgoer-throws-drink-cardi-b-she-hurls-microphone-them/ |
Trump could be indicted soon in Georgia. Here’s a look at that investigation
ATLANTA (AP) — A Georgia prosecutor is expected to seek a grand jury indictment in the coming weeks in her investigation into efforts by Donald Trump and his Republican allies to overturn the former president’s 2020 election loss.
Fulton County District Attorney Fani Willis began investigating more than two years ago, shortly after a recording was released of a January 2021 phone call Trump made to Georgia’s secretary of state.
Willis has strongly hinted that any indictment would come between July 31 and August 18. One of two grand juries seated July 11 is expected to hear the case.
If Trump is indicted by a Georgia grand jury, it would add to a growing list of legal troubles as he campaigns for president. Trump is set to go to trial in New York in March to face state charges related to hush-money payments made during the 2016 presidential campaign. And he has another trial scheduled for May on federal charges related to his handling of classified documents. He has pleaded not guilty in those cases.
The Justice Department is also investigating Trump’s role in trying to halt the certification of 2020 election results in the run-up to the Jan. 6, 2021, assault on the U.S. Capitol. Trump said he’s been told he’s a target of that investigation, which likely has some overlap with the one in Georgia.
Details of the Georgia investigation that have become public have fed speculation that Willis, a Democrat, is building a case under the Georgia Racketeer Influenced and Corrupt Organizations Act, which would allow her to charge numerous people in a potentially wide-ranging scheme.
Here are six investigative threads Willis and her team have explored:
THE PHONE CALLS
The Georgia investigation was prompted by the Jan. 2, 2021 phone call Trump made to Georgia Secretary of State Brad Raffensperger. Trump suggested the state’s top elections official could help “find” the votes needed to put him ahead of Democrat Joe Biden in the state.
“All I want to do is this: I just want to find 11,780 votes, which is one more than we have,” Trump is heard saying on a recording of the call, which was leaked to news outlets. “Because we won the state.”
Trump has insisted he did nothing wrong and has repeatedly said the call was “perfect.”
Trump also called other top state officials in his quest to overturn his 2020 election loss, including Gov. Brian Kemp, then-House Speaker David Ralston, Attorney General Chris Carr and the top investigator in the secretary of state’s office.
U.S. Sen. Lindsey Graham, a South Carolina Republican, also called Raffensperger shortly after the November election. Raffensperger said at the time that Graham asked whether he had the power to reject certain absentee ballots, which Raffensperger has said he interpreted as a suggestion to toss out legally cast votes.
Graham has denied wrongdoing, saying he just wanted to learn about the signature verification process.
FAKE ELECTORS
Biden won Georgia by a margin of fewer than 12,000 votes. Just over a month after the election, on Dec. 14, 2020, a group 16 Georgia Democratic electors met in the Senate chamber at the state Capitol to cast the state’s Electoral College votes for him. They each marked paper ballots that were counted and confirmed by a voice roll call.
That same day, in a committee meeting room at the Capitol, 16 prominent Georgia Republicans — a lawmaker, activists and party officials — met to sign a certificate falsely stating that Trump had won and declaring themselves the state’s “duly elected and qualified” electors. They sent that certificate to the National Archives and the U.S. Senate.
Georgia was one of seven battleground states that Trump lost where Republican fake electors signed and submitted similar certificates. Trump allies in the U.S. House and Senate used those certificates to argue for delaying or blocking the certification of the election during a joint session of Congress.
Prosecutors in Fulton County have said in court filings that they believe Trump associates worked with state Republicans to coordinate and execute the plan.
The multi-state effort was ultimately unsuccessful. Despite public pressure from Trump and his supporters, then-Vice President Mike Pence refused on Jan. 6, 2021, to introduce the unofficial pro-Trump electors. After the attack on the U.S. Capitol put a violent halt to the certification process, lawmakers certified Biden’s win in the early hours of Jan. 7, 2021.
At least eight of the fake electors have since reached immunity deals with Willis’ team. And a judge last summer barred Willis from prosecuting another one, Lt. Gov. Burt Jones, because of a conflict of interest.
FALSE CLAIMS OF ELECTION FRAUD
Republican state lawmakers held several hearings at the Georgia Capitol in December 2020 to examine alleged problems with the November election. During those meetings, former New York mayor Rudy Giuliani and other Trump allies made unproven claims of widespread election fraud.
They alleged that election workers tallying absentee ballots at State Farm Arena in Atlanta had told outside observers to leave and then pulled out “suitcases” of unlawful ballots and began scanning them. The Trump allies played clips of surveillance video from the arena to support their allegations. State and federal officials investigated and said there was no evidence of election fraud at the site.
Some Trump allies also said thousands of people who were ineligible — including people convicted of felonies, people younger than the age of 18, people who had voted in another state — had cast votes in Georgia. The secretary of state’s office has debunked those claims.
ALLEGED ATTEMPTS TO PRESSURE ELECTION WORKER
Two of the election workers seen in the State Farm Arena surveillance video, Ruby Freeman and her daughter Wandrea “Shaye” Moss, said they faced relentless harassment online and in person as a result of the allegations made by Trump and his allies.
Giuliani last week conceded that statements he made about the two election workers were false.
In a bizarre episode detailed by prosecutors in court filings, a woman traveled from Chicago to Georgia and met with Freeman on Jan. 4, 2021. The woman initially said she wanted to help Freeman but then warned that Freeman could go to prison and tried to pressure her into falsely confessing to committing election fraud, prosecutors wrote in court filings last year.
ELECTION EQUIPMENT ACCESSED
Trump-allied lawyer Sidney Powell and others hired a computer forensics team to copy data and software on election equipment in Coffee County, some 200 miles southeast of Atlanta, according to invoices, emails, security video and deposition testimony produced in response to subpoenas in a long-running lawsuit.
The county Republican Party chair at the time — who also served as a fake elector — greeted them when they arrived at the local elections office on Jan. 7, 2021, and some county elections officials were also on hand during the daylong visit. The secretary of state’s office has said this amounted to “alleged unauthorized access” of election equipment, and the Georgia Bureau of Investigation is looking into it at the secretary of state’s request.
Two other men who have been active in efforts to question the 2020 election results also visited Coffee County later that month and spent hours inside.
U.S. ATTORNEY RESIGNATION
U.S. Attorney BJay Pak, the top federal prosecutor in Atlanta, abruptly resigned two days after Trump called Raffensperger and a day after a recording of that call was made public. During that conversation, Trump called Pak a “never-Trumper,” implying that he didn’t support the president.
In December 2020, then-U.S. Attorney General William Barr asked Pak to investigate allegations by Giuliani and other Trump allies of widespread election fraud. Pak, who had been appointed by Trump in 2017, reported back that he had found no evidence of such fraud.
In August 2021, Pak told the U.S. Senate Judiciary Committee, which was investigating Trump’s post-election actions, that he resigned on Jan. 4, 2021, after learning from Department of Justice officials that Trump did not believe enough was being done to investigate allegations of election fraud and wanted him gone as U.S. attorney.
Copyright 2023 The Associated Press. All rights reserved. | https://www.wagmtv.com/2023/07/31/trump-could-be-indicted-soon-georgia-heres-look-that-investigation/ | 2023-07-31T11:20:42 | 1 | https://www.wagmtv.com/2023/07/31/trump-could-be-indicted-soon-georgia-heres-look-that-investigation/ |
New nuclear unit now serving customers with clean, reliable energy 24/7
ATLANTA, July 31, 2023 /PRNewswire/ -- Georgia Power declared today that Plant Vogtle Unit 3 has entered commercial operation and is now serving customers and the State of Georgia. The new unit represents a long-term investment in the state's clean energy future and will provide reliable, emissions-free energy to customers for decades to come.
"The Plant Vogtle 3 & 4 nuclear expansion is another incredible example of how Georgia Power is building a reliable and resilient energy future for our state," said Kim Greene, chairman, president and CEO of Georgia Power. "It is important that we make these kinds of long-term investments and see them through so we can continue providing clean, safe, reliable and affordable energy to our 2.7 million customers. Today's achievement is a testament to our commitment to doing just that, and it marks the first day of the next 60 to 80 years that Vogtle Unit 3 will serve our customers with clean, reliable energy."
Vogtle Unit 3 is the first newly-constructed nuclear unit in the U.S. in over 30 years and can power an estimated 500,000 homes and businesses. Once all four units are online, the Plant Vogtle site will be the largest generator of clean energy in the nation and support continued growth in Georgia as more industries, businesses and families come to the state.
"Today is a historic day for the State of Georgia, Southern Company, and the entire energy sector, as we continue transforming the way we power the lives of millions of Americans," said Chris Womack, president and CEO of Southern Company. "With Unit 3 completed, and Unit 4 in the final stages of construction and testing, this project shows just how new nuclear can and will play a critical role in achieving a clean energy future for the United States. Bringing this unit safely into service is a credit to the hard work and dedication of our teams at Southern Company and the thousands of additional workers who have helped build that future at this site, as well as all of the partners who have helped make this day a reality."
Nuclear energy is the only zero-emission baseload energy source available today, offering high reliability, and efficient operations around the clock. Nuclear energy currently provides approximately 25% of Georgia Power's overall energy mix, including the existing units at Plant Vogtle and Georgia's other nuclear facility at Plant Hatch in Baxley, Georgia.
"The Vogtle expansion is an American energy success story and would not be possible without the support of strong public and private partners like our partners at North America's Building Trades Unions," said Tom Fanning, chairman of the Board of Directors for Southern Company. "We continue to appreciate their support and those who have stood with us at the local, state and federal levels to complete this new clean energy source to serve electric customers. Providing leadership in our industry and a commitment to safety and quality are in Southern Company's DNA. Today's milestone at the Vogtle expansion site underscores this legacy, and I couldn't be prouder of the dedication our teams have shown in seeing Unit 3 through to completion."
The final stages of construction and testing continue at Vogtle Unit 4, with the unit projected to be placed in service during the late fourth quarter 2023 or the first quarter of 2024. The unit completed hot functional testing in May, in significantly less time than Unit 3 as the team continues leveraging best practices and learnings from the earlier unit. The Vogtle site has also received nuclear fuel for Unit 4, with a total of 157 fuel assemblies necessary for the safe and reliable startup of the unit.
Also, last week, Georgia Power announced the receipt of the 103(g) finding from the Nuclear Regulatory Commission (NRC) for Vogtle Unit 4. This finding was confirmed in an official letter received by Southern Nuclear and signifies that the new unit has been constructed and will be operated in conformance with the Combined License and NRC regulations. No further NRC findings are necessary in order for Southern Nuclear to load fuel or begin the startup sequence for the new unit.
The new Vogtle units are an essential part of Georgia Power's commitment to delivering clean, safe, reliable and affordable energy to its 2.7 million customers. Southern Nuclear will operate the new units on behalf of the co-owners: Georgia Power, Oglethorpe Power, MEAG Power and Dalton Utilities.
About Georgia Power
Georgia Power is the largest electric subsidiary of Southern Company (NYSE: SO), America's premier energy company. Value, Reliability, Customer Service and Stewardship are the cornerstones of the company's promise to 2.7 million customers in all but four of Georgia's 159 counties. Committed to delivering clean, safe, reliable and affordable energy, Georgia Power maintains a diverse, innovative generation mix that includes nuclear, coal and natural gas, as well as renewables such as solar, hydroelectric and wind. Georgia Power focuses on delivering world-class service to its customers every day and the company is recognized by J.D. Power as an industry leader in customer satisfaction. For more information, visit www.GeorgiaPower.com and connect with the company on Facebook (Facebook.com/GeorgiaPower), Twitter (Twitter.com/GeorgiaPower) and Instagram (Instagram.com/ga_power).
Cautionary Note Regarding Forward-Looking Statements
Certain information contained in this release is forward-looking information based on current expectations and plans that involve risks and uncertainties. Forward-looking information includes, among other things, statements concerning the projected in-service date for Plant Vogtle Unit 4 and the future operations of Plant Vogtle Units 3 and 4. Georgia Power cautions that there are certain factors that can cause actual results to differ materially from the forward-looking information that has been provided. The reader is cautioned not to put undue reliance on this forward-looking information, which is not a guarantee of future performance and is subject to a number of uncertainties and other factors, many of which are outside the control of Georgia Power; accordingly, there can be no assurance that such suggested results will be realized. The following factors, in addition to those discussed in Georgia Power's Annual Report on Form 10-K for the year ended December 31, 2022, and subsequent securities filings, could cause actual results to differ materially from management expectations as suggested by such forward-looking information: the ability to control costs and avoid cost and schedule overruns during the development, construction, and operation of facilities or other projects, including Plant Vogtle Unit 4, which includes components based on new technology that only within the last few years began initial operation in the global nuclear industry at this scale, due to current and/or future challenges which include, but are not limited to, changes in labor costs, availability and productivity, challenges with the management of contractors or vendors, subcontractor performance, adverse weather conditions, shortages, delays, increased costs, or inconsistent quality of equipment, materials, and labor, contractor or supplier delay, the impacts of inflation, delays due to judicial or regulatory action, nonperformance under construction, operating, or other agreements, operational readiness, including specialized operator training and required site safety programs, engineering or design problems or any remediation related thereto, design and other licensing-based compliance matters, challenges with start-up activities, including major equipment failure, or system integration, and/or operational performance, continued challenges related to the COVID-19 pandemic or future pandemic health events, continued public and policymaker support for projects, environmental and geological conditions, delays or increased costs to interconnect facilities to transmission grids, and increased financing costs as a result of changes in market interest rates or as a result of project delays; the ability to overcome or mitigate the current challenges, or challenges yet to be identified, at Plant Vogtle Unit 4, that could further impact the cost and schedule for the project; legal proceedings and regulatory approvals and actions related to construction projects, such as Plant Vogtle Unit 4, including Georgia Public Service Commission approvals and U.S. Nuclear Regulatory Commission ("NRC") actions; under certain specified circumstances, a decision by holders of more than 10% of the ownership interests of Plant Vogtle Unit 3 and 4 not to proceed with construction; the notices of tender by Oglethorpe Power Corporation and the City of Dalton of a portion of their ownership interests in Plant Vogtle Units 3 and 4 to Georgia Power, including related litigation; the ability to construct facilities in accordance with the requirements of permits and licenses (including satisfaction of NRC requirements), to satisfy any environmental performance standards and the requirements of tax credits and other incentives, and to integrate facilities into the Southern Company system upon completion of construction; the inherent risks involved in operating and constructing nuclear generating facilities; the ability of counterparties of Georgia Power to make payments as and when due and to perform as required; the direct or indirect effect on Georgia Power's business resulting from cyber intrusion or physical attack and the threat of cyber and physical attacks; catastrophic events such as fires, earthquakes, explosions, floods, tornadoes, hurricanes and other storms, droughts, pandemic health events, political unrest, wars or other similar occurrences; the potential effects of the continued COVID-19 pandemic; and the direct or indirect effects on Georgia Power's business resulting from incidents affecting the U.S. electric grid or operation of generating or storage resources. Georgia Power expressly disclaim any obligation to update any forward–looking information.
View original content to download multimedia:
SOURCE Georgia Power | https://www.kfyrtv.com/prnewswire/2023/07/31/vogtle-unit-3-goes-into-operation/ | 2023-07-31T11:20:45 | 0 | https://www.kfyrtv.com/prnewswire/2023/07/31/vogtle-unit-3-goes-into-operation/ |
BALTIMORE — The Rangers have one of the best records in the American League and got a lot better Saturday trading for three-time Cy Young winner Max Scherzer. On Sunday, Texas made another deal to acquire more pitching, starter Jordan Montgomery and reliever Chris Stratton.
The Blue Jays, currently positioned to make the playoffs as an AL wild card, lost All-Star closer Jordan Romano to an injury on Saturday and then replaced him Sunday by trading for Jordan Hicks, who throws in the 100s and has touched 105.
The Angels acquired two hitters late Sunday night, Randal Grichuk and C.J. Cron, after trading for top-of-the-rotation starter Lucas Giolito and reliever Reynaldo Lopez last Wednesday.
“I’m following what’s happening around us, what other teams are adding,” Yankees utility player Isiah Kiner-Falefa said before Sunday night’s 9-3 loss to the Orioles. “The Rangers and other clubs are making some good moves.”
BUY YANKEES TICKETS: STUBHUB, VIVID SEATS, TICKETSMARTER, TICKETMASTER
The Yankees?
They probably need significant upgrades if they’re going to play themselves into a postseason spot and GM Brian Cashman didn’t complete any weekend deals while his club was losing two of three at Oriole Park.
Maybe the Yankees will do something Monday or on Tuesday before the 6 p.m., deadline to add an impact bat that’s sorely needed even with Aaron Judge finally off the injured list, preferably a left fielder.
Or maybe the Yankees will stand pat, or even do a little selling. The Marlins want Gleyber Torres badly. Other contenders probably would give up decent prospects for Domingo German, Harrison Bader, Clay Holmes and others.
“It’s always a wild time,” Kiner-Falefa said. “Last year we made moves in the last 10 minutes. That’s when we got Bader. I think anytime you can help your team get better, it’s an exciting time.”
What’s it been like for the Yankees watching other AL playoff contenders get better and their team play the waiting game with the trade-deadline hourglass almost done draining sand?
“You see it with interest, of course, being in the game and fall in the sport,” manager Aaron Boone said before Sunday’s blowout loss. “That’s all stuff out of (my) control. I see it. I acknowledge it. But it’s not something for me to worry about.
“We’ve got to get our guys ready to go. Getting Judge back is a big deal. Getting Nester (Cortes) and getting (Jonathan Loaisiga) back are all going to be significant things that happen.”
Those three players coming off the IL should improve the Yankees’ offense, rotation and bullpen, but this is the time of the year for big-market contenders to really gear up for the home stretch.
How much better would the Yankees’ lineup be if Cashman had made the Cubs an offer they couldn’t refuse for former MVP outfielder Cody Bellinger before Chicago caught fire, played itself into contention and opted not to sell?
Bellinger apparently is untouchable now, so the Yankees probably will have to settle for a second-tier bat if they add one, perhaps the Mets’ Tommy Pham.
“The deadline is always tricky, especially this year with so many teams in the mix and going for it,” Yankees first baseman Anthony Rizzo said after the worst game of his career, 0-for-5 with five strikeouts. “I think we have the guys here.
If the Yankees don’t get hot and stay hot soon, their playoff hopes are going to be done all but mathematically. That’s why adding this week could make or break their season.
A lot of Yankees fans probably will be angry if Cashman doesn’t do something significant to improve a 55-50 last-place ballclub that is nine games out of first and 3 1/2 out of a wild-card spot.
“I think that’s the beauty of sport and the beauty of loving a team, following a team,” Boone said. “You want to see your team be the best they could be. I guess I understand that.”
Boone isn’t ruling out Cashman making a big or little splash by Tuesday.
“I think anything’s possible,” Boone said. “One thing this time of year tells you is you never know. There are things that come and go. It’s looking like something’s going to happen to going away to all of a sudden coming together at the last minute. So you never know what’s going to happen.”
You know Boone has to be hoping Cashman works a big deal or two before Tuesday’s deadline, but he’s not going to publicly campaign.
“I think it’s a slight to the people we have in our room that I think are totally capable of still reaching all of our hopes and dreams,” Boone said. “So I’m not going to go lobby for something that may or may not happen. If something doesn’t happen, then what?
“I know our guys and our team feel very confident in our ability to get right and play a high level of baseball these final two months. That’s how I look at things the way. If things come and a deal gets done for something, we’ll welcome those people.”
Thank you for relying on us to provide the journalism you can trust. Please consider supporting us with a subscription.
Randy Miller may be reached at rmiller@njadvancemedia.com. | https://www.nj.com/yankees/2023/07/yankees-react-to-al-contenders-making-deals-while-brian-cashman-waits-to-do-nothing.html | 2023-07-31T11:20:49 | 1 | https://www.nj.com/yankees/2023/07/yankees-react-to-al-contenders-making-deals-while-brian-cashman-waits-to-do-nothing.html |
WATCH: Concertgoer throws drink at Cardi B; she hurls microphone at them
Published: Jul. 31, 2023 at 6:58 AM EDT|Updated: 22 minutes ago
LAS VEGAS (CNN) - Cardi B hurled her microphone at a fan during a concert in Las Vegas on Saturday.
The rapper was performing her song “Bodak Yellow” when a concertgoer threw a drink at her.
In seconds, Cardi B threw her microphone into the crowd as the song continued to play.
Security guards rushed to the stage.
More security guards are then seen flocking to the person in the crowd as she watched from the stage before continuing with her set.
There’s no word on what happened to the fan or if any charges will be filed.
Copyright 2023 CNN Newsource. All rights reserved. | https://www.wagmtv.com/2023/07/31/watch-concertgoer-throws-drink-cardi-b-she-hurls-microphone-them/ | 2023-07-31T11:20:49 | 0 | https://www.wagmtv.com/2023/07/31/watch-concertgoer-throws-drink-cardi-b-she-hurls-microphone-them/ |
The Nation's Largest Network for Affordable Housing Protects Consumers from Unfair Fees and Costs
BOCA RATON, Fla., July 31, 2023 /PRNewswire/ -- AffordableHousing.com today announced it will join the White House and a compendium of government agencies and other private sector companies in large-scale efforts to end junk fees and ensure that Americans are provided with honest, transparent pricing. More than 100 million property searches per year are performed on AffordableHousing.com–the largest platform for affordable housing in the nation.
"For decades, families have relied on us to help them find affordable housing," says Richard Cupelli, CEO at AffordableHousing.com. "We take pride in advocating for these families, so it was a natural fit for us to join forces with the Administration and other socially responsible companies to help protect consumers in our industry."
On July 19, 2023, the White House published a Fact Sheet announcing its crack-down on junk fees in the rental market, highlighting private-sector commitments supporting this initiative made by the three major rental housing platforms: AffordableHousing.com, Zillow, and Apartments.com.
Late last year, the President called on federal agencies, Congress, and private companies to take action to address junk fees across the economy. The initiative aims to ensure Americans are provided with honest, transparent pricing. By February 2023, the Consumer Financial Protection Bureau (CFPB) announced proposed rules limiting credit card late fees. The Federal Communications Commission (FCC) finalized a rule requiring cable and internet providers to list fees up front. And the Department of Transportation (DOT) proposed a requirement for airlines and booking services show the full price of a plane ticket, including baggage and other fees.
In March, HUD Secretary Marcia Fudge released an open letter to housing providers and state and local governments, encouraging them to adopt policies promoting greater fairness and transparency of fees faced by renters. Substantial research shows such fees obstruct comparison shopping, impede competition, and lead to consumers paying more.
A long-standing resource for families seeking affordable housing, AffordableHousing.com has policies in place supporting this transparency and protecting its customers from unfair fees.
Renters can search available properties free on AffordableHousing.com, and property owners are required to be upfront about all refundable and non-refundable rental fees and costs. AffordableHousing.com also does not charge rental application fees.
"Our socially responsible technology platform has allowed us to establish the largest network of affordable housing in the nation," says Cupelli. "We understand the accountability that comes with our standing in the industry and the trust that our customers place in us."
As a hub for housing agencies across the nation, AffordableHousing.com also allows state and local governments to have their own customized website that serves their local community, enforces their specific regulatory requirements, centralizes all affordable housing, and simplifies the application and approval process.
"We are working with AffordableHousing.com to implement the Vermont Affordable Housing Hub, which will allow families to easily find and apply to all affordable housing in the state," says Kathleen Berk, Executive Director at Vermont State Housing Authority. "By utilizing AffordableHousing.com's custom housing hub to build our state-specific site, we can streamline compliance with state laws, which have strict application fee guidelines. We can also add safeguards to protect our families by providing the Clear and Fair Lease template for property owners to use. These leases will also comply with affordable housing programs, like Section 8."
AffordableHousing.com also rewards reputable property owners. Those with a history of good standing can qualify for a Trusted Owner Badge, which ensures their credibility to prospective renters on the site and increases consumer confidence. Trusted Owners also receive prominent listing status.
Earning and maintaining status as a Trusted Owner requires providing various levels of documentation to verify qualifications and authenticity, adhering to all relevant federal, state, and local laws, and complying with the site's reasonable fee guidelines.
Together with its research partner, Learning Collider (www.learningcollider.org), AffordableHousing.com is conducting research into the real cost of administrative fees, the impact of fee transparency in rental listings, and the effectiveness of platform features like the common application for rental and government programs—an endeavor that the company has been urging agencies to adopt for years.
"Our research partnership with AffordableHousing.com has allowed us to analyze the impacts of rental fees on low-income families in real-time," says Peter Bergman, Professor at UT Austin and Director of the Learning Collider research lab. "Together, we are advancing research to identify junk fees and establish transparent fee practices, easing the path to affordable rentals for families across the U.S."
The President announced in latest White House Fact Sheet, released on July 27, 2023, further plans to protect renters, naming AffordableHousing.com as an ally in the initiative and endorsing the site's plans to deploy additional consumer protection tools by the end of the year, including "Clear and Fair" digital leases, which will align with the principles outlined in the White House Blueprint for a Renter Bill of Rights. Property owners who use these "Clear and Fair" digital leases will be acknowledged on AffordableHousing.com.
About AffordableHousing.com: For more than 20 years, AffordableHousing.com has provided innovative technology and real solutions that help solve some of the most complex challenges impacting the availability of affordable housing in the United States. By simplifying access to available resources, AffordableHousing.com boosts participation in government programs, increasing the much-needed supply of affordable housing nationwide, and providing more homes to more families.
View original content to download multimedia:
SOURCE AffordableHousing.com | https://www.kfyrtv.com/prnewswire/2023/07/31/white-house-announces-partnership-with-affordablehousingcom-end-junk-fees/ | 2023-07-31T11:20:52 | 0 | https://www.kfyrtv.com/prnewswire/2023/07/31/white-house-announces-partnership-with-affordablehousingcom-end-junk-fees/ |
SHANGHAI, July 31, 2023 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced that it will report its unaudited financial results for the second quarter ended June 30, 2023, before the U.S. market opens on Thursday, August 24, 2023.
111's management team will host an earnings conference call at 7:30 AM U.S. Eastern Time on Thursday, August 24, 2023 (7:30 PM Beijing Time on the same day).
Details for the conference call are as follows:
Conference Topic: 111, Inc. Second Quarter 2023 Earnings Conference Call
Registration Link: https://s1.c-conf.com/diamondpass/10032701-ygfhis.html
All participants must use the link provided above to complete the online registration process in advance of the conference call. Upon registering, each participant will receive a set of participant dial-in numbers, the Direct Event passcode, and a unique Registration ID, which can be used to join the conference call.
Please dial in 15 minutes before the call is scheduled to begin and provide the Direct Event passcode and unique Registration ID you have received upon registering to join the call.
A telephone replay of the call will be available after the conclusion of the conference call until August 31, 2023
United States: +1 855 883 1031
Mainland China: 4001 209 216
Hong Kong: 800 930 639
International: +61 7 3107 6325
Conference ID: 10032701
A live and archived webcast of the conference call will be available on the website at https://edge.media-server.com/mmc/p/iw7ck9oc
About 111, Inc.
111, Inc. (NASDAQ: YI) ("111" or the "Company") is a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China. The Company provides consumers with better access to pharmaceutical products and healthcare services directly through its online retail pharmacy, 1 Pharmacy, and indirectly through its offline virtual pharmacy network. The Company also offers online healthcare services through its internet hospital, 1 Clinic, which provides consumers with cost-effective and convenient online consultation, electronic prescription service, and patient management service. In addition, the Company's online platform, 1 Medicine Marketplace, serves as a one-stop shop for pharmacies to source a vast selection of pharmaceutical products. With the largest virtual pharmacy network in China, 111 enables offline pharmacies to better serve their customers with cloud-based services. 111 also provides an omni-channel drug commercialization platform to its strategic partners, which includes services such as digital marketing, patient education, data analytics, and pricing monitoring.
For more information on 111, please visit: http://ir.111.com.cn/.
View original content:
SOURCE 111, Inc. | https://www.wagmtv.com/prnewswire/2023/07/31/111-announce-second-quarter-2023-unaudited-financial-results-august-24-2023-conference-call-follow/ | 2023-07-31T11:20:56 | 0 | https://www.wagmtv.com/prnewswire/2023/07/31/111-announce-second-quarter-2023-unaudited-financial-results-august-24-2023-conference-call-follow/ |
- Revenue of RMB9,908 Million in the Second Quarter, Up 6.7% Year-over-Year;
Excluding COVID-19 Commercial Projects, Up 39.5% - Revenue of RMB18,871 Million in the First Half, Up 6.3% Year-over-Year;
Excluding COVID-19 Commercial Projects, Up 27.9% - Net Profit Attributable to Owners of the Company for the First Half Increased 14.6% to RMB 5,313 Million
- Diluted Earnings per Share (EPS) for the First Half Increased 20.9% to RMB1.79
- Adjusted Non-IFRS Net Profit Attributable to Owners of the Company for the First Half Increased 18.5% to RMB5,095 Million
- Adjusted Non-IFRS Diluted EPS for the First Half Increased 18.5% to RMB1.73[1]
- Free Cash Flow Achieved RMB2,926 Million for the First Half, Turned Positive and Grew Strongly
SHANGHAI, July 31, 2023 /PRNewswire/ -- WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries to advance discoveries and deliver groundbreaking treatments to patients, is pleased to announce its financial results for the first half ending June 30, 2023 ("Reporting Period").
This release provides a summary of the results and is not intended to be a comprehensive report. For additional information, please refer to the 2023 Interim Report and other relevant announcements published on the websites of the Shanghai Stock Exchange (www.sse.com.cn) and the Stock Exchange of Hong Kong (www.hkexnews.hk), and the designated media for dissemination of the relevant information. Investors are advised to exercise caution and be aware of the investment risks in trading Company shares.
All financial information disclosed in this press release is prepared based on International Financial Reporting Standards (IFRS), in currency of RMB.
The 2023 Interim Report of the Company has not been audited.
Second Quarter 2023 Financial Highlights
Revenue grew 6.7% year-over-year to RMB9,908 million, excluding COVID-19 commercial projects, revenue grew strongly by 39.5%. This is primarily attributable to the Company's continued excellent execution of our unique Contract Research, Development and Manufacturing Organization (CRDMO) business model to achieve strong synergy and continuous growth:
- WuXi Chemistry revenue grew 2.6% year-over-year to RMB7,034 million, excluding COVID-19 commercial projects, revenue grew strongly by 51.6%. Adjusted non-IFRS gross profit grew 12.9% year-over-year to RMB3,216 million, with a gross profit margin of 45.7%.
- WuXi Testing revenue grew 23.6% year-over-year to RMB1,638 million and adjusted non-IFRS gross profit grew 36.2% year-over-year to RMB640 million, with a gross profit margin of 39.1%.
- WuXi Biology revenue grew 17.5% year-over-year to RMB656 million and adjusted non-IFRS gross profit grew 21.3% year-over-year to RMB 271 million, with a gross profit margin of 41.4%.
- WuXi ATU revenue grew 22.9% year-over-year to RMB389 million and adjusted non-IFRS gross profit was RMB(16) million, with a gross profit margin of (4.2)%
- WuXi DDSU revenue declined 17.9% year-over-year to RMB176 million and adjusted non-IFRS gross profit grew year-over-year 5.2% to RMB63 million, with a gross profit margin of 35.8%. Meanwhile, we received the first royalty income from customers in the second quarter, which is a breakthrough for DDSU.
Unit: RMB million
- IFRS gross profit increased 18.1% year-over-year to RMB4,030 million. Gross profit margin was 40.7%[2]
- Adjusted non-IFRS gross profit increased 16.4% year-over-year to RM4,177 million. Adjusted non-IFRS gross margin was 42.2%.
- Net profit attributable to owners of the Company increased 5.1% year-over-year to RMB3,145 million.
- Adjusted non-IFRS net profit attributable to owners of the Company increased 22.4% year-over-year to RMB2,753 million.
First-Half 2023 Financial Highlights
Revenue grew 6.3% year-over-year to RMB18,871 million, excluding COVID-19 commercial projects, revenue grew strongly by 27.9%. This is primarily attributable to the Company's continued excellent execution of our unique Contract Research, Development and Manufacturing Organization (CRDMO) business model to achieve strong synergy and continuous growth:
- WuXi Chemistry revenue grew 3.8% year-over-year to RMB13,467 million, excluding COVID-19 commercial projects, revenue grew strongly by 36.1%. Adjusted non-IFRS gross profit grew 14.9% year-over-year to RMB6,103 million, with a gross profit margin of 45.3%.
- WuXi Testing revenue grew 18.7% year-over-year to RMB3,091 million and adjusted non-IFRS gross profit grew 26.1% year-over-year to RMB1,168 million, with a gross profit margin of 37.8%.
- WuXi Biology revenue grew 13.0% year-over-year to RMB1,233 million and adjusted non-IFRS gross profit grew 15.1% year-over-year to RMB511 million, with a gross profit margin of 41.5%.
- WuXi ATU revenue grew 16.0% year-over-year to RMB714 million and adjusted non-IFRS gross profit was RMB(40) million, with a gross profit margin of (5.7)%.
- WuXi DDSU revenue declined 24.9% year-over-year to RMB342 million and adjusted non-IFRS gross profit declined 26.2% year-over-year to RMB103 million, with a gross profit margin of 30.1%. Meanwhile, DDSU achieved a breakthrough in receiving the first royalty income from customers.
Unit: RMB million
- IFRS gross profit increased 17.6% year-over-year to RMB7,556 million. Gross profit margin was 40.0%[3].
- Adjusted non-IFRS gross profit increased 15.7% year-over-year to RMB7,855 million. Adjusted non-IFRS gross margin was 41.6%.
- Net profit attributable to owners of the Company increased 14.6% year-over-year to RMB 5,313 million.
- Adjusted non-IFRS net profit attributable to owners of the Company increased 18.5% year-over-year to RMB5,095 million.
- Diluted EPS increased 20.9% year-over-year to RMB1.79, while adjusted diluted non-IFRS EPS increased by 18.5% year-over-year to RMB1.73.
- Free cash flow achieved RMB2,926 million, turned positive and grew strongly year-over-year.
First-Half 2023 Business Operation Highlights
- As an industry innovation enabler, we grow together with our customers. In the first half of 2023, we added over 600 new customers, and in total we served more than 6,000 active customers over the past 12 months. Backlog grew 25% year-over-year excluding COVID-19 commercial projects. We continued to optimize our cross-platform synergies to better serve our customers worldwide, strengthen our unique competitive advantage as a fully integrated Contract Research, Development and Manufacturing Organization (CRDMO) and Contract Testing, Development and Manufacturing Organization (CTDMO) platform, and provide one-stop services for our customers from discovery to development and manufacturing. The diversified revenue streams from customers across regions ensure the stability and resilience of the Company's financial performance.
- WuXi Chemistry: Integrated CRDMO Business Model Drives Steady Growth, with Continued Expansion in New Modalities (WuXi TIDES)
- In the past 12 months, we successfully synthesized and delivered more than 420,000 new compounds to customers, which grew 20% year-over-year. Through our chemistry drug discovery services, we enabled our customers to accelerate their research while generating opportunities for our downstream business units. In the past 12 months, 120 molecules have transitioned from R to D&M, representing a year-on-year growth of 21%. Through our "follow-the-customer" and "follow-the-molecule" strategies, we established trusted partnerships with our global customers, supporting the sustainable growth of our CRDMO business.
- We continued executing our "long-tail" strategy. Demand from "long-tail" customers in discovery services of small molecule and new modalities continued to grow, with the number of new customers growing 17% year-over-year.
- In the first half of 2023, D&M services revenue grew 2.1% year-over-year to RMB9.67 billion. Excluding COVID-19 commercial projects, D&M services revenue grew strongly by 54.5%.
- In the first half of 2023, we added 583 molecules to our D&M pipeline. To date, our D&M pipeline consists of 2,819 molecules, including 56 commercial projects, 59 in phase III, 301 in phase II and 2,403 in phase I and pre-clinical stages, among which, 8 commercial and phase III projects were added in the first half of 2023.
- In the first half of 2023, TIDES revenue grew 37.9% year-over-year to RMB1.33 billion. As of June 30, 2023, backlog of TIDES grew strongly by 188% year-over-year. We expect revenue growth from TIDES business to exceed 70% in 2023.
- The number of TIDES D&M customers increased 25% year-over-year to 121, and the number of TIDES molecules increased 46% year-over-year to 207.
- WuXi Testing: Lab Testing Services Drive Steady Growth, Clinical Business Fully Recovered
- The Company provides a full range of laboratory testing services for our customers, including drug metabolism and pharmacokinetics (DMPK), toxicology, and bioanalysis for drug development testing, as well as medical device testing. We provide customers with high-quality services, realize "one report for global submission," and enable customers to save time, reduce costs and increase efficiency.
- H1 2023 revenue from drug safety evaluation services grew 24% year-over-year. We maintained our industry leadership position in Asia Pacific for drug safety evaluation services that meet global regulatory requirements. In the first half of 2023, new lab testing facilities in Qidong and Suzhou began operations as scheduled, ensuring the business growth to accelerate in the second half of 2023.
- Moreover, we continued to enhance capabilities related to new modalities, with comprehensive coverage such as target protein degradation, nucleic acids, conjugates, and cell and gene therapies (CGT), etc.
- SMO revenue grew strongly by 53.9% in Q2 2023 and 34.3% in H1 2023, maintaining a leadership position in China. In the first half of 2023, SMO supported 25 new drug approvals for customers.
- In the first half of 2023, clinical CRO enabled our customers to obtain 8 IND approvals and submit 3 NDA filings.
- WuXi Biology: Strong Contribution from New Modalities; Early Discovery Screening Platform Continued to Generate Downstream Opportunities
- WuXi ATU: CTDMO Business Model Drives Growth
- WuXi DDSU: the First Year to Receive New Drug Application (NDA) Approval of New Drugs Developed for Customers; Breakthrough to Receive the First Royalty Income
Our Commitment to ESG
As an industry innovation enabler, a trusted partner and a contributor to the global healthcare industry, the Company is committed to environmental protection and sustainability, and to being a good global corporate citizenship.
Our outstanding ESG performance has been recognized by major global ESG rating agencies, including MSCI, S&P Global, Sustainalytics, CDP and EcoVadis. In June 2023, we received the fourth "Silver" medal recognition from EcoVadis for our Couvet site in Switzerland.
By the first half of 2023, our carbon emission intensity, energy consumption intensity and water use intensity reduced by 20.1%, 18.4%, and 31.6%, respectively, as compared to the baseline year 2020.
As we continue to advance our sustainability strategy, we embrace our shared responsibility to be good stewards of the environment.
Management Comment
Dr. Ge Li, Chairman and CEO of WuXi AppTec, said, "We continued to achieve steady growth of revenue, net profit, and free cash flow in the first half of 2023. Our revenue increased 6.3% year-over-year to RMB18.87 billion, or 27.9% if excluding COVID-19 commercial projects. Our adjusted non-IFRS net profit attributable to owners of the Company increased 18.5% year-over-year, outpacing the revenue growth rate, and our free cash flow achieved RMB2.93 billion, as a result of the Company's pursuit of operational excellence and productivity."
"The Company's performance in the first half of 2023 demonstrated that WuXi AppTec's unique CRDMO and CTDMO business models can effectively meet the growing demands from customers worldwide and continue to drive solid growth for the Company. In 2023, we aim to deliver a 5-7% revenue growth, increase adjusted non-IFRS gross profit by 13-14%, and expand free cash flow by 750-850%. We remain committed to prioritizing our customers' needs and enhancing our capacity and capabilities as we support our customers' efforts to bring groundbreaking therapies to patients around the world. Together, we can realize our vision that 'every drug can be made and every disease can be treated'."
About WuXi AppTec
As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec's integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, cell and gene therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received an AA ESG rating from MSCI in 2022 and its open-access platform is enabling more than 6,000 customers from over 30 countries to improve the health of those in need – and to realize the vision that "every drug can be made and every disease can be treated." Please visit: http://www.wuxiapptec.com
Forward-Looking Statements
This press release may contain certain "forward-looking statements" which are not historical facts, but instead are predictions about future events based on our beliefs as well as assumptions made by and information currently available to our management. Although we believe that our predictions are reasonable, future events are inherently uncertain and our forward-looking statements may turn out to be incorrect. Our forward-looking statements are subject to risks relating to, among other things, the ability of our service offerings to compete effectively, our ability to meet timelines for the expansion of our service offerings, our ability to protect our customers' intellectual property, unforeseeable international tension, competition, the impact of emergencies and other force majeure. Our forward-looking statements in this press release speak only as of the date on which they are made, and we assume no obligation to update any forward-looking statements except as required by applicable law or listing rules. Accordingly, you are strongly cautioned that reliance on any forward-looking statements involves known and unknown risks and uncertainties. All forward-looking statements contained herein are qualified by reference to the cautionary statements set forth in this section. All information provided in this press release is as of the date of this press release and are based on assumptions that we believe to be reasonable as of this date, and we do not undertake any obligation to update any forward-looking statement, except as required under applicable law.
Use of Non-IFRS and Adjusted Non-IFRS Financial Measures
We provide non-IFRS gross profit and non-IFRS net profit attributable to owners of the Company, which exclude share-based compensation expenses, issuance expenses of convertible bonds, fair value gain or loss from derivative component of convertible bonds, foreign exchange-related gains or losses, amortization of intangible assets acquired in business combinations, non-financial assets impairment, etc. We also provide adjusted non-IFRS net profit attributable to owners of the Company and earnings per share, which further exclude realized and unrealized gains or losses from our venture capital investments and joint ventures. Neither is required by, or presented in accordance with IFRS.
We believe that the adjusted financial measures used in this press release are useful for understanding and assessing our core business performance and operating trends, and we believe that management and investors may benefit from referring to these adjusted financial measures in assessing our financial performance by eliminating the impact of certain unusual, non-recurring, non-cash and non-operating items that we do not consider indicative of the performance of our core business. Such adjusted non-IFRS net profit attributable to owners of the Company, the management of the Company believes, is widely accepted and adopted in the industry the Company is operating in. However, the presentation of these adjusted non-IFRS financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with IFRS. You should not view adjusted results on a stand-alone basis or as a substitute for results under IFRS, or as being comparable to results reported or forecasted by other companies.
For more information, please contact:
Ms. Ruijia Tang (for investors)
IR Director
Email: tang_ruijia@wuxiapptec.com
Mr. Davy Wu (for media)
PR Director
Email: davy_wu@wuxiapptec.com
View original content:
SOURCE WuXi AppTec | https://www.kfyrtv.com/prnewswire/2023/07/31/wuxi-apptec-announced-strong-results-second-quarter-first-half-2023-top-an-exceptionally-strong-year-2022/ | 2023-07-31T11:20:58 | 1 | https://www.kfyrtv.com/prnewswire/2023/07/31/wuxi-apptec-announced-strong-results-second-quarter-first-half-2023-top-an-exceptionally-strong-year-2022/ |
BEIJING, July 31, 2023 /PRNewswire/ -- 36Kr Holdings Inc. ("36Kr" or the "Company") (NASDAQ: KRKR), a prominent brand and a pioneering platform dedicated to serving New Economy participants in China, today announced the launch of its 36Kr Media Lab in Silicon Valley, an initiative to embrace the large language models (LLM) revolution taking place in the content creation industry and optimize the application of artificial intelligence (AI) for the new economy sector.
36Kr Silicon Valley Media Lab's first project leveraging LLM, "Empty Office," will experimentally explore scenarios where AI can think and work as humans, enhancing content production efficiency and reducing costs. Through "Empty Office," 36Kr is also building innovative media solutions that will transform traditional video, graphic and text communications into avant-garde dialogues between customized AI characters and audiences. These network-based dialogues will be naturally and seamlessly driven by real-time data generation, and available anytime, anywhere.
At the same time, 36Kr Silicon Valley Media Lab continues to focus on tailoring its LLM to the new economy sector. By utilizing dedicated financial and business datasets, including enterprises' financial results, news, market dynamics and knowledge repositories, among other resources, to train its LLM to thoroughly understand and analyze business information, 36Kr has developed a model that keenly grasps the business nuances to generate accurate analysis and interpretation. 36Kr Silicon Valley Media Lab constantly maintains its database, serving as the reference foundation to ensure that its fact-based model produces rigorous and up-to-date business and financial analysis.
Furthermore, 36Kr's professionally-training, fine-tuning capability enables its LLM-empowered "Empty Office" to quickly and efficiently create informative content for the new economy sector. For instance, in the case of a business event, such as a new product launch, an AI agent can instantly extract relevant data from the database, automatically perform a comprehensive analysis, and issue reports within just seconds. This top-speed response gives 36Kr's business and financial-focused media platform an unrivaled edge.
Mr. Dagang Feng, Co-chairman and CEO of 36Kr, commented, "The launch of 36Kr Silicon Valley Media Lab is a testament to our AI technology acumen and vision as well as our commitment to extending media's boundaries. By integrating pioneering AI technology into content creation, 36Kr will constantly elevate the efficiency and quality of content production alongside the rapid advancement of the LLM, fostering a superior content ecosystem encompassing business, finance and technology, further turbocharging the evolution of the New Economy. As we adopt and develop more AI tools amid the technology's rapid advancement, we are strategically positioning the Company to break new ground and ultimately drive long-term growth for our business."
About 36Kr Holdings Inc.
36Kr Holdings Inc. is a prominent brand and a pioneering platform dedicated to serving New Economy participants in China with the mission of empowering New Economy participants to achieve more. The Company started its business with high-quality New Economy-focused content offerings, covering a variety of industries in China's New Economy with diverse distribution channels. Leveraging traffic brought by high-quality content, the Company has expanded its offerings to business services, including online advertising services, enterprise value-added services, and subscription services, to address the evolving needs of New Economy companies and upgrading needs of traditional companies. The Company is supported by a comprehensive database and strong data analytics capabilities. Through diverse service offerings and significant brand influence, the Company is well-positioned to continuously capture the high growth potential of China's New Economy.
For more information, please visit: http://ir.36kr.com.
Safe Harbor Statement
This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: the Company's goal and strategies; the Company's future business development, results of operations and financial condition; relevant government policies and regulations relating to our business and industry; the Company's expectations regarding the use of proceeds from this offering; the Company's expectations regarding demand for, and market acceptance of, its services; the Company's ability to maintain and enhance its brand; the Company's ability to provide high-quality content in a timely manner to attract and retain users; the Company's ability to retain and hire quality in-house writers and editors; the Company's ability to maintain cooperation with third-party professional content providers; the Company's ability to maintain relationships with third-party platforms; general economic and business conditions in China; possible disruptions in commercial activities caused by natural or human-induced disasters; and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in the Company's filings with the SEC. All information provided in this press release and in the attachments is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.
For investor and media inquiries, please contact:
In China:
36Kr Holdings Inc.
Investor Relations
Tel: +86 (10) 8965-0708
E-mail: ir@36kr.com
The Piacente Group, Inc.
Jenny Cai
Tel: +86 (10) 6508-0677
E-mail: 36Kr@tpg-ir.com
In the United States:
The Piacente Group, Inc.
Brandi Piacente
Tel: +1-212-481-2050
E-mail: 36Kr@tpg-ir.com
View original content:
SOURCE 36Kr Holdings Inc. | https://www.wagmtv.com/prnewswire/2023/07/31/36kr-launches-silicon-valley-media-lab-empower-content-ecosystem-with-llm-based-ai-technology/ | 2023-07-31T11:21:02 | 0 | https://www.wagmtv.com/prnewswire/2023/07/31/36kr-launches-silicon-valley-media-lab-empower-content-ecosystem-with-llm-based-ai-technology/ |
GUANGZHOU, China, July 31, 2023 /PRNewswire/ -- Yatsen Holding Limited ("Yatsen" or the "Company") (NYSE: YSG), a leading China-based beauty group, today announced that it has published its 2022 Environmental, Social and Governance ("ESG") report, outlining the Company's progress and performance in key ESG areas.
The report provides a comprehensive review of Yatsen's ESG initiatives and developments, including corporate governance, research and development, employee rights protection, human capital development, environmental sustainability and social responsibility, among others.
To view the report in full, please visit the ESG section on the Yatsen Investor Relations website. Alternatively, please click here for the English version and here for the Chinese version of the 2022 report.
About Yatsen Holding Limited
Yatsen Holding Limited (NYSE: YSG) is a leading China-based beauty group with the mission of creating an exciting new journey of beauty discovery for consumers around the world. Founded in 2016, the Company has launched and acquired numerous color cosmetics and skincare brands, including Perfect Diary, Little Ondine, Abby's Choice, Galénic, DR.WU (its mainland China business), Eve Lom, Pink Bear and EANTiM. The Company's flagship brand, Perfect Diary, is one of the leading color cosmetics brands in China in terms of retail sales value. The Company primarily reaches and engages with customers directly, both online and offline, with an expansive presence across all major e-commerce, social and content platforms in China.
For more information, please visit http://ir.yatsenglobal.com/.
For investor and media inquiries, please contact:
In China:
Yatsen Holding Limited
Investor Relations
E-mail: ir@yatsenglobal.com
The Piacente Group, Inc
Hui Fan
Tel: +86-10-6508-0677
E-mail: yatsen@thepiacentegroup.com
In the United States:
The Piacente Group, Inc.
Brandi Piacente
Tel: +1-212-481-2050
E-mail: yatsen@thepiacentegroup.com
View original content:
SOURCE Yatsen Holding Limited | https://www.kfyrtv.com/prnewswire/2023/07/31/yatsen-issues-2022-esg-report/ | 2023-07-31T11:21:05 | 1 | https://www.kfyrtv.com/prnewswire/2023/07/31/yatsen-issues-2022-esg-report/ |
- Cash, cash equivalents, and marketable securities totaled $349.0 million as of June 30, 2023
- Announced positive interim data from BHV-7000 EEG biomarker study demonstrating evidence of central nervous system (CNS) target engagement, confirming previously reported preclinical and clinical data, and highlighting the paradigm-changing potential of BHV-7000 in the treatment of epilepsy and mood disorders
- Brain penetrant TYK2/JAK1 inhibitor, BHV-8000, advanced into Phase 1 with projected therapeutic concentrations achieved and well-tolerated profile observed to date
- Advanced targeted extracellular protein degradation platform with potential to support numerous clinical candidates across a broad range of high unmet need indications
- Orphan drug designation (ODD) granted by the European Commission for taldefgrobep alfa a novel anti-myostatin adnectin, for the treatment of spinal muscular atrophy (SMA)
- Type A meeting planned with FDA regarding troriluzole program in Spinocerebellar Ataxia Type 3 (SCA3) and enrollment in Phase 3 obsessive compulsive disorder (OCD) trial expected to complete at end of 2023
NEW HAVEN, Conn., July 31, 2023 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today reported financial results for the second quarter ended June 30, 2023, and provided a review of recent accomplishments and anticipated upcoming milestones.
Vlad Coric, M.D., Chairman and Chief Executive Officer of Biohaven, commented, "In less than a year since our spin-off, the Biohaven team has driven strong and consistent progress across multiple drug development platforms. We were excited to recently report positive interim data from the ongoing EEG biomarker study of our lead Kv7 activator, BHV-7000. As expected, BHV-7000 demonstrated CNS activity consistent with what has been reported in EEG studies with other Kv7 channel activators in development that are clinically effective in treating epilepsy and with other approved anti-seizure medications. Importantly, BHV-7000 demonstrates CNS target engagement but is not associated with the typical CNS adverse events associated with other ASMs, like somnolence and fatigue. We look forward to completing the higher dose groups in this EEG study and initiating Phase 2/3 studies with our once daily, extended-release oral formulation later this year."
Dr. Coric continued, "We also shared a number of equally exciting announcements across our broader pipeline this quarter. We successfully administered the first three doses in the SAD portion of our ongoing SAD/MAD study evaluating BHV-8000, an oral, brain-penetrant, dual TYK2/JAK1 inhibitor. Potential therapeutic concentrations of BHV-8000 were achieved and BHV-8000 was well tolerated with only mild adverse events reported, reinforcing our plans to start a Phase 2 clinical trial with BHV-8000 in Parkinson's disease and potentially other neuroinflammatory diseases in 2024. In addition, we have advanced IND enabling preclinical studies and remain on track to submit an IND with our IgG degrader, BHV-1300, later this year. We also anticipate submitting an IND with our IgA degrader in 2024 as we continue to advance multiple clinical degrader candidates across a wide range of indications. We also shared key updates for our taldefgrobep alfa program (an anti-myostatin) with enrollment completion in our pivotal study in SMA and a planned Phase 2 trial initiation in obesity."
"Finally, I want to reaffirm Biohaven's commitment to the SCA3 patient community in spite of the recent disappointing regulatory decision by the FDA not to review our submitted NDA. Given the seriousness of SCA3 and consistent treatment benefits observed across multiple prespecified outcome measures, including an 80% delay in disease progression over the one-year study period with substantial risk reduction in falls, we believe that full consideration of all available data is warranted for this ultra-rare disease. Biohaven has built its foundation around our patient mission and we plan to continue to work with regulatory agencies to try to advance troriluzole for individuals suffering from SCA3."
Second Quarter 2023 and Recent Business Highlights
- Announced positive interim data from EEG biomarker study with BHV-7000 - In July 2023, the Company provided a preliminary data update from the ongoing electroencephalogram (EEG) biomarker study for the Kv7 Channel Activator platform. Preliminary Phase 1 data confirmed evidence of target engagement in the central nervous system for subjects with projected therapeutic concentrations of BHV-7000 (based on the EC50 from preclinical models), measured by changes from baseline in EEG spectral power that occurred after dosing. These pharmacodynamic (PD) effects were similar to those reported in the literature for anti-seizure medicines (ASMs), including Kv7 activators in development that are clinically effective in treating epilepsy. BHV-7000's PD effects were also differentiated from those reported for other Kv7 activators including, specifically, the absence of increases in EEG spectral power in frequency bands associated with drowsiness and somnolence. Results from the low-dose group validate the preclinical hypothesis, confirm the Phase 1 SAD/MAD clinical data, and provide strong support for Biohaven's plans to initiate pivotal studies with BHV-7000 in focal epilepsy and bipolar disorder in the second half of 2023. The preliminary data highlight BHV-7000's differentiation and potentially favorable clinical profile compared to other ASMs, and the Company expects to present the complete EEG results by the end of the year. Additionally, new pharmacokinetic data from multiple clinical formulations being studied has now confirmed a once daily extended-release oral formulation that will be used in the Phase 2/3 clinical programs.
- Successfully dosed three cohorts with single ascending doses of oral, brain penetrant, dual TYK2/JAK1 agent, BHV-8000 - In July 2023, the Company announced that it successfully dosed three cohorts in the SAD portion of an ongoing SAD/MAD Phase 1 study evaluating brain penetrant TYK2/JAK1 agent, BHV-8000 in healthy volunteers. The ongoing Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics (PK) and PD of single and multiple ascending doses of BHV-8000 in healthy volunteers. Based on the preliminary data available, projected therapeutic concentrations of BHV-8000 were achieved, and BHV-8000 was well tolerated with only mild adverse events reported. These data provide support for further development of BHV-8000, and the Company anticipates beginning a Phase 2 clinical trial with BHV-8000 in Parkinson's disease and potentially other neuroinflammatory diseases in 2024. The Company had previously reported initiation of dosing with BHV-8000 in the Phase 1 study at Biohaven's R&D Day in May 2023.
- Reported on continued progress observed with Biohaven's first-in-class bispecific IgG degrader, BHV-1300, as compound advances to IND filing in 2H2023 - In July 2023, the Company shared an update on BHV-1300's highly competitive safety, manufacturable and PD profile. The Company is assembling a pipeline of partially de-risked, follow-on IgG degraders as well as antigen-specific degraders providing both optionality and a sustainable output of drug candidates for several years. An IND application for BHV-1300 is on track for submission in 2023 and an IND application for Biohaven's IgA degrader on track for submission in 2024
- Type A meeting planned to comprehensively address FDA's concerns in connection with Troriluzole program in SCA3 - In July 2023, the Company announced that the FDA informed Biohaven it would not review the recently submitted New Drug Application (NDA) for troriluzole for the treatment of spinocerebellar ataxia type 3 (SCA3), an ultra-rare, genetically-defined, neurodegenerative disease associated with progressive disability, frequent falls, loss of ambulation, speech and swallowing impairment, and premature death that is the most common SCA genotype worldwide. The FDA informed Biohaven it would not review the application given that the study's primary endpoint was not met and thus, would not permit a substantive review. Biohaven is committed to working closely with the FDA to bring troriluzole to people with SCA3 as quickly as possible given no therapy is currently approved for this ultra-rare genetic disorder. Biohaven plans to request a Type A meeting to comprehensively address FDA's concerns cited in the refusal to file letter.
- EMA orphan drug designation granted for taldefgrobep alfa for the treatment of SMA: - In July 2023, the Company announced that taldefgrobep alfa received orphan drug designation (ODD) from the European Commission for taldefgrobep for the treatment of SMA. Taldefgrobep previously received Fast-Track and ODD from the FDA. At Biohaven's R&D Day, the Company announced plans to complete randomization of approximately 180 patients in global SMA trial.
Upcoming Milestones:
Biohaven is progressing its product candidates through clinical programs in a number of common and rare disorders. The Company plans to reach significant pipeline milestones in the coming periods. Biohaven expects to:
- Announce Phase 1 EEG study results by year-end 2023: The Company expects to present complete results from its ongoing EEG study with BHV-7000 in healthy volunteers by the end of the year.
- Initiate Phase 2/3 studies with BHV-7000 in the second half of 2023: Biohaven expects to initiate pivotal trials in patients with focal epilepsy and bipolar disorder in the second half of 2023.
- Submit IND with BHV-1300, the Company's lead extracellular degrader: The Company expects to submit an IND with pan-IgG degrader BHV-1300 in the second half of 2023 and expects to initiate Phase 2 studies in 2024.
- Submit IND with selective Gd-IgA1 degrader: The Company expects to submit an IND with a Gd-IgA1 degrader indicated for IgA nephropathy in the first half of 2024.
- Initiate Phase 2 study with BHV-8000: The Company commenced Phase 1 studies with BHV-8000, an oral, brain-penetrant, dual TYK2/JAK1 inhibitor for neuroinflammatory disorders, in the first half of 2023 and expects to initiate a Phase 2 study in Parkinson's disease in 2024.
- Submit IND with BHV-2100 in chronic pain: The Company expects to submit an IND with BHV-2100, a selective TRPM3 antagonist in the Company's ion channel platform, in the second half of 2023.
- Complete enrollment in Phase 3 study of troriluzole in OCD in 2023: Two Phase 3 randomized, double-blind, placebo-controlled studies of troriluzole in OCD are expected to enroll up to 700 patients (in each trial) across nearly 200 global study sites. The Company anticipates completing enrollment in at least one Phase 3 trial by year-end 2023.
- Complete enrollment in Phase 3 clinical study of taldefgrobep alfa in SMA: The Company expects to complete enrollment in the study of taldefgrobep in SMA in the second half of 2023.
- Continue advancements across multiple neuroscience and immunoscience indications: The Company's preclinical pipeline includes a platform of bispecific degraders of extracellular proteins directed against IgG, IgA and other targets, TRPM3 and Kv7 family of ion channels, and other undisclosed targets, including those with disease-modifying potential.
Capital Position:
Cash, cash equivalents and marketable securities as of June 30, 2023 was $349.0 million, including $13.9 million of restricted cash, and excluding $40.4 million of cash payable to Biohaven Pharmaceutical Holding Company Ltd. (the Former Parent), compared to $467.9 million, including $2.5 million of restricted cash, and excluding $35.2 million of cash payable to the Former Parent, as of December 31, 20221.
Second Quarter 2023 Financial Highlights:
Research and Development (R&D) Expenses: R&D expenses, including non-cash share-based compensation costs, were $79.5 million for the three months ended June 30, 2023, compared to $177.1 million for the three months ended June 30, 2022. Non-cash share-based compensation expense was $2.5 million for the three months ended June 30, 2023, a decrease of $10.3 million as compared to the same period in 2022. Non-cash share-based compensation expense was higher in the second quarter of 2022 primarily because expense allocated from the Former Parent equity plan, prior to the spin-off, was based on equity awards with higher grant date fair values.
General and Administrative (G&A) Expenses: General and administrative expenses were $14.5 million for the three months ended June 30, 2023, compared to $20.0 million for the three months ended June 30, 2022. The decrease of $5.5 million was primarily due to decreased non-cash share-based compensation costs. Non-cash share-based compensation expense was $2.2 million for the three months ended June 30, 2023, a decrease of $5.8 million as compared to the same period in 2022. Non-cash share-based compensation expense was higher in the second quarter of 2022 primarily because expense allocated from the Former Parent equity plan, prior to the spin-off, was based on equity awards with higher grant date fair values.
Other Income (Expense), Net: Other income (expense), net was a net income of $5.8 million for the three months ended June 30, 2023, compared to net expense of $0.1 million for the three months ended June 30, 2022. The increase of $5.9 million was primarily due to an increase in net investment income and an increase of $1.7 million in other income related to our transition services provided to the Former Parent, which is largely non-recurring.
Net Loss: Biohaven reported a net loss for the three months ended June 30, 2023, of $90.3 million, or $1.32 per share, compared to $203.3 million, or $5.16 per share, for the same period in 2022. Non-GAAP adjusted net loss for the three months ended June 30, 2023 was $85.7 million, or $1.25 per share, compared to $182.5 million, or $4.63 per share for the same period in 2022. These non-GAAP adjusted net loss and non-GAAP adjusted net loss per share measures, more fully described below under "Non-GAAP Financial Measures," exclude non-cash share-based compensation charges. A reconciliation of the GAAP financial results to non-GAAP financial results is included in the tables below. For periods prior to Biohaven's spin-off from the Former Parent on October 3, 2022 (the "Spin-Off"), net loss per share and non-GAAP adjusted net loss per share were calculated based on the 39,375,944 common shares of Biohaven distributed to the Former Parent shareholders at the time of the distribution, including common shares issued in connection with the Former Parent share options that were settled on October 3, 2022 and common shares issued in connection with the Former Parent restricted share units that vested on October 3, 2022. The same number of shares is being utilized for the calculation of basic and diluted earnings per share for all periods presented prior to the Spin-Off.
Non-GAAP Financial Measures
This press release includes financial results prepared in accordance with accounting principles generally accepted in the United States (GAAP), and also certain non-GAAP financial measures. In particular, Biohaven has provided non-GAAP adjusted net loss and adjusted net loss per share, which are adjusted to exclude non-cash share-based compensation, which is substantially dependent on changes in the market price of common shares. Non-GAAP financial measures are not an alternative for financial measures prepared in accordance with GAAP. However, Biohaven believes the presentation of non-GAAP adjusted net loss and adjusted net loss per share, when viewed in conjunction with GAAP results, provides investors with a more meaningful understanding of ongoing operating performance and can assist investors in comparing Biohaven's performance between periods.
In addition, these non-GAAP financial measures are among those indicators Biohaven uses as a basis for evaluating performance, and planning and forecasting future periods. These non-GAAP financial measures are not intended to be considered in isolation or as a substitute for GAAP financial measures. A reconciliation between these non-GAAP measures and the most directly comparable GAAP measures is provided later in this news release.
About Biohaven
Biohaven is a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases. Biohaven's experienced management team brings with it a track record of delivering new drug approvals for products for diseases such as migraine, depression, bipolar and schizophrenia. The company is advancing a pipeline of therapies for diseases, many of which have limited or no treatment options, leveraging its proven drug development capabilities and proprietary platforms, including Kv7 ion channel modulation for epilepsy and neuronal hyperexcitability, glutamate modulation for obsessive-compulsive disorder and spinocerebellar ataxia, myostatin inhibition for neuromuscular diseases and metabolic disorders, and brain-penetrant TYK2/JAK1 inhibition for neuroinflammatory disorders. Biohaven's portfolio of early- and late-stage product candidates also includes discovery research programs focused on TRPM3 channel activation for neuropathic pain, CD-38 antibody recruiting, bispecific molecules for multiple myeloma, antibody drug conjugates (ADCs), and targeted extracellular protein degradation platform technology (MoDE™) with potential application in neurological disorders, cancer, and autoimmune diseases.
Forward-looking Statements
This news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including "continue", "plan", "will", "believe", "may", "expect", "anticipate" and similar expressions, is intended to identify forward-looking statements. Investors are cautioned that any forward-looking statements, including statements regarding the future development, timing and potential marketing approval and commercialization of development candidates, are not guarantees of future performance or results and involve substantial risks and uncertainties. Actual results, developments and events may differ materially from those in the forward-looking statements as a result of various factors including: the expected timing, commencement and outcomes of Biohaven's planned and ongoing clinical trials; the timing of planned interactions and filings with the FDA; the timing and outcome of expected regulatory filings; complying with applicable U.S. regulatory requirements; the potential commercialization of Biohaven's product candidates; the potential for Biohaven's product candidates to be first in class therapies; and the effectiveness and safety of Biohaven's product candidates. Additional important factors to be considered in connection with forward-looking statements are described in Biohaven's filings with the Securities and Exchange Commission, including within the sections titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations". The forward-looking statements are made as of the date of this new release, and Biohaven does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
MoDEs is a trademark of Biohaven Therapeutics Ltd.
Investor Contact:
Jennifer Porcelli
Vice President, Investor Relations
jennifer.porcelli@biohavenpharma.com
+1 (201) 248-0741
Media Contact:
Mike Beyer
Sam Brown Inc.
mikebeyer@sambrown.com
+1 (312) 961-2502
View original content to download multimedia:
SOURCE Biohaven Ltd. | https://www.wagmtv.com/prnewswire/2023/07/31/biohaven-reports-second-quarter-2023-financial-results-recent-business-developments/ | 2023-07-31T11:21:09 | 0 | https://www.wagmtv.com/prnewswire/2023/07/31/biohaven-reports-second-quarter-2023-financial-results-recent-business-developments/ |
The cutting-edge platform empowers B2B SaaS start-ups to reduce churn, increase upsell, and boost NRR
WILMINGTON, Del., July 31, 2023 /PRNewswire/ -- ZapScale, a new-age customer success platform, is making waves in the industry by offering an unrivalled one-day onboarding experience along with the ability to track 150 customer data points for a comprehensive 360-degree view of customer health. This ground-breaking feature sets ZapScale apart from its competitors.
The secret behind ZapScale's lightning-fast onboarding lies in its comprehensive toolkit. With a robust framework of 40 pre-built KPI-based health frameworks, 60 pre-designed playbooks to automate CS ops, and seamless native integrations with all popular tools, ZapScale empowers businesses to gain complete visibility over customer data. With deep customer health insights, ZapScale's customers have seen an improvement in retention and increase in upsell opportunities.
Manasij Ganguli, Founder and CEO of ZapScale, shares his personal motivation for creating this game-changing platform: "ZapScale was born out of my passion to empower B2B SaaS start-ups with an efficient and effective CS platform. Having faced numerous customer success challenges in my previous start-up, which I successfully sold in 2019, I realized the critical need for a solution that could streamline, optimize, and accelerate CS operations.
For small to mid-sized businesses that have limited time and resources, implementing a CS platform has historically been a daunting task, taking weeks, if not months, to set up essential elements like customer health, playbooks, and integrations. ZapScale has addressed this challenge by offering a user-friendly and efficient implementation process, eliminating waste of time and resources. Now, businesses can seamlessly focus on their customers right from day 1."
ZapScale eliminates the traditional barriers and time-consuming processes associated with implementing CS platforms using key in-built features that facilitate custom mapping, support custom fields, and require no unique key to integrate applications, ensuring a tailored yet quick integration experience.
ZapScale is swiftly gaining traction in the market, with 30+ global companies already using the customer success platform. Starting at $249 per month, with a one-month free trial, ZapScale is helping businesses significantly improve their customer success initiatives.
For more information about ZapScale and to schedule a demo, visit www.zapscale.com.
Contact:
Nikita Kalra
Marketing Head, ZapScale
nikita@zapscale.com
Logo: https://mma.prnewswire.com/media/2097823/ZS_Logo.jpg
View original content:
SOURCE ZapScale | https://www.kfyrtv.com/prnewswire/2023/07/31/zapscale-sets-new-industry-standard-with-easiest-customer-success-platform-one-day-onboarding/ | 2023-07-31T11:21:12 | 1 | https://www.kfyrtv.com/prnewswire/2023/07/31/zapscale-sets-new-industry-standard-with-easiest-customer-success-platform-one-day-onboarding/ |
SAN FRANCISCO, July 31, 2023 /PRNewswire/ -- Today, Blitz Insurance, a specialty insurance carrier, partners with Ascend to modernize payment experiences for insurance brokers selling in specialty markets. With this partnership, Blitz Insurance will open new customer segments by offering both direct bill and premium financing into their payments workflow.
"When we looked into the market for a solution, Ascend was the right choice. Ascend meets our needs for a better payments experience for our partners while reducing everyone's operational expenses," said Brandon Murphy, Chief Distribution Officer of Blitz Insurance. "We will now have the ability to not only expand to direct bill and a premium finance option but also simplify the movement of money between us and our partners."
With Ascend, Blitz Insurance is now able to provide a direct bill in addition to their existing agency bill workflow - allowing brokers to decide what billing method works best for them. By utilizing Ascend, Blitz Insurance not only grows their footprint of appointed brokers but also gains administrative efficiency by automating what would otherwise have been a large operational undertaking.
Ascend automatically attributes incoming payments to policies in real time, speeding up the reconciliation process. By modernizing the payments experience and speeding up the reconciliation of incoming premiums, Blitz Insurance can offer a best-in-class experience to its brokers and agents.
"We find that across the insurance ecosystem - companies want to provide a seamless payment workflow for their customers and their teams," said Andrew Wynn, co-CEO of Ascend. "Ascend is built so brokers and carriers can offer this experience without shouldering the administrative resources and costs needed to support these operations."
About Ascend
Ascend is the first insurance payments platform that automates financial operations from collections and financing to carrier and commission payables. Founded by two-time insurtech entrepreneurs Andrew Wynn and Praveen Chekuri, Ascend helps insurance brokers, MGAs, and carriers improve their bottom lines by eliminating expensive and labor-intensive payment workflows. To learn more, please visit LinkedIn, Twitter or check out https://www.useascend.com/.
About Blitz Insurance
Blitz is a tech-driven insurer revolutionizing the $60B specialty market catering to SME segment. By leveraging industry knowledge and cutting-edge technology, we deliver a simpler, smarter, and faster coverage experience.
The company is led by a veteran team of insurance and technology experts and has been funded with $25M from its founder & CEO, a Forbes-listed serial entrepreneur in the real estate and insurance industries.
Contact:
Mike Nguyen
press@useascend.com
View original content to download multimedia:
SOURCE Ascend | https://www.wagmtv.com/prnewswire/2023/07/31/blitz-insurance-partners-with-ascend-expand-payment-financing-offerings/ | 2023-07-31T11:21:15 | 1 | https://www.wagmtv.com/prnewswire/2023/07/31/blitz-insurance-partners-with-ascend-expand-payment-financing-offerings/ |
STAMFORD, Conn., July 31, 2023 /PRNewswire/ -- Emeren Group Ltd ("Emeren" or the "Company") (www.emeren.com) (NYSE: SOL), a leading global solar project developer, owner, and operator, recently announced the successful sale of an 11.5 MWp PV project to the Swiss-based energy company MET Group. The project was sold at the Ready-to-Build ("RTB") stage and MET Group will complete the construction and operate the power plant. This is the first project developed to RTB stage by Emeren Germany GmbH, the Berlin-based subsidiary of Emeren Group, since its entry into the market in early 2021. Capcora, a German consulting company, acted as the exclusive sell-side M&A advisor to Emeren.
The new PV power plant will be located in Kentzlin nestled in the state of Mecklenburg-Western Pomerania and the commercial operations are expected to start in the second half of 2024.
Yumin Liu, CEO of Emeren Group, commented, "This project is an important milestone for our business in Germany and represents our commitment to developing renewable energy infrastructure in the region. We look forward to continuing to work with our local partners to build a more sustainable future."
Bernd Wollwerth-Carl, Director of Emeren Germany GmbH, added, "We are delighted to have sold our first RTB project in Germany. Starting from scratch in 2021, we managed to grow quickly in a competitive German PV market, establishing partnerships and building a pipeline of medium and large-scale ground mounted PV plants. With MET, we found a reliable and competent partner and we look forward to further expanding our cooperation."
Christian Hürlimann, Renewables CEO of MET Group, commented, "The Kentzlin project fits well into MET's strategic vision to enter the highly competitive German renewables market, as well as to further expand its renewables portfolio across Europe and particularly in Western Europe. Emeren Group's expertise in renewable energy was instrumental in achieving this milestone, and we anticipate future collaboration on additional projects."
Henning Prigge, Director at Capcora, adds: "We are delighted to have played a pivotal role in Emeren's successful project sale to MET Group, a prominent integrated European energy company. Our long-standing partnership with Emeren has allowed us to witness their growth and success, and we couldn't be happier to have been a part of this milestone. This collaboration reinforces our commitment to providing top-notch support and solutions to our valued clients."
About Emeren Group Ltd
Emeren Group Ltd (NYSE: SOL) is a leading global solar project developer, owner, and operator with a pipeline of projects and IPP assets totaling over 3 GW, as well as a storage pipeline of over 6 GWh across Europe, North America, and Asia. The Company focuses on solar power project development, construction management and project financing services with local professional teams across multiple countries. For more information, go to www.emeren.com.
About MET Group
MET Group is an integrated European energy company, headquartered in Switzerland, with activities and assets in natural gas and power markets. MET is present in 14 countries through subsidiaries, 30 national gas markets, and 22 international trading hubs. MET has extensive experience in operating green (renewable) and flexible (conventional) energy assets, thus providing the widest possible support to energy transition. In 2022, MET Group's consolidated sales revenue amounted to EUR 41.5 billion, the total traded volume of natural gas was 109 BCM including futures, total traded electricity 67 TWh including futures.
About Capcora
Capcora is an independent financial advisory boutique specializing in M&A and project finance services to accelerate the energy transition in Europe. Founded in 2015, the Frankfurt-based company helps its clients succeed in the renewable energy and infrastructure sectors by advising them on sell-side and buy-side transactions, and by raising mezzanine, unitranche or senior debt.
View original content to download multimedia:
SOURCE Emeren Group Ltd | https://www.wagmtv.com/prnewswire/2023/07/31/emeren-group-announces-sale-first-rtb-solar-power-project-germany/ | 2023-07-31T11:21:22 | 1 | https://www.wagmtv.com/prnewswire/2023/07/31/emeren-group-announces-sale-first-rtb-solar-power-project-germany/ |
BEIJING, July 31, 2023 /PRNewswire/ -- Gravitas Education Holdings, Inc. ("GEHI" or the "Company") (NYSE: GEHI), a leading early childhood education service provider in China, today announced that it will hold an extraordinary general meeting of shareholders (the "EGM") at 3/F, No. 28 Building, Fangguyuan Section 1, Fangzhuang Fengtai District, Beijing 100078, People's Republic of China, at 10:00 a.m. (Beijing time) on September 11, 2023, for the purposes of considering and, if thought fit, approving the transactions contemplated in the Agreement and Plan of Merger (the "Merger Agreement"), dated April 18, 2023, by and among the Company, Bright Sunlight Limited, a Cayman Islands exempted company and a direct, wholly owned subsidiary of the Company ("Merger Sub"), Best Assistant Education Online Limited, a Cayman Islands exempted company ("Best Assistant") and a controlled subsidiary of NetDragon Websoft Holdings Limited (HKEX: 0777, "NetDragon"), a Cayman Islands exempted company, and solely for purposes of certain named sections thereof, NetDragon. It is contemplated that Best Assistant will transfer the education business of NetDragon outside of the PRC to Elmtree Inc., a Cayman Islands exempted company limited by shares ("eLMTree") and currently a wholly owned subsidiary of Best Assistant. Pursuant to the Merger Agreement, Merger Sub will merge with and into eLMTree with eLMTree continuing as the surviving company and becoming a wholly owned subsidiary of the Company (the "Merger").
Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each ordinary share of eLMTree issued and outstanding immediately prior to the Effective Time (excluding the Dissenting Shares and the Excluded Shares, each as defined in the Merger Agreement) will be cancelled in exchange for the right to receive a number of validly issued, fully paid and non-assessable ordinary shares of the Company in a transaction exempt from the registration requirements under the Securities Act of 1933.
Shareholders of the Company will also be asked to consider and vote on certain additional Merger-related proposals at the EGM, including, among others:
- that, subject to and conditional upon the Merger becoming effective, the fifth amended and restated memorandum and article of association of the Company be amended and restated by their deletion in their entirety and the substitution of in their place of the sixth amended and restated memorandum and articles of association of the Company (the "A&R MAA") effective immediately prior to the Effective Time of the Merger;
- that, subject to and conditional upon the Merger becoming effective, the name of the Company be changed from "Gravitas Education Holdings, Inc." to "Mynd.ai, Inc." effective immediately prior to the Effective Time;
- that, subject to and conditional upon the Merger becoming effective, immediately prior to the Effective Time, the authorized share capital of the Company be varied as follows: (a) the authorized share capital of the Company shall be varied to US$1,000,000 divided into 1,000,000,000 shares comprising of (i) 990,000,000 ordinary shares of a par value of US$0.001 each (each a "ListCo Ordinary Share") and (ii) 10,000,000 shares of a par value of US$0.001 each of such class or classes (however designated) as the board of directors may determine in accordance with the A&R MAA, and (b) all Class A ordinary shares of the Company prior to the adoption of the A&R MAA, par value US$0.001 per share ("ListCo Class A Ordinary Shares") and all Class B ordinary shares of the Company prior to the adoption of the A&R MAA, par value US$0.001 per share ("ListCo Class B Ordinary Shares") in the authorized share capital of the Company (including all issued and outstanding ListCo Class A Ordinary Shares and ListCo Class B Ordinary Shares, and all authorized but unissued ListCo Class A Ordinary Shares and ListCo Class B Ordinary Shares) shall be re-designated as ListCo Ordinary Shares.
Holders of the Company's ordinary shares whose names are on the register of members of the Company at the close of business in the Cayman Islands on August 7, 2023, are entitled to notice of, and to vote at, the EGM or any adjournment or postponement thereof in person. Holders of the Company's American depositary shares ("ADSs") at the close of business in New York City on August 7, 2023, are entitled to exercise their voting rights for the underlying ordinary shares and must act through Citibank, N.A., the depositary of the Company's ADS program.
The notice of the EGM, which contains the detailed proposals to be presented at the EGM, and the proxy statement related to the EGM, are being filed today with the U.S. Securities and Exchange Commission ("SEC") and can be obtained without charge from the SEC's website (http://www.sec.gov). These documents are also available in the "Financial Information" section of the Company's investor relations website at https://ir.geh.com.cn/. In addition, the proxy materials (including the proxy statement) will be mailed to the Company's shareholders and holders of ADSs.
SHAREHOLDERS AND ADS HOLDERS ARE URGED TO READ CAREFULLY AND IN THEIR ENTIRETY THE PROXY MATERIALS AND OTHER MATERIALS FILED WITH OR FURNISHED TO THE SEC WHEN THEY BECOME AVAILABLE, AS THEY CONTAIN VOTING INSTRUCTIONS AND IMPORTANT INFORMATION ABOUT THE COMPANY, ELMTREE, THE MERGER AND RELATED MATTERS.
This press release is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the transactions described above and shall not constitute an offer to sell or a solicitation of an offer to buy the securities of eLMTree or the Company, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or an exemption therefrom.
Forward-Looking Statements
This press release contains certain "forward-looking statements." These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about the pending transactions described herein, and the parties' perspectives and expectations, are forward-looking statements. Such statements include, but are not limited to, statements regarding the Merger, including the equity values, the benefits of the Merger, expected revenue opportunities, anticipated future financial and operating performance and results, including estimates for growth, the expected management and governance of the combined company, and the expected timing of the transactions. The words "will," "expect," "believe," "estimate," "intend," "plan" and similar expressions indicate forward-looking statements.
Such forward-looking statements are inherently uncertain, and shareholders and other potential investors must recognize that actual results may differ materially from the expectations as a result of a variety of factors. Such forward-looking statements are based upon management's current expectations and include known and unknown risks, uncertainties and other factors, many of which are hard to predict or control, that may cause the actual results, performance, or plans to differ materially from any future results, performance or plans expressed or implied by such forward-looking statements. Such risks and uncertainties include, but are not limited to: (i) risks related to the expected timing and likelihood of completion of the Merger, including the risk that the transaction may not close due to one or more closing conditions to the transaction not being satisfied or waived, such as regulatory approvals not being obtained, on a timely basis or otherwise, or that a governmental entity prohibited, delayed or refused to grant approval for the consummation of the transaction or required certain conditions, limitations or restrictions in connection with such approvals; (ii) the occurrence of any event, change or other circumstances that could give rise to the termination of the applicable transaction agreements; (iii) the risk that there may be a material adverse change with respect to the financial position, performance, operations or prospects of the Company or eLMTree; (iv) risks related to disruption of management time from ongoing business operations due to the Merger; (v) the risk that any announcements relating to the Merger could have adverse effects on the market price of the Company's securities; (vi) the risk that the Merger and its announcement could have an adverse effect on the ability of eLMTree to retain customers and retain and hire key personnel and maintain relationships with their suppliers and customers and on their operating results and businesses generally; (vii) any changes in the business or operating prospects of eLMTree or its businesses; (viii) changes in applicable laws and regulations; and (ix) risks relating to the combined company's ability to enhance its services and products, execute its business strategy, expand its customer base and maintain stable relationship with its business partners.
A further list and description of risks and uncertainties can be found in the proxy statement that will be filed with the SEC by the Company in connection with the Merger, and other documents that the parties may file with or furnish to the SEC, which you are encouraged to read. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. Accordingly, you are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements relate only to the date they were made, and eLMTree, the Company and their subsidiaries and affiliates undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made except as required by law or applicable regulation.
Additional Information and Where to Find It
The Company will file with the SEC and mail to its shareholders and ADS holders a proxy statement in connection with the Merger. Investors and security holders are urged to read the proxy statement when it becomes available because it will contain voting instructions and important information regarding the proposed arrangement. You may access the proxy statement (when available) and other related documents filed by the Company with the SEC at the SEC's website at www.sec.gov. You also may obtain the proxy statement and other documents filed by the Company with the SEC relating to the proposed arrangement for free by accessing the Company's website at https://ir.geh.com.cn/ by clicking on the link for "Financial Information," and then clicking on the link for "SEC Filings."
CONTACT: Gravitas Education Holdings, Inc., Investor Relations, E-mail: ir@geh.com.cn
View original content:
SOURCE Gravitas Education Holdings Inc. | https://www.wagmtv.com/prnewswire/2023/07/31/gehi-hold-extraordinary-general-meeting-shareholders-september-11-2023/ | 2023-07-31T11:21:28 | 1 | https://www.wagmtv.com/prnewswire/2023/07/31/gehi-hold-extraordinary-general-meeting-shareholders-september-11-2023/ |
LA ROMANA, Dominican Republic, July 31, 2023 /PRNewswire/ -- The international known company Hilton Hotels & Resorts opens its doors to its Hilton Garden Inn La Romana hotel project in the Dominican Republic, in collaboration with a group of important investors under the company Riverhome Capital S.A.S., whose main shareholder is the prominent Dominican former major league player, Edwin Encarnación; together with the vision of the lawyer Guillermo Estrella Ramia and the Minister of Tourism, David Collado.
The inauguration was led by Luis Abinader Corona, president of the Dominican Republic and who expressed that "This hotel has something very special, opening up the beach and the sector of La Caleta of La Romana, which for a long time was closed to the province and its visitors. Since private investment must always be accompanied by public infrastructure, we are working on creating them, so we are all part of this development of La Romana."
With an investment of 25 million united states dollars and the creation of more than 300 direct jobs, it is considered as a hotel option for the growing flows of tourists that the area is currently receiving. Located a short distance from other points of relevance, such as La Romana Airport 18 minutes away, Casa de Campo 12 minutes away and Central Romana just a few blocks away.
The new hotel facility has a privileged location on a 5,000 square meters property, located on the coast of the municipal district of La Caleta, La Romana province. With a capacity of 130 rooms, distributed in five of the seven floors of the building, it also counts with swimming pools, two bars, a restaurant, gym, event, meeting and multipurpose rooms, and outdoor areas, ideal for social and corporate celebrations.
The hotel responds to the interest of Edwin Encarnación to invest in the development of his province of origin, who expressed that "from the moment this project was presented to me, I knew that I had to be part and be the one to assume this. I joined the development of this hotel, with the only requirement that most of the workers came from here, from my town La Romana, and we achieved this."
View original content to download multimedia:
SOURCE Grupo De Valle | https://www.wagmtv.com/prnewswire/2023/07/31/hilton-garden-inn-la-romana-dominican-republic-celebrates-its-opening/ | 2023-07-31T11:21:35 | 1 | https://www.wagmtv.com/prnewswire/2023/07/31/hilton-garden-inn-la-romana-dominican-republic-celebrates-its-opening/ |
- CARDIO-TTRansform is the largest, most comprehensive ATTR-CM study with more than 1,400 patients enrolled
- Eplontersen is currently under U.S. FDA review for ATTRv-polyneuropathy, with ATTR-CM representing a second, larger potential patient population
CARLSBAD, Calif., July 31, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the completion of enrollment in the Phase 3 CARDIO-TTRansform cardiovascular outcomes study of eplontersen in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), a large and growing patient population at risk of life-threatening cardiovascular (CV) events. The study enrolled more than 1,400 patients.
Eplontersen is an investigational antisense medicine designed to inhibit the production of transthyretin and slow the progression of cardiomyopathy for people living with hereditary or wild-type ATTR-CM.
"CARDIO-TTRansform is the largest and most comprehensive ATTR-CM study ever conducted. The evaluation of eplontersen in this broad, diverse patient population will enable robust and clinically meaningful analysis of the composite endpoint of CV mortality and recurrent CV events," said Eugene Schneider, M.D., executive vice president and chief clinical development officer for Ionis. "It will also allow us to gather data from important patient subsets, including patients with or without stabilizer therapy and those with or without hereditary disease within the evolving ATTR-CM landscape. We look forward to reporting results as early as the first half of 2025."
As part of a global development and commercialization agreement, Ionis and AstraZeneca are seeking regulatory approval for eplontersen for the treatment of transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) in the U.S. and plan to seek regulatory approval in Europe and other parts of the world. The U.S. Food and Drug Administration accepted the New Drug Application for eplontersen for the treatment of ATTRv-PN with a PDUFA action date of Dec. 22, 2023. Eplontersen was granted Orphan Drug Designation in the U.S.
For more information on the CARDIO-TTRansform study, please visit www.clinicaltrials.gov (NCT04136171).
About the CARDIO-TTRansform Study
CARDIO-TTRansform is a global, double-blind, randomized, placebo-controlled Phase 3 cardiovascular outcome study in more than 1,400 patients with ATTR cardiomyopathy (ATTR-CM). It is designed to compare eplontersen to placebo in patients with both wild-type ATTRwt-CM and hereditary ATTRv-CM who are either naïve to treatment or on a currently available standard of care. The primary composite endpoint is cardiovascular (CV) mortality and recurrent CV clinical events comparing the two study arms up to week 140. Secondary endpoints include the change from baseline in the 6-minute walk test (6MWT) and the Kansas City Cardiomyopathy Questionnaire (KCCQ) scores at week 121, as well as the rates of CV mortality, CV clinical events and all-cause mortality at week 140.
About Eplontersen
Eplontersen is an investigational LIgand-Conjugated Antisense (LICA) medicine designed to inhibit the production of TTR protein. Eplontersen is being developed as a monthly self-administered subcutaneous injection to treat all types of ATTR. ATTR amyloidosis is a systemic, progressive and fatal disease in which patients experience multiple overlapping clinical manifestations caused by the inappropriate formation and aggregation of TTR amyloid deposits in various tissues and organs, including peripheral nerves, heart, intestinal tract, eyes, kidneys, central nervous system, thyroid and bone marrow. The progressive accumulation of TTR amyloid deposits in these tissues and organs leads to organ failure and eventually death.
About Transthyretin-mediated Amyloid Cardiomyopathy (ATTR-CM)
Transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed and potentially fatal disease. It is caused by the accumulation of misfolded TTR protein in the cardiac muscle. Patients experience ongoing debilitating heart damage resulting in progressive heart failure, which results in death within three to five years from disease onset. ATTR-CM includes both the genetic and wild-type form of the disease. Worldwide, there are an estimated 300,000 – 500,0001,2 patients with ATTR-CM.
About Ionis Pharmaceuticals, Inc.
For more than 30 years, Ionis has been a leader in RNA-targeted therapy, pioneering new markets and changing standards of care. Ionis currently has four marketed medicines and a promising late-stage pipeline highlighted by cardiovascular and neurological franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision to become the leader in genetic medicine, utilizing a multi-platform approach to discover, develop and deliver life-transforming therapies.
To learn more about Ionis visit www.ionispharma.com and follow us on Twitter @ionispharma.
Ionis' Forward-looking Statements
This press release includes forward-looking statements regarding Ionis' business and the therapeutic and commercial potential of eplontersen, Ionis' technologies and other products in development. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties including those related to our commercial products and the medicines in our pipeline, and particularly those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended Dec. 31, 2022, and the most recent Form 10-Q quarterly filing, which are on file with the Securities and Exchange Commission. Copies of these and other documents are available from the Company.
In this press release, unless the context requires otherwise, "Ionis," "Company," "we," "our," and "us" all refer to Ionis Pharmaceuticals and its subsidiaries.
Ionis Pharmaceuticals® is a registered trademark of Ionis Pharmaceuticals, Inc.
1 Mohamed-Salem L, et al. Prevalence of wild type ATTR assessed as myocardial uptake in bone scan in the elderly population. Int J Cardiol. 2018 Nov 1;270:192-196. doi: 10.1016/j.ijcard.2018.06.006.
2 Cuscaden C, et al. Estimation of prevalence of transthyretin (ATTR) cardiac amyloidosis in an Australian subpopulation using bone scans with echocardiography and clinical correlation. J Nucl Cardiol. 2020 May 8. doi: 10.1007/s12350-020-02152-x.
View original content to download multimedia:
SOURCE Ionis Pharmaceuticals, Inc. | https://www.wagmtv.com/prnewswire/2023/07/31/ionis-completes-enrollment-landmark-phase-3-cardio-ttransform-study-patients-with-ttr-mediated-amyloid-cardiomyopathy/ | 2023-07-31T11:21:42 | 1 | https://www.wagmtv.com/prnewswire/2023/07/31/ionis-completes-enrollment-landmark-phase-3-cardio-ttransform-study-patients-with-ttr-mediated-amyloid-cardiomyopathy/ |
Juggernaut and Mr. Highman will continue as substantial shareholders of Bobbie. The acquisition positions the combined company as the third largest fully integrated infant and toddler brand in the U.S., creating a more resilient industry for American families
WASHINGTON, July 31, 2023 /PRNewswire/ -- Juggernaut Capital Partners, a leading middle market private equity investor primarily in the consumer and healthcare sectors, is pleased to announce the sale of Nature's One, the pediatric nutrition company founded by Jay Highman which set the bar for quality and innovation in formula over decades. Joining forces with Bobbie Baby, Inc., the nation's fastest growing infant formula company, the combined business will be the first of its kind in pediatric nutrition.
"Nature's One is a true pioneer in the pediatric nutrition space. Juggernaut partnered with founder, Jay Highman, to accelerate product development and vertical integration initiatives. Over the past five years, the company completed the first FDA-approved clinical feeding study of an organic infant formula and designed and constructed the first newly built infant formula facility in the U.S. in 35 years," said John Shulman, Founder and Managing Partner at Juggernaut. "It has been a pleasure to partner with Jay and his team. We believe the combination with Bobbie cements the organization as a continued disruptor and a next-generation industry leader. We are proud to continue as a meaningful shareholder in the go-forward company."
Founded in 1997, Nature's One introduced the first organic baby formula to the U.S. market. Recognized for its dedication to purity and quality, all of the company's formulas have received the Clean Label Project's Purity Award and have tested best in class for purity and nutrition when compared to popular baby formulas sold in the U.S. Nature's One operates the only independent, FDA audited organic infant nutrition facility in the U.S.
Nature's One was advised by CG / Sawaya Partners (operating under Canaccord Genuity) and Morgan Lewis & Bockius LLP. Bobbie was advised by Perella Weinberg Partners LP and Goodwin Procter LLP.
About Juggernaut Capital Partners:
Juggernaut Capital Partners is a leading private equity firm focusing on lower middle market companies, primarily in the consumer and healthcare sectors. Juggernaut is currently investing out of Juggernaut Capital Partners V, L.P. For more information on Juggernaut Capital Partners, please visit www.juggernautcap.com.
About Nature's One:
Founded in 1997, Nature's One introduced the first organic formula, Baby's Only® Organic in the United States. Nature's One has dedicated 25 years to the research, development, and sourcing of pure ingredients. Recognized as the first and highest-ranked formulas for purity and nutritional superiority by the Clean Label Project, Baby's Only Formulas are preferred by parents who want to offer their child a "Better Start…for Life™." Baby's Only Formulas are sold nationally at Whole Foods, Target, Walmart, Sam's Club, and many fine natural food retailers, as well online at www.naturesone.com.
About Bobbie:
Bobbie is the mission-driven organic pediatric nutrition company that exists to build a parenting culture of confidence, not comparison. Founded in 2018, Bobbie hit the market with its flagship European-inspired formula in 2021 as the first direct-to-consumer, subscription-based infant formula in the U.S. Today, it's proud to be the only mom-founded and led infant formula brand in the world, and the fastest-growing in the U.S. since the 1980's. Bobbie is focused on providing purposefully sourced, USDA Organic products made with simple ingredients – crafted right here in America, for American families. For more information, visit www.hibobbie.com.
View original content:
SOURCE Juggernaut Capital Partners | https://www.wagmtv.com/prnewswire/2023/07/31/juggernaut-capital-partners-natures-one-founder-jay-highman-have-sold-natures-one-bobbie-baby-inc/ | 2023-07-31T11:21:48 | 0 | https://www.wagmtv.com/prnewswire/2023/07/31/juggernaut-capital-partners-natures-one-founder-jay-highman-have-sold-natures-one-bobbie-baby-inc/ |
BURLINGTON, N.C., July 31, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced it will host an Investor Day on Thursday, September 14, 2023, in New York City, beginning at 1:00 p.m. ET and is expected to conclude by approximately 4:00 p.m. ET.
This event will highlight Labcorp's go-forward strategy from Labcorp Chairman & CEO Adam Schechter, followed by business overviews and a longer-term financial outlook. Presentations will be followed by a Q&A session.
A live webcast of the event will be available through the Labcorp Investor Relations website beginning at 1:00 p.m. ET. A replay of the webcast and supporting materials will be available after the conclusion of the event.
About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's more than 60,000 employees serve clients in over 100 countries, worked on over 80% of the new drugs approved by the FDA in 2022 and performed more than 600 million tests for patients around the world. Learn more about us at www.Labcorp.com or follow us on LinkedIn and Twitter @Labcorp.
View original content to download multimedia:
SOURCE Labcorp | https://www.wagmtv.com/prnewswire/2023/07/31/labcorp-host-investor-day-september-14-2023/ | 2023-07-31T11:21:54 | 0 | https://www.wagmtv.com/prnewswire/2023/07/31/labcorp-host-investor-day-september-14-2023/ |
BEIJING (AP) — China imposed restrictions Monday on exports of long-range civilian drones, citing Russia’s war in Ukraine and concern that drones might be converted to military use.
Chinese leader Xi Jinping’s government is friendly with Moscow but says it is neutral in the 18-month-old war. It has been stung by reports that both sides might be using Chinese-made drones for reconnaissance and possibly attacks.
Export controls will take effect Tuesday to prevent use of drones for “non-peaceful purposes,” the Ministry of Commerce said in a statement. It said exports still will be allowed but didn’t say what restrictions would apply.
China is a leading developer and exporter of drones. DJI Technology Co., one of the global industry's top competitors, announced in April 2022 it was pulling out of Russia and Ukraine to prevent its drones from being used in combat.
“The risk of some high specification and high-performance civilian unmanned aerial vehicles being converted to military use is constantly increasing,” the Ministry of Commerce said.
Restrictions will apply to drones that can fly beyond the natural sight distance of operators or stay aloft more than 30 minutes, have attachments that can throw objects and weigh more than seven kilograms (15½ pounds), according to the ministry.
“Since the crisis in Ukraine, some Chinese civilian drone companies have voluntarily suspended their operations in conflict areas,” the Ministry of Commerce said. It accused the United States and Western media of spreading “false information” about Chinese drone exports.
The government on Friday defended its dealings with Russia as “normal economic and trade cooperation” after a U.S. intelligence report said Beijing possibly provided equipment used in Ukraine that might have military applications.
The report cited Russian customs data that showed Chinese state-owned military contractors supplied drones, navigation equipment, fighter jet parts and other goods.
The Biden administration has warned Beijing of unspecified consequences if it supports the Kremlin's war effort. Last week's report didn't say whether any of the trade cited might trigger U.S. retaliation.
Xi and Russian President Vladimir Putin declared before the February 2022 invasion that their governments had a "no-limits" friendship. Beijing has blocked efforts to censure Moscow in the United Nations and has repeated Russian justifications for the attack.
China has “always opposed the use of civilian drones for military purposes,” the Ministry of Commerce said. “The moderate expansion of drone control by China this time is an important measure to demonstrate the responsibility of a responsible major country.”
The Ukrainian government appealed to DJI in March 2022 to stop selling drones it said the Russian ministry was using to target missile attacks. DJI rejected claims it leaked data on Ukraine’s military positions to Russia. | https://www.springfieldnewssun.com/nation-world/china-imposes-curbs-on-drone-exports-citing-ukraine-and-concern-about-military-use/ESYH57N7HJCZTKYR2QBMYTNHVA/ | 2023-07-31T11:21:55 | 1 | https://www.springfieldnewssun.com/nation-world/china-imposes-curbs-on-drone-exports-citing-ukraine-and-concern-about-military-use/ESYH57N7HJCZTKYR2QBMYTNHVA/ |
HONG KONG (AP) — A French man is believed to have fallen to his death from a high-rise residential building in Hong Kong last week, police said on Monday, with local media outlets identifying him as daredevil Remi Lucidi.
Police said a 30-year-old man's body was found on a patio in the city's upscale Mid-Levels area. He was believed to have engaged in extreme sports, police said, without identifying him.
Officers conducted an initial investigation and said he apparently fell from a rooftop. No suicide note was found at the scene, they said. The cause of his death would have to be verified by an autopsy, they added.
Local media, including the South China Morning Post, said the man was Lucidi, 30. The Post cited an unnamed source saying he was last seen alive knocking on a penthouse window on the 68th floor of a residential tower on Thursday evening. The Associated Press has not been able to verify his identity.
Lucidi, who used the name “Remi Enigma” on social media, last posted a photo of Hong Kong's night view a week ago on Instagram and tagged the location as Times Square in shopping district Causeway Bay. The photo appeared to be taken from above.
Supporters mourned him on social media.
Lucidi posted to Instagram as he climbed various tall structures around the world and took selfies, including one he captioned, “Above the Sky, 425m” and tagged Dubai as the location. | https://www.springfieldnewssun.com/nation-world/french-daredevil-who-climbed-towers-around-world-believed-to-have-fallen-to-his-death-in-hong-kong/IES6XBAESNESTGZ26KZMTMYNKQ/ | 2023-07-31T11:22:01 | 1 | https://www.springfieldnewssun.com/nation-world/french-daredevil-who-climbed-towers-around-world-believed-to-have-fallen-to-his-death-in-hong-kong/IES6XBAESNESTGZ26KZMTMYNKQ/ |
Adult Males are Slightly More Likely to Live with Parents Than Their Female Counterparts
58% of Gen Z Consumers Live with Family Members
SAN FRANCISCO, July 31, 2023 /PRNewswire/ -- LendingClub Corporation (NYSE: LC), the parent company of LendingClub Bank, America's leading digital marketplace bank, today released findings from the 24th edition of the Reality Check: Paycheck-To-Paycheck research series, conducted in partnership with PYMNTS. The Household Finances Deep Dive Edition examines the impact of household composition on consumers' ability to manage expenses and put aside savings. The series draws on insights from a survey of 4,602 U.S. consumers conducted from June 5 to June 16, as well as analysis of other economic data.
The Paycheck-to-Paycheck Landscape
In June 2023, 61% of U.S. consumers lived paycheck to paycheck, unchanged from June 2022 — as is the share of those struggling to pay bills (at 21%) — even though more middle-income consumers cited living paycheck to paycheck in June 2023 than last year. Among consumers earning $50,000 to $100,000, 65% lived paycheck to paycheck as of June 2023, compared to 60% in June 2022. Meanwhile, the shares of high-income consumers — those earning more than $100,000 annually — and low-income consumers — those earning less than $50,000 annually — living paycheck to paycheck in June 2023 sit at 45% and 77%, respectively, relatively unchanged from June 2022.
This stability in the financial situation of U.S. households indicates that consumers continue to adapt to inflationary pressures, finding ways to manage their spending and live within their means.
Household Composition Determines Financial Lifestyle
Consumers living with only a partner or spouse are likely to face less financial hardship, while those with dependents and those living with friends or housemates are more likely to live paycheck to paycheck.
The research finds that 86% of consumers live with one or more people, and one-third of paycheck-to-paycheck consumers live in households of four or more people. Consumers not living paycheck to paycheck are most likely to reside in two-person households, at 41%. Meanwhile, 49% of millennials and 55% of bridge millennials live in households of four or more people, making them the age groups most likely to reside in the largest households.
There is also a direct correlation among household size, stage of life and financial lifestyle. As household size increases, the ratio of income earners to non-earners typically falls, attributable to households with dependent children. When looking at the share of paycheck-to-paycheck consumers who live in a two-member household, the data finds that 54% do so — 7 percentage points below the sample average. Meanwhile, at 66%, consumers with children under the age of 18 are 12% more likely to live paycheck to paycheck than those without children, at 59%. Among consumers living with friends or housemates, 77% live paycheck to paycheck — the most likely to do so. This suggests that those sharing expenses with a partner or spouse fare better, that is until they have children or even parents to support.
"As household size increases, the ratio of income earners to household members typically falls, creating a higher likelihood of financial distress," said Alia Dudum, LendingClub's Money Expert. "The relationship between household income and household composition explains why many families tend to struggle financially and why millennials and bridge millennials, many of whom are in their peak child-rearing years, tend to remain financially vulnerable."
Economic Considerations Top Reason to Stay in the Family Household
Economics are the main driver for consumers to live with family longer, with 43% wanting to save money and 30% unable to afford housing independently. Besides economic reasons, consumers remain at home to maintain family ties (24%), for transitional reasons (23%), and to provide care (22%).
At one-fifth (20%), adult males are slightly more likely to live with parents than their female counterparts (18%), a phenomenon that grows significantly among those financially struggling (26% of males compared to 18% of females). At 58%, Gen Z is the generation most likely to stay with family members, with 50% citing economic reasons. Members of Gen Z living with three or more people — often familial settings — spent 22% of their income on housing, compared to 30% of those living alone or with a partner.
That said, consumers living with family members to offset expenses are not planning extended stays. For example, one-third of those consumers expect to move out in the coming year, particularly millennials and bridge millennials.
Financial Transparency Determined by Relationship Status
Financial transparency within shared households is paramount to ensure bills are paid and expenses are covered, but the transparency level depends on who consumers live with. Couples living together share financial information 87% of the time and have a joint bank account 76% of the time. Parents are also likely to discuss finances with the children residing in their household, with 45% of parents sharing financial information with their children and 34% granting them access to a shared account. Bill splitting is the most common financial interaction for consumers living with friends or housemates, at 74%. Additionally, borrowing money from other household members is a financial option many use to make ends meet, with consumers mostly engaging in this practice with parents or siblings, at 47%, and friends and housemates, at 44%.
Families and couples maintain outstanding credit card balances that are significantly higher, on average, than those of consumers who live alone. Consumers with children under the age of 18 average 50% more credit card debt than those who live alone. Families represent the lion's share of credit card spending, holding average balances of $6,300 for consumers living with a partner and $7,200 for those living with children under 18. Living with a partner or children also significantly increases a consumer's likelihood of having an auto loan or mortgage.
"With today's inflationary pressures, sharing household finances has become not only common but crucial," continued Dudum. "The increasing complexity of modern lifestyles and the rising cost of living have necessitated a shift in the way consumers approach household finances. One person solely bearing the burden of managing all financial matters has become a minority practice. Instead, couples, families, and even roommates increasingly jointly navigate their economic realities, and it's a trend that is here to stay."
To view the full report, visit: https://www.pymnts.com/study/reality-check-paycheck-to-paycheck-inflation-household-spending-shared-expenses/
Methodology
New Reality Check: The Paycheck-to-Paycheck Report — The Household Finances Deep Dive Edition is based on a census-balanced survey of 4,602 U.S. consumers conducted from June 5 to June 16, as well as analysis of other economic data. The data in this report is not intended to be a representation of LendingClub's core member base. The Paycheck-to-Paycheck series expands on existing data published by government agencies, such as the Federal Reserve System and the Bureau of Labor Statistics, to provide a deep look into the core elements of American consumers' financial wellness: income, savings, debt and spending choices. Our sample was balanced to match the U.S. adult population in a set of key demographic variables: 51% of respondents identified as female, 33% were college-educated and 38% declared incomes of more than $100,000 per year.
About LendingClub
LendingClub Corporation (NYSE: LC) is the parent company of LendingClub Bank, National Association, Member FDIC. LendingClub Bank is the leading digital marketplace bank in the U.S., where members can access a broad range of financial products and services designed to help them pay less when borrowing and earn more when saving. Based on more than 150 billion cells of data and over $85 billion in loans, our advanced credit decisioning and machine-learning models are used across the customer lifecycle to expand seamless access to credit for our members while generating compelling risk-adjusted returns for our loan investors. Since 2007, more than 4.7 million members have joined the Club to help reach their financial goals. For more information about LendingClub, visit https://www.lendingclub.com.
Contact:
For Investors: IR@lendingclub.com
Media Contact: Press@lendingclub.com
PYMNTS Contact: information@PYMNTS.com
View original content to download multimedia:
SOURCE LendingClub Corporation | https://www.wagmtv.com/prnewswire/2023/07/31/lendingclub-pymnts-research-shows-86-consumers-live-with-one-or-more-people-yet-those-living-with-only-partners-or-spouses-reap-financial-benefits/ | 2023-07-31T11:22:01 | 0 | https://www.wagmtv.com/prnewswire/2023/07/31/lendingclub-pymnts-research-shows-86-consumers-live-with-one-or-more-people-yet-those-living-with-only-partners-or-spouses-reap-financial-benefits/ |
After one week of Best of Springfield voting, several categories have risen to the top with the most votes.
Which of the finalists do you want to win in these most popular contests? Click here to go to the ballot and cast your vote.
Voting will go through Friday, Aug. 11, and you can vote once per day per contest. So stay involved and let us know who you think is the Best of Springfield.
Best Annual Festival
• Enon Apple Butter Festival
• South Vienna Corn Festival
• Springfield Rotary Gourmet Food Truck Competition
• Summer Arts Festival
Best Appetizers
• Charlo’s Provisions & Eatery
• O’Conners Irish Pub
• Station1
• Stella Bleu Bistro
• Texas Roadhouse
Best Asian Food
• Golden Chopsticks
• Speakeasy Ramen
• Sushi Hikari Moe
• Tasty Wok
Best Assisted Living/Retirement/Rehab Facility
• Forest Glen Health Campus
• Ohio Masonic Retirement Community
• Villa Springfield Rehabilitation and Healthcare Center
• Wooded Glen Health Campus
Best Auto Repair
• Brake Pros
• Hooten Automotive
• Rogers Garage
• Zima Automotive
Best Auto/Truck/Motorcycle Dealer
• Bill Marine Auto Center
• Jay North LLC
• Jeff Wyler Springfield Auto Mall
• SVG Buick GMC in Springfield
Best Bakery
• D. Sweets, Cookies & Gifts, LLC
• Le Torte Dolci
• Proverbs 31 Macarons
• Schuler’s Bakery
Best Band
• Allison Road
• Factory Line
• Matt Clarkson Band
• The Temps
Best Bar/Brewpub
• Mother Stewart’s Brewing
• Mug & Jug Tavern
• O’Conners Irish Pub
• Station1
Best Barbershop
• Beards & Beaus
• East High Barber Co.
• Minette’s Barber-Styling
• Nice Cuts Barber Shop
Click here to go to the ballot and cast your vote. | https://www.springfieldnewssun.com/news/best-of-springfield-here-are-the-10-most-popular-categories-after-a-week-of-voting/C6JAGEJRD5AOHBILI3IK2HRWTE/ | 2023-07-31T11:22:07 | 0 | https://www.springfieldnewssun.com/news/best-of-springfield-here-are-the-10-most-popular-categories-after-a-week-of-voting/C6JAGEJRD5AOHBILI3IK2HRWTE/ |
HOUSTON, July 31, 2023 /PRNewswire/ -- McDermott has been awarded a project management consultancy (PMC) and engineering, procurement, and construction management (EPCM) contract for the Naphtha Cracker Expansion (Phase II) polypropylene expansion and new ethylene derivative unit project from Indian Oil Corporation Limited (IOCL). The project is located at the Panipat Refinery and Petrochemical Complex, located 62 miles (100 kilometers) from New Delhi, India.
The project will increase the ethylene production capacity of the naphtha cracker unit (NCU) by approximately 20 percent. The additional ethylene and propylene production will act as feed for downstream polymer units. The polymer products will be used for the manufacture of household and industrial items, including containers, automobile parts, furniture, and heavy-duty films.
"McDermott is currently executing four other projects for IOCL, including the maleic anhydride (MAH) unit at the same site, allowing us to leverage our local resources and expertise while realizing synergies," said Vaseem Khan, Senior Vice President, Global Operations. "Furthermore, the project supports the growing demand for ethylene and propylene which will reduce imports and accelerate economic development in the area."
McDermott will provide comprehensive EPCM services and overall project management for the duration of the project, which will be executed from its Center of Excellence in Gurugram, India.
About McDermott
McDermott is a premier, fully-integrated provider of engineering and construction solutions to the energy industry. Our customers trust our technology-driven approach engineered to responsibly harness and transform global energy resources into the products the world needs. From concept to commissioning, McDermott's innovative expertise and capabilities advance the next generation of global energy infrastructure—empowering a brighter, more sustainable future for us all. Operating in over 54 countries, McDermott's locally-focused and globally-integrated resources include more than 30,000 employees, a diversified fleet of specialty marine construction vessels and fabrication facilities around the world. To learn more, visit www.mcdermott.com.
Forward-Looking Statements
McDermott cautions that statements in this press release which are forward-looking, and provide other than historical information, involve risks, contingencies and uncertainties. These forward-looking statements include, among other things, statements about the expected scope and execution of the project discussed in this press release. Although we believe that the expectations reflected in those forward-looking statements are reasonable, we can give no assurance that those expectations will prove to have been correct. Those statements are made by using various underlying assumptions and are subject to numerous risks, contingencies and uncertainties, including, among others: adverse changes in the markets in which we operate or credit or capital markets; our inability to successfully execute on contracts in backlog; changes in project design or schedules; the availability of qualified personnel; changes in the terms, scope or timing of contracts, contract cancellations, change orders and other modifications and actions by our customers and other business counterparties; changes in industry norms; actions by lenders, other creditors, customers and other business counterparties of McDermott; and adverse outcomes in legal or other dispute resolution proceedings. If one or more of these risks materialize, or if underlying assumptions prove incorrect, actual results may vary materially from those expected. You should not place undue reliance on forward-looking statements. This communication reflects the views of McDermott's management as of the date hereof. Except to the extent required by applicable law, McDermott undertakes no obligation to update or revise any forward-looking statement.
Contacts:
Global Media Relations
Reba Reid
Senior Director, Global Communications and Marketing
+1 281 588 5636
RReid@McDermott.com
Business Line Media Relations
Barbara Knight
Senior Director, Business Line Communications and Marketing
+971 56 403 2903
BBKnight@McDermott.com
View original content to download multimedia:
SOURCE McDermott International, Ltd | https://www.wagmtv.com/prnewswire/2023/07/31/mcdermott-selected-petrochemical-expansion-project-by-iocl/ | 2023-07-31T11:22:08 | 0 | https://www.wagmtv.com/prnewswire/2023/07/31/mcdermott-selected-petrochemical-expansion-project-by-iocl/ |
The nights before games were always the toughest times for Darrelle Revis.
One of the NFL's most dominant cornerbacks would lie in bed thinking about what he needed to accomplish the next day on the field. Revis would go over the game plan, the notes from his film studies, the receivers' routes and their tendencies.
Over and over until he'd fall asleep.
He'd wake up mentally prepared — and that brief anxiety would be replaced by supreme confidence.
“Restless nights, I'd say to start with,” Revis said. "Covering some of the greatest wide receivers in the game and future Hall of Famers at that time, I was probably the most nervous out of anybody on the field if I had that assignment.
“For me, it's kind of looking at yourself in the mirror and saying to yourself, ‘It’s either me or him. I just have to stand up to the challenge.' For me, I just took on the responsibility to take that assignment and try to shut him down.”
Revis did exactly that for most of his brilliant 11-year NFL career, including eight seasons over two stints with the New York Jets.
So much so, he earned the popular “Revis Island” nickname, a fitting tribute to how he'd single-handedly make many receivers disappear — lost on an island — from opponents' game plans.
“This is a once-in-a-lifetime type corner,” former Jets coach Rex Ryan once said. “And that’s a fact.”
Tough to argue, and voters for the Pro Football Hall of Fame made Revis a first-ballot inductee following a career during which he routinely locked down one side of the field with his air-tight coverage.
He also gave plenty of opposing offensive coordinators plenty of restless nights of their own.
“I just felt I had the ability and skill set and the coaching staff who believed in me that I had the ability to shut them down,” Revis said.
That was perhaps most evident during the 2009 season, when Revis had arguably the greatest year at his position.
Ever.
Randy Moss, Chad Johnson, Andre Johnson, Steve Smith, Terrell Owens, Reggie Wayne and Roddy White were all non-factors against the Jets that season — because they couldn't shake Revis.
“I shouldn’t have even suited up,” Wayne said after having just a 1-yard catch in Indianapolis' playoff loss to New York that season.
Green Bay cornerback Charles Woodson won the AP Defensive Player of the Year award that year, but Ryan insisted Revis should've been the choice after having “the best year a corner has ever had.”
Revis had six interceptions and set an NFL record that still stands with 31 passes defensed that season. He never really came close to matching those marks in any season the rest of his career — because teams simply stopped throwing his way.
That was the ultimate sign of respect.
“It was a very comforting thing as a player that we'd have a guy that can take away the greatest weapon of the other team's offensive players,” former Jets center and long-time teammate Nick Mangold said. “So it was very much like a security blanket, like, we've got him, so we’re good.”
Revis was drafted by the Jets out of the University of Pittsburgh with the 14th overall pick in 2007 when they traded up 11 spots to add a player they believed could change their defense. And he certainly delivered, making an instant impact under coach Eric Mangini before thriving as the heart of Ryan's defense.
“One of the highlights for me is just being drafted,” Revis said. “Just fulfilling that dream. Just the hills I had to run at an incline, the abs, the pushups, the overtime, just put into everything to try to even dare myself to be one of the best or one of the greatest or amount to be somewhat of the next Deion Sanders, in a way.”
The comparisons quickly became a regular thing for Revis, whose abilities were often measured up against the likes of Sanders, Woodson, Rod Woodson, Ty Law, Champ Bailey and Mel Blount.
Until the debates began about whether Revis was actually the best cornerback ever.
That's subjective, of course, with some pointing out Revis' relatively short period of greatness. A knee injury wiped out his 2012 season and a contract dispute — he had a few of those, helping set the market for cornerbacks — ended with him being traded to Tampa Bay the following offseason.
Revis won a Super Bowl the next year with New England, irking Jets fans, but he returned to New York in 2015 and played two more seasons for his original team. After a short stint with Kansas City in 2017, Revis retired. He was inducted into the Jets' ring of honor last year.
His playing legacy came with his performance in games, but he built a reputation for striving to be great with his intense approach during practice. Revis would get on teammates who weren't giving their all, and his goal was to not give up a catch to anyone.
And if he did, Revis would be ticked off. About catches that didn't even count — to everyone other than Revis.
“Every practice, to him, was a game,” Mangold said. “So he was going out there and no one was going to catch a ball on him. It was the result of his competitive nature. He was always working to win.”
—
AP NFL: https://apnews.com/hub/nfl and https://twitter.com/AP_NFL
Credit: AP
Credit: AP
Credit: AP
Credit: AP | https://www.springfieldnewssun.com/news/ohio/revis-shut-down-his-nerves-and-then-the-nfls-best-wide-receivers-on-his-way-to-the-hall-of-fame/UZHMAQA2WVA7TJOAZSBSEVJILY/ | 2023-07-31T11:22:14 | 1 | https://www.springfieldnewssun.com/news/ohio/revis-shut-down-his-nerves-and-then-the-nfls-best-wide-receivers-on-his-way-to-the-hall-of-fame/UZHMAQA2WVA7TJOAZSBSEVJILY/ |
Recruiting Season Is in Full Swing for Professional Football Players to Join Virtual Fan Engagement Channel
NAPLES, Fla., July 31, 2023 /PRNewswire/ -- Notable Live is announcing that it has added three more Pro Football Hall of Fame players to the Notable Live line-up for the upcoming season. In addition to existing players Emmitt Smith and Ray Lewis, Notable Live is excited to add Cris Carter, Champ Bailey and Ed Reed to the Notable Live team. This comes as a fast follow to Notable Live's recent multi-year commercial agreement with eBay and its Series A financing round led by eBay Ventures.
Notable Live is a tech-enabled virtual engagement platform that connects fans to teams, leagues and players in a way they have always dreamed about through an immersive experience. Notable Live, co-founded in 2018 by Pro Football Hall of Famer Emmitt Smith and entrepreneurial veteran Mike Antonucci, helps players monetize their image and personal brands not just on game day, but every day.
Through one set of login credentials, the Notable Live platform unlocks an expansive catalog of one-to-many engagement experiences, including live events and on-demand content. On the platform's commerce-enabled exchange, players, teams and leagues can activate live auction or marketplace functions to sell physical memorabilia, digital content, in-person experiences or other unique offerings. All items offered on the Notable Live platform and its associated channels can be authentically bought and sold across the growing and loyal community of Notable Live fans.
"The multi-billion annual sports memorabilia market is rapidly evolving to include new digital experiences, and Notable Live continues to grow its comprehensive platform for both the college and professional sports markets. We are pleased to announce the continued expansion of our roster of NFL athletes on our platform," said Mike Antonucci, co-founder and CEO of Notable Live.
"The fans bring their passion for the game and for their favorite players, ensuring the memorabilia space remains more about the fans than about the athletes," added Emmitt Smith, co-founder of Notable Live. "We are excited to continue expanding our platform with fellow Hall of Famers and other athletes."
About Notable Live
Notable Live was co-founded in 2018 by avid sports fan Mike Antonucci and Pro Football Hall of Famer Emmitt Smith to create a unique platform providing sports fans with unparalleled access to their favorite notables via virtual interactive events. Notable Live, a mobile app available on the App Store and Google Play, grants fans real access to notables by putting them "in the room" together for memorable virtual experiences. Connect with Notable Live at www.notable.live or on Instagram, Facebook, Twitter, YouTube, Threads for iOS and Threads for Google Play.
View original content to download multimedia:
SOURCE Notable Live | https://www.wagmtv.com/prnewswire/2023/07/31/notable-live-adds-three-gold-jackets/ | 2023-07-31T11:22:15 | 0 | https://www.wagmtv.com/prnewswire/2023/07/31/notable-live-adds-three-gold-jackets/ |
BALTIMORE, July 31, 2023 /PRNewswire/ -- Opteev Technologies, Inc., a pioneering technology company at the forefront of diagnostics, has filed a patent (Patent Application #63/513,007) for a revolutionary multiplex biochip for respiratory infection diagnostics. The groundbreaking polymer-based biochip offers the potential to test multiple pathogens responsible for respiratory infections, including SARS-CoV-2, RSV, and Influenza, and precisely identify the specific virus or bacteria in under 1 minute. This game-changing technology paves the way for an ultra-rapid, portable, and accurate syndromic diagnostic device to empower healthcare providers with immediate results at their fingertips.
The tiny biochip can directly detect whole viruses in real-time in both processed and unprocessed samples such as saliva or nasal swab and has demonstrated an unprecedented accuracy rate of 99.49% with an impressive limit of detection in its analytical performance evaluation. Furthermore, the biosensor achieves fine-tuned specificity by carefully selecting specific virus-binding peptides, enabling accurate identification of target viruses in complex samples. To ensure precise and reliable virus detection, the biochip utilizes artificial intelligence to optimize the frequency range effectively mitigating the impact of interfering noise signals.
Unlike conventional respiratory panels that cost tens of thousands of dollars and take days to provide results, Opteev's multiplex biochip will offer healthcare providers affordable syndromic testing with the ability to process samples at the point of care, allowing for the simultaneous detection and specific identification of multiple pathogens instantaneously. This breakthrough technology will eliminate the need for speculation by providing healthcare providers with the critical information needed to deliver the most effective treatment options at the point of care.
"With the development of our multiplex biochip, we are revolutionizing point-of-care diagnostics," said Dr. Mesfin Meshesha, Vice President of Virology & Diagnostics at Opteev Technologies. "The potential of this technology to transform patient care, streamline operations, and reduce costs is truly remarkable."
As Opteev Technologies continues to push the boundaries of point-of-care diagnostics, the company welcomes potential collaborations and partnerships to further develop and commercialize its multiplex biochip. "Together, we can shape the future of diagnostics and unlock the massive potential of our game-changing multiplex biochip," said Conrad Bessemer, Opteev's Chairman and Co-founder.
For more information about Opteev Technologies and its groundbreaking multiplex biochip, please visit www.opteev.com.
Opteev Technologies, Inc., headquartered in Baltimore, MD, is a pioneering technology company at the forefront of diagnostics. With a strong focus on respiratory pathogen detection, Opteev is committed to developing innovative solutions that revolutionize the field of point-of-care diagnostics. As a subsidiary of Novatec, Inc., a trusted manufacturer and supplier of machinery and sensor technology, Opteev leverages decades of experience to drive advancements in healthcare.
Media Contact:
Dana Gardner
Vice President
dgardner@opteev.com
Phone: 443-457-5214
View original content to download multimedia:
SOURCE Opteev Technologies, Inc | https://www.wagmtv.com/prnewswire/2023/07/31/opteev-develops-worlds-first-multiplex-biochip-that-precisely-identifies-covid-flu-rsv-respiratory-pathogens-under-1-minute/ | 2023-07-31T11:22:21 | 1 | https://www.wagmtv.com/prnewswire/2023/07/31/opteev-develops-worlds-first-multiplex-biochip-that-precisely-identifies-covid-flu-rsv-respiratory-pathogens-under-1-minute/ |
Mobile Visual Processing Solutions Coupled with Dedicated Game Tuning Services Take Mobile Gaming Experience to a Brand-New Level
SHANGHAI, July 31, 2023 /PRNewswire/ -- Pixelworks, Inc. (NASDAQ: PXLW), a leading provider of innovative visual processing solutions, today announced the official launch of its new IRX gaming experience brand. As a brand targeted at smartphone users, IRX is grounded on Pixelworks' mobile visual processing solutions and coupled with in-depth game tuning services. This combination leverages Pixelworks' expertise to achieve ultra-smooth gaming experience and the highest picture quality for different types of games on mobile devices. In addition, it exercises effective control of power consumption, latency and other performance variables to ensure stable and long-lasting gaming with optimal visual performance, providing end users with unparalleled mobile gaming experiences.
The IRX gaming experience is enabled by a portfolio of technology advantages and product application experiences based on the Company's innovative distributed rendering architecture. More specifically, Pixelworks' ultra-low latency MotionEngine® technology, low power super-resolution technology, AI Always-on HDR and other technologies bring optimized rendering capabilities to smartphones that exceed what can be achieved by a traditional chipset. Together with Pixelworks' profound tuning experience for different games on various mobile devices the result is a meaningfully enriched visual experience for smartphone users, which is the core foundation for the IRX gaming experience.
The IRX gaming experience brand will be supported by a certification program for mobile devices that incorporates Pixelworks visual processors. The certification program will be backed by a suite of visual quality evaluation systems agreed upon with smartphone manufacturers to ensure that Pixelworks powered smartphones provide the most outstanding gaming performance and utmost visual quality for consumers.
The IRX branded certification program is comprised of both device certification and game tuning services. Pixelworks will optimize the rendering capabilities and display quality of top games on mobile devices based on its visual processors' capabilities as well as the devices' performance characteristics. Smartphones that meet the technical requirements as well as Pixelworks' visual processing standards will be granted the IRX branded certification, and games that meet Pixelworks' visual quality requirements will be included in the IRX-supported game list. To date, there are 20 top games being enlisted on the IRX-supported game list, which can be found on Pixelworks' official IRX gaming experience website. Furthermore, Pixelworks plans to establish expanded communication channels with consumers to help further educate end users on the benefits of the IRX gaming experience.
"IRX is a gaming experience brand from Pixelworks targeted directly towards mobile device users." said Ting Xiong, President of Pixelworks China. "Pixelworks would like to empower smartphone manufacturers to break the ceiling of mobile gaming experience from content optimization to performance enhancement with its innovative rendering technologies and years of game tuning and optimization experience. Additionally, we are also aiming to develop and promote consumer awareness around how to better evaluate visual display quality and the mobile gaming experience, enabling them to make smarter choices when purchasing a smartphone. By utilizing professional technologies and services to build more links across both products and users, we hope to drive mutual growth through in-depth interactions while bringing display performance and the mobile gaming experience to a brand-new level."
About Pixelworks
Pixelworks provides industry-leading content creation, video delivery and display processing solutions and technology that enable highly authentic viewing experiences with superior visual quality, across all screens – from cinema to smartphone and beyond. The Company has more than 20 years of history delivering image processing innovation to leading providers of consumer electronics, professional displays and video streaming services.
For more information, please visit the company's web site at www.pixelworks.com.
Note: Pixelworks, MotionEngine and the Pixelworks logo are trademarks of Pixelworks, Inc. All other trademarks are the property of their respective owners.
View original content to download multimedia:
SOURCE Pixelworks, Inc. | https://www.wagmtv.com/prnewswire/2023/07/31/pixelworks-announces-launch-irx-gaming-experience-brand/ | 2023-07-31T11:22:28 | 0 | https://www.wagmtv.com/prnewswire/2023/07/31/pixelworks-announces-launch-irx-gaming-experience-brand/ |
Elvina Kalieva 2023 Livesport Prague Open 2021 Odds
Elvina Kalieva's round of 32 match in the Livesport Prague Open 2021 will be versus Linda Noskova. Kalieva is +4000 to win this tournament at Tennis Club Sparta Praha.
Find all the latest odds for the 2023 Livesport Prague Open 2021 and place your bets with a new user bonus from BetMGM.
Kalieva at the 2023 Livesport Prague Open 2021
- Next Round: Round of 32
- Tournament Dates: July 28 - August 6
- Venue: Tennis Club Sparta Praha
- Location: Prague, Czechia
- Court Surface: Hard
Watch live sports without cable! Sign up today for a free trial to Fubo!
Kalieva's Next Match
Kalieva will meet Noskova in the round of 32 on Tuesday, August 1 at 5:00 AM ET, after getting past Tayisiya Morderger 6-2, 6-3 in the qualification final.
Kalieva is listed at +375 to win her next matchup against Noskova. Check out the latest odds for the entire field at BetMGM.
Want to bet on Kalieva? Head to BetMGM using our link for a bonus bet special offer for new players!
Kalieva Stats
- Kalieva defeated Morderger 6-2, 6-3 on Sunday in the qualifying round.
- In five tournaments over the past year, Kalieva is yet to win a title, and her overall record is 3-5.
- Kalieva has a record of 2-3 on hard courts over the last 12 months.
- In her eight matches over the past year, across all court surfaces, Kalieva has averaged 18.6 games.
- On hard courts, Kalieva has played five matches over the past 12 months, and she has totaled 20.8 games per match while winning 49.0% of games.
- Over the past year, Kalieva has been victorious in 12.5% of her return games and 28.6% of her service games.
- Kalieva has claimed 50% of her service games on hard courts and 11.1% of her return games over the past 12 months.
Not all offers available in all states, please visit BetMGM for the latest promotions for your area. Must be 21+ to gamble, please wager responsibly. If you or someone you know has a gambling problem, contact 1-800-GAMBLER.
© 2023 Data Skrive. All rights reserved. | https://www.dakotanewsnow.com/sports/betting/2023/07/28/elvina-kalieva-livesport-prague-open-2021-betting-odds/ | 2023-07-31T11:22:32 | 1 | https://www.dakotanewsnow.com/sports/betting/2023/07/28/elvina-kalieva-livesport-prague-open-2021-betting-odds/ |
Introducing the industry's first-ever utility side-by-side with a 1500cc 3-cylinder engine for more power to make tough jobs easier and the industry's only STEELDRIVE transmission for greater durability
MINNEAPOLIS, July 31, 2023 /PRNewswire/ -- Polaris Off Road, the global leader in powersports and off-road innovation, is once again breaking new ground with the industry's first extreme duty utility side-by-side: the all-new RANGER XD 1500. With its unprecedented capability, brute strength and unmatched comfort, the new extreme duty class of RANGER side-by-sides are engineered with the first-ever ProStar 1500cc 3-cylinder engine that offers an industry-leading 110 horsepower, the industry-exclusive STEELDRIVE automatic transmission for greater durability and precise control, and over 70 new accessories for enhanced customization, highlighted by Polaris' exclusive Lock & Ride MAX system. The RANGER XD 1500 establishes a new benchmark for utility side-by-sides.
"We spent over five years meeting with farmers, ranchers, large acreage property owners and big game hunters to develop an extreme duty vehicle that was missing from the market. From its ProStar 1500cc engine to the industry's only STEELDRIVE transmission, RANGER XD 1500 is unlike anything else offered today and is yet another example of our relentless commitment to advancing the industry with fresh thinking and innovative solutions that meet the real-world needs of our utility customers," said Steve Menneto, President of Polaris Off Road.
"Polaris RANGER has been the No. 1 selling utility side-by-side brand for more than 15 years and with the introduction of RANGER Extreme Duty, we've taken the industry's hardest-working lineup and expanded it," said Chris Judson, Vice President of Off Road Utility. "A segment of our utility customers said they are facing exceptionally large tasks and they simply need a machine with more power, more torque, more hauling and towing capacity, and more durability. And our team set out to deliver just that, incorporating dozens of new features and the latest engineering to make the RANGER XD 1500 more capable, stronger, and more comfortable than any other utility side-by-side out there."
Unprecedented Capability
Farmers, ranchers, and large landowners routinely haul and tow heavy loads around the property, and they've been asking for a solution when it comes to their heaviest tasks. The RANGER XD 1500 delivers unprecedented capability for hard-working customers to haul more, tow more, and get more done in less time. With the industry's only 1500cc utility engine, the RANGER XD 1500 provides over 30% more power and over 50% more torque than the next closest competitor.
- ProStar 1500cc 3-Cylinder Engine – Effortless towing, hauling, and confidence in tough terrain with an industry-leading 110HP and 105 lb-ft torque.
- 1,500 lb Cargo Box Capacity – Three-quarter ton box capacity providing nearly 50% more box volume than existing models for maximum productivity with fewer trips and bigger loads.
- 3,500 lb Towing Capacity – For those routinely towing heavy loads on the property, drive better productivity with nearly 40% more towing than existing models.
- Industry-leading Ground Clearance – All RANGER XD 1500 models get 15" of ground clearance with high-clearance arched A-arms to overcome large obstacles.
Brute Strength
Utility customers asked for a more durable, longer lasting offering to maximize their uptime and drive efficiency. Designed to last longer than any model before it, RANGER XD 1500 is the industry's most durable utility side-by-side and has been engineered from the ground up to be stronger and stand up to the demands of the longest days.
- Industry-exclusive STEELDRIVE transmission – Offers a 100 percent steel constructed belt that delivers smooth, precise operation and a fully sealed, liquid-cooled design for unmatched durability.
- High-Strength Steel Heavy Duty Frame – RANGER XD 1500 has a high-strength steel one-piece chassis featuring 160 percent more torsional stiffness for a smoother ride and better cab sealing.
- Industry-leading Service Intervals – RANGER XD 1500 offers the industry's longest service intervals so customers can maximize their uptime.
Unmatched Comfort
- From the farm to remote backcountry, utility customers work from before the sun rises to after it sets, and need something that delivers all-day comfort. Beyond industry-leading capability and durability, the RANGER XD 1500 prioritizes comfort across the entire lineup to keep customers going strong on the longest days.
- Most Spacious Interior – Equipped with the most spacious and premium cab available in utility side-by-sides, the XD 1500 offers increased leg and shoulder room, making it easy to enter and exit the vehicle. Adjustable seating and a telescopic steering wheel lets drivers find the perfect fit for height and riding preferences.
- Premium Seating – Contoured seating with added bolstering provides more rider comfort along with a center seat that flips down into an armrest with additional cup holders.
- Available Heated Seats – For comfort on the coldest days, RANGER XD 1500 NorthStar Ultimate is the first utility side-by-side that comes from the factory with heated seats.
- Drive Modes – RANGER XD 1500 comes with an intuitive and easy-to-use rotary drive mode selector that lets customers choose from four different drive modes, including:
- Heating and Air Conditioning (HVAC) – Riders can stay comfortable in harsh weather conditions in the RANGER XD 1500 NorthStar Edition, featuring an all-new HVAC system and a fully-enclosed, next generation ProShield cab that's been redesigned with improved sealing to prevent dust and water intrusion, while locking in the temperature from the climate-controlled cab.
- Sun Visors – All-new integrated sun visors provide improved visibility throughout the day for added confidence while driving.
- RIDE COMMAND – Available 7" waterproof touchscreen display powered by RIDE COMMAND technology featuring a back-up camera, GPS navigation regardless of cell service, and AM/FM radio with Bluetooth® streaming capability.
- RIDE COMMAND+ – Customers can keep tabs on their vehicle directly from the Polaris App and access critical vehicle information like vehicle location, maintenance reminders, and issue diagnostics right from the palm of their hand with the industry's only connected-vehicle technology. Available from the factory on NorthStar Ultimate.
Customization
Customers have been asking for increased versatility, durability, and ease of use for the different work applications they face throughout the day. With over 70 new Polaris Engineered Accessory options designed specifically for the RANGER XD 1500, plus options from partners brands including JBL®, Rhino Rack®, Pro Armor, Kolpin, and HD Parts, customers have more opportunity than ever before to make their vehicle fit their specific needs.
- Lock & Ride MAX – Polaris' easiest to use, most versatile, and confident accessory attachment platform ever. With customizable configurations and the ability to reconfigure on the fly with no tools required, this new accessory platform allows users to prepare for their day, their way. Customers can simply choose and place their accessory, lock it in place, and ride confidently knowing their gear is secure.
- New JBL® Audio – Polaris partnered with JBL® to create the highest performing audio system ever included in a RANGER from the factory. For customers wanting to turn it up a notch, the JBL® Trail Pro 4200 audio upgrade adds rear speakers and two subwoofers for an immersive audio experience.
- Glacier Pro HD Plow – New 84" plow designed for faster, more efficient plowing during the winter months. A hydraulic plow lift and angle kit can be paired with an all-new plow controller to manage the largest plow Polaris has ever offered, all without ever leaving the comfort of the cab.
2024 RANGER XD 1500 Premium: Starting at US $29,999 / CAN $36,199
The RANGER XD 1500 Premium commands a large presence thanks to heavy-duty components and the industry's largest bumper, providing complete front-end protection. The vehicle comes equipped with one of the most comprehensive standard packages in a side-by-side to date including 29" tires, tilt steering and seat slider for customizable comfort, four drive modes, high output LED headlights for enhanced visibility, and USB ports with multiple charging capabilities. The vehicle also comes equipped with boosted brakes and heavy-duty suspension to ensure performance across a variety of off-road environments.
2024 RANGER XD 1500 NorthStar Premium: Starting at US $39,999 / CAN $48,799
The next step up is the RANGER XD 1500 NorthStar Premium. This machine features a fully enclosed cab with HVAC temperature and five different mode controls, lockable full doors with power windows and a fixed front glass windshield. Additional features include an electronically controlled power tilt bed to dump heavy loads with ease, an overhead switch panel for easy accessorization, and an overhead rear work light to illuminate the cargo box in low-light conditions. NorthStar Premium comes stock with 30" Kenda® CrossTrail tires and available 32" tires to overcome large obstacles and tough terrain.
2024 RANGER XD 1500 NorthStar Ultimate: Starting at US $44,999 / CAN $54,499
Rounding out the lineup is the RANGER XD 1500 NorthStar Ultimate, which features everything from the NorthStar Premium trim, plus the 7" infotainment display powered by RIDE COMMAND and heated seats. The NorthStar Ultimate trim also delivers an immersive sound experience, featuring full AM/FM radio with Bluetooth® streaming capability and industry-exclusive JBL® speakers for precise audio and premium sound. Finally, the vehicle comes standard with RIDE COMMAND+, allowing for vehicle health monitoring and more.
The 2024 RANGER XD 1500 lineup is expected to begin shipping to dealers in late summer. To learn more about the 2024 RANGER family, please visit https://ranger.polaris.com/en-us/ or join the conversation and follow on Facebooksm, Instagramsm, YouTubesm and Twittersm.
About Polaris
As the global leader in powersports, Polaris Inc. (NYSE: PII) pioneers product breakthroughs and enriching experiences and services that have invited people to discover the joy of being outdoors since our founding in 1954. Polaris' high-quality product line-up includes the Polaris RANGER®, RZR® and Polaris GENERAL™ side-by-side off-road vehicles; Sportsman® all-terrain off-road vehicles; military and commercial off-road vehicles; snowmobiles; Indian Motorcycle® mid-size and heavyweight motorcycles; Slingshot® moto-roadsters; Aixam quadricycles; Goupil electric vehicles; and pontoon and deck boats, including industry-leading Bennington pontoons. Polaris enhances the riding experience with a robust portfolio of parts, garments, and accessories. Proudly headquartered in Minnesota, Polaris serves more than 100 countries across the globe. www.polaris.com
Warning: vehicle rollaway can cause serious injury or death. This vehicle can roll whenever the gear selector is not in the park position. Always shift to park when stopping the engine or leaving the vehicle. When leaving the vehicle on an incline is unavoidable, use extra care. If leaving the vehicle unattended, block the rear wheels on the downhill side and keep children, pets, and others away form the gear selector. Notice: Vehicle payload and trailer weight will affect the angle of hill on which the vehicle will hold.
Kenda® is a registered trademark of Kenda Rubber Industrial Co, Ltd.
Bluetooth® is a registered trademark of Bluetooth Sig, Inc.
JBL® is a registered trademark of Harman International Industries, Incorporated
Rhino-Rack® is a registered trademark of Rhino Rack Australia Pty Limited
Unless noted, trademarks are the property of Polaris Industries Inc.
View original content to download multimedia:
SOURCE Polaris Inc. | https://www.wagmtv.com/prnewswire/2023/07/31/polaris-expands-its-ranger-lineup-with-all-new-ranger-xd-1500-an-entirely-new-class-extreme-duty-utility-side-by-sides/ | 2023-07-31T11:22:35 | 1 | https://www.wagmtv.com/prnewswire/2023/07/31/polaris-expands-its-ranger-lineup-with-all-new-ranger-xd-1500-an-entirely-new-class-extreme-duty-utility-side-by-sides/ |
Highlights Include the Return of Polaris Sportsman 570 and XP 1000 Hunt Editions, Along with a Host of
Aesthetic and Performance Upgrades Across the Lineup
MINNEAPOLIS, July 31, 2023 /PRNewswire/ -- On the heels of debuting its innovative Polaris XPEDITION and the all new Extreme Duty RANGER XD 1500, Polaris Off Road today unveiled updates for 2024 to the off-road industry's most expansive lineup. The 2024 lineup features a host of rider-inspired updates and refreshed styling and new colors. Additionally, the customer-favorite Polaris Sportsman 570 and XP 1000 Hunt editions make a return, and a Premium trim offering is now available on the 2024 GENERAL 1000 to provide customers with an upgrade in style and performance. RIDE COMMAND+ also received enhanced features for 2024, delivering unmatched connectivity and peace of mind to riders through all-new Location Bump Alerts and Check-In Messages.
"From the completely redesigned 2024 RZR XP and the industry's first "adventure side-by-side" Polaris XPEDITION, to our introduction of the all-new RANGER XD 1500, this year has been a powerful showcase of our ongoing commitment to lead the industry and innovate for our riders," said Steve Menneto, President of Polaris Off Road. "While those revolutionary product debuts are pivotal, our unwavering focus on refining and enhancing our current offerings based on customer needs and feedback remains essential, and that's what the 2024 updates represent."
From fresh new styles and colorways, to improved trim levels that appeal to a wide variety of riders, the Polaris Off Road 2024 model year lineup and RIDE COMMAND+ technology enhancements include the following:
RIDE COMMAND+:
Making its debut last fall, RIDE COMMAND+, the industry's first connected-vehicle technology, continues to roll out new enhancements to its service for 2024. With new features like Location Alerts, that will notify the owner if its vehicle has been bumped or moved from its last location, owners can now protect their vehicle more than ever before. RIDE COMMAND+ is now available as a factory option for 2024 RZR Pro R Ultimate, RANGER XD 1500 NorthStar, RANGER XP 1000 NorthStar, Polaris XPEDITION NorthStar and Sportsman XP 1000 RIDE COMMAND Edition. This service is also available on most 2024 RZR, RANGER, Sportsman and Polaris XPEDITION models as an accessory install.
Sportsman
Polaris Sportsman, the long-standing No. 1 selling automatic 4x4 ATV, is reintroducing the Sportsman 570 and XP 1000 Hunt Editions, while also implementing key improvements across the core 2024 lineup. A customer favorite, specifically designed to meet the unique needs of hunters, the Sportsman 570 and XP 1000 Hunt editions include accessories such as the 3,500 lb Polaris Winch, Kolpin Gun Scabbard & Mount, Kolpin Ratchet Claws and more.
Additionally, the 2024 Sportsman 450 and 570 lineup boasts several quality refinements for a better riding experience including a new rear brake pedal for reduced pedal effort and feel, improved sealing around the shifter, and enhanced seat fitment delivering a more comfortable ride. The 570 EPS trim and above will also include enhanced PVT clutch sealing with a higher intake location for better performance in wet conditions.
For added utility, the model year 2024 Sportsman 570 lineup will be equipped with new LED lights for the Premium and Utility HD for added visibility from dawn to dusk.
New color options also are available for the 570 Premium and Trail, 570 Ride Command Edition, Sportsman 850 Premium and Ultimate Trail, Sportsman XP 1000 Ultimate Trail, Sportsman XP 1000 High Lifter Edition, Scrambler XP 1000 S and Sportsman XP 1000 S.
The 2024 Sportsman lineup starts at $6,999 US MSRP and will begin shipping to dealers this early fall. For additional pricing on the entire model lineup, visit https://www.polaris.com/en-us/off-road/sportsman/
GENERAL
Polaris GENERAL is the industry's most versatile crossover side-by-side, capable of tackling tough trails, while also knocking out tasks around the property. For 2024, the GENERAL 1000 receives a new Premium trim offering that provides both style and performance enhancements. Featuring 14" wheels with 27" Coronado tires, and FOX® Podium QS3® shocks that riders can adjust between soft, medium and firm based on terrain changes, the new Premium trim will deliver a smooth ride over rugged terrain, while LED headlights provide greater visibility at morning and night. These upgrades will help riders knock out more tasks and hit the trails confidently in the GENERAL 1000.
Additionally, new colorways on the GENERAL 1000 model include Ghost Gray and Volcanic Orange. The Premium and Ultimate trim levels for the GENERAL XP will feature new colors and graphics in Matte Silver Quartz and Polaris Blue.
The 2024 GENERAL lineup starts at $17,499 US MSRP and will begin shipping to dealers this summer. For additional pricing on the entire model lineup, visit https://www.polaris.com/en-us/off-road/general/
RZR
Polaris RZR, the No. 1 sport side-by-side brand, receives fresh new colors and graphics across its lineup, helping riders make a bold statement when hitting the trails. The 2024 RZR Trail and RZR Trail S are now available in Storm Blue on the Sport trim and two-tone Storm Blue with White Lightning on the Ultimate. Both Sport and Ultimate trim levels now receive the same upgraded steering wheel offered in the fully-redesigned 2024 RZR XP that provides a sportier feel while driving on trails. New for 2024, the RZR Trail and Trail S Sport level feature electric power steering and LED headlights standard, providing riders easier steering input on tight trail corners and enhanced visibility. Additionally for 2024, the RZR Trail S Ultimate trim now features Walker Evans Racing® shocks, while the Sport trim moved to ZF Sachs shocks, both offering riders plush suspension performance against the rugged terrain.
For 2024, the RZR Pro XP Sport and Premium models feature Walker Evans Racing® shocks, while the Ultimate will continue to be equipped with FOX® Live Valve shocks with DYNAMIX active suspension. Both the Premium and Ultimate trim received a refresh with new graphics on the Super Graphite colorway.
Lastly and by consumer demand, the Wide Open lineup of RZR Pro R and RZR Turbo R receives refreshed color options for 2024. For the first time since launching, the RZR Pro R Ultimate is available in an all-new Matte Onyx Black with Lifted Lime accents or Matte Heavy Metal, while the Premium trim level is offered in Matte Heavy Metal. The 2024 RZR Turbo R also welcomes vibrant new colors like Velocity Blue with Green Burst accents and Military Tan with Orange Burst accents.
The 2024 RZR lineup starts at $15,999 US MSRP and will begin shipping to dealers this fall. For additional pricing on the entire model lineup, visit https://www.polaris.com/en-us/off-road/rzr/
RANGER
In addition to the newly launched Extreme Duty RANGER XD 1500, the Polaris RANGER lineup receives a variety of rider-inspired upgrades and quality refinements for 2024. RANGER SP 570 gets new color options, while the NorthStar Edition gets exclusive tailgate badging and new 25" 8-ply Pro Armor X-Terrain tires for added durability and enhanced puncture resistance.
Additionally, Polaris expands the color options for the RANGER 1000 Premium which will now be offered in the sleek Granite Grey color and graphics, while the XP 1000 will be featured in two new options: Desert Sand and Super Graphite with orange burst accents. Furthermore, the RANGER XP 1000 NorthStar Ultimate model boasts connectivity features such as vehicle health, issue diagnostics, and maintenance reminders enabled by RIDE COMMAND+.
The 2024 RANGER lineup starts at $11,699 US MSRP and will begin shipping to dealers this fall. For additional pricing on the entire model lineup, visit https://www.polaris.com/en-us/off-road/ranger/
Youth
Dedicated to inspiring the next generation of riders, Polaris Off Road delivers the industry's largest and most varied lineup of youth offerings. For 2024, the Polaris ORV Youth lineup receives a refresh with eye-catching new colors and graphics. This lineup continues to provide industry-leading safety features that give parents peace of mind and help instill confidence in growing riders, including pin code start, adjustable speed limiter, geofencing, helmet aware technology and industry-exclusive safety gear kit.
Specifically, the 2024 RZR 200 EFI is now offered in Storm Gray and a new graphic pattern with bright red accents. The Outlaw 70 EFI ATV is offered in Velocity Blue with either Lifted Lime or Fierce Fuchsia accents, while the Outlaw 110 EFI is now offered in both Bright White with Polaris Blue and Bright White with Radiant Green details.
The 2024 Polaris Youth lineup starts at $2,999 US MSRP and will begin shipping to dealers this winter. For additional pricing on the entire model lineup, visit https://www.polaris.com/en-us/off-road/shop-by-use/youth/
Polaris XPEDITION
The Polaris XPEDITION, which recently launched in May 2023, is the first-of-its-kind adventure side-by-side, combining the all-terrain capabilities of traditional side-by-sides with comfort and cargo capabilities typically associated with overlanding at the highest level. With a host of standard features and optional configurations to accommodate the greatest range of outdoor pursuits and enable consumers to keep chasing the wild, the 2024 Polaris XPEDITION XP and ADV are the most adaptable, comfortable and capable adventure machine on the market.
The 2024 Polaris XPEDITION lineup starts at $28,999 US MSRP and is currently shipping to dealers. For additional pricing on the entire model lineup, visit https://www.polaris.com/en-us/off-road/polaris-xpedition/
To learn more about the Polaris ORV 2024 lineup and to stay up to date on testing and demo opportunities, please visit https://offroad.polaris.com/en-us/ or join the conversation and follow on FacebookSM, InstagramSM, YouTubeSM and TwitterSM. Walker Evans Racing® is a registered trademark of Walker Evans Enterprises Incorporated; FOX® is a registered trademark of Fox Factory Inc.
About Polaris
As the global leader in powersports, Polaris Inc. (NYSE: PII) pioneers product breakthroughs and enriching experiences and services that have invited people to discover the joy of being outdoors since our founding in 1954. Polaris' high-quality product line-up includes the Polaris RANGER®, RZR® and Polaris GENERAL™ side-by-side off-road vehicles; Sportsman® all-terrain off-road vehicles; military and commercial off-road vehicles; snowmobiles; Indian Motorcycle® mid-size and heavyweight motorcycles; Slingshot® moto-roadsters; Aixam quadricycles; Goupil electric vehicles; and pontoon and deck boats, including industry-leading Bennington pontoons. Polaris enhances the riding experience with a robust portfolio of parts, garments, and accessories. Proudly headquartered in Minnesota, Polaris serves more than 100 countries across the globe. www.polaris.com
View original content to download multimedia:
SOURCE Polaris Inc. | https://www.wagmtv.com/prnewswire/2023/07/31/polaris-off-road-stays-gas-with-2024-lineup-featuring-rider-inspired-updates-amp-refreshed-styles-its-industry-leading-range-side-by-sides-atvs/ | 2023-07-31T11:22:41 | 1 | https://www.wagmtv.com/prnewswire/2023/07/31/polaris-off-road-stays-gas-with-2024-lineup-featuring-rider-inspired-updates-amp-refreshed-styles-its-industry-leading-range-side-by-sides-atvs/ |
Many movie and TV productions are now on pause, with writers and actors on strike. So you may be wondering if it is still worth paying all that money for a half dozen streaming services or more.
The good news is that there is a growing list of streaming services out there with plenty of content that you can watch completely free.
Like many of us, Cara Nicolas feels she pays for too many TV streams.
"I think I have seven or eight streaming services now," she said. "I watch MAX and Hulu and sometimes Netflix. We have Disney Plus too."
But now, this young advertising executive wants to cut back because the writers' strike means fewer new shows. So she is checking out some free services that offer thousands of old movies and series.
Consumer Reports recently analyzed all the free streaming services available now and suggests you may want to take a look at:
- Amazon Freevee
- Crackle
- Pluto TV
- Tubi TV
- Roku channel
Click here to read the full report.
So what's the catch?
According to Consumer Reports, you won't find recently released films like Barbie or popular HBO shows, but you will get a decent variety for free. In exchange, you'll be watching more ads, according to Jim Willcox of Consumer Reports.
"You're even starting to see right now some companies promoting the fact that 'oh, we only have three ads per hour' or something like that," he said.
If you're thinking you really don't want to subscribe to another two, three, or four services, the reality is that you don't have to.
A lot of those free streaming services have a lot of the same content," Willcox said,
That means both free services, and the giants like Netflix and Hulu, have to differentiate their content while also offering affordable options.
"Clearly consumers are hitting a threshold in terms of how much money they're willing to pay each month," Willcox said.
Nicolas says those free services can keep you entertained, strike or no strike.
"There is never a shortage of content to watch," she said.
That way you don't waste your money.
__________________________
"Don't Waste Your Money" is a registered trademark of Scripps Media, Inc. ("Scripps").
Follow John:
- Facebook:John Matarese Money
- Instagram: @johnmataresemoney
- Twitter: @JohnMatarese
For more consumer news and money saving advice, go to www.dontwasteyourmoney.com | https://www.wmar2news.com/money/consumer/dont-waste-your-money/watch-tv-free-with-these-no-charge-streaming-services | 2023-07-31T11:22:44 | 0 | https://www.wmar2news.com/money/consumer/dont-waste-your-money/watch-tv-free-with-these-no-charge-streaming-services |
The Avocados From Mexico® Chocolate Dulce De Leche Cupcake will be available at Sprinkles bakeries nationwide for one week beginning July 31
DALLAS, July 31, 2023 /PRNewswire/ -- Talk about a perfect pairing! Avocados From Mexico®, the number one selling avocado brand in the U.S., is making National Avocado Day even better by partnering with renowned dessert bakery chain Sprinkles for a delicious collaboration – a limited-edition cupcake featuring fresh Mexican avocados.
The Avocados From Mexico® Chocolate Dulce De Leche Sprinkles cupcake is a delectable banana cupcake that's studded with pecans and generously filled with a soft dulce de leche core. And to top it all off? A zesty frosting that blends rich cream cheese and chocolate made with fresh Mexican avocados for a delightful, creamy finish.
"The new Avocados From Mexico Chocolate Dulce De Leche cupcake features the highest quality and best-tasting ingredients," said Sprinkles Vice President, Culinary, Charles Craig. "By blending fresh avocado and smooth cream cheese alongside the banana and dulce de leche cupcake, we were able to elevate all the ingredients resulting in a cupcake that is out-of-this world. We can't wait for fans to try it!"
Beginning on July 31, National Avocado Day, consumers can make their week better by enjoying Avocados From Mexico in cupcake form — available at Sprinkles nationwide through August 6.
"Avocados From Mexico make everything better, and we're so proud that our avocados will get to shine in a unique way on National Avocado Day," said Kelly Burke, Director of Brand Marketing at Avocados From Mexico. "Our brand is known for bringing the good times with great tasting avocados. We are excited to partner with a beloved brand like Sprinkles to spark good times in a new way with everyone's favorite sweet treat."
"Sprinkles Cupcakes has always taken an innovative approach to classic desserts, and this new collaboration with Avocados From Mexico is no exception," said Sprinkles CMO, Michelle Wong. "Avocados From Mexico was an obvious choice for their quality and taste, and we can't wait for our guests to discover our latest cupcake, starring this beloved fruit."
To learn more about Avocados From Mexico, visit https://avocadosfrommexico.com, Facebook (facebook.com/avocadosfrommexico), Instagram (@avocadosfrommexico) or Twitter (@AvosFromMexico). #MakeItBetter #AFMxSprinkles
About Avocados From Mexico
Avocados From Mexico is a wholly-owned subsidiary of the Mexican Hass Avocado Importers Association (MHAIA), formed for the purpose of advertising, promotion, public relations and research for all stakeholders of Avocados From Mexico. Under agreements, MHAIA and the Association of Avocado Exporting Producers & Packers of Mexico (APEAM) have combined resources to fund and manage Avocados From Mexico, with the intent to provide a focused, highly- effective and efficient marketing program in the United States. Avocados From Mexico is headquartered in Irving, Texas.
About Sprinkles
Sprinkles offers premium cupcakes, cakes and cookies that are baked fresh in small batches throughout the day and handcrafted with only the finest ingredients. Sprinkles opened its first bakery in Beverly Hills in 2005, drawing long lines of loyal cupcake fans and celebrity endorsements. Sprinkles prides themselves in being passionate innovators and since debuting the world's first Cupcake ATM, the brand has introduced layer cakes, cookies and brownies, launched a national shipping platform and has grown to over 70 bakeries and ATMs coast-to-coast. Sprinkles launched domestic and international franchising in 2022. For additional information on Sprinkles, follow @sprinklescupcakes on social and visit www.sprinkles.com.
CONTACT: Ana Ambrosi, aambrosi@avocadosfrommexico.com
View original content to download multimedia:
SOURCE Avocados From Mexico | https://www.wagmtv.com/prnewswire/2023/07/31/sweet-news-avocados-mexico-sprinkles-launch-limited-edition-cupcake-national-avocado-day/ | 2023-07-31T11:22:47 | 0 | https://www.wagmtv.com/prnewswire/2023/07/31/sweet-news-avocados-mexico-sprinkles-launch-limited-edition-cupcake-national-avocado-day/ |
ARIZONA
President Joe Biden coming to Arizona to talk about climate change, clean energy
Dan Nowicki
Arizona Republic
President Joe Biden is returning to Arizona next month as part of a Western swing touting the Inflation Reduction Act's impact on fighting climate change and progress on boosting the clean-energy and manufacturing industries.
Biden will visit Arizona, New Mexico and Utah from Monday, Aug. 7, to Wednesday, Aug. 9.
Besides climate change and clean energy, Biden is expected to talk about other key priorities, the White House said.
This is a developing story. Check back to azcentral.com for updates. | https://www.azcentral.com/story/news/politics/arizona/2023/07/31/joe-biden-to-visit-arizona-to-tout-inflation-reduction-act/70495899007/ | 2023-07-31T11:22:49 | 0 | https://www.azcentral.com/story/news/politics/arizona/2023/07/31/joe-biden-to-visit-arizona-to-tout-inflation-reduction-act/70495899007/ |
SHANGHAI, July 31, 2023 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced that it will report its unaudited financial results for the second quarter ended June 30, 2023, before the U.S. market opens on Thursday, August 24, 2023.
111's management team will host an earnings conference call at 7:30 AM U.S. Eastern Time on Thursday, August 24, 2023 (7:30 PM Beijing Time on the same day).
Details for the conference call are as follows:
Conference Topic: 111, Inc. Second Quarter 2023 Earnings Conference Call
Registration Link: https://s1.c-conf.com/diamondpass/10032701-ygfhis.html
All participants must use the link provided above to complete the online registration process in advance of the conference call. Upon registering, each participant will receive a set of participant dial-in numbers, the Direct Event passcode, and a unique Registration ID, which can be used to join the conference call.
Please dial in 15 minutes before the call is scheduled to begin and provide the Direct Event passcode and unique Registration ID you have received upon registering to join the call.
A telephone replay of the call will be available after the conclusion of the conference call until August 31, 2023
United States: +1 855 883 1031
Mainland China: 4001 209 216
Hong Kong: 800 930 639
International: +61 7 3107 6325
Conference ID: 10032701
A live and archived webcast of the conference call will be available on the website at https://edge.media-server.com/mmc/p/iw7ck9oc
About 111, Inc.
111, Inc. (NASDAQ: YI) ("111" or the "Company") is a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China. The Company provides consumers with better access to pharmaceutical products and healthcare services directly through its online retail pharmacy, 1 Pharmacy, and indirectly through its offline virtual pharmacy network. The Company also offers online healthcare services through its internet hospital, 1 Clinic, which provides consumers with cost-effective and convenient online consultation, electronic prescription service, and patient management service. In addition, the Company's online platform, 1 Medicine Marketplace, serves as a one-stop shop for pharmacies to source a vast selection of pharmaceutical products. With the largest virtual pharmacy network in China, 111 enables offline pharmacies to better serve their customers with cloud-based services. 111 also provides an omni-channel drug commercialization platform to its strategic partners, which includes services such as digital marketing, patient education, data analytics, and pricing monitoring.
For more information on 111, please visit: http://ir.111.com.cn/.
View original content:
SOURCE 111, Inc. | https://www.1011now.com/prnewswire/2023/07/31/111-announce-second-quarter-2023-unaudited-financial-results-august-24-2023-conference-call-follow/ | 2023-07-31T11:22:49 | 0 | https://www.1011now.com/prnewswire/2023/07/31/111-announce-second-quarter-2023-unaudited-financial-results-august-24-2023-conference-call-follow/ |
SHENZHEN, China, July 31, 2023 /PRNewswire/ -- Taoping Inc. (Nasdaq: TAOP, the "Company" or "Taoping"), today announced that the board of directors of the Company approved a one-for-ten reverse stock split of the Company's issued and outstanding ordinary shares, no par value (the "Ordinary Shares"). Beginning August 1, 2023, the Company's Ordinary Shares will be trading on a split-adjusted basis under the same symbol "TAOP" but with new CUSIP number, G8675V 127.
As a result of the share consolidation, each ten Ordinary Shares outstanding will automatically combine and convert to one issued and outstanding Ordinary Share without any action on the part of shareholders who hold their shares in brokerage accounts or "street name". Shareholders holding certificates of Ordinary Shares are expected to receive instructions from the Company's transfer agent, Transhare Corporation, regarding procedures for exchanging share certificates. All outstanding options, warrants and other rights to purchase the Company's Ordinary Shares will be adjusted proportionately as a result of the reverse stock split. No fractional shares will be issued as a result of the reverse stock split, and instead, all such fractional shares resulting from the reverse stock split will be rounded up to the nearest whole share.
The reverse stock split is intended to increase the per share trading price of the Ordinary Shares to satisfy the $1.00 minimum bid price requirement for continued listing on the NASDAQ Stock Market. Following the reverse stock split the Company will have approximately 1.86 million Ordinary Shares issued and outstanding, exclusive of shares issuable under outstanding options and warrants. The reverse stock split will not affect the number of total authorized Ordinary Shares of the Company.
About Taoping Inc.
Taoping Inc. (Nasdaq: TAOP) has a long history of successfully leveraging technology in the development of innovative solutions to help customers in both the private and public sectors to more effectively communicate and market to their desired targets. The Company has built a far-reaching city partner ecosystem and comprehensive portfolio of high-value, high-traffic areas for its products, which are aligned together with Taoping's smart cloud platform, cloud services and solutions, new media and artificial intelligence. For more information about Taoping, please visit www.taop.com. You can also follow us via LinkedIn, Twitter or YouTube.
Safe Harbor Statement
This press release contains "forward-looking statements" that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, such as statements regarding our estimated future results of operations and financial position, our strategy and plans, and our objectives or goals, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. We have attempted to identify forward-looking statements by terminology including "anticipates," "believes," "can," "continue," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "should," or "will" or the negative of these terms or other comparable terminology. Our actual results may differ materially or perhaps significantly from those discussed herein, or implied by, these forward-looking statements. There are a significant number of factors that could cause actual results to differ materially from statements made in this press release, including: our potential inability to achieve or sustain profitability or reasonably predict our future results due to our limited operating history of providing smart cloud services, the effects of the global Covid-19 pandemic, the emergence of additional competing technologies, changes in domestic and foreign laws, regulations and taxes, uncertainties related to China's legal system and economic, political and social events in China, the volatility of the securities markets; and other risks including, but not limited to, those that we discussed or referred to in the Company's disclosure documents filed with the U.S. Securities and Exchange Commission (the "SEC") available on the SEC's website at www.sec.gov, including the Company's most recent Annual Report on Form 20-F as well as in our other reports filed or furnished from time to time with the SEC. The forward-looking statements included in this press release are made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking statements, other than as required by applicable law.
View original content to download multimedia:
SOURCE Taoping Inc. | https://www.wagmtv.com/prnewswire/2023/07/31/taoping-announces-1-for-10-reverse-stock-split/ | 2023-07-31T11:22:53 | 1 | https://www.wagmtv.com/prnewswire/2023/07/31/taoping-announces-1-for-10-reverse-stock-split/ |
BEIJING, July 31, 2023 /PRNewswire/ -- 36Kr Holdings Inc. ("36Kr" or the "Company") (NASDAQ: KRKR), a prominent brand and a pioneering platform dedicated to serving New Economy participants in China, today announced the launch of its 36Kr Media Lab in Silicon Valley, an initiative to embrace the large language models (LLM) revolution taking place in the content creation industry and optimize the application of artificial intelligence (AI) for the new economy sector.
36Kr Silicon Valley Media Lab's first project leveraging LLM, "Empty Office," will experimentally explore scenarios where AI can think and work as humans, enhancing content production efficiency and reducing costs. Through "Empty Office," 36Kr is also building innovative media solutions that will transform traditional video, graphic and text communications into avant-garde dialogues between customized AI characters and audiences. These network-based dialogues will be naturally and seamlessly driven by real-time data generation, and available anytime, anywhere.
At the same time, 36Kr Silicon Valley Media Lab continues to focus on tailoring its LLM to the new economy sector. By utilizing dedicated financial and business datasets, including enterprises' financial results, news, market dynamics and knowledge repositories, among other resources, to train its LLM to thoroughly understand and analyze business information, 36Kr has developed a model that keenly grasps the business nuances to generate accurate analysis and interpretation. 36Kr Silicon Valley Media Lab constantly maintains its database, serving as the reference foundation to ensure that its fact-based model produces rigorous and up-to-date business and financial analysis.
Furthermore, 36Kr's professionally-training, fine-tuning capability enables its LLM-empowered "Empty Office" to quickly and efficiently create informative content for the new economy sector. For instance, in the case of a business event, such as a new product launch, an AI agent can instantly extract relevant data from the database, automatically perform a comprehensive analysis, and issue reports within just seconds. This top-speed response gives 36Kr's business and financial-focused media platform an unrivaled edge.
Mr. Dagang Feng, Co-chairman and CEO of 36Kr, commented, "The launch of 36Kr Silicon Valley Media Lab is a testament to our AI technology acumen and vision as well as our commitment to extending media's boundaries. By integrating pioneering AI technology into content creation, 36Kr will constantly elevate the efficiency and quality of content production alongside the rapid advancement of the LLM, fostering a superior content ecosystem encompassing business, finance and technology, further turbocharging the evolution of the New Economy. As we adopt and develop more AI tools amid the technology's rapid advancement, we are strategically positioning the Company to break new ground and ultimately drive long-term growth for our business."
About 36Kr Holdings Inc.
36Kr Holdings Inc. is a prominent brand and a pioneering platform dedicated to serving New Economy participants in China with the mission of empowering New Economy participants to achieve more. The Company started its business with high-quality New Economy-focused content offerings, covering a variety of industries in China's New Economy with diverse distribution channels. Leveraging traffic brought by high-quality content, the Company has expanded its offerings to business services, including online advertising services, enterprise value-added services, and subscription services, to address the evolving needs of New Economy companies and upgrading needs of traditional companies. The Company is supported by a comprehensive database and strong data analytics capabilities. Through diverse service offerings and significant brand influence, the Company is well-positioned to continuously capture the high growth potential of China's New Economy.
For more information, please visit: http://ir.36kr.com.
Safe Harbor Statement
This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: the Company's goal and strategies; the Company's future business development, results of operations and financial condition; relevant government policies and regulations relating to our business and industry; the Company's expectations regarding the use of proceeds from this offering; the Company's expectations regarding demand for, and market acceptance of, its services; the Company's ability to maintain and enhance its brand; the Company's ability to provide high-quality content in a timely manner to attract and retain users; the Company's ability to retain and hire quality in-house writers and editors; the Company's ability to maintain cooperation with third-party professional content providers; the Company's ability to maintain relationships with third-party platforms; general economic and business conditions in China; possible disruptions in commercial activities caused by natural or human-induced disasters; and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in the Company's filings with the SEC. All information provided in this press release and in the attachments is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.
For investor and media inquiries, please contact:
In China:
36Kr Holdings Inc.
Investor Relations
Tel: +86 (10) 8965-0708
E-mail: ir@36kr.com
The Piacente Group, Inc.
Jenny Cai
Tel: +86 (10) 6508-0677
E-mail: 36Kr@tpg-ir.com
In the United States:
The Piacente Group, Inc.
Brandi Piacente
Tel: +1-212-481-2050
E-mail: 36Kr@tpg-ir.com
View original content:
SOURCE 36Kr Holdings Inc. | https://www.1011now.com/prnewswire/2023/07/31/36kr-launches-silicon-valley-media-lab-empower-content-ecosystem-with-llm-based-ai-technology/ | 2023-07-31T11:22:56 | 1 | https://www.1011now.com/prnewswire/2023/07/31/36kr-launches-silicon-valley-media-lab-empower-content-ecosystem-with-llm-based-ai-technology/ |
16TH annual event features turtles named after characters in Disney's frighteningly fun adventure movie, "Haunted Mansion," now playing in theaters.
VERO BEACH, Fla., July 31, 2023 /PRNewswire/ -- Over the weekend at Disney's Vero Beach Resort, researchers from the Sea Turtle Conservancy (STC) and Disney Conservation released two sea turtles as part of the 16th annual Tour de Turtles "migration marathon." Tour de Turtles is a fun, educational event that follows the migration of sea turtles from their nesting beaches to their feeding grounds and, ultimately, provides scientific data on how best to protect their species.
The Disney Conservation Fund (DCF) and Disney Cruise Line are each sponsoring a turtle this year, whose names, Madame Leota and Harriet, are the names of characters in Disney's frighteningly fun adventure movie "Haunted Mansion," now playing in theaters. Not unlike Gabbie, another character in the film who enlists a motley crew of so-called spiritual experts to help rid their home of supernatural squatters – Tour de Turtles brings together a team of researchers from the STC and Disney Conservation annually to undertake a daunting mission - using satellite telemetry to track two female turtles to determine where and how far they swim during the migration season.
Each turtle swims to raise awareness about various threats to sea turtle survival. The turtle to swim the furthest distance will win the Tour de Turtles race.
"Disney's commitment to sea turtle conservation in Vero Beach spans 20 years, and we are very proud to have recently watched our 1.5 millionth sea turtle hatchling leave the nest and shuffle its way to the ocean," said Mark Penning, Vice President of Disney's Animals, Science and Environment. "Southeast Florida hosts one of the largest nesting aggregations of loggerhead sea turtles, making up to 40 percent of the global loggerhead population. The team has recorded more than 20,000 sea turtle nests on our survey route since the program began."
The data collected during Tour de Turtles helps researchers, conservationists and governing agencies make more informed decisions about sea turtle conservation and management. Since the launch of the event in 2008, STC and Disney have collaborated to study 29 sea turtles outfitted with satellite transmitters and released from Disney's Vero Beach Resort. Continuing its commitment to strengthen youth education programs in port communities around the world, Disney Cruise Line proudly supported local students from Club Esteem from Melbourne, Florida, to participate in this year's event. DCF also has directed more than $5.1 million to support global sea turtle conservation efforts.
"Disney is a fantastic collaborator," said David Godfrey, STC Executive Director. "Disney's commitment to conservation, passion for environmental education, and effectiveness at communicating with audiences have made the Tour de Turtles a fun and successful program since it was launched over a decade ago."
In addition to Tour de Turtles, the Disney Conservation team has dedicated nearly 19,000 hours to studying and monitoring sea turtle nests during the summer nesting season along the five-mile coastline at Disney's Vero Beach Resort. From approximately May to October, Disney Vacation Club members and resort guests also have the opportunity to assist the team by joining outings to observe real-time sea turtle research while learning how they can take action to protect sea turtles. So far this year, the Disney Conservation team has a record-breaking number of nests along their survey route – nearly 2,000 by August, well above the average 1,500 normally counted in an entire season.
Tour de Turtles is a research and education program of the Sea Turtle Conservancy and Disney's support is just one example of bringing Disney Planet Possible to life by taking action to make a happier, healthier planet possible for all. To learn more and follow the turtles' migration, visit the Tour de Turtles website at www.tourdeturtles.org
ABOUT DISNEY'S VERO BEACH RESORT
Disney's Vero Beach Resort, a Disney Vacation Club Resort, offers spacious vacation villas along the pristine Atlantic coastline. The resort is located less than a two-hour drive from the Walt Disney World Resort, and its design reflects the Treasure Coast region where it is situated. Disney Vacation Club, a leader in vacation ownership, debuted in 1991 with a flexible, vacation points-based system rather than the traditional fixed-week timeshare model. Disney Vacation Club Members are able to choose from among a variety of exciting vacation destinations, including a stay at any Disney Vacation Club Resort or one of thousands of other vacation options in destinations around the world.
ABOUT DISNEY'S "HAUNTED MANSION"
Inspired by the classic theme park attraction, Disney's "Haunted Mansion" is about a woman and her son who enlist a motley crew of so-called spiritual experts to help rid their home of supernatural squatters.
Directed by Justin Simien, the film features an all-star cast ensemble including LaKeith Stanfield, Tiffany Haddish, Owen Wilson, Danny DeVito, Rosario Dawson, Chase W. Dillon and Daniel Levy, with Jamie Lee Curtis and Jared Leto as The Hatbox Ghost. The film's producers are Dan Lin and Jonathan Eirich, with Nick Reynolds and Tom Peitzman serving as executive producers.
View original content to download multimedia:
SOURCE Walt Disney World | https://www.wagmtv.com/prnewswire/2023/07/31/tour-de-turtles-celebrates-sea-turtles-supernatural-science-disneys-vero-beach-resort/ | 2023-07-31T11:22:59 | 0 | https://www.wagmtv.com/prnewswire/2023/07/31/tour-de-turtles-celebrates-sea-turtles-supernatural-science-disneys-vero-beach-resort/ |
- Cash, cash equivalents, and marketable securities totaled $349.0 million as of June 30, 2023
- Announced positive interim data from BHV-7000 EEG biomarker study demonstrating evidence of central nervous system (CNS) target engagement, confirming previously reported preclinical and clinical data, and highlighting the paradigm-changing potential of BHV-7000 in the treatment of epilepsy and mood disorders
- Brain penetrant TYK2/JAK1 inhibitor, BHV-8000, advanced into Phase 1 with projected therapeutic concentrations achieved and well-tolerated profile observed to date
- Advanced targeted extracellular protein degradation platform with potential to support numerous clinical candidates across a broad range of high unmet need indications
- Orphan drug designation (ODD) granted by the European Commission for taldefgrobep alfa a novel anti-myostatin adnectin, for the treatment of spinal muscular atrophy (SMA)
- Type A meeting planned with FDA regarding troriluzole program in Spinocerebellar Ataxia Type 3 (SCA3) and enrollment in Phase 3 obsessive compulsive disorder (OCD) trial expected to complete at end of 2023
NEW HAVEN, Conn., July 31, 2023 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today reported financial results for the second quarter ended June 30, 2023, and provided a review of recent accomplishments and anticipated upcoming milestones.
Vlad Coric, M.D., Chairman and Chief Executive Officer of Biohaven, commented, "In less than a year since our spin-off, the Biohaven team has driven strong and consistent progress across multiple drug development platforms. We were excited to recently report positive interim data from the ongoing EEG biomarker study of our lead Kv7 activator, BHV-7000. As expected, BHV-7000 demonstrated CNS activity consistent with what has been reported in EEG studies with other Kv7 channel activators in development that are clinically effective in treating epilepsy and with other approved anti-seizure medications. Importantly, BHV-7000 demonstrates CNS target engagement but is not associated with the typical CNS adverse events associated with other ASMs, like somnolence and fatigue. We look forward to completing the higher dose groups in this EEG study and initiating Phase 2/3 studies with our once daily, extended-release oral formulation later this year."
Dr. Coric continued, "We also shared a number of equally exciting announcements across our broader pipeline this quarter. We successfully administered the first three doses in the SAD portion of our ongoing SAD/MAD study evaluating BHV-8000, an oral, brain-penetrant, dual TYK2/JAK1 inhibitor. Potential therapeutic concentrations of BHV-8000 were achieved and BHV-8000 was well tolerated with only mild adverse events reported, reinforcing our plans to start a Phase 2 clinical trial with BHV-8000 in Parkinson's disease and potentially other neuroinflammatory diseases in 2024. In addition, we have advanced IND enabling preclinical studies and remain on track to submit an IND with our IgG degrader, BHV-1300, later this year. We also anticipate submitting an IND with our IgA degrader in 2024 as we continue to advance multiple clinical degrader candidates across a wide range of indications. We also shared key updates for our taldefgrobep alfa program (an anti-myostatin) with enrollment completion in our pivotal study in SMA and a planned Phase 2 trial initiation in obesity."
"Finally, I want to reaffirm Biohaven's commitment to the SCA3 patient community in spite of the recent disappointing regulatory decision by the FDA not to review our submitted NDA. Given the seriousness of SCA3 and consistent treatment benefits observed across multiple prespecified outcome measures, including an 80% delay in disease progression over the one-year study period with substantial risk reduction in falls, we believe that full consideration of all available data is warranted for this ultra-rare disease. Biohaven has built its foundation around our patient mission and we plan to continue to work with regulatory agencies to try to advance troriluzole for individuals suffering from SCA3."
Second Quarter 2023 and Recent Business Highlights
- Announced positive interim data from EEG biomarker study with BHV-7000 - In July 2023, the Company provided a preliminary data update from the ongoing electroencephalogram (EEG) biomarker study for the Kv7 Channel Activator platform. Preliminary Phase 1 data confirmed evidence of target engagement in the central nervous system for subjects with projected therapeutic concentrations of BHV-7000 (based on the EC50 from preclinical models), measured by changes from baseline in EEG spectral power that occurred after dosing. These pharmacodynamic (PD) effects were similar to those reported in the literature for anti-seizure medicines (ASMs), including Kv7 activators in development that are clinically effective in treating epilepsy. BHV-7000's PD effects were also differentiated from those reported for other Kv7 activators including, specifically, the absence of increases in EEG spectral power in frequency bands associated with drowsiness and somnolence. Results from the low-dose group validate the preclinical hypothesis, confirm the Phase 1 SAD/MAD clinical data, and provide strong support for Biohaven's plans to initiate pivotal studies with BHV-7000 in focal epilepsy and bipolar disorder in the second half of 2023. The preliminary data highlight BHV-7000's differentiation and potentially favorable clinical profile compared to other ASMs, and the Company expects to present the complete EEG results by the end of the year. Additionally, new pharmacokinetic data from multiple clinical formulations being studied has now confirmed a once daily extended-release oral formulation that will be used in the Phase 2/3 clinical programs.
- Successfully dosed three cohorts with single ascending doses of oral, brain penetrant, dual TYK2/JAK1 agent, BHV-8000 - In July 2023, the Company announced that it successfully dosed three cohorts in the SAD portion of an ongoing SAD/MAD Phase 1 study evaluating brain penetrant TYK2/JAK1 agent, BHV-8000 in healthy volunteers. The ongoing Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics (PK) and PD of single and multiple ascending doses of BHV-8000 in healthy volunteers. Based on the preliminary data available, projected therapeutic concentrations of BHV-8000 were achieved, and BHV-8000 was well tolerated with only mild adverse events reported. These data provide support for further development of BHV-8000, and the Company anticipates beginning a Phase 2 clinical trial with BHV-8000 in Parkinson's disease and potentially other neuroinflammatory diseases in 2024. The Company had previously reported initiation of dosing with BHV-8000 in the Phase 1 study at Biohaven's R&D Day in May 2023.
- Reported on continued progress observed with Biohaven's first-in-class bispecific IgG degrader, BHV-1300, as compound advances to IND filing in 2H2023 - In July 2023, the Company shared an update on BHV-1300's highly competitive safety, manufacturable and PD profile. The Company is assembling a pipeline of partially de-risked, follow-on IgG degraders as well as antigen-specific degraders providing both optionality and a sustainable output of drug candidates for several years. An IND application for BHV-1300 is on track for submission in 2023 and an IND application for Biohaven's IgA degrader on track for submission in 2024
- Type A meeting planned to comprehensively address FDA's concerns in connection with Troriluzole program in SCA3 - In July 2023, the Company announced that the FDA informed Biohaven it would not review the recently submitted New Drug Application (NDA) for troriluzole for the treatment of spinocerebellar ataxia type 3 (SCA3), an ultra-rare, genetically-defined, neurodegenerative disease associated with progressive disability, frequent falls, loss of ambulation, speech and swallowing impairment, and premature death that is the most common SCA genotype worldwide. The FDA informed Biohaven it would not review the application given that the study's primary endpoint was not met and thus, would not permit a substantive review. Biohaven is committed to working closely with the FDA to bring troriluzole to people with SCA3 as quickly as possible given no therapy is currently approved for this ultra-rare genetic disorder. Biohaven plans to request a Type A meeting to comprehensively address FDA's concerns cited in the refusal to file letter.
- EMA orphan drug designation granted for taldefgrobep alfa for the treatment of SMA: - In July 2023, the Company announced that taldefgrobep alfa received orphan drug designation (ODD) from the European Commission for taldefgrobep for the treatment of SMA. Taldefgrobep previously received Fast-Track and ODD from the FDA. At Biohaven's R&D Day, the Company announced plans to complete randomization of approximately 180 patients in global SMA trial.
Upcoming Milestones:
Biohaven is progressing its product candidates through clinical programs in a number of common and rare disorders. The Company plans to reach significant pipeline milestones in the coming periods. Biohaven expects to:
- Announce Phase 1 EEG study results by year-end 2023: The Company expects to present complete results from its ongoing EEG study with BHV-7000 in healthy volunteers by the end of the year.
- Initiate Phase 2/3 studies with BHV-7000 in the second half of 2023: Biohaven expects to initiate pivotal trials in patients with focal epilepsy and bipolar disorder in the second half of 2023.
- Submit IND with BHV-1300, the Company's lead extracellular degrader: The Company expects to submit an IND with pan-IgG degrader BHV-1300 in the second half of 2023 and expects to initiate Phase 2 studies in 2024.
- Submit IND with selective Gd-IgA1 degrader: The Company expects to submit an IND with a Gd-IgA1 degrader indicated for IgA nephropathy in the first half of 2024.
- Initiate Phase 2 study with BHV-8000: The Company commenced Phase 1 studies with BHV-8000, an oral, brain-penetrant, dual TYK2/JAK1 inhibitor for neuroinflammatory disorders, in the first half of 2023 and expects to initiate a Phase 2 study in Parkinson's disease in 2024.
- Submit IND with BHV-2100 in chronic pain: The Company expects to submit an IND with BHV-2100, a selective TRPM3 antagonist in the Company's ion channel platform, in the second half of 2023.
- Complete enrollment in Phase 3 study of troriluzole in OCD in 2023: Two Phase 3 randomized, double-blind, placebo-controlled studies of troriluzole in OCD are expected to enroll up to 700 patients (in each trial) across nearly 200 global study sites. The Company anticipates completing enrollment in at least one Phase 3 trial by year-end 2023.
- Complete enrollment in Phase 3 clinical study of taldefgrobep alfa in SMA: The Company expects to complete enrollment in the study of taldefgrobep in SMA in the second half of 2023.
- Continue advancements across multiple neuroscience and immunoscience indications: The Company's preclinical pipeline includes a platform of bispecific degraders of extracellular proteins directed against IgG, IgA and other targets, TRPM3 and Kv7 family of ion channels, and other undisclosed targets, including those with disease-modifying potential.
Capital Position:
Cash, cash equivalents and marketable securities as of June 30, 2023 was $349.0 million, including $13.9 million of restricted cash, and excluding $40.4 million of cash payable to Biohaven Pharmaceutical Holding Company Ltd. (the Former Parent), compared to $467.9 million, including $2.5 million of restricted cash, and excluding $35.2 million of cash payable to the Former Parent, as of December 31, 20221.
Second Quarter 2023 Financial Highlights:
Research and Development (R&D) Expenses: R&D expenses, including non-cash share-based compensation costs, were $79.5 million for the three months ended June 30, 2023, compared to $177.1 million for the three months ended June 30, 2022. Non-cash share-based compensation expense was $2.5 million for the three months ended June 30, 2023, a decrease of $10.3 million as compared to the same period in 2022. Non-cash share-based compensation expense was higher in the second quarter of 2022 primarily because expense allocated from the Former Parent equity plan, prior to the spin-off, was based on equity awards with higher grant date fair values.
General and Administrative (G&A) Expenses: General and administrative expenses were $14.5 million for the three months ended June 30, 2023, compared to $20.0 million for the three months ended June 30, 2022. The decrease of $5.5 million was primarily due to decreased non-cash share-based compensation costs. Non-cash share-based compensation expense was $2.2 million for the three months ended June 30, 2023, a decrease of $5.8 million as compared to the same period in 2022. Non-cash share-based compensation expense was higher in the second quarter of 2022 primarily because expense allocated from the Former Parent equity plan, prior to the spin-off, was based on equity awards with higher grant date fair values.
Other Income (Expense), Net: Other income (expense), net was a net income of $5.8 million for the three months ended June 30, 2023, compared to net expense of $0.1 million for the three months ended June 30, 2022. The increase of $5.9 million was primarily due to an increase in net investment income and an increase of $1.7 million in other income related to our transition services provided to the Former Parent, which is largely non-recurring.
Net Loss: Biohaven reported a net loss for the three months ended June 30, 2023, of $90.3 million, or $1.32 per share, compared to $203.3 million, or $5.16 per share, for the same period in 2022. Non-GAAP adjusted net loss for the three months ended June 30, 2023 was $85.7 million, or $1.25 per share, compared to $182.5 million, or $4.63 per share for the same period in 2022. These non-GAAP adjusted net loss and non-GAAP adjusted net loss per share measures, more fully described below under "Non-GAAP Financial Measures," exclude non-cash share-based compensation charges. A reconciliation of the GAAP financial results to non-GAAP financial results is included in the tables below. For periods prior to Biohaven's spin-off from the Former Parent on October 3, 2022 (the "Spin-Off"), net loss per share and non-GAAP adjusted net loss per share were calculated based on the 39,375,944 common shares of Biohaven distributed to the Former Parent shareholders at the time of the distribution, including common shares issued in connection with the Former Parent share options that were settled on October 3, 2022 and common shares issued in connection with the Former Parent restricted share units that vested on October 3, 2022. The same number of shares is being utilized for the calculation of basic and diluted earnings per share for all periods presented prior to the Spin-Off.
Non-GAAP Financial Measures
This press release includes financial results prepared in accordance with accounting principles generally accepted in the United States (GAAP), and also certain non-GAAP financial measures. In particular, Biohaven has provided non-GAAP adjusted net loss and adjusted net loss per share, which are adjusted to exclude non-cash share-based compensation, which is substantially dependent on changes in the market price of common shares. Non-GAAP financial measures are not an alternative for financial measures prepared in accordance with GAAP. However, Biohaven believes the presentation of non-GAAP adjusted net loss and adjusted net loss per share, when viewed in conjunction with GAAP results, provides investors with a more meaningful understanding of ongoing operating performance and can assist investors in comparing Biohaven's performance between periods.
In addition, these non-GAAP financial measures are among those indicators Biohaven uses as a basis for evaluating performance, and planning and forecasting future periods. These non-GAAP financial measures are not intended to be considered in isolation or as a substitute for GAAP financial measures. A reconciliation between these non-GAAP measures and the most directly comparable GAAP measures is provided later in this news release.
About Biohaven
Biohaven is a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases. Biohaven's experienced management team brings with it a track record of delivering new drug approvals for products for diseases such as migraine, depression, bipolar and schizophrenia. The company is advancing a pipeline of therapies for diseases, many of which have limited or no treatment options, leveraging its proven drug development capabilities and proprietary platforms, including Kv7 ion channel modulation for epilepsy and neuronal hyperexcitability, glutamate modulation for obsessive-compulsive disorder and spinocerebellar ataxia, myostatin inhibition for neuromuscular diseases and metabolic disorders, and brain-penetrant TYK2/JAK1 inhibition for neuroinflammatory disorders. Biohaven's portfolio of early- and late-stage product candidates also includes discovery research programs focused on TRPM3 channel activation for neuropathic pain, CD-38 antibody recruiting, bispecific molecules for multiple myeloma, antibody drug conjugates (ADCs), and targeted extracellular protein degradation platform technology (MoDE™) with potential application in neurological disorders, cancer, and autoimmune diseases.
Forward-looking Statements
This news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including "continue", "plan", "will", "believe", "may", "expect", "anticipate" and similar expressions, is intended to identify forward-looking statements. Investors are cautioned that any forward-looking statements, including statements regarding the future development, timing and potential marketing approval and commercialization of development candidates, are not guarantees of future performance or results and involve substantial risks and uncertainties. Actual results, developments and events may differ materially from those in the forward-looking statements as a result of various factors including: the expected timing, commencement and outcomes of Biohaven's planned and ongoing clinical trials; the timing of planned interactions and filings with the FDA; the timing and outcome of expected regulatory filings; complying with applicable U.S. regulatory requirements; the potential commercialization of Biohaven's product candidates; the potential for Biohaven's product candidates to be first in class therapies; and the effectiveness and safety of Biohaven's product candidates. Additional important factors to be considered in connection with forward-looking statements are described in Biohaven's filings with the Securities and Exchange Commission, including within the sections titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations". The forward-looking statements are made as of the date of this new release, and Biohaven does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
MoDEs is a trademark of Biohaven Therapeutics Ltd.
Investor Contact:
Jennifer Porcelli
Vice President, Investor Relations
jennifer.porcelli@biohavenpharma.com
+1 (201) 248-0741
Media Contact:
Mike Beyer
Sam Brown Inc.
mikebeyer@sambrown.com
+1 (312) 961-2502
View original content to download multimedia:
SOURCE Biohaven Ltd. | https://www.1011now.com/prnewswire/2023/07/31/biohaven-reports-second-quarter-2023-financial-results-recent-business-developments/ | 2023-07-31T11:23:02 | 1 | https://www.1011now.com/prnewswire/2023/07/31/biohaven-reports-second-quarter-2023-financial-results-recent-business-developments/ |
This Launch Marks the Latest Expansion of the Brand's Complexion Offerings as it Doubles Down on The Skincare-Meets-Makeup Hybrid Category
NEW YORK, July 31, 2023 /PRNewswire/ -- TULA Skincare, the leading clinically proven probiotic extract powered skincare brand has announced the expansion of its complexion offerings to include concealer.
After learning that TULA's customers were looking for a skin brightening eye treatment along with a concealer, the brand created a state-of-the-art clean skincare-makeup hybrid that delivers skin-boosting benefits with high-performance medium-to-full coverage.
Available in a 20-shade range, the dermatologist-tested, Radiant Skin Brightening Serum Concealer is infused with TULA's unique Rainbow Seabright™ Elixir. This clinically-proven serum-like formula instantly conceals dark circles and discoloration for longwearing, crease-proof results, while brightening the appearance of skin over time. Additional ingredients include TULA's S6Pro Complex® - a US patent pending super six blend of prebiotics and probiotic extracts to help soothe skin, improve skin smoothness and maintain skin balance, along with eye peptides and tea leaf caffeine to help improve the look of dark circles, skin texture, and eye bags. The Radiant Skin Brightening Serum Concealer can be paired with the brand's Radiant Skin Brightening Serum Skin Tint or Filter Primer Blurring & Moisturizing Primer to help build one's complexion wardrobe, or spot conceal for a no-makeup, makeup look.
"Expanding our complexion category to include a concealer was a natural next step for us, especially knowing the strong desire our customers have had for an eye treatment with brightening benefits." said TULA Skincare CEO, Savannah Sachs. " We are excited to have another offering for our glow getters that will surely be a staple in their skincare and beauty routines."
To mark the launch, TULA will be executing a multi-channel launch campaign across its digital platform, and organic social, paid media, and influencer channels. Efforts will include launching a custom "shade finder" on tula.com to help customers find their perfect match concealer shade, highlighting content speaking to the "no-makeup, makeup" and makeup-skincare hybrid trends across TikTok and Instagram, and partnering with a curated set of influencers and providing them with an early access link exclusively for their followers to purchase the concealer prior to launch. In addition to tula.com, the concealer will launch in Ulta Beauty stores nationwide and online and will be featured in an upcoming issue of the Ulta Beauty Magazine, with in-store complexion events planned in the coming months in multiple doors.
TULA's Radiant Skin Brightening Serum Concealer will be available for purchase on July 31 on tula.com, and will retail for $32.
About TULA Skincare
TULA is a doctor-founded skincare brand built on clinically proven formulas powered by probiotic extracts. We believe that the same types of ingredients which are good for your body are also great for your skin. We focus on being healthy, not perfect and on empowering everyone to feel confident in their skin.
Media Contact: Zoe Jeans at Bux + Bewl Communications: zoe@buxandbewl.com
View original content to download multimedia:
SOURCE TULA Skincare | https://www.wagmtv.com/prnewswire/2023/07/31/tula-skincare-launches-new-radiant-skin-brightening-serum-concealer/ | 2023-07-31T11:23:05 | 1 | https://www.wagmtv.com/prnewswire/2023/07/31/tula-skincare-launches-new-radiant-skin-brightening-serum-concealer/ |
SHANGHAI, July 31, 2023 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced that it will report its unaudited financial results for the second quarter ended June 30, 2023, before the U.S. market opens on Thursday, August 24, 2023.
111's management team will host an earnings conference call at 7:30 AM U.S. Eastern Time on Thursday, August 24, 2023 (7:30 PM Beijing Time on the same day).
Details for the conference call are as follows:
Conference Topic: 111, Inc. Second Quarter 2023 Earnings Conference Call
Registration Link: https://s1.c-conf.com/diamondpass/10032701-ygfhis.html
All participants must use the link provided above to complete the online registration process in advance of the conference call. Upon registering, each participant will receive a set of participant dial-in numbers, the Direct Event passcode, and a unique Registration ID, which can be used to join the conference call.
Please dial in 15 minutes before the call is scheduled to begin and provide the Direct Event passcode and unique Registration ID you have received upon registering to join the call.
A telephone replay of the call will be available after the conclusion of the conference call until August 31, 2023
United States: +1 855 883 1031
Mainland China: 4001 209 216
Hong Kong: 800 930 639
International: +61 7 3107 6325
Conference ID: 10032701
A live and archived webcast of the conference call will be available on the website at https://edge.media-server.com/mmc/p/iw7ck9oc
About 111, Inc.
111, Inc. (NASDAQ: YI) ("111" or the "Company") is a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China. The Company provides consumers with better access to pharmaceutical products and healthcare services directly through its online retail pharmacy, 1 Pharmacy, and indirectly through its offline virtual pharmacy network. The Company also offers online healthcare services through its internet hospital, 1 Clinic, which provides consumers with cost-effective and convenient online consultation, electronic prescription service, and patient management service. In addition, the Company's online platform, 1 Medicine Marketplace, serves as a one-stop shop for pharmacies to source a vast selection of pharmaceutical products. With the largest virtual pharmacy network in China, 111 enables offline pharmacies to better serve their customers with cloud-based services. 111 also provides an omni-channel drug commercialization platform to its strategic partners, which includes services such as digital marketing, patient education, data analytics, and pricing monitoring.
For more information on 111, please visit: http://ir.111.com.cn/.
View original content:
SOURCE 111, Inc. | https://www.wkyt.com/prnewswire/2023/07/31/111-announce-second-quarter-2023-unaudited-financial-results-august-24-2023-conference-call-follow/ | 2023-07-31T11:23:09 | 1 | https://www.wkyt.com/prnewswire/2023/07/31/111-announce-second-quarter-2023-unaudited-financial-results-august-24-2023-conference-call-follow/ |
SAN FRANCISCO, July 31, 2023 /PRNewswire/ -- Today, Blitz Insurance, a specialty insurance carrier, partners with Ascend to modernize payment experiences for insurance brokers selling in specialty markets. With this partnership, Blitz Insurance will open new customer segments by offering both direct bill and premium financing into their payments workflow.
"When we looked into the market for a solution, Ascend was the right choice. Ascend meets our needs for a better payments experience for our partners while reducing everyone's operational expenses," said Brandon Murphy, Chief Distribution Officer of Blitz Insurance. "We will now have the ability to not only expand to direct bill and a premium finance option but also simplify the movement of money between us and our partners."
With Ascend, Blitz Insurance is now able to provide a direct bill in addition to their existing agency bill workflow - allowing brokers to decide what billing method works best for them. By utilizing Ascend, Blitz Insurance not only grows their footprint of appointed brokers but also gains administrative efficiency by automating what would otherwise have been a large operational undertaking.
Ascend automatically attributes incoming payments to policies in real time, speeding up the reconciliation process. By modernizing the payments experience and speeding up the reconciliation of incoming premiums, Blitz Insurance can offer a best-in-class experience to its brokers and agents.
"We find that across the insurance ecosystem - companies want to provide a seamless payment workflow for their customers and their teams," said Andrew Wynn, co-CEO of Ascend. "Ascend is built so brokers and carriers can offer this experience without shouldering the administrative resources and costs needed to support these operations."
About Ascend
Ascend is the first insurance payments platform that automates financial operations from collections and financing to carrier and commission payables. Founded by two-time insurtech entrepreneurs Andrew Wynn and Praveen Chekuri, Ascend helps insurance brokers, MGAs, and carriers improve their bottom lines by eliminating expensive and labor-intensive payment workflows. To learn more, please visit LinkedIn, Twitter or check out https://www.useascend.com/.
About Blitz Insurance
Blitz is a tech-driven insurer revolutionizing the $60B specialty market catering to SME segment. By leveraging industry knowledge and cutting-edge technology, we deliver a simpler, smarter, and faster coverage experience.
The company is led by a veteran team of insurance and technology experts and has been funded with $25M from its founder & CEO, a Forbes-listed serial entrepreneur in the real estate and insurance industries.
Contact:
Mike Nguyen
press@useascend.com
View original content to download multimedia:
SOURCE Ascend | https://www.1011now.com/prnewswire/2023/07/31/blitz-insurance-partners-with-ascend-expand-payment-financing-offerings/ | 2023-07-31T11:23:09 | 0 | https://www.1011now.com/prnewswire/2023/07/31/blitz-insurance-partners-with-ascend-expand-payment-financing-offerings/ |
Launch demonstrates companies' commitment to bringing complex generic medicines to the market to help increase patient access
PITTSBURGH and WOODBURY, Minn., July 31, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, and Kindeva Drug Delivery L.P. today announced the launch of Breyna™ (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, the first generic version of AstraZeneca's Symbicort® with an Abbreviated New Drug Application (ANDA) approved by the U.S. Food and Drug Administration (FDA). Breyna, a drug-device combination product, is indicated for certain patients with asthma or chronic obstructive pulmonary disease (COPD) and will be immediately available in both 80 mcg/4.5 mcg and 160 mcg/4.5 mcg dosage strengths.
Viatris Head of North America Jose Cotarelo said: "We are excited to bring Breyna to the U.S. market for the many Americans living with asthma and COPD. This launch represents years of hard work breaking down barriers to access and builds upon our past successes of bringing other complex products to market as we continue to move up the value chain. Being the first to bring an FDA-approved generic version of Symbicort to patients is a true example of how access is the cornerstone of our mission to empower people worldwide to live healthier at every stage of life."
The indications for Breyna include asthma in patients six years of age and older, and the maintenance treatment of airflow obstruction and reducing exacerbations in patients with COPD, including chronic bronchitis and/or emphysema. Breyna is not indicated for the relief of acute bronchospasm. The 160 mcg/4.5 mcg is the only strength indicated for the treatment of COPD. COPD is a term used to describe a certain kind of chronic lung disease and is characterized by breathlessness; it affects more than 16 million Americans. Asthma causes swelling of the airways resulting in difficulty breathing, and approximately 25 million Americans have the chronic condition.
Milton Boyer, CEO of Kindeva Drug Delivery, added: "The launch of Breyna represents a significant milestone as it is the first FDA-approved generic version of Symbicort in the U.S., one of the most prescribed complex drug-device combination products to treat asthma and COPD. We are pleased for Viatris as well as the many Kindeva colleagues who have worked tirelessly to leverage our complex drug-delivery expertise for this important respiratory product — supporting a persistent need to continue bringing more quality medicines for asthma and COPD to patients."
To further expand access to Breyna, Viatris has established a copay program offered for eligible commercially-insured patients, which may help reduce out-of-pocket expenses on prescriptions to as little as $20 per 30-day supply. The program offers $30/month or up to $360 per year with 12 refills annually. The program will be available in August.
About Breyna
Breyna is indicated for the treatment of asthma in patients 6 years and older not adequately controlled on a long-term asthma-control medication such as an inhaled corticosteroid (ICS) or whose disease warrants initiation of treatment with both an ICS and long-acting beta2-adrenergic agonists (LABA). Breyna 160 mcg/4.5 mcg dosage is indicated for the maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema, and Breyna 160 mcg/4.5 mcg is also indicated to reduce exacerbations of COPD. Breyna is NOT indicated for the relief of acute bronchospasm.
Important Safety Information
Breyna is contraindicated in the primary treatment of status asthmaticus or other acute episode of asthma or COPD where intensive measures are required, and in hypersensitivity to any of the ingredients in Breyna. Use of long-acting beta2-adrenergic agonists (LABA) as monotherapy (without inhaled corticosteroids [ICS]) for asthma is associated with an increased risk of asthma-related death. Available data from controlled clinial trials also suggest that use of LABA as monotherapy increases the risk of asthma-related hospitalization in pediatric and adolescent patients. These findings are considered a class effect of LABA. When LABA are used in fixed dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared to ICS alone. Breyna is NOT a rescue medication and does NOT replace fast-acting inhalers to treat acute symptoms. Breyna should not be initiated in patients during rapidly deteriorating episodes of asthma or COPD. Patients who are receiving Breyna should not use additional formoterol or other LABA for any reason. Localized infections of the mouth and pharynx with Candida albicans has occurred in patients treated with Breyna. Patients should rinse the mouth after inhalation of Breyna. Lower respiratory tract infections, including pneumonia, have been reported following the administration of ICS. Due to possible immunosuppression, potential worsening of infections could occur. A more serious or even fatal course of chickenpox or measles can occur in susceptible patients. It is possible that systemic corticosteroid effects such as hypercorticism and adrenal suppression may occur, particularly at higher doses. Particular care is needed for patients who are transferred from systemically active corticosteroids to ICS. Deaths due to adrenal insufficiency have occurred in asthmatic patients during and after transfer from systemic corticosteroids to less systemically available ICS. Caution should be exercised when considering administration of Breyna in patients on long-term ketoconazole and other known potent CYP3A4 inhibitors. As with other inhaled medications, paradoxical bronchospasm may occur with Breyna. Immediate hypersensitivity reactions may occur, as demonstrated by cases of urticaria, angioedema, rash, and bronchospasm. Excessive beta-adrenergic stimulation has been associated with central nervous system and cardiovascular effects. Breyna should be used with caution in patients with cardiovascular disorders especially coronary insufficiency, cardiac arrhythmias, and hypertension. Long-term use of ICS may result in a decrease in bone mineral density (BMD Assessment of BMD is recommended prior to initiating Breyna and periodically thereafter. ICS may result in a reduction in growth velocity when administered to pediatric patients. Glaucoma, increased intracolular pressure, and cataracts have been reported following the administration of ICS, including budesonide, a component of Breyna. Close monitoring for glaucoma and cataracts is warranted in patients with a change in vision or history of increased intraocular pressure. In rare cases, patients on ICS may present with systemic eosinophilic conditions. Breyna should be used with caution in patients with convulsive disorders, thyrotoxicosis, diabetes mellitus, ketoacidosis, and in patients who are unusually responsive to sympathomimetic amines. The most common adverse reactions ≥3% reported in asthma clinical trials included nasopharyngitis, headache, upper respiratory tract infection, pharyngolaryngeal pain, sinusitis, influenza, back pain, nasal congestion, stomach discomfort, vomiting, and oral candidiasis. The most common adverse reactions ≥3% reported in COPD clinical trials included nasopharyngitis, oral candidiasis, bronchitis, sinusitis, and upper respiratory tract infection. Breyna should be administered with caution to patients being treated with MAO inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents. Beta-blockers may not only block the pulmonary effect of beta-agonists, such as formoterol, but may produce severe bronchospasm in patients with asthma. ECG changes and/or hypokalemia associated with nonpotassium-sparing diuretics may worsen with concomitant beta-agonists. Use caution with the coadministration of Breyna.
About Viatris
Viatris Inc. (NASDAQ: VTRS) is a global healthcare company empowering people worldwide to live healthier at every stage of life. We provide access to medicines, advance sustainable operations, develop innovative solutions and leverage our collective expertise to connect more people to more products and services through our one-of-a-kind Global Healthcare Gateway®. Formed in November 2020, Viatris brings together scientific, manufacturing and distribution expertise with proven regulatory, medical and commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories. Viatris' portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally recognized brands, complex generic and branded medicines, and a variety of over-the-counter consumer products. With more than 38,000 colleagues globally, Viatris is headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at viatris.com and investor.viatris.com, and connect with us on Twitter at @ViatrisInc, LinkedIn and YouTube.
About Kindeva Drug Delivery
Kindeva Drug Delivery is a global contract development manufacturing organization focused on drug-device combination products. Kindeva Drug Delivery develops and manufactures products across a broad range of complex drug-delivery formats, including injectables (autoinjector, intradermal, microneedle), pulmonary & nasal, and transdermal patches. Its service offering spans early-stage feasibility through commercial scale drug product fill-finish, container closure system manufacturing, and drug-device product assembly. Kindeva Drug Delivery serves a global client base from its nine manufacturing and research and development facilities located in the U.S. and U.K. For more information, please visit www.kindevadd.com.
Forward-Looking Statements
This press release includes statements that constitute "forward-looking statements." These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward looking statements may include statements that the launch of Breyna demonstrates the companies' commitment to bringing complex generic medicines to the market to help increase patient access; Breyna will be immediately available in both 80 mcg/4.5 mcg and 160 mcg/4.5 mcg dosage strengths; this launch represents years of hard work breaking down barriers to access and builds upon our past successes of bringing other complex products to market as we continue to move up the value chain; to further expand access to Breyna, Viatris has established a copay program offered for eligible commercially-insured patients, which may help reduce out-of-pocket expenses on prescriptions to as little as $20 per 30-day supply; and, the program will be available in August. Factors that could cause or contribute to such differences include, but are not limited to: the possibility that the Company may be unable to realize the intended benefits of, or achieve the intended goals or outlooks with respect to, its strategic initiatives; the possibility that the Company may be unable to achieve expected benefits, synergies and operating efficiencies in connection with acquisitions, divestitures, or its global restructuring program, within the expected timeframe or at all; impairment charges or other losses related to the divestiture or sale of businesses or assets; the Company's failure to achieve expected or targeted future financial and operating performance and results; the potential impact of public health outbreaks, epidemics and pandemics, including the ongoing challenges and uncertainties posed by COVID-19; actions and decisions of healthcare and pharmaceutical regulators; changes in healthcare and pharmaceutical laws and regulations in the U.S. and abroad; any regulatory, legal or other impediments to Viatris' ability to bring new products to market, including but not limited to "at-risk" launches; Viatris' or its partners' ability to develop, manufacture, and commercialize products; the scope, timing and outcome of any ongoing legal proceedings, and the impact of any such proceedings; any significant breach of data security or data privacy or disruptions to our information technology systems; risks associated with international operations; the ability to protect intellectual property and preserve intellectual property rights; changes in third-party relationships; the effect of any changes in Viatris' or its partners' customer and supplier relationships and customer purchasing patterns; the impacts of competition; changes in the economic and financial conditions of Viatris or its partners; uncertainties and matters beyond the control of management, including general economic conditions, inflation and exchange rates; failure to execute stock repurchases consistent with current expectations; stock price volatility; and the other risks described in Viatris' filings with the Securities and Exchange Commission (SEC). Viatris routinely uses its website as a means of disclosing material information to the public in a broad, non-exclusionary manner for purposes of the SEC's Regulation Fair Disclosure (Reg FD). Viatris undertakes no obligation to update these statements for revisions or changes after the date of this release other than as required by law.
View original content to download multimedia:
SOURCE Viatris Inc. | https://www.wagmtv.com/prnewswire/2023/07/31/viatris-announces-launch-breyna-budesonide-formoterol-fumarate-dihydrate-inhalation-aerosol-first-fda-approved-generic-version-symbicort-people-with-asthma-chronic-obstructive-pulmonary-disease-partnership-with-kindeva/ | 2023-07-31T11:23:11 | 1 | https://www.wagmtv.com/prnewswire/2023/07/31/viatris-announces-launch-breyna-budesonide-formoterol-fumarate-dihydrate-inhalation-aerosol-first-fda-approved-generic-version-symbicort-people-with-asthma-chronic-obstructive-pulmonary-disease-partnership-with-kindeva/ |
BEIJING, July 31, 2023 /PRNewswire/ -- 36Kr Holdings Inc. ("36Kr" or the "Company") (NASDAQ: KRKR), a prominent brand and a pioneering platform dedicated to serving New Economy participants in China, today announced the launch of its 36Kr Media Lab in Silicon Valley, an initiative to embrace the large language models (LLM) revolution taking place in the content creation industry and optimize the application of artificial intelligence (AI) for the new economy sector.
36Kr Silicon Valley Media Lab's first project leveraging LLM, "Empty Office," will experimentally explore scenarios where AI can think and work as humans, enhancing content production efficiency and reducing costs. Through "Empty Office," 36Kr is also building innovative media solutions that will transform traditional video, graphic and text communications into avant-garde dialogues between customized AI characters and audiences. These network-based dialogues will be naturally and seamlessly driven by real-time data generation, and available anytime, anywhere.
At the same time, 36Kr Silicon Valley Media Lab continues to focus on tailoring its LLM to the new economy sector. By utilizing dedicated financial and business datasets, including enterprises' financial results, news, market dynamics and knowledge repositories, among other resources, to train its LLM to thoroughly understand and analyze business information, 36Kr has developed a model that keenly grasps the business nuances to generate accurate analysis and interpretation. 36Kr Silicon Valley Media Lab constantly maintains its database, serving as the reference foundation to ensure that its fact-based model produces rigorous and up-to-date business and financial analysis.
Furthermore, 36Kr's professionally-training, fine-tuning capability enables its LLM-empowered "Empty Office" to quickly and efficiently create informative content for the new economy sector. For instance, in the case of a business event, such as a new product launch, an AI agent can instantly extract relevant data from the database, automatically perform a comprehensive analysis, and issue reports within just seconds. This top-speed response gives 36Kr's business and financial-focused media platform an unrivaled edge.
Mr. Dagang Feng, Co-chairman and CEO of 36Kr, commented, "The launch of 36Kr Silicon Valley Media Lab is a testament to our AI technology acumen and vision as well as our commitment to extending media's boundaries. By integrating pioneering AI technology into content creation, 36Kr will constantly elevate the efficiency and quality of content production alongside the rapid advancement of the LLM, fostering a superior content ecosystem encompassing business, finance and technology, further turbocharging the evolution of the New Economy. As we adopt and develop more AI tools amid the technology's rapid advancement, we are strategically positioning the Company to break new ground and ultimately drive long-term growth for our business."
About 36Kr Holdings Inc.
36Kr Holdings Inc. is a prominent brand and a pioneering platform dedicated to serving New Economy participants in China with the mission of empowering New Economy participants to achieve more. The Company started its business with high-quality New Economy-focused content offerings, covering a variety of industries in China's New Economy with diverse distribution channels. Leveraging traffic brought by high-quality content, the Company has expanded its offerings to business services, including online advertising services, enterprise value-added services, and subscription services, to address the evolving needs of New Economy companies and upgrading needs of traditional companies. The Company is supported by a comprehensive database and strong data analytics capabilities. Through diverse service offerings and significant brand influence, the Company is well-positioned to continuously capture the high growth potential of China's New Economy.
For more information, please visit: http://ir.36kr.com.
Safe Harbor Statement
This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: the Company's goal and strategies; the Company's future business development, results of operations and financial condition; relevant government policies and regulations relating to our business and industry; the Company's expectations regarding the use of proceeds from this offering; the Company's expectations regarding demand for, and market acceptance of, its services; the Company's ability to maintain and enhance its brand; the Company's ability to provide high-quality content in a timely manner to attract and retain users; the Company's ability to retain and hire quality in-house writers and editors; the Company's ability to maintain cooperation with third-party professional content providers; the Company's ability to maintain relationships with third-party platforms; general economic and business conditions in China; possible disruptions in commercial activities caused by natural or human-induced disasters; and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in the Company's filings with the SEC. All information provided in this press release and in the attachments is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.
For investor and media inquiries, please contact:
In China:
36Kr Holdings Inc.
Investor Relations
Tel: +86 (10) 8965-0708
E-mail: ir@36kr.com
The Piacente Group, Inc.
Jenny Cai
Tel: +86 (10) 6508-0677
E-mail: 36Kr@tpg-ir.com
In the United States:
The Piacente Group, Inc.
Brandi Piacente
Tel: +1-212-481-2050
E-mail: 36Kr@tpg-ir.com
View original content:
SOURCE 36Kr Holdings Inc. | https://www.wkyt.com/prnewswire/2023/07/31/36kr-launches-silicon-valley-media-lab-empower-content-ecosystem-with-llm-based-ai-technology/ | 2023-07-31T11:23:16 | 0 | https://www.wkyt.com/prnewswire/2023/07/31/36kr-launches-silicon-valley-media-lab-empower-content-ecosystem-with-llm-based-ai-technology/ |
STAMFORD, Conn., July 31, 2023 /PRNewswire/ -- Emeren Group Ltd ("Emeren" or the "Company") (www.emeren.com) (NYSE: SOL), a leading global solar project developer, owner, and operator, recently announced the successful sale of an 11.5 MWp PV project to the Swiss-based energy company MET Group. The project was sold at the Ready-to-Build ("RTB") stage and MET Group will complete the construction and operate the power plant. This is the first project developed to RTB stage by Emeren Germany GmbH, the Berlin-based subsidiary of Emeren Group, since its entry into the market in early 2021. Capcora, a German consulting company, acted as the exclusive sell-side M&A advisor to Emeren.
The new PV power plant will be located in Kentzlin nestled in the state of Mecklenburg-Western Pomerania and the commercial operations are expected to start in the second half of 2024.
Yumin Liu, CEO of Emeren Group, commented, "This project is an important milestone for our business in Germany and represents our commitment to developing renewable energy infrastructure in the region. We look forward to continuing to work with our local partners to build a more sustainable future."
Bernd Wollwerth-Carl, Director of Emeren Germany GmbH, added, "We are delighted to have sold our first RTB project in Germany. Starting from scratch in 2021, we managed to grow quickly in a competitive German PV market, establishing partnerships and building a pipeline of medium and large-scale ground mounted PV plants. With MET, we found a reliable and competent partner and we look forward to further expanding our cooperation."
Christian Hürlimann, Renewables CEO of MET Group, commented, "The Kentzlin project fits well into MET's strategic vision to enter the highly competitive German renewables market, as well as to further expand its renewables portfolio across Europe and particularly in Western Europe. Emeren Group's expertise in renewable energy was instrumental in achieving this milestone, and we anticipate future collaboration on additional projects."
Henning Prigge, Director at Capcora, adds: "We are delighted to have played a pivotal role in Emeren's successful project sale to MET Group, a prominent integrated European energy company. Our long-standing partnership with Emeren has allowed us to witness their growth and success, and we couldn't be happier to have been a part of this milestone. This collaboration reinforces our commitment to providing top-notch support and solutions to our valued clients."
About Emeren Group Ltd
Emeren Group Ltd (NYSE: SOL) is a leading global solar project developer, owner, and operator with a pipeline of projects and IPP assets totaling over 3 GW, as well as a storage pipeline of over 6 GWh across Europe, North America, and Asia. The Company focuses on solar power project development, construction management and project financing services with local professional teams across multiple countries. For more information, go to www.emeren.com.
About MET Group
MET Group is an integrated European energy company, headquartered in Switzerland, with activities and assets in natural gas and power markets. MET is present in 14 countries through subsidiaries, 30 national gas markets, and 22 international trading hubs. MET has extensive experience in operating green (renewable) and flexible (conventional) energy assets, thus providing the widest possible support to energy transition. In 2022, MET Group's consolidated sales revenue amounted to EUR 41.5 billion, the total traded volume of natural gas was 109 BCM including futures, total traded electricity 67 TWh including futures.
About Capcora
Capcora is an independent financial advisory boutique specializing in M&A and project finance services to accelerate the energy transition in Europe. Founded in 2015, the Frankfurt-based company helps its clients succeed in the renewable energy and infrastructure sectors by advising them on sell-side and buy-side transactions, and by raising mezzanine, unitranche or senior debt.
View original content to download multimedia:
SOURCE Emeren Group Ltd | https://www.1011now.com/prnewswire/2023/07/31/emeren-group-announces-sale-first-rtb-solar-power-project-germany/ | 2023-07-31T11:23:16 | 0 | https://www.1011now.com/prnewswire/2023/07/31/emeren-group-announces-sale-first-rtb-solar-power-project-germany/ |